<SEC-DOCUMENT>0001485003-22-000108.txt : 20220808
<SEC-HEADER>0001485003-22-000108.hdr.sgml : 20220808
<ACCEPTANCE-DATETIME>20220808080126
ACCESSION NUMBER:		0001485003-22-000108
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220808
DATE AS OF CHANGE:		20220808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sesen Bio, Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		221142608

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-444-8550

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sesn-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e2242ac9-1511-42db-a08a-ac050036e5da,g:27c8282b-5e55-4664-b4e1-3a6627cbab54,d:90488ba6460948abaea2097aabfb6299--><html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:sesn="http://www.sesenbio.com/20220630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sesn-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M181LTEtMS0xLTcwMDYw_664c11a5-68da-44fa-a701-29e28b496b8c">0001485003</ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M182LTEtMS0xLTcwMDYw_fe6624ba-fb11-4a46-8bed-307b2b806bfb">Dec 31</ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M183LTEtMS0xLTcwMDYw_0d43ff09-2b56-414c-9b4b-d1bfd1eeb547">2022</ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M184LTEtMS0xLTcwMDYw_b28f3007-ed44-4aca-8b31-32ff84122a99">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M185LTEtMS0xLTcwMDYw_835f8a9c-ac37-48a6-a4c6-08cee8e45425">false</ix:nonNumeric><ix:nonNumeric contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_12b4d2e7-50cf-486e-9f55-531f61e9b030">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_31abd46a-5b00-4492-b73c-c6d432a04ad5">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_481dba29-3a20-4f06-a044-73c8436545ee">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_897ed270-6cb7-4b09-83f1-a713e11dbc4b">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_7413172c-d3a5-4068-a39f-148f182a4c0b">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_ea5c27f0-7ff4-4a17-899a-400e6d9e6d97">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_0bf1b90e-c07f-46a0-9567-ec2c0325b103">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_1319265b-1386-40c8-9f75-781056e69617">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sesn-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29b4bcc98fb446586c8d0938f7a6cdf_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i09ec16c102264bf888a63583634b10b9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iee48bd4076a144b6bcecb0df8e12665f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6d8077dece4a95940087e255f75bc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i345971d52bde416886e88795d548811c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i677b1480fd064f218483dcf37f0aa72c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084e153e02ad4c0fbdaeba8fea7f0792_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814ff665c79642eb9c63201f9f6aa4c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie970ce934b1e4c17b1f8e5435783799b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba13d9d0682407bb0b32862ba63462c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c99c9b6effb411d93633cf284df66a8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6ecaf1deb82450595375aa26194263c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8643db175ec94af8835005bd348c2a15_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d91c72b3c9a48f698faa963f06f6585_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i788239f286ce4a7aaf34d9b6448f7b19_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdee19feaf04f8eb7b2e7516c8272ba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cbf3dbf085a4f5aa6d333be0b69cc50_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5331cf0a882c45b18c3f7c5cdd34d580_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba7a3599765459e9e5050731fd4dcd0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea6d35dc5474aa581a55e2b57ae57c6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i212d6b0e7fc04d0bb334aee4c3d885fb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90e014d0d0846a6a6300ee56057382d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b29b8876ac49d4ada09cbcefec48ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbb5504ef7a4410cbd3d49b7bc9eac22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7b04bc3e3454a688ae44dcb39bfc41e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8644b1d6b1492195108a81bd629611_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0208600fe4024d29a9aa9d6917193edb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50a087530030427d9767a04597f4120d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2d58ed494f4424abbfc10d0ab04193_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f839115e09747288556177ec1208f7c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie063900bace246ea9ac9229220ed605a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a952d29209497aa9e963b66ddf48ba_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id06576b00b094f1a849c81ba939934c9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691732dc107c4eb19beb797b845714a5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1e1c1185b384bb9b9a302d5f694d2b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f292f26d18474a88618593f2028cde_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4548660807654ebfad44b93c626bb154_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e1083313744230858402ce1024fb35_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc68b87db60469baad7a2624334af31_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca4bd64eb504b02826a9652e4a84714_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a7b16d33054ed2bb2f3e95123e6d0c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ddf69ac8bf84700b67bf4be374a19f5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i791f0580873d401f8150577ee2f295da_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i927224fa40114d4e9fa1b0f9ea67129d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf9ab52935a412db213d105924c9a17_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1375cc14b49437b91d5bbba570298c2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3dde4b5cd0247c48f35a95c8521f4b9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f8bfc830bc347e7ba385a21bc092a5d_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0e3fdec0c73b4a429111263d24db668c_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0b5fa857364bf4a51985aa66895ef9_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idded2fb700664bad9763afed64edafd0_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4937ec1ad1154d88925e0cabccbc0017_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idddfae85f074434a95d80a49f60b90a8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c7832156a94fdeb7e233a110f7b809_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c2028a693348b8951ec9bd0156057c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe177cf9141643909f6abc3b8fa7d37d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9372277261a1442382a0a57cd6b64879_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86a276b795564af5900e3ccde170c211_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93597cbef52346f8bf33793b3445c748_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c6a63221e74f49a77225cfd89d52e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6ff544a1cd473cb1b5466e70e8581d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic13e854370344e64955121ce52f8efd8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077703176cde4f50813269c0d4bc4948_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086d18af784f4ef89dd43b1a93d419d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id227aede38f346d295f8bb264c9c69d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2830d319d1ee4478869015d679421f00_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60aca7f4595d416dac4c7c3f1aed4ccb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f36ed152cc4886975102feb1d3dcf2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa3364e01f0e4f3e8b9b4b9e879f7cda_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e6014176bb47daa77e93b8e95c92eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68913e68ad7b4a54a86589572b03f916_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:LitigationSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e566e4a4b842db8188c3f55dbff512_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:GermanVATRecoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaafbcb1be87d432d8ded324e6ed76889_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b037e30ee240a693feec6491f28390_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i043a889ad00d41bcbc065be28275a745_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia31cefc9e53e4fdea0146b38e97b9152_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75f8be7fd9a44548a385a47a21fdcbfa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5bc92acb0454bdeb25962fc1d1aef23_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>sesn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i148c02076fb6482087594002227223b6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i54a5e53888604de7b9eccc5f75d78406_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="ia060ccaf4f3043ab8f16a7a015f9e80e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a99add6a0641b5ab55bf3282467a0d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84bae78e3b8749b39293629af79a1b2a_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f7003911044ca29a413fb1818f5c6c_D20210601-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce363488c7540a6a587912208af7e0f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35961c53b42e43cbb0b81da04777d408_D20211129-20211129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-29</xbrli:startDate><xbrli:endDate>2021-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7960c58d87094e0aafb92767a535f891_I20210502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8cab4c047e42a1993c113f9407d7c0_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e690f5ae31c41b7a191fa0ff85bf14a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e430eedf22b467aac65cdb1b465bb18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if12ac6d811ab49fea4ae767cff635f67_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879f338421144cd692f89c4e9f0c73c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf83b58ca25c49e192a0c8602c5b4cf2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc92bb70d08454e949c18da6144865f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9bd2cea79e94911a9584a49e07abbb3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3787aa8d02ce4f859f8c5f466f0d274a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab2fae56c82b4d01a53b53d0d8ad8169_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018c376ae85743729c4cc85b9d0082c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa49d50600f4d809f73a21b67293288_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>sesn:vote</xbrli:measure></xbrli:unit><xbrli:context id="if3f5defe37004a80beffaabe3c084441_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c5616a1e704030a81402b94effbad5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69cb4439e7f34192bda24252ab0db0d6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95be96bc66a447e49b2e6b3eb139bb61_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4361a004833c45998527402787d53315_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c9b9934bd1f4b4a87e74584ffe44869_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i364de02410824f29aef894a8c443af3b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f346e6310724b48be23ba52453dfd1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib269223dc4c241d2ab59180afde39e5e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3afe3a9ad2a74fa9a621bbc8ca349720_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a150a7d69f42ab95bb4eebf536a4eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd894f48683d467eade7ea10a3423375_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d2c5c201c146a29dc3f4aaab1fa94b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if89d59ad112c41c1a5e5e4945e45b3a0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1832afd10f54cc791caad58fb173350_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b6f3706013458ab5961aa0a088fa40_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6362c9affd304cba8c070c705be6dd77_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i369610441fa049a9b3af81518e15d50d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i831e2ac854704d1aae0e81436d368ad4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic013dea044994c0b9999755d2814f233_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d8a6c363c94c7ebb181ec0e4902d6d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5c4a87f8a04b809066ca30fe8adea9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a6d05611034f0cbfbdc965d1641901_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b119b75001e4eb591c83a48aca8ad9e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdffcc8e474644f1a7bc79d73e44c345_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c426ecc6b6e483ab968812e43898fb8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i371ff9f9dd74484bbb7af64395b59cb2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3d53abab674300a3e66f4bbf777a4d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30153c69f900480b8a7b0d198d30b92d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c58c1e89d74a42975680f91f9ea952_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7184f2bd1645489a8e93fd75f730b37a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb927ed78cfd4508b0462135a3c2436f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2701137d4d3d4c4e8e5113cfb9b9bf7d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib379188f80ee457e82a023166eab9d6d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd5ecb234e84849a3ef40071493ded8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c124cc8b22a40b89b467199316812d8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie611da9814584f9980040a27dfc0cff0_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if40d7dc2760c4b73a1bf0f58cb0cea20_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67dda89a221d455f9646b0da9c4929bc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa54545585df44e4b7d3a89233f8dfaf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df208e090e4403eb77e13ead4f86d17_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9d2c51fc9d34a20a514bea566541f46_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015ea6430d994fbc8697ad17d12ffea0_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e3af4b7d2cd45f48969782be08ae91a_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice9190fd4c5e4b23a2cfa99f52b8d06e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316721534e954709ac4ca98fac589f21_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ebc00eafc24ccc9dfc43c74893c366_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd52d29ba82b4fc3a132c9324d52f501_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03957233ce864a5a98dacdf6ed5a459b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5814f76b2747c3bb68d3ded24afaba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734f190a8be94ab0a3e93a4104c4affb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4286168bb23741ed8ede08217b5079cd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i278e1922f5954901947c7da7b025ffda_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idddc6e09a127406fb21bab2cff01e6a3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d49584882e49c39b789667e1aa8b9a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5887d0c8af474b9da60db574f802c013_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd2fc190c9bb4eac8b5f0a896433b557_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided647db41004402b85556f36c1a5a6a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a0f88a3ce248ca80278fd875407820_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f185aabf3c422eb49cc6accab9e6cd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517f238357944a0796854ba08409d69f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad270b4c89440e0821ae038d2cb2389_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b0b2106a50498eb917274f3a68063a_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i665443501e7f49ecae379e80a026aa5e_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f79c7546bc741bfb209ea4731a1b39f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72b00192c39e430cbe5b0b12c9d8d89c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie820aa9d32f54e368d97eb79949bb246_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i877a2547d28941a6974c361f55d0df05_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9d33e85d61e44c4bfd117e7d31fe670_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18a706cafcaf41aab0bf2bbae702174f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d04fb2cb1d2410b8938ae078b9fd516_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6f9d2a8d9b34e2ea5321b0774bc4cd3_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a026aa3a4334726bbd5d5b4169de5ac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i21cd86819fc94d60888b84c9fbec1cd9_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec3b8c8266c54149935b053a4854e949_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01807f2cd89e4e9d84b0e1ec13338d5f_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f3a1555672448da4256c36f647a2ea_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icedd019379624203beb6559637b67e52_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e7893a75ac4fcdbb28b05eddc7e79e_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d94eda0f1e46ba9ba00a785398fb15_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87cb0e785fa74c60b27360b6bae115b5_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8afbb1e24e95451fb3040230f72e3eea_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0efda518e014299bbb43462ac3cc850_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d81161a92ef494db5814266170b94b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida7114209f954433a73b2aa4e6273e7f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaebb9ac802f4499ab5d494233003436d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1ee3d4b0ed4b6d81693a3b78436a98_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a23e83ac0484f0bbab51200be62df4c_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6542b5648ea045f58f4c69b28422077a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd055427f2ee4af697e38e23fd5f01bc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6822798f98d34751ae079338ed021602_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>sesn:period</xbrli:measure></xbrli:unit><xbrli:context id="ia2e62709d9af4f339539c651a584c514_I20220715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0492cdffd25d4cf78dc20d704adfe705_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40d181b700547bea2d9b69343d99848_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60749fcbb0ad4615afcf10b65d11d107_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2ff8e61fcd46c299eab19b8098175a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b71a855e3048d9a5e32abd82f7ed34_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96799ba5a814f0c8caad764cfa9b749_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff51dfb75a942b18163f303609e9cf2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1922ec39f2664925917602d82aac09b7_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i166f7d51c9a04607804af70090d9f047_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33b6c64b39074311ba0d20d253292de1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd9b4c5e3f1a4695a42133604689308c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa9628d22de45f283290aaf3f3b037b_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id693de1f894a4b41bfff465cc3f75051_D20210805-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4b88050bd14031af553100cd13d2ae_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i224d2937076040b695691239c9bdd50d_D20210830-20210830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>sesn:position</xbrli:measure></xbrli:unit><xbrli:context id="i924d818132a640e4bbf0b520aa8af43a_D20220715-20220715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-15</xbrli:startDate><xbrli:endDate>2022-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7f6776eada4e709a71593d6e50e7c4_I20220808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-08</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i90488ba6460948abaea2097aabfb6299_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg3_c2c83ef4-1795-47bc-a72d-3e590f1a7b6f">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6NDJiNWRhYWEyMzczNGVkZWEwMTJjM2FkZmVkMGY3MDAvdGFibGVyYW5nZTo0MmI1ZGFhYTIzNzM0ZWRlYTAxMmMzYWRmZWQwZjcwMF8wLTAtMS0xLTcwMDYw_070370d1-b7c3-4526-9e13-7eefc14a01f4">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xMzY_e35130b5-f828-49ba-9cca-61491bc92709">June&#160;30, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6NmQ5NzMzYjg4NzdjNDRjOTk4NTdlZDY0MTRlNjU1NTAvdGFibGVyYW5nZTo2ZDk3MzNiODg3N2M0NGM5OTg1N2VkNjQxNGU2NTU1MF8wLTAtMS0xLTcwMDYw_2a9401fd-e869-48c0-a486-a9f9a405b295">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from _____ to _____</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTgz_09fe0734-2692-4281-a71c-1cea123274cd">001-36296</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg4_038b90b8-277e-4238-a7c9-068a95489130">Sesen Bio, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6MWFlYTI4M2Q3NTQ3NGI2YThiZDZhYzQ5Mzg1ZTY2NjMvdGFibGVyYW5nZToxYWVhMjgzZDc1NDc0YjZhOGJkNmFjNDkzODVlNjY2M18wLTAtMS0xLTcwMDYw_95f68828-ba34-4e37-bd4a-8ccafc793bf5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6MWFlYTI4M2Q3NTQ3NGI2YThiZDZhYzQ5Mzg1ZTY2NjMvdGFibGVyYW5nZToxYWVhMjgzZDc1NDc0YjZhOGJkNmFjNDkzODVlNjY2M18wLTEtMS0xLTcwMDYw_b9336f1b-283b-445a-9211-9112fcf6e75d">26-2025616</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTAtMS0xLTcwMDYwL3RleHRyZWdpb246OThlODkyOGQ4MmZjNDU2MzkwMjk4NDg5MDEwNGViM2FfNA_16061b1d-bfae-4ad8-8d65-890dd1a725e8">245 First Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTAtMS0xLTcwMDYwL3RleHRyZWdpb246OThlODkyOGQ4MmZjNDU2MzkwMjk4NDg5MDEwNGViM2FfOA_424d16d6-1aae-4e01-acd1-3713bdc67c3b">Suite 1800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTAtMS0xLTcwMDYwL3RleHRyZWdpb246OThlODkyOGQ4MmZjNDU2MzkwMjk4NDg5MDEwNGViM2FfMTE_53852441-c8b5-4445-bc4a-277d9e60974f">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTAtMS0xLTcwMDYwL3RleHRyZWdpb246OThlODkyOGQ4MmZjNDU2MzkwMjk4NDg5MDEwNGViM2FfMTU_1b8712f6-9d51-4f4a-a814-c80b80540b21">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTEtMS0xLTcwMDYw_4eb7b64a-24d4-4e2b-b0d5-aea4f562a86f">02142</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8zNTY_208d6176-4974-4c37-88b1-0ea3b7fd5ca0">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg5_9839d3a3-142b-4f3d-92bb-d52542b28bc2">444-8550</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.472%"><tr><td style="width:1.0%"></td><td style="width:43.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6OWJlZTBhMzJhYWEyNGU2YTk5ZDM5ODM0MDgzODRhYzkvdGFibGVyYW5nZTo5YmVlMGEzMmFhYTI0ZTZhOTlkMzk4MzQwODM4NGFjOV8xLTAtMS0xLTcwMDYw_c4ef3a0f-1feb-4831-9b8b-d1dc49ccff05">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6OWJlZTBhMzJhYWEyNGU2YTk5ZDM5ODM0MDgzODRhYzkvdGFibGVyYW5nZTo5YmVlMGEzMmFhYTI0ZTZhOTlkMzk4MzQwODM4NGFjOV8xLTEtMS0xLTcwMDYw_e88b67ef-e090-414a-8e3c-c91baf7dc28f">SESN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6OWJlZTBhMzJhYWEyNGU2YTk5ZDM5ODM0MDgzODRhYzkvdGFibGVyYW5nZTo5YmVlMGEzMmFhYTI0ZTZhOTlkMzk4MzQwODM4NGFjOV8xLTItMS0xLTcwMDYw_53654ff6-2c2a-464f-9597-e901db2a2153">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg0_1e8dc16a-514a-47c6-b167-e33f3cb123fb">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg1_126974ed-8841-45d0-9279-eff044643ed1">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer," &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.166%"><tr><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YmEzMDNiODA4NzRiNDQ1NmIyNjdmZjI4MGFlNTViNjkvdGFibGVyYW5nZTpiYTMwM2I4MDg3NGI0NDU2YjI2N2ZmMjgwYWU1NWI2OV8wLTAtMS0xLTcwMDYw_371fe01e-f228-47fd-a4a9-3e95dce3ff2c">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YmEzMDNiODA4NzRiNDQ1NmIyNjdmZjI4MGFlNTViNjkvdGFibGVyYW5nZTpiYTMwM2I4MDg3NGI0NDU2YjI2N2ZmMjgwYWU1NWI2OV8wLTMtMS0xLTcwMDYw_edc56ada-a9d7-4777-8aed-8b2a6050ab86">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YmEzMDNiODA4NzRiNDQ1NmIyNjdmZjI4MGFlNTViNjkvdGFibGVyYW5nZTpiYTMwM2I4MDg3NGI0NDU2YjI2N2ZmMjgwYWU1NWI2OV8xLTMtMS0xLTcwMDYw_615994a7-24d3-4950-a29a-bd6c3667f505">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTkx_b10542f8-9336-46d6-af57-c5b81260c99d">&#9746;</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="ia29b4bcc98fb446586c8d0938f7a6cdf_I20220801" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTE4_b97523c4-8b2f-4c64-948d-a11d4a2d8313">199,463,645</ix:nonFraction> shares of the registrant's common stock outstanding as of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;1, 2022</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i90488ba6460948abaea2097aabfb6299_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Report on Form 10-Q for the Quarterly Period Ended June&#160;30, 2022</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I - FINANCIAL INFORMATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets as of June&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June&#160;30, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June&#160;30, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_985">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June&#160;30, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;June&#160;30, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_85">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_103">4</a><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_103">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_106">41</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II - OTHER INFORMATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_112">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_115">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities and Use of Proceeds.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_118">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_118">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_118">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_118">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_121">46</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i90488ba6460948abaea2097aabfb6299_124">SIGNATURES</a></span></div></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i90488ba6460948abaea2097aabfb6299_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i90488ba6460948abaea2097aabfb6299_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements</span></div><div id="i90488ba6460948abaea2097aabfb6299_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except share and per share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMy0xLTEtMS03MDA2MA_3dafca32-0f32-4b30-a799-d122a1c9bbe9">72,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMy0zLTEtMS03MDA2MA_5bbce7e2-d4d7-487a-94a2-6c5e4eed910a">162,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNC0xLTEtMS03Njk0Ng_8d11abd3-5470-4aaa-bd10-300f0f1ad3a0">69,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNC0zLTEtMS03Njk0Ng_63a8efc2-8da9-47a2-a7ca-d6d2066b22c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNC0xLTEtMS03MDA2MA_0f317f1d-beb0-4537-bd58-e65659a6efa1">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNC0zLTEtMS03MDA2MA_b9944da8-9646-4aae-b412-9972f91c917e">21,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNS0xLTEtMS03MDA2MA_72d62aa7-5a0e-476a-a7f7-e22da2f83d46">14,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNS0zLTEtMS03MDA2MA_d8ca2ce1-933c-4019-81b2-14e898f84c45">3,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNi0xLTEtMS03MDA2MA_5bf177ec-b02c-4b5a-b59d-6349dad78a2e">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNi0zLTEtMS03MDA2MA_a29e7a13-1e5a-4f3f-a42b-fb5b84474ba0">18,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfOC0xLTEtMS03MDA2MA_5f3514b4-6e9b-43cf-ba43-a23de3f75708">156,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfOC0zLTEtMS03MDA2MA_2d04c6df-5377-417b-8f92-4c17ae479212">205,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTEtMS0xLTEtNzAwNjA_3e79bb3e-9b6c-43b0-ab47-06bf7aa36586">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTEtMy0xLTEtNzAwNjA_a89cd406-0136-4696-9ed6-bf1834903f2f">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTItMS0xLTEtNzQwNTA_6986f132-8153-40d1-b718-b39c63a15d71">19,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTItMy0xLTEtNzQwNTM_e9599499-9bfa-4026-b3a4-d922bb18c894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTItMS0xLTEtNzAwNjA_b4869669-e7ae-47ac-8011-79ad650b4241">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTItMy0xLTEtNzAwNjA_6c15b82c-8287-45b6-af9e-314419edfe98">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTMtMS0xLTEtNzAwNjA_f8af27a0-7afa-475f-8ab6-fbb07e5dfbf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTMtMy0xLTEtNzAwNjA_473e1204-d2cd-4300-9a78-fe8388d8fd97">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTQtMS0xLTEtNzAwNjA_db1a6657-223a-4af9-b287-85b26ff75bc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTQtMy0xLTEtNzAwNjA_823635d4-e80e-4e7f-ab7a-277062277ad6">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTUtMS0xLTEtNzAwNjA_fd472c4e-9127-4f67-9ed3-deb93a18af10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTUtMy0xLTEtNzAwNjA_d7a30136-1ebc-4f11-a853-81ad0039a6b9">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTYtMS0xLTEtNzAwNjA_33f64a72-03d1-4e7f-83bc-95090d368003">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTYtMy0xLTEtNzAwNjA_04759891-8688-4e26-b2f9-8582f73fb165">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTctMS0xLTEtNzAwNjA_f3bc0116-205c-44e9-9829-1f291eb04d58">19,743</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTctMy0xLTEtNzAwNjA_0fc44751-229d-42fd-add7-b19708297a94">35,142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTgtMS0xLTEtNzAwNjA_eb190a55-f8ef-4da4-9cd5-f40b8200db4c">176,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTgtMy0xLTEtNzAwNjA_cebb7f8c-fe16-4578-900f-1957b5ceb1f9">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjItMS0xLTEtNzAwNjA_3427aa13-320c-40df-9eed-5db8a3088a69">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjItMy0xLTEtNzAwNjA_684ccd0d-9222-4338-8fc8-f898322010f2">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjMtMS0xLTEtNzAwNjA_aef5b72c-3daa-450e-bbc9-a6ac76f668a5">29,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjMtMy0xLTEtNzAwNjA_e4c06892-3874-4286-8c00-303fc79005ad">8,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjYtMS0xLTEtNzAwNjA_d5c81e3e-d367-47c1-bdcf-98da0640a53a">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjYtMy0xLTEtNzAwNjA_d096286b-2f83-43eb-bd9d-fde1cf793b4d">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjctMS0xLTEtNzAwNjA_024ee76c-2267-47c1-8fe6-ee911d3e1a32">32,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjctMy0xLTEtNzAwNjA_bad692fe-88a9-4ae2-a946-4fd2c5c36375">11,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzAtMS0xLTEtNzAwNjA_dc501500-e130-4c11-9e82-79fb9cbcd0e8">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzAtMy0xLTEtNzAwNjA_c3e178e9-6b15-4d09-8f14-0a7d4f7941e0">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzEtMS0xLTEtNzAwNjA_773685a0-c74c-40e4-9018-25968d9dcd7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzEtMy0xLTEtNzAwNjA_84e86509-9800-4cad-95f6-e4feba822d7b">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzItMS0xLTEtNzAwNjA_831a6262-b720-4d3e-a163-be31bdcf1cec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzItMy0xLTEtNzAwNjA_70a58daf-2e72-48af-a251-4a48acafd15f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzQtMS0xLTEtNzAwNjA_0ed5fc48-0f7c-4675-82e9-579b1991b463">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzQtMy0xLTEtNzAwNjA_c188ac02-d038-4f2f-9996-d519fe7f29c0">57,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzUtMS0xLTEtNzAwNjA_4a552dad-38b7-4fd0-8d7f-bf9ac17f756a">33,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzUtMy0xLTEtNzAwNjA_be5e9844-2328-4b40-9d53-6f05b5027f36">69,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl8yMQ_511139a2-0427-46d9-a451-1740cdeda5df"><ix:nonFraction unitRef="usdPerShare" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl8yMQ_6c3ef609-086a-483e-9853-756874251500">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl80NQ_a31a2599-3f6a-4bdf-8954-43a9aca359e5"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl80NQ_c464c08f-f0f7-4caa-a1ad-0bc80d0a319c">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl84MA_200c48fc-023d-4818-a05b-e13077bae98a"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl84MA_643fc72a-867a-4bd5-8ceb-5c0dbb259631"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl84MA_bcb3137d-32b2-47e6-a889-dc316ba79d96"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl84MA_c012d034-1b5f-43ff-a7be-80e1b8c5ef5a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMS0xLTEtNzAwNjA_02a06a2e-41a0-42ae-9cf0-f6a2bfa969ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMy0xLTEtNzAwNjA_a98ce850-1cf1-4180-8731-1628ff5d4cc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml8xOA_3042d888-9b2d-486f-912d-b3fe6dcedeb4"><ix:nonFraction unitRef="usdPerShare" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml8xOA_8766cef8-23cf-420d-92f0-2a94b61fc1fb">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml80Mg_66245f72-8839-4e3e-baef-cbb0f7410e3e"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml80Mg_856d25df-0abe-4581-af72-1d8b6f3e6713">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml83Nw_752b67a1-ecc2-458b-812d-77b5a2033449"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml83Nw_a5ea1609-cf54-4be7-b3cd-00fc2593415d"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml83Nw_b0162653-31f5-45e7-958d-c100ffe24751"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml83Nw_e05c1f29-3c13-4029-adce-9bd77ab4565d">199,463,645</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMS0xLTEtNzAwNjA_8e67d72e-db7d-4c72-a7a9-ac8d2a66564d">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMy0xLTEtNzAwNjA_6f69f6f8-61bc-4c83-8ae6-fffcdf318207">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDAtMS0xLTEtNzAwNjA_ab0a0c39-6f8d-4e08-9182-fbd51bf4166a">491,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDAtMy0xLTEtNzAwNjA_cc185670-815b-43d2-89e8-4ba4015b2a04">487,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDMtMS0xLTEtNzg0NDY_b6536bc5-41c2-4152-8edc-8bf2ba60e6e8">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDMtMy0xLTEtNzg0NDY_b203e266-cfca-4a8a-b9eb-351f35f360be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDEtMS0xLTEtNzAwNjA_11e5ae41-8348-48a5-8394-d21132593ad0">349,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDEtMy0xLTEtNzAwNjA_54795ca4-2746-487b-ae2c-2099e48a8ca7">316,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDItMS0xLTEtNzAwNjA_4833c746-b21a-42f0-a093-d7015a2d8409">142,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDItMy0xLTEtNzAwNjA_3b052a93-c051-4d08-bbf2-1526e2756cff">171,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDMtMS0xLTEtNzAwNjA_ef24a8ef-603d-48f3-afba-0f19b537badb">176,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDMtMy0xLTEtNzAwNjA_287796d0-04d5-473c-9593-fa16f2b0544f">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i90488ba6460948abaea2097aabfb6299_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:55.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_12b4d2e7-50cf-486e-9f55-531f61e9b030"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_31abd46a-5b00-4492-b73c-c6d432a04ad5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_481dba29-3a20-4f06-a044-73c8436545ee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_897ed270-6cb7-4b09-83f1-a713e11dbc4b">License and related revenue</span></span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0xLTEtMS03MDA2MA_959d152a-6ede-4add-a2fa-76d8bb10b616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0zLTEtMS03MDA2MA_70ea6784-40c3-49a7-b831-2badecc3e3d6">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC01LTEtMS03MDkyNQ_b75350d5-b2f4-4b77-9de3-24277a43ce3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC03LTEtMS03MDkyNQ_ae74f260-b467-415b-ae9a-55cce06f8361">6,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNS0xLTEtMS03MDA2MA_2ad50d83-60c7-4b6b-b6de-d866403401e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNS0zLTEtMS03MDA2MA_31672ca6-8776-4828-92e2-1ecd8540a23f">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNS01LTEtMS03MjUwMA_8e5f5cb9-0d57-4821-a274-ed780a39bcf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNS03LTEtMS03MjUwMA_02f6fbcd-5fca-4a0c-9c66-4093b6387805">6,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOC0xLTEtMS03MDA2MA_b8bdd652-6ebe-47da-942c-3dc70729c7b0">29,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOC0zLTEtMS03MDA2MA_a562fe03-dd69-42f4-9673-6405561e252e">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOC01LTEtMS03MDkzNA_180ff0bd-dfa2-4182-b9b2-194952aefd2a">34,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOC03LTEtMS03MDkzNA_aca34931-382b-48dc-88bf-fd85803cb8ad">13,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOS0xLTEtMS03MDA2MA_50f02178-cd97-45a4-962b-99977b7f5785">15,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOS0zLTEtMS03MDA2MA_c02d4b04-c2e3-4ef7-8257-5cd248794e7b">6,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOS01LTEtMS03MDkzNA_7ea578f9-8fbb-439d-bd2f-6443c79a6415">24,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOS03LTEtMS03MDkzNA_393080f5-e85f-4bf9-9bcd-04e7261a3fa8">12,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTEtMS0xLTEtNzAwNjA_2e8afabf-f029-4d4d-89cd-900e598d70da">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTEtMy0xLTEtNzAwNjA_05043c3a-e292-4bd2-aa60-c14ee952c208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTEtNS0xLTEtNzUyMjM_b14f5220-5153-42e0-bbe6-79cb8589be34">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTEtNy0xLTEtNzUyMjM_21cccc07-0cdd-49d4-bea4-5809114b6e3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTItMS0xLTEtNzAwNjA_6e46e45a-5b61-4a94-aa23-337aaebad46d">37,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTItMy0xLTEtNzAwNjA_d84769e4-d0a6-4682-a6a4-114faee01fa8">13,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTItNS0xLTEtNzA5NDE_279280c2-eb4e-44d9-8aac-50b3c97f0b4e">50,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTItNy0xLTEtNzA5NDE_ad2bbe31-97f1-4eb7-bda0-0f56c01c7ea7">61,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTMtMS0xLTEtNzAwNjA_1d154794-2d38-44d2-a90d-1aaaa0bbb54d">35,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTMtMy0xLTEtNzAwNjA_e626511c-40f1-4f21-9986-cd0fa1200e90">27,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTMtNS0xLTEtNzI1MDA_feba90a9-9a11-4a7d-be86-2e27602a0d0b">36,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTMtNy0xLTEtNzI1MDA_6980c24a-d3d5-418d-90f6-9bfd42f0ef04">87,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTUtMS0xLTEtNzAwNjA_c30f46e0-36c2-438e-b77b-62d0d6415be4">35,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTUtMy0xLTEtNzAwNjA_9c347fe0-c4c2-4fe0-9374-4eb07c7ffe70">25,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTUtNS0xLTEtNzA5NDY_c1230777-9d48-429f-8900-ad4dcd16eca8">36,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTUtNy0xLTEtNzA5NDY_44b09389-5020-47ae-9255-3e62711e3960">80,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTYtMS0xLTEtNzAwNjA_bf1a9eb3-ec8a-4670-aa02-25b17e10423e">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTYtMy0xLTEtNzAwNjA_cb735712-d192-4cde-8316-43977982a315">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTYtNS0xLTEtNzA5NDY_174a2b8c-91c8-40a9-be00-dcd5f224f248">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTYtNy0xLTEtNzA5NDY_f8bf3ef5-80eb-49b7-98e7-3559f278ab20">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTctMS0xLTEtNzAwNjA_4a8226a1-02f7-4d79-8818-ffddc0af247a">35,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTctMy0xLTEtNzAwNjA_0e2aa015-774f-4c7b-9e18-9a82dbd3fa55">25,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTctNS0xLTEtNzI1MDA_64e3a29e-6915-4183-b4d8-337f91c2b8d8">36,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTctNy0xLTEtNzI1MDA_98da88d2-3ebf-4a94-a601-d30ea1125429">80,666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTgtMS0xLTEtNzAwNjA_6a063a21-d3cc-4f22-805b-f2236810de4f">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTgtMy0xLTEtNzAwNjA_a625607d-d989-46db-af4f-f147edf0b923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTgtNS0xLTEtNzA5NTY_0bf0c043-6ed1-4030-b423-bcdbbd528eb5">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTgtNy0xLTEtNzA5NTY_00e3d02c-6833-4bf9-bd48-e3e56b0f692f">288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss After Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTktMS0xLTEtNzAwNjA_79c4cb55-8cf8-4437-badf-08d6432ce31b">31,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTktMy0xLTEtNzAwNjA_35633ca1-cfa6-4e20-9fbd-3a0b027f386e">25,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTktNS0xLTEtNzI1MDI_aa40bf07-3af3-4403-bee0-b9eacc4fd57b">32,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTktNy0xLTEtNzI1MDI_00191262-547e-44a0-bd18-2d3f7daa26d1">80,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtMS0xLTEtNzAwNjA_baf60690-574d-461a-b8a5-1be0f3ac83a2"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtMS0xLTEtNzAwNjA_d0e58ffa-94ec-4040-905e-3f35cbd8d298">31,960</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtMy0xLTEtNzAwNjA_0b4daf31-d484-45f2-a0c7-2b394b7a79c1"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtMy0xLTEtNzAwNjA_a30cace2-2f67-425a-b617-5eec4d9dc945">25,442</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtNS0xLTEtNzA5NzA_00e13b88-4e62-47c1-b3c4-6efd17d91bfd"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtNS0xLTEtNzA5NzA_b029def3-f78e-4a5c-9b49-58979b050607">32,767</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtNy0xLTEtNzA5NzA_162e0c5a-8572-4544-b59d-b38378abeaa0"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtNy0xLTEtNzA5NzA_675b5b70-8467-4972-9cd8-de59c772509f">80,954</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtMS0xLTEtNzAwNjA_034a56f4-a697-4e34-bc19-9f43b1802dd2"><ix:nonFraction unitRef="usdPerShare" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtMS0xLTEtNzAwNjA_bed63fad-41b6-4bde-a35b-dc2537481970">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtMy0xLTEtNzAwNjA_88ef3fbe-eaf2-4cc5-9749-b30bc0e727cb"><ix:nonFraction unitRef="usdPerShare" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtMy0xLTEtNzAwNjA_d13e9da2-4eee-42c6-8153-3c762280ae9a">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtNS0xLTEtNzI1MDI_cfb30eaf-0adb-4dbc-a712-1e72c2ed88dd"><ix:nonFraction unitRef="usdPerShare" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtNS0xLTEtNzI1MDI_fa687fc9-a361-4c17-b850-bf1339c7a06d">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtNy0xLTEtNzI1MDI_8c0793d7-61b0-4163-b3ec-a62e6c141eb8"><ix:nonFraction unitRef="usdPerShare" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtNy0xLTEtNzI1MDI_bb1bbac7-3a8f-467d-8911-bfa0aea2efe0">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtMS0xLTEtNzAwNjA_6d44f531-0b23-48a3-88cb-ba433933e791"><ix:nonFraction unitRef="shares" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtMS0xLTEtNzAwNjA_d8ba8be1-9dca-49c8-8d83-35a141b5949a">199,464</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtMy0xLTEtNzAwNjA_0bc76b6b-e26a-4ffd-8914-a5c4c4dd243c"><ix:nonFraction unitRef="shares" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtMy0xLTEtNzAwNjA_0d238d41-0ff9-4841-a5f4-cc162d35de79">175,393</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtNS0xLTEtNzA5OTA_a3850f09-ba38-40e4-be36-107af52d9f46"><ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtNS0xLTEtNzA5OTA_d840cf2d-0031-4b0b-bdba-1a45136f67a4">199,464</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtNy0xLTEtNzA5OTA_00cb87b0-408f-46d6-bb5a-32506801615a"><ix:nonFraction unitRef="shares" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtNy0xLTEtNzA5OTA_d427fe75-f57c-43c2-8686-17be12918159">166,264</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i90488ba6460948abaea2097aabfb6299_985"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except per share data)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:55.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzMtMS0xLTEtNzk3NTU_92daea97-f122-4fe2-9ed0-febe0ef3c17e">31,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzMtMy0xLTEtNzk3NTU_6b7bd309-4842-4c1d-b9a3-a28ade3157e1">25,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzMtNS0xLTEtNzk3NTU_2686909f-c359-4746-9706-7259c6347bec">32,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzMtNy0xLTEtNzk3NTU_7ccaabe1-a510-4852-97ff-971e2f63ba78">80,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzQtMS0xLTEtNzk3NTU_775fb7a8-301d-4993-9aa8-ac9216951503">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzQtMy0xLTEtNzk3NTU_12a37321-c025-42a9-81a3-3b10b9971afd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzQtNS0xLTEtNzk3NTU_eddde06a-bb32-4192-bc8e-9343825df878">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzQtNy0xLTEtNzk3NTU_c9531cc8-9e6b-4c3e-9703-0deca8637dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzUtMS0xLTEtNzk3NTU_5a626cdb-b77d-4f8a-9b5f-3d83e39c0743">32,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzUtMy0xLTEtNzk3NTU_603447ae-93e0-4883-b923-b0ae931429ab">25,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzUtNS0xLTEtNzk3NTU_144e8fb3-0aad-4a80-bbd1-a556fa5152b2">33,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzUtNy0xLTEtNzk3NTU_6a660a93-740b-4070-9e50-8e195bb16561">80,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i90488ba6460948abaea2097aabfb6299_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae6d8077dece4a95940087e255f75bc6_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi0xLTEtMS03MDA2MA_e0f5e36a-d69f-41ed-8ba0-77d57d7fbf75">199,463,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6d8077dece4a95940087e255f75bc6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi0zLTEtMS03MDA2MA_2daf1b5e-961d-4b65-b3ce-353ec3502f2f">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345971d52bde416886e88795d548811c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi01LTEtMS03MDA2MA_67566b37-86d9-4796-9b93-e2f250642be9">487,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i677b1480fd064f218483dcf37f0aa72c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi03LTEtMS03NDY1NA_bf399817-56d6-4f7b-9dce-c4db962776d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i084e153e02ad4c0fbdaeba8fea7f0792_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi03LTEtMS03MDA2MA_ed31d187-62df-4d97-9512-feb61a4a55d1">316,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi05LTEtMS03MDA2MA_5d0147f6-c4c3-4d5f-a774-b44bc4c221e7">171,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814ff665c79642eb9c63201f9f6aa4c3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMy03LTEtMS03MDA2MA_94b6692f-fd49-4ad4-907a-a9b08dfd0bd9">807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie970ce934b1e4c17b1f8e5435783799b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMy05LTEtMS03MDA2MA_c9b30e32-95e2-4694-9b64-369dd00b480d">807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba13d9d0682407bb0b32862ba63462c_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfNC01LTEtMS03MDA2MA_78b0fe6e-b035-4929-8ac1-c8607958ebcb">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie970ce934b1e4c17b1f8e5435783799b_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfNC05LTEtMS03MDA2MA_205923e5-83d0-4d02-8eb0-afcb9446acbb">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c99c9b6effb411d93633cf284df66a8_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtMS0xLTEtNzAwNjA_003d34e5-f7bf-41d9-b25b-7224c05a0185">199,463,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c99c9b6effb411d93633cf284df66a8_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtMy0xLTEtNzAwNjA_2f31a680-5134-4072-80e9-67fdffda15e3">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ecaf1deb82450595375aa26194263c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtNS0xLTEtNzAwNjA_5b3d98f4-17f0-4500-be29-9aeb32e4adfd">489,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8643db175ec94af8835005bd348c2a15_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtNy0xLTEtNzU3NjE_799aca37-47a8-47e0-a16a-bdc289af3a37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d91c72b3c9a48f698faa963f06f6585_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtNy0xLTEtNzAwNjA_fc33628a-7d31-46bd-8d16-5551acedcd28">317,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i788239f286ce4a7aaf34d9b6448f7b19_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtOS0xLTEtNzAwNjA_2828ab42-c157-4502-8869-26a6b75abfe8">172,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbdee19feaf04f8eb7b2e7516c8272ba_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTEtNy0xLTEtNzEwMzc_769864db-5462-4807-a93c-981054ed97a3">31,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTEtOS0xLTEtNzI1MTQ_22f1d6eb-1988-4fee-8082-34a8ae5decb5">31,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cbf3dbf085a4f5aa6d333be0b69cc50_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTItNS0xLTEtNzEwMzc_643efa1b-d837-45e5-bdf0-3362680c2245">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTItOS0xLTEtNzI1MTQ_a33c04b0-84d2-4718-a646-384e8d0d32da">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5331cf0a882c45b18c3f7c5cdd34d580_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNy0xLTEtNzYyNjI_cf427b31-63a6-4f1e-8cd8-eaf6be64804d">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMTEtMS0xLTc2NjQ5_ad5cf1c6-39b9-43f8-9ed7-0b38c331d9fb">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ba7a3599765459e9e5050731fd4dcd0_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMS0xLTEtNzI1MjI_cfc6a47d-f346-4a38-86dd-b04259de3001">199,463,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba7a3599765459e9e5050731fd4dcd0_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMy0xLTEtNzI1MjI_289cfdfa-b2c0-41c5-9abe-ef6ebeb66c30">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea6d35dc5474aa581a55e2b57ae57c6_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNS0xLTEtNzI1MjI_0c33c49f-1cf4-4f81-a01d-c7583b965330">491,464</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212d6b0e7fc04d0bb334aee4c3d885fb_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNy0xLTEtNzQ2NjA_6d965c66-3579-4b3d-a37e-9dbe628907c6">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic90e014d0d0846a6a6300ee56057382d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNy0xLTEtNzI1MjI_49204c58-dc79-4fa6-b417-98177de6b2c9">349,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtOS0xLTEtNzI1MjI_e7e3bbfc-34f8-4bad-bb8e-f51f5d67108f">142,358</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:38pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0b29b8876ac49d4ada09cbcefec48ec_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMS0xLTEtNzAwNjA_d02bab12-fd69-4673-9c00-f983f3cf85b3">140,449,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b29b8876ac49d4ada09cbcefec48ec_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMy0xLTEtNzAwNjA_2fa2e163-17e9-4ca3-9dba-6fed97f6368b">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb5504ef7a4410cbd3d49b7bc9eac22_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNS0xLTEtNzAwNjA_4f3e070b-5a0d-4812-9b7b-5ddcc15e6b5e">306,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b04bc3e3454a688ae44dcb39bfc41e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTgtNy0xLTEtNzQ3MTg_38389b96-ccd2-486f-8752-3b19656e6af9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e8644b1d6b1492195108a81bd629611_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNy0xLTEtNzAwNjA_0cdc2c4e-d89e-4eee-803c-9bb83f3cdc11">315,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0208600fe4024d29a9aa9d6917193edb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtOS0xLTEtNzAwNjA_903d3f30-e2fb-44fa-990e-88e78be48070">9,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50a087530030427d9767a04597f4120d_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTUtNy0xLTEtNzAwNjA_00c704bf-bb45-4785-b827-340414ad97f2">55,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTUtOS0xLTEtNzAwNjA_c91726b9-2a18-4638-87fa-d4c9c9e4ef2c">55,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2d58ed494f4424abbfc10d0ab04193_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTYtNS0xLTEtNzAwNjA_2fd4ad69-69e4-4b97-a850-8b4867a1cf3f">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTYtOS0xLTEtNzAwNjA_e9cb5872-8739-4c3c-b29c-503fed6e44fb">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f839115e09747288556177ec1208f7c_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTctMS0xLTEtNzAwNjA_6fc255a1-a806-43c6-a185-461f306454a7">30,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2d58ed494f4424abbfc10d0ab04193_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTctNS0xLTEtNzAwNjA_4d2ea9bc-ba04-49a7-8c67-e4d468d119a0">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTctOS0xLTEtNzAwNjA_7f9e2b0a-0ebf-4a3a-a6f7-d85325341e4d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f839115e09747288556177ec1208f7c_D20210101-20210331" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTktMS0xLTEtNzAwNjA_be7d1544-d7eb-46ef-b48d-ada93af9d6e6">852,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f839115e09747288556177ec1208f7c_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTktMy0xLTEtNzAwNjA_be6c051b-433a-4a0e-9410-7a7b0eb7e10e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2d58ed494f4424abbfc10d0ab04193_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTktNS0xLTEtNzAwNjA_77ee5fff-8d0f-41fd-bf9a-8a7ce637dff5">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTktOS0xLTEtNzAwNjA_3707dab1-e349-4ee6-8969-04ac4ac1f305">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjpjY2Y0NjU0OWFlZjk0OGY2OWFkYWE1YzI5OTIxZDk1Ml8xMDk5NTExNjI3ODYx_02129dc6-dfa9-443f-a5bc-504db2fb5849">2.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie063900bace246ea9ac9229220ed605a_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtMS0xLTEtNzAwNjA_abf168d4-dd1b-41b8-90f5-bae5a04610b2">30,645,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie063900bace246ea9ac9229220ed605a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtMy0xLTEtNzAwNjA_2d72f29b-3526-4c72-b69e-a0f8bbeeaa2c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a952d29209497aa9e963b66ddf48ba_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtNS0xLTEtNzAwNjA_c3fd49da-ab37-4f0f-ba4b-2aa9c4410729">72,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtOS0xLTEtNzAwNjA_998497db-c5b5-41d0-9e3e-2577010039aa">72,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id06576b00b094f1a849c81ba939934c9_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtMS0xLTEtNzAwNjA_f3f541dd-283c-4201-a1f8-784cabec3fc3">171,978,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06576b00b094f1a849c81ba939934c9_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtMy0xLTEtNzAwNjA_1c2df08a-cd33-40e4-a10f-afd3407784f4">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691732dc107c4eb19beb797b845714a5_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtNS0xLTEtNzAwNjA_002b5bc0-bc17-4ef8-a426-c7f4d2806a18">380,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e1c1185b384bb9b9a302d5f694d2b8_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjUtNy0xLTEtNzU3NjQ_950ed899-2701-47bf-9800-54af478fa409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84f292f26d18474a88618593f2028cde_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtNy0xLTEtNzAwNjA_6e563804-6bc7-4ff7-9512-d35e164590b4">371,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4548660807654ebfad44b93c626bb154_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtOS0xLTEtNzAwNjA_6a06e793-25c8-4dc6-ad71-f4964412dbd4">9,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1e1083313744230858402ce1024fb35_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjYtNy0xLTEtNzExMDA_7a61ba20-5e1d-40ad-a159-cc585d708060">25,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjYtOS0xLTEtNzI1MTc_6b7683fe-5c1e-46bb-b813-ebb03d5a9577">25,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc68b87db60469baad7a2624334af31_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjctNS0xLTEtNzExMDA_08832eb7-4976-47cf-a81a-7d667dbc6f24">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjctOS0xLTEtNzI1MTc_616d0efa-2179-42f6-9b7e-ab36172ad711">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtMC0xLTEtNzEwOTMvdGV4dHJlZ2lvbjpiZWVkMGM5YmM0Yzc0MDAzYjNhNDljM2ViNWY2NzBiYV8xMDk5NTExNjI4MDMz_d993b6d3-8387-43b3-9a42-bc0f1bc3c72b">2.0</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ca4bd64eb504b02826a9652e4a84714_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtMS0xLTEtNzExMDA_27395baa-4916-4533-a878-1cceb20ce1e9">16,482,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca4bd64eb504b02826a9652e4a84714_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtMy0xLTEtNzExMDA_4372b299-0378-469a-bc52-1a2562a986fc">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a7b16d33054ed2bb2f3e95123e6d0c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtNS0xLTEtNzExMDA_80010d2c-df90-4aa2-b65e-19f5e231660f">64,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ddf69ac8bf84700b67bf4be374a19f5_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtOS0xLTEtNzI1MjA_6cda305e-79ec-4ee0-a497-d41ca1f164c3">64,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i791f0580873d401f8150577ee2f295da_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktMS0xLTEtNzI1MjA_2ba5a1c9-d849-45b2-bd59-1db801a6a7d6">188,460,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791f0580873d401f8150577ee2f295da_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktMy0xLTEtNzI1MjA_745c02e0-7970-42ee-b254-6cdabc4bd091">188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927224fa40114d4e9fa1b0f9ea67129d_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktNS0xLTEtNzI1MjA_cbeafb36-3fa1-4985-a860-b3dd567d3503">446,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf9ab52935a412db213d105924c9a17_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktNy0xLTEtNzU3NjQ_2668d847-5f7b-498e-b501-558b41228ea8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1375cc14b49437b91d5bbba570298c2_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktNy0xLTEtNzI1MjA_6834822d-3eab-49b4-ab50-dc59ea22a533">396,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3dde4b5cd0247c48f35a95c8521f4b9_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktOS0xLTEtNzI1MjA_4963352c-2901-462a-8e44-a2cc67338fb5">49,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i90488ba6460948abaea2097aabfb6299_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMy0xLTEtMS03MDA2MA_b6d33bcf-e74e-45d0-846e-257dcb254899">32,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMy0zLTEtMS03MDA2MA_58ffa1d0-67bd-4c45-a022-22b23dcba7af">80,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNS0xLTEtMS03MDA2MA_66e1e7cc-bfb3-4256-967c-ca175646cf63">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNS0zLTEtMS03MDA2MA_073f8ecf-e261-4fa9-8128-1d0858d71849">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNi0xLTEtMS03MDA2MA_59beb4d2-1f4d-457d-90d1-503fb92c90fe">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNi0zLTEtMS03MDA2MA_a6ee63d8-b948-40eb-bbc5-fc91b78a6512">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNy0xLTEtMS03MDA2MA_279280c2-eb4e-44d9-8aac-50b3c97f0b4e">50,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNy0zLTEtMS03MDA2MA_ad2bbe31-97f1-4eb7-bda0-0f56c01c7ea7">61,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfOS0xLTEtMS03MDA2MA_e556a6a2-152a-4064-a202-cb98f3382dc5">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfOS0zLTEtMS03MDA2MA_f294d89a-ff8b-4cc7-8219-acd6b8af0053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTEtMS0xLTEtNzAwNjA_bc1672a0-c790-49a1-a700-b3cd45df92d5">20,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTEtMy0xLTEtNzAwNjA_677ae23d-6866-4ad2-a8d8-3d27420eaf59">2,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTItMS0xLTEtNzAwNjA_7af36498-4bfc-4931-bdaa-9004cc362446">10,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTItMy0xLTEtNzAwNjA_9c556a55-e5fb-4eb7-97ea-5125e927bb93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTMtMS0xLTEtNzAwNjA_f2656187-c99c-4756-a668-b77ef9a4f56b">17,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTMtMy0xLTEtNzAwNjA_fed439b9-1225-405a-9138-4778941496d1">20,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTQtMS0xLTEtNzAwNjA_59b98267-8eb3-41f0-8614-956884cf852e">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTQtMy0xLTEtNzAwNjA_648f54ea-f515-414c-94af-396c8991cad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTUtMS0xLTEtNzAwNjA_9c22230d-d96f-4ac3-897c-11d52fc92bb5">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTUtMy0xLTEtNzAwNjA_17a47bd4-d9a5-4e25-b80a-0443da8086e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTYtMS0xLTEtNzQ1Mzk_a098ca98-3e9a-4e9c-85e0-fdb51b8c4f45">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTYtMy0xLTEtNzQ1Mzk_0204e2ab-e063-463b-b089-40ee02a74ff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTctMS0xLTEtNzAwNjA_613b5474-c794-4564-bfbd-9f50e2133bf2">1,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTctMy0xLTEtNzAwNjA_831d6beb-1b15-41a0-b51c-135d502054a7">1,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTgtMS0xLTEtNzAwNjA_d8452813-e961-4bbd-a69c-b879751914e1">17,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTgtMy0xLTEtNzAwNjA_7a723ea0-8a24-40bf-a67d-c411e6926f34">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTktMS0xLTEtNzAwNjA_1d7e6fcc-b246-4545-8ca5-15c7d66e0f48">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTktMy0xLTEtNzAwNjA_40ba5e98-cb2f-47b2-8e3a-27bae0eb81f8">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjAtMS0xLTEtNzAwNjA_efdf25c9-0afd-4bee-8e5e-5a2c78084e6a">1,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjAtMy0xLTEtNzAwNjA_cd0a6af1-83fe-4a52-a00f-abf8c4b45100">41,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjMtMS0xLTEtODAwNDM_59df365f-5e4c-405f-9908-8b0640f32b4d">89,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjMtMy0xLTEtODAwNDM_8face984-6365-47af-867a-00c3b7458cc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjItMS0xLTEtNzAwNjA_9ca10c8f-ffa9-432c-ae0f-5e65826ae827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjItMy0xLTEtNzAwNjA_2cb7d95e-8cdd-4019-b34e-e7b59cb50552">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjMtMS0xLTEtNzAwNjA_cf1df462-ef5c-47ed-b07d-347692fb11a4">89,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjMtMy0xLTEtNzAwNjA_1da10b99-d68c-4a60-b807-dd947a51f5ae">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM Offering, net of<br/>issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjYtMS0xLTEtNzAwNjA_66c447d2-1a14-4d31-b71f-bc892f425e71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjYtMy0xLTEtNzAwNjA_30691f16-f005-481d-a845-7bca134e8371">136,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjctMS0xLTEtNzAwNjA_2d90bdd9-d506-4ecf-b360-3e441fe38484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjctMy0xLTEtNzAwNjA_f8138acd-3120-4a8f-a615-9a643f8d790c">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjgtMS0xLTEtNzAwNjA_e15561b1-c9e5-477f-a76e-8022111810ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjgtMy0xLTEtNzAwNjA_1ec870f6-2cb1-4846-83c8-0898e2b01b04">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzAtMS0xLTEtNzAwNjA_e33ab4dd-3e19-4955-b6af-a91b968c12e0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzAtMy0xLTEtNzAwNjA_0bbdd6c1-7d6d-4fdd-a025-1c37c5681718">137,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzEtMS0xLTEtNzAwNjA_fe5f4950-1792-48a7-b405-5d142276855d">90,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzEtMy0xLTEtNzAwNjA_f818fab4-1eee-413e-a474-bec7ad56e4bf">95,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzItMS0xLTEtNzAwNjA_b7305d25-11b5-416c-b110-d5ad7ecf0a32">162,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0208600fe4024d29a9aa9d6917193edb_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzItMy0xLTEtNzAwNjA_9408ba98-bc19-4bec-b104-940104d5fd56">55,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzMtMS0xLTEtNzAwNjA_d3cb76e0-f333-4a17-9a57-36c39f66ce75">72,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3dde4b5cd0247c48f35a95c8521f4b9_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzMtMy0xLTEtNzAwNjA_ca2f95a9-bad0-48cc-8dab-84ca736d4d7d">151,056</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental cash flow disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzYtMS0xLTEtNzAwNjA_9fea9eb1-1f2a-43e2-8b42-6c141d7d8868">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzYtMy0xLTEtNzAwNjA_f095e2dd-cf97-4dd5-b94a-6efb97c6eb8d">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of equipment included in accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNDAtMS0xLTEtNzAwNjA_b67ef5d1-caed-4417-a0b4-e63debe7afbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNDAtMy0xLTEtNzAwNjA_fae91113-c423-4ae0-a183-2a1ee3a7ba66">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i90488ba6460948abaea2097aabfb6299_34"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNTQ1Mg_c27ff4be-8c4b-4c46-9c20-0cf85d4f1a86" continuedAt="i6a58a284505248139b93b148f9b51890" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="i6a58a284505248139b93b148f9b51890" continuedAt="ibeb22a30432140b0ad832b78b9c58bbb"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA, which are further described below. The Company has turned its primary focus to the careful assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022. Additionally, the Company intends to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with bacillus Calmette-Gu&#233;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#8220;CMC&#8221;) issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued <ix:nonFraction unitRef="shares" contextRef="i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930" decimals="-5" name="sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfMzM2Mw_6eee6eb6-0920-4cb0-b9b7-f22ecd2c23d0">4.0</ix:nonFraction> million shares of its common stock to the Selling Shareholders, which at that time represented approximately <ix:nonFraction unitRef="number" contextRef="i7f8bfc830bc347e7ba385a21bc092a5d_I20160930" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfMzQ2Nw_1aa0f47f-f15a-4fae-8e4b-e03b60526897">19.9</ix:nonFraction>% of the voting power of the Company as of immediately prior to the issuance of such shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i0e3fdec0c73b4a429111263d24db668c_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfMzkyNg_048ffeb4-6432-431f-9cc8-5c9fbaf89ee9">12.5</ix:nonFraction> million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i6e0b5fa857364bf4a51985aa66895ef9_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDA1NQ_b67b687d-0b0a-4952-8bdc-77f4edb3e825">7.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="idded2fb700664bad9763afed64edafd0_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDIwMQ_71ae952b-d58b-4df7-8dad-8e8c200f7b07">3.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to <ix:nonFraction unitRef="number" contextRef="i4937ec1ad1154d88925e0cabccbc0017_D20160901-20160930" decimals="2" name="sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDMxMw_a23a260a-ad32-45f7-8551-c2fe0daaf830">2</ix:nonFraction>% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) <ix:nonNumeric contextRef="i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDU4MA_bef220c6-067c-4fd0-9874-326c7e588bcb">fifteen years</ix:nonNumeric> after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first <ix:nonNumeric contextRef="i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDg5NQ_4678b1c3-f1f5-4efe-a10d-66ccec52c658">seven years</ix:nonNumeric> following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibeb22a30432140b0ad832b78b9c58bbb">United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of June&#160;30, 2022, none of these individuals are active employees of the Company or members of the Company's board of directors.</ix:continuation> </span></div><div id="i90488ba6460948abaea2097aabfb6299_37"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNy9mcmFnOjA3OGFmNjBmMTg2NzRkNjRiYTA4OTA1NWRhNDNkZmZlL3RleHRyZWdpb246MDc4YWY2MGYxODY3NGQ2NGJhMDg5MDU1ZGE0M2RmZmVfMzg5NQ_20f549a7-1cdd-4c74-a913-116c6efdcec1" continuedAt="i1336d86773ae49e68b98f606be8ab37e" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i1336d86773ae49e68b98f606be8ab37e"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNy9mcmFnOjA3OGFmNjBmMTg2NzRkNjRiYTA4OTA1NWRhNDNkZmZlL3RleHRyZWdpb246MDc4YWY2MGYxODY3NGQ2NGJhMDg5MDU1ZGE0M2RmZmVfMzg5Mg_f4d86a16-59ea-4f11-8934-1fdcc4727f9f" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNy9mcmFnOjA3OGFmNjBmMTg2NzRkNjRiYTA4OTA1NWRhNDNkZmZlL3RleHRyZWdpb246MDc4YWY2MGYxODY3NGQ2NGJhMDg5MDU1ZGE0M2RmZmVfMzg5Mw_69c004aa-abf9-4f95-9ecd-7ab784d4a0c9" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNy9mcmFnOjA3OGFmNjBmMTg2NzRkNjRiYTA4OTA1NWRhNDNkZmZlL3RleHRyZWdpb246MDc4YWY2MGYxODY3NGQ2NGJhMDg5MDU1ZGE0M2RmZmVfMzg5NA_cc38149b-7016-4cec-b3be-1b5a5c206adf" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div></ix:nonNumeric></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_40"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80MC9mcmFnOmY2ZGM2MTg5Yjc1NzRmZDg5ZjBmMzhmNzk4YzUxNmUzL3RleHRyZWdpb246ZjZkYzYxODliNzU3NGZkODlmMGYzOGY3OThjNTE2ZTNfMzYw_19733c2d-5737-4664-abfd-63e9ba61344f" continuedAt="i0c9dcbf7d950444b820c665ad246f9f9" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0c9dcbf7d950444b820c665ad246f9f9">The Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.</ix:continuation></span></div><div id="i90488ba6460948abaea2097aabfb6299_43"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80My9mcmFnOjdiN2UzNzg0N2NjZjRjOGE5MDVkNzQ1NDIyN2QxYTQ4L3RleHRyZWdpb246N2I3ZTM3ODQ3Y2NmNGM4YTkwNWQ3NDU0MjI3ZDFhNDhfMjQ3Nw_297b6c65-42e9-4120-8b7a-2dd3eb8f0d2e" continuedAt="i2a6eeb35bb8d46cb869df62d6ce25cbc" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="i2a6eeb35bb8d46cb869df62d6ce25cbc" continuedAt="i6a808145b92b444f981d7f641dc9245e"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80My9mcmFnOjdiN2UzNzg0N2NjZjRjOGE5MDVkNzQ1NDIyN2QxYTQ4L3RleHRyZWdpb246N2I3ZTM3ODQ3Y2NmNGM4YTkwNWQ3NDU0MjI3ZDFhNDhfMjQ3OA_3aac6355-f6e3-499b-9d0b-d0d662d00f58" continuedAt="ic8aacf71b14447ca8c783909368f012f" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i6a808145b92b444f981d7f641dc9245e"><ix:continuation id="ic8aacf71b14447ca8c783909368f012f"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div></ix:continuation></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_46"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNzAyNw_a5fbae29-c1ae-4ab6-960d-bdc0d8608c28" continuedAt="icf7b141144b942e29af003aac92afc19" escape="true">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="icf7b141144b942e29af003aac92afc19" continuedAt="ic23dcd0eff2142b19065aec83c92395c"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNzAyOA_67654f55-7a9f-4fc5-abc6-9c9383beea68" continuedAt="ie2d5c75fb9874ca88122a0b9d7103aa1" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:continuation id="ie2d5c75fb9874ca88122a0b9d7103aa1" continuedAt="i437beed0ff9248c7b54e9df138341077">Level 3</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i437beed0ff9248c7b54e9df138341077">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.</ix:continuation> </span></div><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNzAyOQ_1a39565e-bb0b-4dc7-a724-e29c026debd7" continuedAt="i21a55550b4a94e34bea66b826e97317d" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idddfae85f074434a95d80a49f60b90a8_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC0xLTEtMS03MDA2MA_9b1ffaef-fb92-4125-9daa-ddaaed15b5ad">40,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c7832156a94fdeb7e233a110f7b809_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC0zLTEtMS03MDA2MA_903af906-1f59-4fed-bd11-19609d3efe9d">40,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC01LTEtMS03MDA2MA_f4433f1f-3527-4845-8c8f-c04f8ef3299a">40,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c2028a693348b8951ec9bd0156057c_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC03LTEtMS03MDA2MA_bee888d5-73ad-4294-8aa1-7a5eba5d5ba9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe177cf9141643909f6abc3b8fa7d37d_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC05LTEtMS03MDA2MA_bbee6e55-2b99-478f-998c-df32183eb2db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idddfae85f074434a95d80a49f60b90a8_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi0xLTEtMS03NDIzMw_99d7f39c-d730-4cb6-8cb1-f025236f2cc9">89,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c7832156a94fdeb7e233a110f7b809_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi0zLTEtMS03NDIzMw_826abd20-4bab-492a-a03e-ece93a9f93db">89,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi01LTEtMS03NDIzMw_936bf8be-271c-4467-a1e4-e87801e3dc57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c2028a693348b8951ec9bd0156057c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi03LTEtMS03NDIzMw_3bd857c6-e9cb-4143-adc1-5514d2001439">89,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe177cf9141643909f6abc3b8fa7d37d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi05LTEtMS03NDIzMw_48cb915a-6ac5-4449-94ac-8708d29c2f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idddfae85f074434a95d80a49f60b90a8_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy0xLTEtMS03MDA2MA_c1d6a48c-7055-4af4-9144-07a9d9b4635a">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c7832156a94fdeb7e233a110f7b809_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy0zLTEtMS03MDA2MA_43d5ee5f-eb72-4438-82c2-f2ada802dc3b">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy01LTEtMS03MDA2MA_07f440a9-104b-4210-969c-41fff902ff49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c2028a693348b8951ec9bd0156057c_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy03LTEtMS03MDA2MA_1a9c141c-015c-485d-9f58-993b689018d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe177cf9141643909f6abc3b8fa7d37d_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy05LTEtMS03MDA2MA_edc96e78-fc28-4cbc-9248-61a0ecc7a91a">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ic23dcd0eff2142b19065aec83c92395c" continuedAt="i1a5b9970672047bb91b5fd7d34c7933b"><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i21a55550b4a94e34bea66b826e97317d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9372277261a1442382a0a57cd6b64879_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC0xLTEtMS03MDA2MA_af41636c-fd8b-4eeb-b597-4f29499f80c5">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a276b795564af5900e3ccde170c211_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC0zLTEtMS03MDA2MA_c5dae4bf-f159-47d9-a03b-e0b06279f1aa">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93597cbef52346f8bf33793b3445c748_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC01LTEtMS03MDA2MA_49629f33-98a2-4257-978f-cd9ea9eded26">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c6a63221e74f49a77225cfd89d52e5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC03LTEtMS03MDA2MA_22455369-7564-44eb-81cb-05e2412cec8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6ff544a1cd473cb1b5466e70e8581d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC05LTEtMS03MDA2MA_ec10833d-c4ae-4dda-99d9-9c38c6761fbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9372277261a1442382a0a57cd6b64879_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy0xLTEtMS03MDA2MA_4ad5b0c2-654f-4cc8-8d95-a7a2a8ce3e86">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a276b795564af5900e3ccde170c211_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy0zLTEtMS03MDA2MA_05e085d7-10d4-405c-b849-5af8db4f09ae">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93597cbef52346f8bf33793b3445c748_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy01LTEtMS03MDA2MA_7c2f87e4-6ff6-4f4e-9bea-af7401722f0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c6a63221e74f49a77225cfd89d52e5_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy03LTEtMS03MDA2MA_658b3fc6-6cfe-45ff-bdda-91d8506d727a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6ff544a1cd473cb1b5466e70e8581d_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy05LTEtMS03MDA2MA_5b943f66-22d1-4b97-badd-daa147d83e44">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from <ix:nonFraction unitRef="number" contextRef="ic13e854370344e64955121ce52f8efd8_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfODc5NjA5MzA0NDk3Mw_006ca314-d2f3-4ed0-adb1-4e46c10d6bf7">10.2</ix:nonFraction>% as of June&#160;30, 2022 to <ix:nonFraction unitRef="number" contextRef="i077703176cde4f50813269c0d4bc4948_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfMzU4Mg_aac6f89b-3e6b-46bc-a361-f2176e424812">8.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i086d18af784f4ef89dd43b1a93d419d2_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfMzU4OA_005ee2e9-481f-4ffe-b4c9-8f1afba02280">9.3</ix:nonFraction>% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development in the US of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Additionally, the Company intends to seek a partner for the further development of Vicineum. The Company expects that any partner who acquires Vicineum from the Company will be obligated to make any payments that become payable to the former shareholders of Viventia under the Share Purchase Agreement. Accordingly, as of June&#160;30, 2022, the Company no longer expects to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential <ix:nonFraction unitRef="number" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNjA0NzMxMzk3OTU5OQ_afdcc93b-406c-47a3-bdf3-0fd9898aa8ed">2</ix:nonFraction>% earnout payment related to the Greater China region since those territory rights have already been out-licensed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the balance as of June&#160;30, 2022 relates to contingent consideration for projected net sales in the Greater China region as compared to the balance as of December&#160;31, 2021 which was based upon projected world-wide net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNzAzMA_457680fb-8ed4-4249-a9b7-cedc4177ad87" continuedAt="i6ad58ac029ee4ffe888d34d84c047cc5" escape="true">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i1a5b9970672047bb91b5fd7d34c7933b"><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><ix:continuation id="i6ad58ac029ee4ffe888d34d84c047cc5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id227aede38f346d295f8bb264c9c69d9_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOmVmMWI1MWIxYWQ4ODQwMDlhODYyYmJhZTNlNDU0YTAyL3RhYmxlcmFuZ2U6ZWYxYjUxYjFhZDg4NDAwOWE4NjJiYmFlM2U0NTRhMDJfMC0xLTEtMS03MDA2MA_a6d063e6-11e9-463a-ae0a-223c94903d74">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2830d319d1ee4478869015d679421f00_D20220101-20220630" decimals="-3" sign="-" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOmVmMWI1MWIxYWQ4ODQwMDlhODYyYmJhZTNlNDU0YTAyL3RhYmxlcmFuZ2U6ZWYxYjUxYjFhZDg4NDAwOWE4NjJiYmFlM2U0NTRhMDJfMi0xLTEtMS03MDA2MA_1fdcccc5-78e4-47bc-9f81-f20c94639583">50,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aca7f4595d416dac4c7c3f1aed4ccb_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOmVmMWI1MWIxYWQ4ODQwMDlhODYyYmJhZTNlNDU0YTAyL3RhYmxlcmFuZ2U6ZWYxYjUxYjFhZDg4NDAwOWE4NjJiYmFlM2U0NTRhMDJfMy0xLTEtMS03MDA2MA_c1e7c30d-1cca-403c-b914-b2f46061c14e">1,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s contingent consideration was determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts were determined using an earnout rate of <ix:nonFraction unitRef="number" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNDI0Mw_f1234538-7dce-446a-b592-93222eaec270">2</ix:nonFraction>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNDM0Mg_c21476ef-c1e3-4659-9fb7-fbcb98b4c884">2</ix:nonFraction>% earnout was derived from the Company&#8217;s weighted-average cost of capital, which has fluctuated from <ix:nonFraction unitRef="number" contextRef="if7f36ed152cc4886975102feb1d3dcf2_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNDQ1Mg_0220f68f-bcb1-48f8-aa3d-a05cc39921c1">9.3</ix:nonFraction>% as of December&#160;31, 2021 to <ix:nonFraction unitRef="number" contextRef="ic13e854370344e64955121ce52f8efd8_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfODc5NjA5MzA0NTYxMQ_006ca314-d2f3-4ed0-adb1-4e46c10d6bf7">10.2</ix:nonFraction>% as of June&#160;30, 2022. As of December&#160;31, 2021, the balance also reflected potential milestone payments which constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was <ix:nonFraction unitRef="number" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNDY4Mg_d1bd6ef4-2381-4f46-b619-7089865d4110">8.0</ix:nonFraction>% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfMTA5OTUxMTY0NjA5Ng_279280c2-eb4e-44d9-8aac-50b3c97f0b4e">50.2</ix:nonFraction>&#160;million for the six months ended June 30, 2022 was driven by the Company's decision to voluntarily pause further development of Vicineum.</span></div></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_49"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfNTE1_ba85157f-0e14-4687-9c28-f2f5d8ef518d" continuedAt="i4fbc1d05872a4ca8a366c45e271a0bf2" escape="true">RECEIVABLES </ix:nonNumeric></span></div><ix:continuation id="i4fbc1d05872a4ca8a366c45e271a0bf2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="ifa3364e01f0e4f3e8b9b4b9e879f7cda_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfNjU_2b8ea801-4bad-4510-ad9e-d8e8e6eb29b8">0.1</ix:nonFraction>&#160;million compared to $<ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfODA_7fd90a46-923e-4dae-b42e-7fdb719a2dbc">21.0</ix:nonFraction>&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $<ix:nonFraction unitRef="usd" contextRef="ie9e6014176bb47daa77e93b8e95c92eb_I20211231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfMTM4_08adc5d8-25ea-4469-bb4d-13799b6fcb0e">20.0</ix:nonFraction>&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfMzUy_436fa8be-4052-4349-b967-10d8244b9cbb">14.0</ix:nonFraction>&#160;million compared to $<ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfMzY3_ff333a7a-2506-4ac2-917d-daedae55082a">3.5</ix:nonFraction>&#160;million as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase is driven by expected insurance recovery of $<ix:nonFraction unitRef="usd" contextRef="i68913e68ad7b4a54a86589572b03f916_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfNDk0NzgwMjMyNTg4NA_0a396c59-3088-45ef-889e-0ca6535b9a85">13.0</ix:nonFraction>&#160;million related to the preliminary settlements of the securities and derivative litigation. This was partially offset by the receipt of $<ix:nonFraction unitRef="usd" contextRef="i22e566e4a4b842db8188c3f55dbff512_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfNjA0NzMxMzk1MzY3NQ_49b08ef0-872c-4f5c-b898-d73879ab1889">2.4</ix:nonFraction>&#160;million for German value-added tax ("VAT") recovery in the first half of 2022, related to drug substance sent to Baxter in 2020 and 2019.</span></div></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_964"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NjQvZnJhZzozMzMwZTY1ZTIxNjk0NzgxYTFmN2FkNTQ4MGVmYTc5Ny90ZXh0cmVnaW9uOjMzMzBlNjVlMjE2OTQ3ODFhMWY3YWQ1NDgwZWZhNzk3XzYwNDczMTM5NTY1MjA_1f63bc32-c67e-442f-b549-4830a739b5c2" continuedAt="i840c65c19e544e04b2c67a9f71e04227" escape="true">PREPAID EXPENSES </ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i840c65c19e544e04b2c67a9f71e04227">The prepaid expenses balance as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-5" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NjQvZnJhZzozMzMwZTY1ZTIxNjk0NzgxYTFmN2FkNTQ4MGVmYTc5Ny90ZXh0cmVnaW9uOjMzMzBlNjVlMjE2OTQ3ODFhMWY3YWQ1NDgwZWZhNzk3XzQ5NDc4MDIzMjk4NDQ_63da4698-3732-452f-8752-e0b5614e0a20">0.8</ix:nonFraction>&#160;million compared to $<ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NjQvZnJhZzozMzMwZTY1ZTIxNjk0NzgxYTFmN2FkNTQ4MGVmYTc5Ny90ZXh0cmVnaW9uOjMzMzBlNjVlMjE2OTQ3ODFhMWY3YWQ1NDgwZWZhNzk3XzQ5NDc4MDIzMjk3NjE_46983600-f753-41f8-b142-62a0ba0668c5">25.7</ix:nonFraction>&#160;million as of December&#160;31, 2021. In light of the Company's decision to voluntarily pause further development of Vicineum, the Company evaluated prepaid balances and determined that the prepayments for the manufacturing of Vicineum, including consumables, had no future economic benefit or value. Pursuant to ASC Topic 730, Certain Nonrefundable Advance Payment, the Company expensed $<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-5" name="sesn:ExpensesPreviouslyClassifiedAsPrepaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NjQvZnJhZzozMzMwZTY1ZTIxNjk0NzgxYTFmN2FkNTQ4MGVmYTc5Ny90ZXh0cmVnaW9uOjMzMzBlNjVlMjE2OTQ3ODFhMWY3YWQ1NDgwZWZhNzk3XzE2NDkyNjc0NDY0NzY_3a67bc44-33b1-47e0-b035-e63596b3d793">25.2</ix:nonFraction>&#160;million of prepaids during the three months ended June 30, 2022.</ix:continuation> </span></div><div id="i90488ba6460948abaea2097aabfb6299_52"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNjkxOQ_3ac1e7cf-a43a-4ef9-b8d0-56556f2ab2a2" continuedAt="i30c384d72a8e400fa8b0dc1ce0b73a7b" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="i30c384d72a8e400fa8b0dc1ce0b73a7b" continuedAt="i63d5e3f23e604a3b8f02ceef9e330930"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNjkyMA_9ec8fc02-3d1d-4fbf-adea-b11c7cd9e452" continuedAt="i64b1de266d96493d9ba8648fd341f7b6" escape="true">The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="i64b1de266d96493d9ba8648fd341f7b6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafbcb1be87d432d8ded324e6ed76889_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOjU4OTkyZWQyMTZiYzRiOTNiYTRiYWNhN2Y0MzhhZGU0L3RhYmxlcmFuZ2U6NTg5OTJlZDIxNmJjNGI5M2JhNGJhY2E3ZjQzOGFkZTRfMy0xLTEtMS03MDA2MA_f8e39180-326f-40f3-bdf3-6fc1d2de0ce0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b037e30ee240a693feec6491f28390_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOjU4OTkyZWQyMTZiYzRiOTNiYTRiYWNhN2Y0MzhhZGU0L3RhYmxlcmFuZ2U6NTg5OTJlZDIxNmJjNGI5M2JhNGJhY2E3ZjQzOGFkZTRfMy0zLTEtMS03MDA2MA_54686371-b954-41a7-b87e-20b788990b6d">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i043a889ad00d41bcbc065be28275a745_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOjU4OTkyZWQyMTZiYzRiOTNiYTRiYWNhN2Y0MzhhZGU0L3RhYmxlcmFuZ2U6NTg5OTJlZDIxNmJjNGI5M2JhNGJhY2E3ZjQzOGFkZTRfNC0xLTEtMS03MDA2MA_24f55546-eefd-4863-b290-5c2b27dbb582">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia31cefc9e53e4fdea0146b38e97b9152_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOjU4OTkyZWQyMTZiYzRiOTNiYTRiYWNhN2Y0MzhhZGU0L3RhYmxlcmFuZ2U6NTg5OTJlZDIxNmJjNGI5M2JhNGJhY2E3ZjQzOGFkZTRfNC0zLTEtMS03MDA2MA_b1f498ea-5ef8-49b7-ae06-2f3d4e49ced9">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the European Union ("EU") rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#8217;s former lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum&#8482; for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there was more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i63d5e3f23e604a3b8f02ceef9e330930"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the EU. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i75f8be7fd9a44548a385a47a21fdcbfa_D20210101-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfMTc2Nw_fea722a3-b2ed-40d3-a9e4-12dd1c310da7">31.7</ix:nonFraction>&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the current range of commercialization timelines and probability of success assumptions. This was primarily due to the fact that the EU asset was burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan was to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in its share price and a resulting decrease in our market capitalization. On July 15, 2022 the Company made the strategic decision to voluntarily pause further development in the US of Vicineum and intends to seek a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of a potential partnering deal to conclude the fair value of EU asset. The Company concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum EU rights of $<ix:nonFraction unitRef="usd" contextRef="id5bc92acb0454bdeb25962fc1d1aef23_D20220101-20220630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNDk0NzgwMjM1NjIxOQ_8dad634f-f57c-4178-8ccd-84a3470cfb10">14.7</ix:nonFraction>&#160;million was fully impaired and written off as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#8217;s most recent impairment test, which was <ix:nonFraction unitRef="number" contextRef="id5bc92acb0454bdeb25962fc1d1aef23_D20220101-20220630" decimals="3" name="sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNjA0NzMxMzk5NjQxNA_fb801dcc-4392-479a-9571-9f62e8e6c4e6">24.5</ix:nonFraction>%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. During the second quarter of 2022 the Company observed continued trends in the Company&#8217;s market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, length and cost of a clinical study, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis, in advance of the Company's typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both the US and outside the US ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. Management also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $<ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNTYzNQ_e1c134a7-3c0e-4f4d-900c-3813de6e88b1">13.1</ix:nonFraction>&#160;million was fully impaired as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#8217;s most recent impairment test, which was <ix:nonFraction unitRef="number" contextRef="id5bc92acb0454bdeb25962fc1d1aef23_D20220101-20220630" decimals="3" name="sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNDk0NzgwMjM2ODYzMA_06704022-b98e-463d-b233-c96c665120a0">24.5</ix:nonFraction>%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. </span></div><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNjA0NzMxMzk5MzAzNg_675e18d5-c339-4a5e-a368-585913276118" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOmJhZThjZmExMzMxMzRlNmRhMmM5NjMxZjQ3YTkzYmI5L3RhYmxlcmFuZ2U6YmFlOGNmYTEzMzEzNGU2ZGEyYzk2MzFmNDdhOTNiYjlfMC0xLTEtMS03ODY5Mg_61a60c28-3e2a-4f45-8674-f89394c9e7a0">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOmJhZThjZmExMzMxMzRlNmRhMmM5NjMxZjQ3YTkzYmI5L3RhYmxlcmFuZ2U6YmFlOGNmYTEzMzEzNGU2ZGEyYzk2MzFmNDdhOTNiYjlfMS0xLTEtMS03ODY5Mg_4cde8446-da80-47ad-8c7b-d01f859d5b9a">13,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOmJhZThjZmExMzMxMzRlNmRhMmM5NjMxZjQ3YTkzYmI5L3RhYmxlcmFuZ2U6YmFlOGNmYTEzMzEzNGU2ZGEyYzk2MzFmNDdhOTNiYjlfMi0xLTEtMS03ODcyNA_5e6a32a8-8541-48f2-9164-f003ab2efa16">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_55"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RleHRyZWdpb246ZGI0MDQ5OTBkODI5NDJmNjkzZmJjNzMwOGQ5YjEwMWFfMTI1_62e4594a-ce43-43d3-a80e-f213712bc9d6" continuedAt="i5644f413c68f4ff1881056e309fb79c1" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i5644f413c68f4ff1881056e309fb79c1"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RleHRyZWdpb246ZGI0MDQ5OTBkODI5NDJmNjkzZmJjNzMwOGQ5YjEwMWFfMTM1_07094331-9945-4eda-a660-0baa6ac64c27" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMS0xLTEtMS03MDA2MA_2405bb6a-8d41-4cc0-ab23-cdc4725d1b8f">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMS0zLTEtMS03MDA2MA_81d095ae-c8ed-4584-b62f-0cf76b529780">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMi0xLTEtMS03MDA2MA_34893809-4254-42eb-b26c-3fbd23f5727b">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMi0zLTEtMS03MDA2MA_687d91db-d5b5-4654-8e07-1b44bb1b571c">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMy0xLTEtMS03MDA2MA_bec83797-cc6c-45a7-8dbd-bb44d5728213">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMy0zLTEtMS03MDA2MA_6854d87e-8991-41c1-8740-67731ddad937">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNC0xLTEtMS03MDA2MA_ad8d41ab-2027-43eb-b308-eac3dc240d66">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNC0zLTEtMS03MDA2MA_5e9b9f78-a525-4051-a711-dfbfb78bd5fa">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including preliminary litigation settlement </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="sesn:AccruedLegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNS0xLTEtMS03NjQxNQ_7bfc20d7-0ed9-497b-a84b-16ddb23e24bb">22,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="sesn:AccruedLegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNS0zLTEtMS03NjQxNQ_87715d0e-f557-436b-a5ee-7845757537e2">1,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNS0xLTEtMS03MDA2MA_3528b125-7e19-47b1-bdbc-dbdb84bce0fe">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNS0zLTEtMS03MDA2MA_1ed81c95-1cc5-47e6-a3f3-1419c13a5f96">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNi0xLTEtMS03MDA2MA_54ee9fcd-6b9c-4785-a7cb-c2ad428ab536">29,851</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNi0zLTEtMS03MDA2MA_af47f4d7-3b28-4a06-be2a-b871c79e324f">8,255</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_58"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfNTcxMQ_1a544a7c-f225-44f8-a85f-700a42753105" continuedAt="ia70b3ec97e2444f4948f4464426ceb96" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ia70b3ec97e2444f4948f4464426ceb96" continuedAt="i3067a4184bfd4c2a9d27d4222e26172e"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, <ix:nonFraction unitRef="lawsuit" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTIxNA_bd70f977-365d-482f-ae84-963cf1641734">three</ix:nonFraction> substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The <ix:nonFraction unitRef="lawsuit" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTU5MA_ae7c94e9-bcb5-481f-8cca-c0204c2ca082">three</ix:nonFraction> complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The <ix:nonFraction unitRef="lawsuit" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTgzMA_ba564895-9c65-4bce-949e-a008efb4143d">three</ix:nonFraction> complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the <ix:nonFraction unitRef="lawsuit" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTk3MQ_2cce167b-285d-4879-8fde-b47fafa46119">three</ix:nonFraction> cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. After the motion was fully briefed and before the court ruled on the motion, on June 3, 2022, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. The parties engaged in mediation on June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers (the &#8220;State Derivative Litigation&#8221;). The <ix:nonFraction unitRef="lawsuit" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTY0OTI2NzQ3Mjg0NA_f25e2eb0-1686-4be3-b9ad-0935ec9bcb04">three</ix:nonFraction> derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i3067a4184bfd4c2a9d27d4222e26172e"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company deemed the settlements of the Securities Litigation, the State Derivative Litigation, the Federal Derivative Litigation, and other potential related derivative claims, probable and amounts reasonably estimable as of June 30, 2022 and accrued $<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-5" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfNjA0NzMxMzk3NTIwNw_e9c36a82-1c35-4583-a04f-860d314af3a0">21.6</ix:nonFraction>&#160;million to litigation related liability. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation, the State Derivative Litigation and the Federal Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_61"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk1OQ_222e4539-f39d-45e4-94dd-d2c6e3e8973b" continuedAt="ic43736fbe6ab48489e4b78e2ad0f99fc" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ic43736fbe6ab48489e4b78e2ad0f99fc"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its <ix:nonFraction unitRef="sqft" contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630" decimals="-2" name="sesn:OperatingLeasesAreaOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTUz_36537782-5bb5-43dd-a561-f340791c3427">31,100</ix:nonFraction> square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional <ix:nonNumeric contextRef="i54a5e53888604de7b9eccc5f75d78406_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMzYx_a84ea351-1b07-4a7f-a29a-52c665516aef">two years</ix:nonNumeric>, through September 2022. The minimum monthly rent under this lease is CAD $<ix:nonFraction unitRef="cad" contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNTAz_09cb2396-a0b8-4401-a2e2-c826078887d8">18,100</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNTIx_dc977c63-2ab9-4e96-a910-2fede064ed9b">14,000</ix:nonFraction> at exchange rates in effect on June&#160;30, 2022). In addition to rent expense, the Company expects to incur CAD $<ix:nonFraction unitRef="cad" contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNjIy_c5c91cec-7781-4bdf-8836-a530ab058f21">18,200</ix:nonFraction> per month related to operating expenses (approximately $<ix:nonFraction unitRef="usd" contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNjgw_3a87d668-8f5f-47aa-976f-98938259ca29">14,100</ix:nonFraction> at exchange rates in effect on June&#160;30, 2022). Operating lease cost under this lease, including the related operating costs, were $<ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNjk3Nw_68fa94b4-0e8d-4f4a-b46f-46ee6ea96ac0">83,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzAwNg_99a2527a-a4c0-42e4-8a44-4ac16d3f4386">165,000</ix:nonFraction> for the three and six months ended June&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzAzOA_00aedfec-fdef-4007-8077-8dd411c2fbf3">84,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzA0Ng_20fc79c3-7ea9-4f29-be10-cd4d20cec9d3">166,000</ix:nonFraction> for the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_7413172c-d3a5-4068-a39f-148f182a4c0b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_ea5c27f0-7ff4-4a17-899a-400e6d9e6d97">other assets</span></span> on the Company's condensed consolidated balance sheets. The right of use asset total was $<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-2" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTA3MA_e88e5eba-46ee-4974-8435-2f20244fed88">41,700</ix:nonFraction> as of June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-2" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzA5MQ_389b8c3d-3e20-438c-8374-73978b773d8a">123,300</ix:nonFraction> as of December&#160;31, 2021. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_0bf1b90e-c07f-46a0-9567-ec2c0325b103"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_1319265b-1386-40c8-9f75-781056e69617">other current liabilities</span></span> and the long-term lease liability is recorded in other liabilities on the Company&#8217;s condensed consolidated balance sheets. The short-term lease liability was $<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-2" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTMyMA_72acc189-ad8c-40ce-bbd4-64a74a85ef82">41,700</ix:nonFraction> as of June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-2" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzEwNw_a2798717-5e5e-4599-9cfe-8809a0cfb459">123,300</ix:nonFraction> as of December&#160;31, 2021. There was no long-term operating lease liability as of June&#160;30, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases are renewed on a month-to-month basis. The minimum monthly rent for these office spaces is $<ix:nonFraction unitRef="usd" contextRef="ia060ccaf4f3043ab8f16a7a015f9e80e_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTgzOQ_1770da8d-6093-400f-a736-72dc9d4e9e3d">2,200</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if8a99add6a0641b5ab55bf3282467a0d_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTg0Ng_d02348fb-be55-421a-92e4-5fe68092cf13">21,000</ix:nonFraction>, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_64"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNTU0OQ_125e302d-5624-4c08-9203-d8d23c12eb84" continuedAt="i3418d2d13afc4833b3c2e379d691e41e" escape="true">STOCKHOLDERS' EQUITY </ix:nonNumeric></span></div><ix:continuation id="i3418d2d13afc4833b3c2e379d691e41e" continuedAt="i16034897d0f04ebbaa386b2646fe14bb"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i84bae78e3b8749b39293629af79a1b2a_I20191129" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNDM0_9b618529-7cf4-48d1-be91-25a2dbc4f3d0">0.001</ix:nonFraction> per share, from time to time through Jefferies (the &#8220;ATM Offering&#8221;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ib2f7003911044ca29a413fb1818f5c6c_D20210601-20210731" decimals="-6" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNjQ2_10564a4f-e879-4398-aed7-f38897a03cc0">200</ix:nonFraction>&#160;million of common stock pursuant to the Sale Agreement of which $<ix:nonFraction unitRef="usd" contextRef="i1ce363488c7540a6a587912208af7e0f_I20220630" decimals="-5" name="sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNzA1_8c146640-34d1-4385-8c57-227e2ae34a15">97.8</ix:nonFraction>&#160;million of common stock remain available for future issuance as of June&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i16034897d0f04ebbaa386b2646fe14bb" continuedAt="i30ff36ea1ac04730b39aa1b4a225d7e2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to <ix:nonFraction unitRef="number" contextRef="i35961c53b42e43cbb0b81da04777d408_D20211129-20211129" decimals="INF" name="sesn:SaleOfStockCommissionFixedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTc4Mw_a810b89e-ac51-4d88-b35e-ba4c45fcbe4f">3.0</ix:nonFraction>% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June&#160;30, 2022. The Company raised $<ix:nonFraction unitRef="usd" contextRef="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTA5OTUxMTYzMzYwOQ_26f32e97-7607-49fd-a8d2-58b7086bc49e">136.8</ix:nonFraction>&#160;million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTA5OTUxMTYzMzYxNQ_8aa496bf-421d-4894-a81d-cb0135410029">47.1</ix:nonFraction>&#160;million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTA5OTUxMTYzMzYyMg_adc123bd-b63b-43b8-bda9-4effc0cd1c20">2.99</ix:nonFraction> per share during the six months ended June 30, 2021. The Company raised $<ix:nonFraction unitRef="usd" contextRef="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTk4MQ_43e3f88d-bd16-49d7-920d-6a91ce798e35">64.3</ix:nonFraction>&#160;million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjAxNw_a4547292-bca4-4c31-b085-27334dd76216">16.5</ix:nonFraction>&#160;million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjA3NA_ea0f883b-0d32-436a-8526-fc3af327e910">4.02</ix:nonFraction> per share during the three months ended June 30, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjE5Ng_5e890395-2caf-4ba2-ba32-d93867250339">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTA5OTUxMTYzMzYzNQ_c4315d61-de54-4494-b7d5-a7ba2420bfd3">4.2</ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjM2OQ_0a2af373-d65f-438b-af6e-374c7ae26dc7">5.0</ix:nonFraction> million shares of "blank check" preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjQxMw_4ea48921-fa6e-48e9-9f1e-648ac45b4b5a">0.001</ix:nonFraction> par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had <ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjg1Nw_742df77a-f3f0-4ed0-9b06-54526007b3f2"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjg1Nw_89e6d50f-da0f-497d-b91e-1a78df6e5f3d"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjg1Nw_90d3a98f-67d8-435d-b922-bd6465f78f6a"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjg1Nw_96d8ef3f-db90-47b8-b885-5ae9169cadb4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred stock issued and outstanding as of June&#160;30, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i7960c58d87094e0aafb92767a535f891_I20210502" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzEyOA_0e6c07ad-7350-48e6-92c0-a60e40995643">200</ix:nonFraction>&#160;million to <ix:nonFraction unitRef="shares" contextRef="ifc8cab4c047e42a1993c113f9407d7c0_I20210503" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzEzNA_7b9662f4-40f4-4823-b27b-7eb08a1a44c1">400</ix:nonFraction>&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately <ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzE0Nw_20581a02-8464-4747-8bf3-bb165bdfce8f"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzE0Nw_58a8dde9-b10e-4aac-b3c7-b02d3bd0e82b"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzE0Nw_b4274d56-7a8a-4c4f-bf63-ea28c4aacfae"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzE0Nw_e58be635-05aa-4109-a17c-c5b4ea8f6680">199</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNTU0Mw_4c254857-9e82-46df-86a0-eef3bf57a457" continuedAt="i72ec846c42024d2b8d3dc3fe7c64f94a" escape="true">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><ix:continuation id="i72ec846c42024d2b8d3dc3fe7c64f94a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:67.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfMS0xLTEtMS03MDA2MA_bd59b38b-66f3-424c-b10a-a2b9783d6f76">199,464</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfMS0zLTEtMS03MDA2MA_eca42b8a-fe77-4a68-bbf1-50bca6665390">199,464</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e690f5ae31c41b7a191fa0ff85bf14a_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfMy0xLTEtMS03MDA2MA_15e533d8-e86f-45c0-82fb-d5aae8c48d2f">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e430eedf22b467aac65cdb1b465bb18_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfMy0zLTEtMS03MDA2MA_170f300a-e879-43e0-ac45-078cab84f160">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if12ac6d811ab49fea4ae767cff635f67_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNC0xLTEtMS03MDA2MA_301fdae9-35f1-49eb-b5d6-4686fb33c393">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i879f338421144cd692f89c4e9f0c73c2_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNC0zLTEtMS03MDA2MA_000ac105-cb62-49cf-a8a1-e26c0378fe64">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf83b58ca25c49e192a0c8602c5b4cf2_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNS0xLTEtMS03MDA2MA_e7a1df98-6623-4c7f-97cf-fa7bc1e1500c">8,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccc92bb70d08454e949c18da6144865f_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNS0zLTEtMS03MDA2MA_5b532874-b00b-4798-8db3-d44b8cf1c629">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9bd2cea79e94911a9584a49e07abbb3_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNi0xLTEtMS03MDA2MA_e3f46eaf-82cc-4f94-a259-ed6cec405c6a">3,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3787aa8d02ce4f859f8c5f466f0d274a_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNi0zLTEtMS03MDA2MA_f7aa461a-4fd0-430a-947b-30fc268f5213">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab2fae56c82b4d01a53b53d0d8ad8169_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNy0xLTEtMS03MDA2MA_2dc3f314-8d0a-4dfd-b5b9-da8c0950a4e6">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i018c376ae85743729c4cc85b9d0082c6_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNy0zLTEtMS03MDA2MA_360997d3-fafc-452d-b784-f9a268128cbd">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfOC0xLTEtMS03MDA2MA_ca7a9570-ba30-4ea7-981f-61e9f44fdfc1">230,263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfOC0zLTEtMS03MDA2MA_b673691c-0c24-432b-842d-89aae603c5bd">229,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="i0aa49d50600f4d809f73a21b67293288_D20220101-20220630" decimals="INF" name="sesn:NumberofVotesEntitledForEachShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzYxMQ_03b62481-d2e5-4e15-988c-55c67106df77">one</ix:nonFraction> vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i30ff36ea1ac04730b39aa1b4a225d7e2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNTU0NA_90c03324-810a-4890-8d9c-0d7797ded20b" continuedAt="i559603ef6f8b48c398fcbfb54024a2f5" escape="true">The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i559603ef6f8b48c398fcbfb54024a2f5"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if3f5defe37004a80beffaabe3c084441_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS0yLTEtMS03MDA2MA_b4f3e198-b21f-418f-a6c9-863dee6a65b2">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40c5616a1e704030a81402b94effbad5_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS02LTEtMS03MDA2MA_58eaa896-eb17-4b69-a135-78f573712cf1">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69cb4439e7f34192bda24252ab0db0d6_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS04LTEtMS03MDA2MA_0564f2e0-49c6-41a8-aae4-1fbb4a7395a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69cb4439e7f34192bda24252ab0db0d6_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS0xMC0xLTEtNzAwNjA_fd3d20a7-8382-4163-9fef-2c59a656d04b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69cb4439e7f34192bda24252ab0db0d6_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS0xMi0xLTEtNzAwNjA_706d56f4-5323-4568-ac31-05818ce44134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3f5defe37004a80beffaabe3c084441_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS0xNC0xLTEtNzAwNjA_b5f9134e-c3ed-4b62-b425-5f5e476f59be">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i95be96bc66a447e49b2e6b3eb139bb61_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi0yLTEtMS03MDA2MA_6fc40324-4bd2-424e-97e1-d511912e9359">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4361a004833c45998527402787d53315_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi02LTEtMS03MDA2MA_edeb76e3-e1bf-437c-abd3-aa10e6c64eab">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c9b9934bd1f4b4a87e74584ffe44869_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi04LTEtMS03MDA2MA_05ff1b2f-198c-42fd-b8fc-d3b354d39b1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c9b9934bd1f4b4a87e74584ffe44869_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi0xMC0xLTEtNzAwNjA_22160fca-b176-4a5e-a418-d899e69fae48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c9b9934bd1f4b4a87e74584ffe44869_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi0xMi0xLTEtNzAwNjA_a0444988-5da0-4b6b-9420-c9b4577335e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95be96bc66a447e49b2e6b3eb139bb61_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi0xNC0xLTEtNzAwNjA_457d83ba-ed77-4962-9831-f16f5029c2c9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i364de02410824f29aef894a8c443af3b_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy0yLTEtMS03MDA2MA_8d279ca4-1d39-4512-b1e4-7c46e7446262">11.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f346e6310724b48be23ba52453dfd1e_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy02LTEtMS03MDA2MA_d3e2fb57-130a-47bd-bf76-aaf7c5dab799">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib269223dc4c241d2ab59180afde39e5e_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy04LTEtMS03MDA2MA_b523c48d-48b9-4331-b6e5-217f82eae191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib269223dc4c241d2ab59180afde39e5e_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy0xMC0xLTEtNzAwNjA_201c28f0-e720-466e-b789-364b5c8f1600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib269223dc4c241d2ab59180afde39e5e_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy0xMi0xLTEtNzAwNjA_9c0ba542-fbbe-45c3-8738-1334357cd070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i364de02410824f29aef894a8c443af3b_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy0xNC0xLTEtNzAwNjA_01b5db97-2e15-43c9-a1e7-4110d427c067">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3afe3a9ad2a74fa9a621bbc8ca349720_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC0yLTEtMS03MDA2MA_2bbf16c3-ecc2-4544-aefb-d82415ffb656">11.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65a150a7d69f42ab95bb4eebf536a4eb_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC02LTEtMS03MDA2MA_2ed9aee8-d219-477d-83d5-5670ced7cb0e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd894f48683d467eade7ea10a3423375_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC04LTEtMS03MDA2MA_1036f754-0a26-476e-8146-611b549268ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd894f48683d467eade7ea10a3423375_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC0xMC0xLTEtNzAwNjA_6b6b0877-9a3b-4867-8e8e-3e41f0f80a62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd894f48683d467eade7ea10a3423375_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC0xMi0xLTEtNzAwNjA_7f49d4c3-bf6d-4b1f-95fc-cb5ec780e094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3afe3a9ad2a74fa9a621bbc8ca349720_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC0xNC0xLTEtNzAwNjA_d8bdc8de-8ec8-42f0-aa7e-15002236b180">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS02LTEtMS03MDA2MA_10cee008-8058-4bf2-a861-b37678e51690">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS04LTEtMS03MDA2MA_cd51f334-05e2-452c-81ce-9ef497daa69d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS0xMC0xLTEtNzAwNjA_f74f2d5a-bfd4-48fa-94b3-0c5bf54d84d8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS0xMi0xLTEtNzAwNjA_5add3671-3e04-45ff-a4f5-c1d4068101f6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS0xNC0xLTEtNzAwNjA_6f909496-af9b-4661-aaa1-23c2398fbc73">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div></ix:continuation></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_67"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RleHRyZWdpb246ZGI5Yzc0NTljMWNjNGMzMDkyODU2MmJhNTM3NDJhZTNfMTM4OA_6af94a48-fe3e-4335-ad3e-87a9e8c311d9" continuedAt="i4cad5e7acdb247d7a298c71c2435d21a" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i4cad5e7acdb247d7a298c71c2435d21a"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RleHRyZWdpb246ZGI5Yzc0NTljMWNjNGMzMDkyODU2MmJhNTM3NDJhZTNfMTM4OQ_82219234-81b4-4c70-a4a9-fb94d03e9c74" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69d2c5c201c146a29dc3f4aaab1fa94b_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMi0xLTEtMS03MDA2MA_96a5f33f-6fb1-463d-9142-85f4b1013da4">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if89d59ad112c41c1a5e5e4945e45b3a0_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMi0zLTEtMS03MDA2MA_83991747-9a62-43f9-9a36-287e86809662">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1832afd10f54cc791caad58fb173350_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMi01LTEtMS03MTc2MQ_2137c497-36f9-4cc4-b11a-32554868a7c2">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2b6f3706013458ab5961aa0a088fa40_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMi03LTEtMS03MTc2MQ_b63dfc19-ca64-4a51-9b17-1a0cbf989ce2">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6362c9affd304cba8c070c705be6dd77_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMy0xLTEtMS03MDA2MA_d038aeee-07f7-44c7-bade-90aa25a79def">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i369610441fa049a9b3af81518e15d50d_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMy0zLTEtMS03MDA2MA_0fbbf7d5-a018-49f6-81e9-dfbc9feac102">17,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i831e2ac854704d1aae0e81436d368ad4_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMy01LTEtMS03MTc2MQ_d2f32e65-14a1-4b53-910c-573d14e12d84">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic013dea044994c0b9999755d2814f233_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMy03LTEtMS03MTc2MQ_9c1484fc-7443-4063-bcb0-9d3f4aa7b6b6">17,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95d8a6c363c94c7ebb181ec0e4902d6d_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC0xLTEtMS03MDA2MA_2906ce16-dbde-4600-9199-bfede13f56ac"><ix:nonFraction unitRef="shares" contextRef="i3a5c4a87f8a04b809066ca30fe8adea9_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC0xLTEtMS03MDA2MA_c0cc2daf-c33f-433a-b911-27c7cbc2b805">8,063</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7a6d05611034f0cbfbdc965d1641901_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC0zLTEtMS03MDA2MA_e346bfad-f56e-4f31-8eac-9aaeb3a6a60e"><ix:nonFraction unitRef="shares" contextRef="i5b119b75001e4eb591c83a48aca8ad9e_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC0zLTEtMS03MDA2MA_ef7e05ff-9cde-4d18-9206-eeb1c8ea1f66">&#8212;</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdffcc8e474644f1a7bc79d73e44c345_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC01LTEtMS03MTc2MQ_1bcfcd7c-eb4a-415e-b03a-0ea3b650a1b3"><ix:nonFraction unitRef="shares" contextRef="i1c426ecc6b6e483ab968812e43898fb8_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC01LTEtMS03MTc2MQ_f716397c-ce53-47dc-96e1-4f468c1a529f">8,063</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i371ff9f9dd74484bbb7af64395b59cb2_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC03LTEtMS03MTc2MQ_66a8dd27-9aa7-45e2-b3a2-6ecd1740339c"><ix:nonFraction unitRef="shares" contextRef="ibf3d53abab674300a3e66f4bbf777a4d_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC03LTEtMS03MTc2MQ_e2cbf525-410b-4f47-9619-db1e278caac2">&#8212;</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNS0xLTEtMS03MDA2MA_621fb7aa-ac8a-4f62-b67d-3bbff4ecf6f0">25,423</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNS0zLTEtMS03MDA2MA_d62c48d5-9b12-47d9-ba3c-c8ba0f5c427a">18,743</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNS01LTEtMS03MjUzNg_094c2dea-0bb5-4250-a1e7-639c5729caef">25,423</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNS03LTEtMS03MjUzNg_9a785620-239f-4bd6-b9ca-9fcf84f110d5">18,743</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_70"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk0OQ_bb14078c-32f3-422c-a254-f5be8e903634" continuedAt="i450f946826294ff1b44f925434d8d8a6" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i450f946826294ff1b44f925434d8d8a6" continuedAt="ibd3a7ae0ab16415fa8adb8c291c3babb"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk1MA_b07b57d9-d84d-4e17-8453-0315d7310852" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"></td><td style="width:238.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30153c69f900480b8a7b0d198d30b92d_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMi0xLTEtMS03MDA2MA_e352acd1-52e8-4f5c-aae6-a5b5db65ca38">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c58c1e89d74a42975680f91f9ea952_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMi0zLTEtMS03MDA2MA_840c1cc7-92b1-4cae-a39c-f3a69dd861a7">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7184f2bd1645489a8e93fd75f730b37a_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMi01LTEtMS03MTU0Mg_bafff51a-b97b-428b-ad2d-baa7a4f0749a">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb927ed78cfd4508b0462135a3c2436f_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMi03LTEtMS03MTU1MA_9d7b709b-e08b-4fd2-9cd8-d4d49a532ec9">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2701137d4d3d4c4e8e5113cfb9b9bf7d_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMy0xLTEtMS03MDA2MA_e97825f7-4437-4cda-ba46-e20a56a7d471">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib379188f80ee457e82a023166eab9d6d_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMy0zLTEtMS03MDA2MA_790d6cb2-2e02-4eb2-ac68-ec8b44206bb7">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd5ecb234e84849a3ef40071493ded8_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMy01LTEtMS03MTU0Mg_b52cfc78-d42a-42e6-b6fb-b24b199ea91b">2,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c124cc8b22a40b89b467199316812d8_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMy03LTEtMS03MTU1MA_9712802f-d5d0-492f-a888-149f97081ad3">1,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfNC0xLTEtMS03MDA2MA_1482d817-cdd7-484b-82cb-715f52faef2a">1,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfNC0zLTEtMS03MDA2MA_6497be89-ddcb-4cb9-84b9-5e457b1a533b">1,259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfNC01LTEtMS03MjU0NQ_4a347a83-8e02-4135-8c4a-23d9a58c9d10">3,696</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfNC03LTEtMS03MjU0NQ_bb4c9a67-961c-4938-8291-b9b532a120fd">2,217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by <ix:nonFraction unitRef="shares" contextRef="ie611da9814584f9980040a27dfc0cff0_D20190601-20190630" decimals="-5" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5NQ_9e7c5dcb-38df-446a-aa34-3d012faad728">7.9</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by <ix:nonFraction unitRef="shares" contextRef="if40d7dc2760c4b73a1bf0f58cb0cea20_D20210501-20210531" decimals="-6" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTU2NA_f4bf573a-5c17-4494-b42d-faa2cd81b57f">12</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately <ix:nonFraction unitRef="shares" contextRef="i67dda89a221d455f9646b0da9c4929bc_I20220630" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTY3Mg_1fd7bb29-f210-4a41-a6b7-1443dc676425">3.1</ix:nonFraction>&#160;million shares of common stock available for issuance under the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a <ix:nonNumeric contextRef="ifa54545585df44e4b7d3a89233f8dfaf_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk0Nw_2aa1bedf-9097-409c-a1ef-6243cff49a31">four-year</ix:nonNumeric> period at the rate of <ix:nonFraction unitRef="number" contextRef="i2df208e090e4403eb77e13ead4f86d17_D20220101-20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTg0OQ_5e81fd83-27a8-4093-92e4-026f37eb5d35">25</ix:nonFraction>% of the grant vesting on the first anniversary of the date of grant and <ix:nonFraction unitRef="number" contextRef="id9d2c51fc9d34a20a514bea566541f46_D20220101-20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTkyMw_ff201e03-1bc2-4c7b-b31a-af74245f1a83">6.25</ix:nonFraction>% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of <ix:nonNumeric contextRef="ifa54545585df44e4b7d3a89233f8dfaf_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTY0OTI2NzQ0OTU4NQ_fd69c6f2-21a2-4f07-8b2f-173a92078721">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i67dda89a221d455f9646b0da9c4929bc_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjYzNw_c08f7597-861d-4fbe-9e01-a8a1f2877e8c">13.6</ix:nonFraction> million stock options outstanding under the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="i015ea6430d994fbc8697ad17d12ffea0_I20211001" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMjg0Ng_0abf78a3-5cb3-4f4d-bf3b-59eda65cfb9d">one</ix:nonFraction> share of the Company&#8217;s common stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately <ix:nonFraction unitRef="number" contextRef="i8e3af4b7d2cd45f48969782be08ae91a_I20211001" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMzE1MQ_b6ca2668-651b-422d-9a39-af41a97fd2de">fifty</ix:nonFraction> percent of then-current base salary. The fair value of PSUs at the grant date was $<ix:nonFraction unitRef="usd" contextRef="i8e3af4b7d2cd45f48969782be08ae91a_I20211001" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTgzOA_7abe3a35-2b7e-4e4b-af4e-a7694d226052">0.4</ix:nonFraction>&#160;million. Each PSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="i8e3af4b7d2cd45f48969782be08ae91a_I20211001" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMzIzNg_f5420bcb-ffaa-4a6f-be56-534db429e727">one</ix:nonFraction> share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of June&#160;30, 2022 achievement was deemed probable for only the cash management milestone, representing $<ix:nonFraction unitRef="usd" contextRef="ice9190fd4c5e4b23a2cfa99f52b8d06e_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTkyNQ_8e832fc8-f79c-4364-a947-25be25d71491">87,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i316721534e954709ac4ca98fac589f21_I20220630" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMzcxNw_25894d21-3599-4af7-9b43-6cf956eec774">20</ix:nonFraction>% of the PSU awards. Therefore, $<ix:nonFraction unitRef="usd" contextRef="i92ebc00eafc24ccc9dfc43c74893c366_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTg5MA_02ed793b-f626-4600-a95a-9716ac57e00c">11,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idd52d29ba82b4fc3a132c9324d52f501_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTg5OQ_0cbc24f7-aee3-4bce-b670-22b4b9fb43a5">33,000</ix:nonFraction> have been expensed during the three and six months ended June 30, 2022, respectively and $<ix:nonFraction unitRef="usd" contextRef="i316721534e954709ac4ca98fac589f21_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTg4MQ_8a1f0271-002e-45dc-9c02-0bb9a2ffe0e0">54,000</ix:nonFraction> remains measured but unrecognized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ibd3a7ae0ab16415fa8adb8c291c3babb" continuedAt="ib9d16543284545349e2d68dcdc13e8ad"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of <ix:nonNumeric contextRef="i03957233ce864a5a98dacdf6ed5a459b_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDY3MQ_114f0cb4-d1c1-4f93-896e-761d1c3527ac">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i03957233ce864a5a98dacdf6ed5a459b_D20220101-20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDcyMw_3f376f56-8c17-4c51-91d4-c88c95216592">0.1</ix:nonFraction> million fully vested stock options outstanding under the 2009 Plan as of June&#160;30, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately <ix:nonFraction unitRef="shares" contextRef="i1d5814f76b2747c3bb68d3ded24afaba_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNTIzMQ_fceab105-4edc-4561-a99c-0a77e860675e">3.5</ix:nonFraction> million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk2Mw_62ad3cc0-4858-46bf-a6fb-b81c3feaaff8" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:41.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMS0xLTEtMS03MDA2MA_b074117c-265a-4cfb-8309-9cdc26f05c9d">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMS0zLTEtMS03MDA2MA_d2e3a15f-5101-4368-8469-7b8cc1002841">1.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i734f190a8be94ab0a3e93a4104c4affb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMS01LTEtMS03MDA2MA_dbc2f835-4c9f-4031-ac51-524902eb43fa">8.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMS03LTEtMS03MDA2MA_932d40d4-67b2-43ac-8dd8-a3d0b64e1213">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMi0xLTEtMS03MDA2MA_c0bcf819-55a9-40fd-8fc4-f8b211103d86">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMi0zLTEtMS03MDA2MA_2b365ee3-1ed4-4424-a569-cd71f190f075">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMy0xLTEtMS03MDA2MA_3a0ea5e2-22e3-4282-99c5-e56e2da01db9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMy0zLTEtMS03MDA2MA_28b44aff-e9de-4b5a-aa48-e0671b95dc19">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNC0xLTEtMS03MDA2MA_3674e18e-629c-47d3-acc0-96b87703d3a8">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNC0zLTEtMS03MDA2MA_8f563fc9-30ef-4cc7-a4a2-bf418215bfbf">1.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNS0xLTEtMS03MDA2MA_670fe141-2fe7-4902-85be-87c74e643cdc">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNS0zLTEtMS03MDA2MA_dee752fe-b4c5-4a5b-b16c-e67e7c35e212">1.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNS01LTEtMS03MDA2MA_502f4cd6-4461-4cf1-9dab-4c4a7e118df8">7.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNS03LTEtMS03MDA2MA_e9d3f204-45ec-4507-b0d4-292f717e1347">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNi0xLTEtMS03MDA2MA_ef753b66-8532-4524-802c-90df3d1a5dbb">9,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNi0zLTEtMS03MDA2MA_f749e7b3-2553-42af-86bd-28c5200ac8d1">1.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNi01LTEtMS03MDA2MA_83c70437-c703-4ad4-a6b5-d8be4161a3e1">7.11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNi03LTEtMS03MDA2MA_59b36cb2-82cd-443a-8c2f-f7d434fe69a5">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense, related to stock options, of $<ix:nonFraction unitRef="usd" contextRef="i4286168bb23741ed8ede08217b5079cd_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5OTUxMTYzNTA3MQ_d6d34b88-246f-4781-aa5a-f3a927bff6cd">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5OTUxMTYzNTA3Nw_f72e93fe-57c9-406e-958e-14773eb6bfc1">2.5</ix:nonFraction> million for the three and six months ended June&#160;30, 2022, respectively and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="idddc6e09a127406fb21bab2cff01e6a3_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5OTUxMTYzNTA4Ng_5ad73616-6f67-4d1f-b284-1d9c2181f4ce">1.3</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5OTUxMTYzNTA5Mw_f6270821-f4dc-4cb5-b1db-f8105c5c8ae7">2.2</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June&#160;30, 2021, respectively. As of June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjUyOA_8427e53d-35d2-4c66-b4c5-cca2e7ec7444">8.6</ix:nonFraction> million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjUzOA_85afafa3-0cdf-48fc-b2ab-306e19717b01">2.36</ix:nonNumeric> years. The weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2022 and 2021 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjAxNg_15b91abd-3696-4a6f-a5de-98f9573dd711">0.46</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjAyMw_3aa259e7-3b05-499f-956f-6f0de92e55ff">2.17</ix:nonFraction>, respectively. <ix:nonFraction unitRef="shares" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0MQ_a1fda340-a876-41b8-b043-c093bc1c04e8">No</ix:nonFraction> stock options were exercised during the six months ended June 30, 2022. </span></div><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk1NA_e5b87275-4da7-4767-8188-5dd2ae131035" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:64.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfMi0xLTEtMS03MDA2MA_8b602c4e-ed57-4447-91fa-9930bc72dede">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfMi0zLTEtMS03MDA2MA_12c9d98d-f686-4d46-ad0b-86673654a67e">3.34</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if12ac6d811ab49fea4ae767cff635f67_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfMy0xLTEtMS03MDA2MA_a2210ebc-432c-4683-bffe-f129a456a464">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i40d49584882e49c39b789667e1aa8b9a_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfMy0zLTEtMS03MDA2MA_7bd2b1e5-0d27-4b1d-984d-cdac9c3f50e9">3.34</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNC0xLTEtMS03MDA2MA_c6a4c827-37b3-429a-b964-11c1e0224aff">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNC0zLTEtMS03MDA2MA_24216456-70d2-4f0b-974e-7cbee099e687">6.04</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNS0xLTEtMS03MDA2MA_6df5ac39-3d1b-462c-96ed-8052825e9230">2.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNS0zLTEtMS03MDA2MA_1e567020-e862-479c-adeb-4e7fbd00db41">0.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNi0xLTEtMS03MDA2MA_ca745a92-f0db-4694-ae61-5a157767f2fa">71.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNi0zLTEtMS03MDA2MA_6c97ddce-8d9a-4d2e-ad25-22c9287b7b93">74.7</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNy0xLTEtMS03MDA2MA_d2c519b9-bfa1-46cd-8588-c6baf83281c6">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNy0zLTEtMS03MDA2MA_a50636e3-8ec7-4769-9ca5-713218b28256">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ib9d16543284545349e2d68dcdc13e8ad" continuedAt="ifd4a70d49a634b8ea991fbf78bb030b4"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units </span></div><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk1NQ_ffc132c2-79b6-4e9e-90ad-82de41763e43" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:60.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMS0xLTEtMS03MDA2MA_f42e0fb7-59df-4d89-8f21-b556dcd74dff">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMS0zLTEtMS03MDA2MA_b1566b51-f392-4bd9-8794-47187b2c45e0">0.80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMi0xLTEtMS03MDA2MA_5181800f-6171-464f-99ab-0bea6a0c302e">4,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMi0zLTEtMS03MDA2MA_299997ff-c49b-4ba0-9214-6faddfd6f6b9">0.68</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled RSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMy0xLTEtMS03NjY5Ng_93ca7ba8-8ecb-4c72-a745-84bb1ea69a89">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMy0zLTEtMS03NjY5OA_13929d6d-7652-47ea-aef6-ef0172599dc8">0.75</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd2fc190c9bb4eac8b5f0a896433b557_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMy0xLTEtMS03MDA2MA_2ac07c39-0891-43b6-b4c5-5924f40990a2">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idd2fc190c9bb4eac8b5f0a896433b557_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMy0zLTEtMS03MDA2MA_fe8ba43a-5ab2-4a7b-857d-a1bdb7ffb508">0.67</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfNC0xLTEtMS03MDA2MA_3819d022-d7b2-49d7-8e2e-fe17670ea0a8">8,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfNC0zLTEtMS03MDA2MA_6af85260-19ba-4e7e-9bdf-3c4b75d64c42">0.72</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="shares" contextRef="ided647db41004402b85556f36c1a5a6a_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjU0OA_2df8fed1-09b0-4281-8eae-0e79e616ad60"><ix:nonFraction unitRef="shares" contextRef="ib5a0f88a3ce248ca80278fd875407820_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjU0OA_4d0104cf-5c44-4311-88a6-c35f8184e6b7">no</ix:nonFraction></ix:nonFraction>t grant any RSUs or PSUs during the six months ended June 30, 2021. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifd4a70d49a634b8ea991fbf78bb030b4">The share-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i75f185aabf3c422eb49cc6accab9e6cd_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjY4NA_12c62753-5cf0-4b30-ba56-f0ca67a4cc9a"><ix:nonFraction unitRef="usd" contextRef="i517f238357944a0796854ba08409d69f_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjY4NA_7d983bbe-6aab-4967-8360-5f385630c96a">0.6</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjY3Nw_18aff027-aa93-42be-acea-5282b9964be5"><ix:nonFraction unitRef="usd" contextRef="idd2fc190c9bb4eac8b5f0a896433b557_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjY3Nw_8288e0da-2109-4a30-a467-9b2251bd66e4">1.2</ix:nonFraction></ix:nonFraction> million, respectively. There was <ix:nonFraction unitRef="usd" contextRef="ib5a0f88a3ce248ca80278fd875407820_D20210101-20210630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjY4Mg_01ae3446-d5aa-4c40-bec5-8feb1a65fdd5"><ix:nonFraction unitRef="usd" contextRef="ided647db41004402b85556f36c1a5a6a_D20210101-20210630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjY4Mg_33787c68-bdce-4a1b-8404-7c3f83294dac">no</ix:nonFraction></ix:nonFraction> shared-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2021. As of June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="idf83b58ca25c49e192a0c8602c5b4cf2_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjc4OA_c7676eb5-199b-4959-8172-4d07c54a0f05"><ix:nonFraction unitRef="usd" contextRef="i0ad270b4c89440e0821ae038d2cb2389_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjc4OA_d741d720-9d0f-4bdc-a026-b3b154ce42a9">3.0</ix:nonFraction></ix:nonFraction>&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs.</ix:continuation> </span></div><div id="i90488ba6460948abaea2097aabfb6299_73"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMjYzNQ_306845c1-1aab-4f90-af09-22e6e9fe0236" continuedAt="i2385bb8302024cbb85e873471d1e6a7a" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i2385bb8302024cbb85e873471d1e6a7a" continuedAt="ia3461c7fb2394e7e9a7d3dfaa99b0e9f"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of <ix:nonFraction unitRef="shares" contextRef="ic9b0b2106a50498eb917274f3a68063a_I20140228" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMzg2_2897de74-3603-4a5c-8baf-4c6fb5691e79">0.2</ix:nonFraction>&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by <ix:nonFraction unitRef="shares" contextRef="i665443501e7f49ecae379e80a026aa5e_D20210501-20210531" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfNjE2_a9e81df5-8257-4fae-9a63-ab957f65a7d4">2.3</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="i5f79c7546bc741bfb209ea4731a1b39f_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfOTYz_9567e95e-d9a1-43a3-89b6-5a628ff16915">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of June&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i72b00192c39e430cbe5b0b12c9d8d89c_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMTM4Ng_938f5541-401a-445a-9b96-e44f918c98d5">2.3</ix:nonFraction>&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP during the six months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to <ix:nonFraction unitRef="number" contextRef="ie820aa9d32f54e368d97eb79949bb246_D20220101-20220630" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMTg0MA_54f60d7a-f37f-4caf-a460-30a9e66de85e">100</ix:nonFraction>% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="ie820aa9d32f54e368d97eb79949bb246_D20220101-20220630" decimals="INF" name="sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMjAzOQ_44b50922-14ca-41c9-941b-86823c64414b">4,000</ix:nonFraction> per year. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia3461c7fb2394e7e9a7d3dfaa99b0e9f">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first <ix:nonFraction unitRef="number" contextRef="i877a2547d28941a6974c361f55d0df05_D20220101-20220630" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMjQzNg_7f651a88-7c1d-4a3c-8934-01923bfed032">4</ix:nonFraction>% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_951"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzYwNDczMTM5NTYyMDM_e15a0e11-db0e-4d90-b35a-fa6ea1e58bc0" continuedAt="i977d426ed7844d689a88b90df08daf39" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i977d426ed7844d689a88b90df08daf39"><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzYwNDczMTM5NTYyMDQ_3194015a-2b41-4134-88a4-ed8a24ceeb25" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:63.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzMtMS0xLTEtNzYwNTY_22f0ac6d-c9fb-4041-beba-9403ec2d7b40">55,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzMtMy0xLTEtNzYwNTY_64c924c4-3a41-46d2-a43f-6fd0aa3082e4">21,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzQtMS0xLTEtNzYwNTY_66104dae-f1e5-4ed8-aea9-5466d76a371b">19,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzQtMy0xLTEtNzYwNTY_f377e6c8-b15a-4cdb-be0f-2bb0dd0bbb32">59,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzUtMS0xLTEtNzcwNjc_931f8d5b-7b8c-4125-981d-cae0481b43ad">36,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzUtMy0xLTEtNzcwNjc_02706232-b989-4536-add7-7842b80636cf">80,666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzYwNDczMTM5NTYyMDU_b6844e5b-e75f-4e00-b1f5-64a203ff9aec" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:63.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpjNGU0ZWIzYWJhN2M0YzcwYTc4ZjE4YjhjN2IwMTMzYy90YWJsZXJhbmdlOmM0ZTRlYjNhYmE3YzRjNzBhNzhmMThiOGM3YjAxMzNjXzUtMS0xLTEtNzYxMDM_7f74b6ea-4ccd-4823-b727-f52d7db213a0">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpjNGU0ZWIzYWJhN2M0YzcwYTc4ZjE4YjhjN2IwMTMzYy90YWJsZXJhbmdlOmM0ZTRlYjNhYmE3YzRjNzBhNzhmMThiOGM3YjAxMzNjXzUtMy0xLTEtNzYxMDM_9ecfef74-162e-4f4a-ad61-204c419e0e11">288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpjNGU0ZWIzYWJhN2M0YzcwYTc4ZjE4YjhjN2IwMTMzYy90YWJsZXJhbmdlOmM0ZTRlYjNhYmE3YzRjNzBhNzhmMThiOGM3YjAxMzNjXzYtMS0xLTEtNzcwNzA_d0999a9e-69e1-4526-a257-7f6806063f2d">3,875</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpjNGU0ZWIzYWJhN2M0YzcwYTc4ZjE4YjhjN2IwMTMzYy90YWJsZXJhbmdlOmM0ZTRlYjNhYmE3YzRjNzBhNzhmMThiOGM3YjAxMzNjXzYtMy0xLTEtNzcwNzA_73525a5e-ca9f-4203-829b-b58a2395a966">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzYwNDczMTM5NTYyMDY_600a3948-98b9-402e-bb55-b0d73357155a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:63.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZToxZmViNThhMWYzMDc0NjMzYWI1NGE4NzYwYzBkMDg4NC90YWJsZXJhbmdlOjFmZWI1OGExZjMwNzQ2MzNhYjU0YTg3NjBjMGQwODg0XzItMS0xLTEtNzYwNTY_9cd3b1f6-c690-4fa0-837d-d9b793ce0e00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZToxZmViNThhMWYzMDc0NjMzYWI1NGE4NzYwYzBkMDg4NC90YWJsZXJhbmdlOjFmZWI1OGExZjMwNzQ2MzNhYjU0YTg3NjBjMGQwODg0XzItMy0xLTEtNzYwNTY_d0a862ef-7f24-4306-a973-dba8e021991f">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZToxZmViNThhMWYzMDc0NjMzYWI1NGE4NzYwYzBkMDg4NC90YWJsZXJhbmdlOjFmZWI1OGExZjMwNzQ2MzNhYjU0YTg3NjBjMGQwODg0XzQtMS0xLTEtNzcwNzM_d12e26d3-9e93-4c1b-af7a-e5838650be2e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZToxZmViNThhMWYzMDc0NjMzYWI1NGE4NzYwYzBkMDg4NC90YWJsZXJhbmdlOjFmZWI1OGExZjMwNzQ2MzNhYjU0YTg3NjBjMGQwODg0XzQtMy0xLTEtNzYwNTY_6b691747-5119-454e-9a0c-997b4bf43ea4">3,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, the Company recorded a benefit from income taxes of $<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjY5MDc_5dd07100-4a60-4837-b68b-ba69557d0adf">3.9</ix:nonFraction> million. In the second quarter of 2022, the Company determined that the fair value of the Vicineum EU rights was <ix:nonFraction unitRef="usd" contextRef="iaafbcb1be87d432d8ded324e6ed76889_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzE2NDkyNjc0NDY3NzU_d456cea5-0416-4a55-9d4e-bde8cfe0955a">zero</ix:nonFraction>, which resulted in an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="id9d33e85d61e44c4bfd117e7d31fe670_D20220401-20220630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjg0Mzc_920f04dc-848c-4c04-812e-c62b30a94e67">14.7</ix:nonFraction>&#160;million. In connection with this impairment charge, the Company reversed the associated deferred tax liability by $<ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-5" sign="-" name="sesn:IncreaseDecreaseInDeferredTaxLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjcyMTU_34f2bd16-489b-48ab-b02f-dfeff22ed4dc">4.0</ix:nonFraction> million as an income tax benefit, partially offset by $<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjcyNTM_ca8fb875-989e-4b6a-b601-24c5af0a7429">0.1</ix:nonFraction> million income tax paid to foreign jurisdictions pursuant to the exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) (the &#8220;Qilu License Agreement&#8221;). Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the six months ended June 30, 2021, the Company recorded a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjg0NDU_1cdb2aec-d571-49bc-addb-5043875cf12b">0.3</ix:nonFraction> million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the Qilu License Agreement.</span></div></ix:continuation><div id="i90488ba6460948abaea2097aabfb6299_76"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="sesn:LicenseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjA4MTQ_c1c504c4-79a7-4922-b7b4-bda4bc3fc667" continuedAt="i034ed90e2e144b2cb82ed04cd8cd301d" escape="true">LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i034ed90e2e144b2cb82ed04cd8cd301d" continuedAt="i55d8c7bc742942e3bb3be7a8f0f526eb"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $<ix:nonFraction unitRef="usd" contextRef="i18a706cafcaf41aab0bf2bbae702174f_D20220101-20220630" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjUz_b190991e-fb56-4f95-8d58-37c8a23f4a07">0.5</ix:nonFraction>&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a <ix:nonFraction unitRef="number" contextRef="i1d04fb2cb1d2410b8938ae078b9fd516_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzY2_6644fcb9-09d6-4a50-844c-b9ea7c07f279">4</ix:nonFraction>% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is <ix:nonFraction unitRef="number" contextRef="i1d04fb2cb1d2410b8938ae078b9fd516_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTA2Mg_36e2c8f2-666d-4be3-bb47-e7cd471b500e">10</ix:nonFraction>% or greater, provided that the royalty rate to Zurich may not be less than <ix:nonFraction unitRef="number" contextRef="i1d04fb2cb1d2410b8938ae078b9fd516_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTEzOQ_179d3426-b1fe-4fbe-94b9-a39bd618bb5c">2</ix:nonFraction>% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="ic6f9d2a8d9b34e2ea5321b0774bc4cd3_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUzMQ_e6073dc2-00cb-48ff-b9ca-c894f8b9d7c8">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9a026aa3a4334726bbd5d5b4169de5ac_D20210701-20210930" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUzOA_7b36323e-1f05-4d16-99da-3e27466011c8">0.5</ix:nonFraction>&#160;million </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i55d8c7bc742942e3bb3be7a8f0f526eb" continuedAt="i56fbd1ce77094e9e96f8974f9d7cfc6b"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to meeting a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of June&#160;30, 2022, the Company may be obligated to pay up to &#8364;<ix:nonFraction unitRef="eur" contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjI5Mw_2eb84144-66b8-464a-a1cf-ab24b4e2e33b">2.4</ix:nonFraction>&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $<ix:nonFraction unitRef="usd" contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjQ0MA_6e98845c-62b4-4287-9537-65a95e7c3182">2.5</ix:nonFraction>&#160;million at exchange rates in effect on June&#160;30, 2022). The Company is also required to pay up to a <ix:nonFraction unitRef="number" contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjUyMw_4697a092-f033-4de7-9159-b3c954907257">3.5</ix:nonFraction>% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to <ix:nonFraction unitRef="number" contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjY5Mg_b7e16036-bced-4822-8087-a793ea204004">1.5</ix:nonFraction>% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;<ix:nonFraction unitRef="eur" contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630" decimals="-3" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzA4NQ_1b9bcaac-c16d-4e1c-bebd-5a7590d96b32">50,000</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630" decimals="0" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzEwMw_d6091320-8b3b-403a-9dda-60e3b4ab94d5">52,148</ix:nonFraction> at exchange rates in effect as of June&#160;30, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i21cd86819fc94d60888b84c9fbec1cd9_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzI1OQ_5f30312c-39f3-422f-b533-2181669f9bd1">0.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i21cd86819fc94d60888b84c9fbec1cd9_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzI2Mw_ab248c61-dae2-4558-a4bb-76cdaf0b357a">0.9</ix:nonFraction>&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="iec3b8c8266c54149935b053a4854e949_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzQ4NA_db051222-3923-48bf-9c23-cbc02670c3b2">0.5</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="iec3b8c8266c54149935b053a4854e949_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzQ4OA_a7bf6267-d5ce-44b2-b742-90ffe16f7362">0.6</ix:nonFraction>&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $<ix:nonFraction unitRef="usd" contextRef="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630" decimals="-4" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNDE5Nw_29eb53a9-1492-4323-a859-149fdbb6b5cd">0.25</ix:nonFraction>&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a <ix:nonFraction unitRef="number" contextRef="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNDUyNw_725978b9-e94a-4e06-a63b-fb45e7b6c6ef">2.5</ix:nonFraction>% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than <ix:nonFraction unitRef="number" contextRef="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNDg0NQ_ae9fe615-5763-4538-9b47-98030e0f59a5">1.75</ix:nonFraction>% of net sales. In addition, the foregoing royalty rates are reduced by <ix:nonFraction unitRef="number" contextRef="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNDkxOA_b08e492c-f753-4bf7-9806-e0a7a08bfc4a">50</ix:nonFraction>% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i01807f2cd89e4e9d84b0e1ec13338d5f_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjEzOA_4a4cbd07-4a66-4884-9b6e-e883364374be">7.5</ix:nonFraction>&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="i01807f2cd89e4e9d84b0e1ec13338d5f_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAdditionalUpFrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjMwNA_659acc48-2574-4c56-ab93-eba463625e69">262.5</ix:nonFraction>&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="ic7f3a1555672448da4256c36f647a2ea_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjQ5MA_0c3159f8-2e96-4107-b35f-26703599b59d">197.5</ix:nonFraction>&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="icedd019379624203beb6559637b67e52_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjYxOQ_a6de7bc1-a875-48aa-9624-024424b931b5">72.5</ix:nonFraction>&#160;million in development milestones, the next of which is $<ix:nonFraction unitRef="usd" contextRef="i71e7893a75ac4fcdbb28b05eddc7e79e_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjY3MA_a194312f-ba9c-498f-affb-165cea38816d">30</ix:nonFraction>&#160;million for initiation of the first Phase III clinical trial, (ii) $<ix:nonFraction unitRef="usd" contextRef="i56d94eda0f1e46ba9ba00a785398fb15_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjczMg_2551bf09-d424-4dd4-bf15-da7d356bb20b">50</ix:nonFraction>&#160;million in regulatory milestones and (iii) $<ix:nonFraction unitRef="usd" contextRef="i87cb0e785fa74c60b27360b6bae115b5_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjc3MA_fd7acc12-5985-4f7f-811a-f6679adb245e">75</ix:nonFraction>&#160;million in commercialization milestones. Additional amounts of up to $<ix:nonFraction unitRef="usd" contextRef="i8afbb1e24e95451fb3040230f72e3eea_D20220101-20220630" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjgzNA_ab8e6a4f-e43a-4eaf-b6b8-b331907f1bee">65</ix:nonFraction>&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $<ix:nonFraction unitRef="usd" contextRef="ie0efda518e014299bbb43462ac3cc850_D20160901-20160930" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzAyMw_625b71b2-ff11-4720-ad1c-222d92077d9d">22.5</ix:nonFraction>&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $<ix:nonFraction unitRef="usd" contextRef="i3d81161a92ef494db5814266170b94b4_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzE2Ng_8d73a963-5ac4-405f-991a-96254f19c361">20</ix:nonFraction>&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i56fbd1ce77094e9e96f8974f9d7cfc6b" continuedAt="id49fdd7213a04f81a46dfdefbf886f11"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification 606, Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606&#8221;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in previous periods. Accordingly, the Company invoiced Roche $<ix:nonFraction unitRef="usd" contextRef="ida7114209f954433a73b2aa4e6273e7f_I20220630" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzU4MA_bd5d125a-be3c-4369-a807-1bf15d05d808">20</ix:nonFraction>&#160;million with payment terms of <ix:nonNumeric contextRef="iaebb9ac802f4499ab5d494233003436d_D20220101-20220630" name="sesn:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzYwNQ_f0cdfdc5-a86a-41c9-bedb-956f0ca58468">30</ix:nonNumeric> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $<ix:nonFraction unitRef="usd" contextRef="i8c1ee3d4b0ed4b6d81693a3b78436a98_D20211001-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzcyMQ_bd8097c3-b024-41d1-bf6d-d8375d41e271">20</ix:nonFraction>&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $<ix:nonFraction unitRef="usd" contextRef="i1a23e83ac0484f0bbab51200be62df4c_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzg0NA_868cbc9e-1de8-4c37-ad1f-99c09395e400">20</ix:nonFraction>&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from <ix:nonFraction unitRef="number" contextRef="i6542b5648ea045f58f4c69b28422077a_I20220630" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzk5OQ_336fd2eb-c27f-4b17-b648-399dd6ff170b">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ifd055427f2ee4af697e38e23fd5f01bc_I20220630" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfODAwNQ_0ddce68a-8ebb-49e9-97a2-cf678709f843">15</ix:nonFraction>% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for <ix:nonFraction unitRef="period" contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630" decimals="INF" name="sesn:LicenseAgreementOptionPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfODM0NA_24b04ef1-2bc0-42b6-aafe-8693323cc088">two</ix:nonFraction> &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $<ix:nonFraction unitRef="usd" contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfODg0Mw_67336d1e-8351-4e90-af67-f49d2b28fe6a">135</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfODg1Mw_95ac6447-4ed6-45e8-a8c7-24001cd855c4">30</ix:nonNumeric> days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within <ix:nonNumeric contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfOTM1OQ_0ac12285-3458-4996-b674-170ec1866ff2">30</ix:nonNumeric> days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $<ix:nonFraction unitRef="usd" contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfOTQ1Nw_a8c3cf9a-090a-4d56-a336-3d325d1f9e18">265</ix:nonFraction>&#160;million, which amount would be reduced to $<ix:nonFraction unitRef="usd" contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfOTQ5NA_eb84696f-7255-4b92-ae46-85c18d285219">220</ix:nonFraction>&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the Roche License Agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the Company executed an asset purchase agreement with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $<ix:nonFraction unitRef="usd" contextRef="ia2e62709d9af4f339539c651a584c514_I20220715" decimals="-6" name="sesn:OtherReceivableAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjA0NzMxMzk3Njk1MQ_9607ca64-1105-4cf8-b14e-e9d29576e320">70</ix:nonFraction>&#160;million. See further discussion in Note 19. "Subsequent Events".</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0492cdffd25d4cf78dc20d704adfe705_D20200730-20200730" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTE3NDc_5a3acec2-bbd4-4db7-9678-22273989ac68">12</ix:nonFraction>&#160;million, and milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i0492cdffd25d4cf78dc20d704adfe705_D20200730-20200730" decimals="-6" name="sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTE3ODk_da30b3cb-8a21-4e04-8742-91cea5f40c4f">23</ix:nonFraction>&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of VAT, which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a <ix:nonFraction unitRef="number" contextRef="i0492cdffd25d4cf78dc20d704adfe705_D20200730-20200730" decimals="2" name="sesn:BusinessCombinationRoyaltyPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTIwOTE_93e5e5c0-7ac7-486d-97a0-c03c617ec5a0">12</ix:nonFraction>% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Qilu Licensed Product in a region and continuing until the latest of (i) <ix:nonNumeric contextRef="id40d181b700547bea2d9b69343d99848_D20200730-20200730" name="sesn:CollaborativeArrangementRoyaltyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjA4MTU_47181c66-3662-4027-8c47-7a73748caf7b">twelve years</ix:nonNumeric> after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="id49fdd7213a04f81a46dfdefbf886f11" continuedAt="i2c1f885ef1f94b54970b584a88bafc3a"><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $<ix:nonFraction unitRef="usd" contextRef="i0208600fe4024d29a9aa9d6917193edb_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUwMDU_fb771275-38f3-4d14-98cf-a66329b6ae2a">11.2</ix:nonFraction>&#160;million and was based on the up-front fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="i60749fcbb0ad4615afcf10b65d11d107_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUwNjE_5ace05ee-8049-4105-a973-7e0d19ad4684">12</ix:nonFraction>&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020. As such, $<ix:nonFraction unitRef="usd" contextRef="i0b2ff8e61fcd46c299eab19b8098175a_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUyNzY_e4ea983b-b5dd-4a4e-bd17-c118938e50df">11.2</ix:nonFraction>&#160;million of the total $<ix:nonFraction unitRef="usd" contextRef="i0b2ff8e61fcd46c299eab19b8098175a_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUyOTI_cc07047a-9703-408f-b5fa-c25ae333152a">11.2</ix:nonFraction>&#160;million transaction price was considered earned and the Company recorded $<ix:nonFraction unitRef="usd" contextRef="id4b71a855e3048d9a5e32abd82f7ed34_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUzNjA_7ea6790e-7bae-43e5-a992-d4dd04c9fc83">11.2</ix:nonFraction>&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $<ix:nonFraction unitRef="usd" contextRef="ib96799ba5a814f0c8caad764cfa9b749_D20210101-20210331" decimals="-6" name="sesn:BusinessCombinationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTU2MzI_90f72a18-c01a-44a9-a749-ec7bef273328">3</ix:nonFraction>&#160;million milestone payment from Qilu, the first milestone payment out of the $<ix:nonFraction unitRef="usd" contextRef="ib96799ba5a814f0c8caad764cfa9b749_D20210101-20210331" decimals="-6" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTU3MDM_9bc3e0c5-587d-4038-8d43-01ff1f279017">23</ix:nonFraction>&#160;million in potential milestone payments. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="ib96799ba5a814f0c8caad764cfa9b749_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTU3NjA_ca6b2cbe-b1bf-4000-81f1-693d252b91d7">2.8</ix:nonFraction>&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i8ff51dfb75a942b18163f303609e9cf2_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTYxNjk_c905199d-a2d4-4749-954b-b63793ab5ecb">0.9</ix:nonFraction>&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1922ec39f2664925917602d82aac09b7_D20201130-20201130" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTcwNzM_72370c4a-6af9-47da-bee7-c9f4be391903">3</ix:nonFraction>&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $<ix:nonFraction unitRef="usd" contextRef="i166f7d51c9a04607804af70090d9f047_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTc1MDQ_155b10db-18b3-4106-9233-521180d3fd95">1.5</ix:nonFraction>&#160;million as of December 31, 2020 and was based on <ix:nonFraction unitRef="number" contextRef="i166f7d51c9a04607804af70090d9f047_I20201231" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTc1NDg_61d38458-9198-47dd-b596-2a468346b508">50</ix:nonFraction>% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($<ix:nonFraction unitRef="usd" contextRef="i166f7d51c9a04607804af70090d9f047_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTc3MDI_a71c004a-b401-419d-87c9-3899255315ec">1.5</ix:nonFraction>&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained within the stated timeline and was initially recorded as deferred revenue. During the second quarter of 2022, the Company changed assumptions in the clinical study design which resulted in longer clinical trial and further delay in regulatory approval in the MENA region. Therefore, the Company reclassed $<ix:nonFraction unitRef="usd" contextRef="i33b6c64b39074311ba0d20d253292de1_I20220630" decimals="-5" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjA0NzMxMzk3ODUxNw_b4c851c9-0e55-4c04-a63e-ce4c43e81545">1.5</ix:nonFraction>&#160;million of deferred revenue to short-term accrued liability as of June 30, 2022. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $<ix:nonFraction unitRef="usd" contextRef="ibd9b4c5e3f1a4695a42133604689308c_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTgzNTU_0447a5c6-7ca1-4337-aec2-421843742006">1.5</ix:nonFraction>&#160;million was recognized in the first quarter of 2021. Additional variable consideration, determined to be </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i2c1f885ef1f94b54970b584a88bafc3a" continuedAt="i48afa1afa03045d0b24bc1d53ddb9a1a"><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022, the Company terminated the MENA License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events."</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i5aa9628d22de45f283290aaf3f3b037b_I20210805" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTkzNzU_0dadc3d7-46d1-457c-a50a-7175c3cb3dd2">1.5</ix:nonFraction>&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $<ix:nonFraction unitRef="usd" contextRef="id693de1f894a4b41bfff465cc3f75051_D20210805-20210805" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTk2MzE_508d3605-c550-4417-a727-55309b05170f">2.0</ix:nonFraction>&#160;million and is also entitled to receive a <ix:nonFraction unitRef="number" contextRef="i8e4b88050bd14031af553100cd13d2ae_I20210805" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTk2Njg_3ed949c1-3aa6-475d-8ded-771fad60cb6c">30</ix:nonFraction>% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of June&#160;30, 2022, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price was estimated by management;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therefore, no revenue was recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i48afa1afa03045d0b24bc1d53ddb9a1a" continuedAt="i2354458c8b814995b5eae077852c13e8"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2354458c8b814995b5eae077852c13e8">, 2022, the Company terminated the EIP License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.</ix:continuation>"</span></div><div id="i90488ba6460948abaea2097aabfb6299_79"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RleHRyZWdpb246ZmY5NDYzOThjMTYyNDkxOGFmM2VhNWMxYjQ0MGRkZDFfODk4_117c7acd-c8e4-4071-b2c3-a2f790cbd539" continuedAt="id8eab1132d714da697afd505594df278" escape="true">RESTRUCTURING AND RELATED ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="id8eab1132d714da697afd505594df278" continuedAt="ieec5301179024e5c8a288a8a51714819"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Restructuring Plan included a reduction in the Company&#8217;s workforce by <ix:nonFraction unitRef="position" contextRef="i224d2937076040b695691239c9bdd50d_D20210830-20210830" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RleHRyZWdpb246ZmY5NDYzOThjMTYyNDkxOGFmM2VhNWMxYjQ0MGRkZDFfNDE5_58fb319e-2844-42d2-b705-b83a9b0b8cf8">18</ix:nonFraction> positions (or approximately <ix:nonFraction unitRef="number" contextRef="i224d2937076040b695691239c9bdd50d_D20210830-20210830" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RleHRyZWdpb246ZmY5NDYzOThjMTYyNDkxOGFmM2VhNWMxYjQ0MGRkZDFfNDUw_e5bf075c-a480-49f1-9d3c-843cf1bba5ed">35</ix:nonFraction>% of the Company&#8217;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RleHRyZWdpb246ZmY5NDYzOThjMTYyNDkxOGFmM2VhNWMxYjQ0MGRkZDFfODk5_ac763922-cf12-4cf3-923d-87d456297432" continuedAt="ib37a1390402845eaa7ebf07027e1dbf3" escape="true">The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="ib37a1390402845eaa7ebf07027e1dbf3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RhYmxlOmQ0OGNjZjZiZmNkOTQ2MWE4ZTM2MGE2ODc1ZTVjMzNjL3RhYmxlcmFuZ2U6ZDQ4Y2NmNmJmY2Q5NDYxYThlMzYwYTY4NzVlNWMzM2NfMC0xLTEtMS03MDA2MA_bfaadc5c-10b3-4628-8ca8-8ae55ae55451">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RhYmxlOmQ0OGNjZjZiZmNkOTQ2MWE4ZTM2MGE2ODc1ZTVjMzNjL3RhYmxlcmFuZ2U6ZDQ4Y2NmNmJmY2Q5NDYxYThlMzYwYTY4NzVlNWMzM2NfMS0xLTEtMS03MDA2MA_0b6cd199-d50b-4fa3-ba8b-e2e4f8f5a9f4">1,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ec16c102264bf888a63583634b10b9_I20220630" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RhYmxlOmQ0OGNjZjZiZmNkOTQ2MWE4ZTM2MGE2ODc1ZTVjMzNjL3RhYmxlcmFuZ2U6ZDQ4Y2NmNmJmY2Q5NDYxYThlMzYwYTY4NzVlNWMzM2NfMi0xLTEtMS03MDA2MA_8d1879da-fa95-492b-a717-c2b4e50a065a">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that substantially all of the accrued restructuring costs as of June&#160;30, 2022 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieec5301179024e5c8a288a8a51714819">Subsequent to June 30, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.</ix:continuation>"</span></div><div id="i90488ba6460948abaea2097aabfb6299_82"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNzYz_9d4fdac1-f518-42ac-8a19-fc1ba79fa242" continuedAt="i780cc8707acc424eabe65dc7825ed227" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i780cc8707acc424eabe65dc7825ed227" continuedAt="ic1a1fed2c2fe47268e61f9c9588b7ccd"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vicineum</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ic1a1fed2c2fe47268e61f9c9588b7ccd" continuedAt="i154f0da5b9c3482abd710843518c06b9"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA. The Company has turned its primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, the Company intends to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our manufacturing operations by terminating the Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A. and the Commercial Manufacturing and Supply Agreement with Baxter on July 17, 2022 and July 20, 2022, respectively. We requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, we have the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. The Company is in the process of assessing the estimated impact of the termination of the Fujifilm MSA and the Baxter CMSA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, the Company terminated its Cooperative Research and Development Agreement with the National Cancer Institute for the development of Vicineum in combination with AstraZeneca&#8217;s immune checkpoint inhibitor durvalumab for the treatment of BCG-unresponsive NMIBC.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Development Partnerships</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s decision to voluntarily pause further development of Vicineum in the US, the Company has commenced the process to wind down its OUS business development partnerships in MENA and Turkey by providing notice of termination for the MENA License Agreement and EIP License Agreement on July 20, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Restructuring Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially complete by the end of the fourth quarter of 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital while the Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, the Company estimates that it will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $<ix:nonFraction unitRef="usd" contextRef="ia2e62709d9af4f339539c651a584c514_I20220715" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNjA0NzMxMzk2NTgwNw_d879b3a3-6b64-4947-9b90-ea6be6d24544">8</ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also expects to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and is in the process of assessing the estimated impact.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale of Legacy Technology to Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company executed an asset purchase agreement (the &#8220;Roche Asset Purchase Agreement&#8221;) with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $<ix:nonFraction unitRef="usd" contextRef="ia2e62709d9af4f339539c651a584c514_I20220715" decimals="-3" name="sesn:OtherReceivableAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNjA0NzMxMzk2NTgzMg_995220ac-e98f-4531-b5f6-357a1dcd0b12">70</ix:nonFraction>&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $<ix:nonFraction unitRef="usd" contextRef="i924d818132a640e4bbf0b520aa8af43a_D20220715-20220715" decimals="-6" name="sesn:ProceedsFromExecutionOfAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNjA0NzMxMzk2NTg0NQ_7f521d62-b3dd-4582-a6d6-74192753793a">40</ix:nonFraction>&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $<ix:nonFraction unitRef="usd" contextRef="ibd7f6776eada4e709a71593d6e50e7c4_I20220808" decimals="-3" name="sesn:OtherReceivableAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNjA0NzMxMzk2NTgxOQ_81e43055-a2de-4923-b291-7318bf4168ec">30</ix:nonFraction>&#160;million payment to the Company upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and Derivative Litigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022 and July 6, 2022, the Company and the plaintiffs in the Securities Litigation engaged in in-person mediation sessions in an attempt to resolve the litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which is subject to court approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in an in-person mediation session in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims. Pursuant to that agreement, the individual defendants </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i154f0da5b9c3482abd710843518c06b9"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will cause the Company to adopt certain enhancements to the Company&#8217;s corporate governance policies and procedures. In exchange, the plaintiffs will dismiss the complaints and, on behalf of the Company, provide broad customary releases to the individual defendants. The agreement is subject to the execution of a definitive stipulation of settlement and, after notice to the Company&#8217;s stockholders, court approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer to Nasdaq Capital Market </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2022, the Company received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) to transfer the listing of the Company&#8217;s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the &#8220;Approval&#8221;). As a result of the Approval, the Company has been granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, the Company received written notice from Nasdaq indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Company was given until July 25, 2022, to regain compliance with the minimum bid price requirement. In response, the Company submitted an application to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock was transferred to the Nasdaq Capital Market effective at the opening of business on July 28, 2022 and will continue to trade under the symbol &#8220;SESN&#8221;. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market and requires that listed companies meet certain financial and liquidity requirements and comply with Nasdaq&#8217;s corporate governance requirements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company&#8217;s common stock must be at least $1.00 for at least ten consecutive business days during the second 180-day grace period. If the Company does not regain compliance during this second grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that if its stock price does not recover sufficiently during the second grace period, it would implement a reverse stock split, if necessary.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_85"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form 10-Q, should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes thereto appearing elsewhere herein and our audited annual consolidated financial statements and related notes thereto and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2022. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, the impact of the COVID-19 pandemic, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to continue to assess potential strategic alternatives with the goal of maximizing shareholder value;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to seek a partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected timing of implementing and completing our restructuring plan following the decision to pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected timing for incurring costs associated with the 2022 Restructuring Plan;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to preserve capital while we continue to assess potential strategic alternatives and seek a potential partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our ability to identify and assess potential strategic alternatives and seek a partner for the further development of Vicineum;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected financial position;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates and our proprietary technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding key advantages of our targeted fusion protein therapeutics (&#8220;TFPT&#8221;) platform; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the amount of future milestone payments pursuant to our Asset Purchase Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;), (the &#8220;Roche Asset Purchase Agreement&#8221;) and any future milestone or royalty payments pursuant our exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) for the development, manufacture and commercialization of Vicineum in China, Hong Kong, Macau and Taiwan ("Greater China") (the &#8220;Qilu License Agreement&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, among others, the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits or enhances shareholder value;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in identifying a partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our exploration and evaluation of strategic alternatives may cause our stock price to fluctuate significantly;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to implement the 2022 Restructuring Plan as currently anticipated or within the timing currently anticipated;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the workforce reduction in connection with the 2022 Restructuring Plan may have a negative impact on our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cost saving initiatives in connection with the 2022 Restructuring Plan may not be successful;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have unanticipated difficulties with preserving capital or unanticipated difficulties in terminating certain contracts and arrangements in connection with the 2022 Restructuring Plan; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may incur unanticipated charges as a result of the 2022 Restructuring Plan; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that the respective courts may not approve any settlements agreed to by the parties to the ongoing securities litigation and the derivative litigation; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to obtain, maintain, defend and enforce patent claims and other intellectual property rights; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to defend against pending or threatened litigation, which may be costly and time-consuming;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not meet the Nasdaq minimum bid price requirement during any compliance period or in the future; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such other factors described throughout Part I, Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Part II, Item 1A. Risk Factors in this Quarterly Report on Form 10-Q and throughout Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;Sesen,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Sesen Bio, Inc. and its subsidiaries.</span></div><div id="i90488ba6460948abaea2097aabfb6299_88"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following our discussions with the United States Food and Drug Administration ("FDA"), which are further described below. We have turned our primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, we intend to seek a partner for the further development of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assessment of Potential Strategic Alternatives</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2022, we announced that we initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this assessment process. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Restructuring Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following the decision to pause further development of Vicineum in the US. Execution of the 2022 Restructuring Plan is expected to be substantially complete by the end of the fourth quarter of 2022. The 2022 Restructuring Plan includes an incremental reduction in our workforce as well as additional cost-saving initiatives intended to preserve capital while we continue to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, we estimate that we will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $8 million. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and are in the process of assessing the estimated impact.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Legacy Technology to Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we executed an asset purchase agreement with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owned by us for up to $70 million. As a result of the Roche Asset Purchase Agreement, the exclusive license agreement between Roche and us was terminated resulting in no further diligence, milestone or royalty payment obligations under such license agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40 million payment to us upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30 million payable to us upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Update</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#8220;CMC&#8221;) issues pertaining to a recent pre-approval inspection and product quality. On August 20, 2021, we withdrew our marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the EU until there is more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the EU. In October 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, we participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, we participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, we participated in a Type B meeting with the FDA to discuss outstanding items related to our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following our discussions with the FDA. As a result of this decision, we no longer plan to pursue regulatory approval of Vicineum for NMIBC in the EU. We have turned our primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, we intend to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prior Phase 3 Clinical Trial &#8211; VISTA Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2015 in the United States and Canada, through our subsidiary Viventia, we commenced our single-arm, multi-center, open-label Phase 3 clinical trial (&#8220;VISTA Trial&#8221;) in patients with BCG-unresponsive NMIBC who have received adequate BCG and whose disease is now BCG-unresponsive, and for whom the then-current standard of care was a radical cystectomy. Based on safety and efficacy data observed with the longer 12-week induction in our Phase 2 clinical trial, the FDA agreed to our plan to employ more frequent dosing in the VISTA Trial, in which the primary endpoints were complete response (&#8220;CR&#8221;) and duration of response (&#8220;DoR&#8221;) in patients with CIS whose disease is BCG-unresponsive. In November 2016, the FDA issued draft guidance regarding appropriate clinical trial design for new drugs and biologics for BCG-unresponsive NMIBC, including the use of single-arm trials. The FDA finalized this guidance in February 2018 and retained many of the recommendations from the 2016 draft guidance regarding clinical trial design, including the use of single-arm trials. We believe that our VISTA Trial design was consistent with these aspects of the FDA&#8217;s guidance. In May 2022, we completed the follow-up phase of the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of the VISTA Trial were CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive and DoR for BCG-unresponsive CIS patients who experience a CR.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate&#8224;:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8224;Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) is 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) shows that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis shows that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy was a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) is 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA Trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. On August 13, 2021, the FDA issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety Results</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%) - all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A., Inc. (&#8220;Fujifilm&#8221;) (the "Fujifilm MSA") for the manufacturing process and technology transfer of Vicineum drug substance production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter (the &#8220;Baxter CMSA&#8221;) for the manufacturing process and technology transfer of Vicineum drug product production.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our manufacturing operations by terminating the Fujifilm MSA and Baxter CMSA on July 17, 2022 and July 20, 2022, respectively. We requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, we have the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. We are in the process of assessing the estimated impact of the termination of the Fujifilm MSA and the Baxter CMSA. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with the University of Zurich (&#8220;Zurich&#8221;) which grants us exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to our targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a License Agreement with Micromet AG (&#8220;Micromet&#8221;), now part of Amgen, Inc., which grants us nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with XOMA Ireland Limited (&#8220;XOMA&#8221;) which grants us non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding our decision to voluntarily pause further development of Vicineum, we have not taken steps to terminate the above mentioned in-license agreements because our outside the United States (&#8220;OUS&#8221;) business development partners have been granted sublicenses to the intellectual property licensed to us under these in-license agreements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">OUS Business Development Partnering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our OUS business development partnerships in the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey by providing notice of termination for the MENA License Agreement and EIP License Agreement on July 20, 2022. In connection with the termination of our exclusive license agreement with our partner in MENA, we are required to refund the $3&#160;million upfront payment paid to us.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan ("Greater China"). We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retain (i) development and commercialization rights in the rest of the world excluding Greater China and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received a total of $10 million in net proceeds associated with the Qilu License Agreement. We are also entitled to receive up to an additional $23 million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i) twelve years after the first commercial sale of Vicineum in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii) the expiration of regulatory or data exclusivity for Vicineum in such region. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application ("IND") for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. We recorded $2.8 million (net of VAT) as license revenue during the three-month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of value-added tax ("VAT") recovery. As such, we recorded $0.9 million of revenue during the three months ended June 30, 2021, for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. We will not be subject to VAT on future potential milestone payments to Qilu. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the Qilu License Agreement, the trial is being run at the sole cost of Qilu.</span></div><div id="i90488ba6460948abaea2097aabfb6299_91"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Related Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue consists of revenue recognized pursuant to our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the Qilu License Agreement, which is assessed under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606"). In the future, we may generate revenue from a combination of milestone payments and royalties in connection with the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of Vicineum for the treatment of NMIBC, which include: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and share-based compensation expense;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract resource organizations (&#8220;CROs&#8221;) and investigative sites that conduct our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with transferring manufacturing capabilities to contract manufacturing organizations ("CMOs") for commercial-scale production;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with regulatory activities; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with license milestone fees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, costs related to manufacturing or purchasing clinical trial materials and technology transfer and license milestone fees, to specific product programs. We do not allocate employee and contractor-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product programs because these costs may be deployed across multiple product programs under research and development and, as such, are separately classified. The table below provides research and development expenses incurred for Vicineum for the treatment of NMIBC and other expenses by category. We expect to significantly reduce our research and development expenses as we turn our primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value and seek a partner for the further development of Vicineum.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not allocate research and development expenses to any other specific product program during the periods presented (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Programs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum for the treatment of NMIBC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct program expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel and other expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and contractor-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform-related lab expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total personnel and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Research and Development</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,944</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation and benefits, in executive, operational, finance, legal, business development and human resource functions. Other general and administrative expenses include facility-related costs, professional fees for legal, estimated payments to settle litigation, insurance, investment banking fees, patent, consulting and accounting services, and pre-commercial United States market research. Our general and administrative expenses may increase due to increases in professional and advisory fees as we assess potential strategic alternatives.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Viventia Acquisition in September 2016, we recorded contingent consideration pertaining to the amounts potentially payable to Viventia's shareholders pursuant to the terms of the Share Purchase Agreement among us, Viventia and the other signatories thereto and are based on regulatory approval in certain markets and future revenue levels. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized in earnings (or loss) for the period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income earned on cash and cash equivalents and, to a lesser extent, any gains or losses on foreign exchange.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit for income taxes is driven by the intangible impairment charge, changing the value of deferred tax liabilities. Provision for income taxes consists of income taxes incurred to non-US jurisdictions pursuant to our OUS business development partnership agreements, including the Qilu License Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_94"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended June 30, 2022 and 2021 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,997)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,598)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,835)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss After Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31,960)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,442)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,518)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any revenue for the three months ended June 30, 2022. Revenue for the three months ended June 30, 2021 was $2.2 million, which was due to clinical supply revenue resulting from the delivery of drug product to Qilu, our OUS business development partner for Greater China and license revenue for additional purchase price due to the recovery of VAT by Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $29.9 million for the three months ended June 30, 2022, compared to $7.2 million for the three months ended June 30, 2021. The increase of $22.7 million was primarily due to the expense of prepaid balances related to consumables and manufacturing reservations as the balances were evaluated and deemed to have no future value ($25.2 million). This increase was partially offset by lower costs associated with manufacturing ($2.5 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $15.6 million for the three months ended June 30, 2022, compared to $6.8 million for the three months ended June 30, 2021. The increase of $8.8 million was primarily due to an increase in legal expense ($10.3 million). This increase was driven by the preliminary settlements of the securities and derivative litigation net of expected insurance recovery ($8.6 million), related legal fees ($0.9 million), legal fees related to the internal review ($0.3 million) and other legal expenses ($0.5 million). This increase was partially offset by a decrease in marketing and commercial expenses, which were incurred in the second quarter of 2021 in preparation for potential commercial launch but were discontinued as a result of the Complete Response Letter received in August 2021 ($1.5 million). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash change in fair value of contingent consideration was income of $37.3 million for the three months ended June 30, 2022, compared to a loss of $13.6 million for the three months ended June 30, 2021. The decrease in the fair value of contingent consideration of $37.3 million for the three months ended June 30, 2022 was driven by our strategic decision to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voluntarily pause further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. We intend to seek a partner for the further development of Vicineum. We expect that any partner who acquires Vicineum from us will be obligated to make any payments to the former shareholders of Viventia under the Share Purchase Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was a loss of $13.6 million for the three months ended June 30, 2021. This was primarily attributable to changes in the competitive landscape, higher probability of regulatory success, expanded patient population, and to a lesser extent by refinement of timelines in certain markets outside the United States, which was prior to the receipt of a CRL from the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit (Provision) from Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, we recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, we determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7 million. In connection with this impairment charge, in the second quarter of 2022, we wrote-down the associated deferred tax liability by $4.0 million as a benefit, partially offset by $0.1 million income tax paid to foreign jurisdictions pursuant to the Qilu License Agreement. Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. No provision for income taxes was recorded for the three months ended June 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net l</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oss</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, net loss was $32.0&#160;million, compared to net loss of $25.4&#160;million for the three months ended June 30, 2021. The change was primarily attributable to increases in R&amp;D and G&amp;A expense ($31.5 million), primarily driven by the reduction of prepaid balances related to consumables and manufacturing reservations and the preliminary settlements of the securities and derivative litigation. Additionally, license and related revenue recognized decreased ($2.2 million). This was partially offset by favorable changes in non-cash related expenses of $27.0 million (including tax benefit). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_1099511628712"></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the six months ended June 30, 2022 and 2021 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,544)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,331)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,833)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,666)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss After Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32,767)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,954)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any revenue for the six months ended June 30, 2022. Revenue for the six months ended June 30, 2021 was $6.5 million, which was due to achieving the IND milestone in China pursuant to the Qilu License Agreement, clinical supply revenue resulting from the delivery of drug product to Qilu, our OUS partner for Greater China, and license revenue for additional purchase price due to the recovery of VAT by Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $34.7 million for the six months ended June 30, 2022, compared to $13.3 million for the six months ended June 30, 2021. The increase of $21.4 million was primarily due to the expense of prepaid balances related to consumables and manufacturing reservations as the balances were deemed to have no future value ($25.2 million). This increase was partially offset by lower costs associated with manufacturing ($3.7 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $24.6 million for the six months ended June 30, 2022, compared to $12.1 million for the six months ended June 30, 2021. The increase of $12.5 million was primarily due to an increase in legal expense ($13.3 million) driven by the preliminary settlements of the securities and derivative litigation net of expected insurance recovery ($8.6 million), related legal fees ($1.2 million), legal fees related to the internal review ($3.2 million) and other legal expenses ($0.3 million). In addition, employee-related compensation, primarily driven by increased headcount and the retention program implemented in the fourth quarter of 2021 ($1.2 million) and increased insurance expense ($0.3 million). This was partially offset by decreases in marketing and commercial expenses ($1.7 million) and consultant fees ($0.9 million), which were incurred during the first half of 2021 in preparation for potential commercial launch but were discontinued as a result of the Complete Response Letter received in August 2021 and other general expenses ($0.1 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash change in fair value of contingent consideration was income of $50.2 million for the six months ended June 30, 2022, compared to a loss of $61.8 million for the six months ended June 30, 2021. The decrease in the fair value of contingent consideration of $50.2 million for the six months ended June 30, 2022 was driven by our strategic decision to voluntarily pause further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. We intend to seek a partner for the further development of Vicineum. We expect that any partner who acquires Vicineum from us will be obligated to make any payments to the former shareholders of Viventia under the Share Purchase Agreement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was a loss of $61.8 million for the six months ended June 30, 2021. This was primarily attributable to changes in the competitive landscape, higher probability of regulatory success, expanded patient population, and to a lesser extent by refinement of timelines in certain markets outside the United States, which was prior to the receipt of a CRL from the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, we recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, we determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7 million. In connection with this impairment charge, in the second quarter of 2022, we wrote-down the associated deferred tax liability by $4.0 million as a benefit, partially offset by $0.1 million income tax paid to foreign jurisdictions pursuant to the Qilu License Agreement. Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the six months ended June 30, 2021, we recorded a provision for income taxes of $0.3 million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 net loss was $32.8&#160;million, compared to net loss of $81.0 million, for the six months ended June 30, 2021. The decrease of $48.2 million was primarily due to decreases in operating expense ($50.3&#160;million) and the tax provision ($4.2&#160;million) partially offset by a decrease in license and related revenue recognized ($6.5 million). The decrease in operating expense ($50.3&#160;million) was driven by non-cash adjustments ($84.2 million), partially offset by a $33.9 million increase in expense. This increase was primarily due to the reduction of our prepaid balances related to consumables and manufacturing reservations and the preliminary settlements of the securities and derivative litigation. </span></div><div id="i90488ba6460948abaea2097aabfb6299_97"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash, cash equivalents and marketable securities of $161.2 million, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net working </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital of $124.4 million an</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d an accu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mulated deficit of $349.0 million. We incurred negative cash flows from operating activities of $1.4 million</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r the six months ended June 30, 2022, compared to negative cash flows of $41.6 million for the six months ended June 30, 2021.We believe that, based on our current operating plans and financial forecasts, our cash, cash equivalents and marketable securities of $161.2 million as of June&#160;30, 2022, are sufficient to fund our current operating plan for at least twelve months from the date of this Form 10-Q filing, August 8, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have received no revenue from sales of our products, and we anticipate that operating losses will continue for the foreseeable future as we continue to assess any potential strategic alternatives that we may pursue. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our IPO, follow-on public offerings, sales effected in ATM offerings, our OUS business development partnerships and license agreements and, to a lesser extent, from a collaboration.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an Open Market Sale Agreement with Jefferies LLC ("Jefferies") dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which we may issue and sell shares of our common stock, par value $0.001 per share from time to time through Jefferies (the "ATM Offering"). In June and July 2021, we filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of our common stock pursuant to the Sale Agreement of which $97.8 million of common shares remain available for future issuance as of June&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for our common stock. We may sell shares of our common stock efficiently from time to time but have no obligation to sell any of our common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable efforts to sell common stock from time to time, as the sales agent, based upon our instructions, which include a prohibition on sales below a minimum price set by us from time to time. We have provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. We did not sell any shares of common stock pursuant to the Sale Agreement during the six months ended June 30, 2022. We raised $136.8&#160;million of net proceeds from the sale of 47.1 million shares of common stock at a weighted-average price of $2.99 per share during the six months ended June 30, 2021, including $64.3&#160;million of net proceeds from the sale of 16.5 million shares of common stock at a weighted-average price of $4.02 per share during the three months ended June 30, 2021. Share issue costs, including sales agent commissions, related to the ATM Offering totaled $2.0 million and $4.2 million for the three and six months ended June 30, 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on our ability to identify and ultimately consummate a strategic transaction. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this assessment process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of risks similar to other clinical companies that have determined to focus primarily on pursuing a strategic transaction, including, but not limited to, those which are described under Part II Item 1A. Risk Factors of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incur substantial expenses if and as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">address our ongoing securities litigation and derivative litigation; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce our personnel and incur related severance and employee-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">wind down and dispose of the equipment and physical infrastructure that had been used to support our research and development activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminate contracts with our CMOs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminate our property leases in Winnipeg, Manitoba, Cambridge, Massachusetts and Philadelphia, Pennsylvania;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restore our Winnipeg manufacturing facility to the state in which it was originally leased; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explore, evaluate and pursue any strategic alternatives in connection with the review process we have initiated.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of any pending or future litigation involving us or our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of the process we have initiated to review strategic alternatives, which may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty and other payments to third-party licensors under our licensing agreements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, or government or other third-party funding To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our assessment of strategic alternatives. If we do not successfully consummate a strategic alternative, our board of directors may decide to pursue a dissolution and liquidation of our company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual and Other Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to our cash requirements from known contractual and other obligations, see the description of Contingent Consideration in Note 5 &#8220;Fair Value Measurement and Financial Instruments,&#8221; as well as the description of our leases in Note 11 &#8220;Leases&#8221;, and the description of our license agreement and collaborations in Note 17, &#8220;License Agreements&#8221; of Part I - Item 1. Financial Statements - Notes to Condensed Consolidated Financial Statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the six months ended June 30, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:68.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Operating Activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,616)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(90,536)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $1.4 million for the six months ended June 30, 2022 and consisted primarily of a net loss of $32.8&#160;million, adjusted for non-cash items including, a decrease in the fair value of contingent consideration ($50.2&#160;million), intangible impairment charge ($27.8&#160;million), share-based compensation ($3.7&#160;million), and a net increase in operating assets and liabilities ($50.1&#160;million). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n operating activities was $41.6 million for the six months ended June 30, 2021 and consisted primarily of a net loss of $81.0 million, which includes $6.5 million of revenue recognized pursuant to certain of our out-license agreements, adjusted for non-cash items, including share-based compensation ($2.2 million), an increase in the fair value of contingent consideration ($61.8 million) and a net decrease in operating assets and liabilities of ($24.7 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $89.1&#160;million for the six months ended June 30, 2022 and consisted of marketable security purchases. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities consisted of de minimis purchases and sales or property and equipment during the six months ended June 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was zero for the six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $137.3 million for the six months ended June 30, 2021 and consisted primarily of $136.8 million net proceeds from the sale of common stock under the ATM Offering.</span></div><div id="i90488ba6460948abaea2097aabfb6299_100"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in accordance with GAAP and the rules and regulations of the SEC require the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Our critical accounting policies are those policies which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Management has determined that our most critical accounting policies are those relating to the fair value of indefinite-lived intangible assets, goodwill; contingent consideration; revenue recognition; development and regulatory milestone payments and other costs; and research and development costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired IPR&amp;D worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, we observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. We have also experienced a sustained decline in share price and a resulting decrease in our market capitalization. On July 15, 2022, we made the strategic decision to voluntarily pause further development in the US of our lead asset, Vicineum, and intend to seek a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. We updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of EU asset. We concluded that the carrying value of our intangible asset of Vicineum EU rights of $14.7&#160;million was fully impaired as of June&#160;30, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on our condensed consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. We recognize a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. We have only one reporting unit. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, we observed continued trends in our market capitalization as compared to the carrying value of our single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, length and cost of a clinical study, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of our typical annual assessment date of October 1. We reassessed the underlying assumptions used to develop our revenue projections, which were then used as significant inputs to determine the fair value of equity. We updated our revenue forecast models based on further expected launch delays in both US and OUS regions. We also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. We also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, we concluded that the carrying value of our goodwill of $13.1 million was fully impaired as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration on our condensed consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the discounted present value of future commercial launch milestones and net sales earnout payments due to the former shareholders of Viventia pursuant to the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are unpredictable and inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2033. The discount rate applied to the 2% earnout was derived from our estimated weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021 to 10.2% as of June&#160;30, 2022. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development in the US of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Additionally, we intend to seek a partner for the further development of Vicineum. We expect any partner who acquires Vicineum from us will be obligated to make any payments to the former shareholders of Viventia under the Share Purchase Agreement. Accordingly, as of June 30, 2022, we no longer expect to pay related milestone and earnout payments, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights have already been out-licensed. Therefore, the June 30, 2022 balance relates to contingent consideration related to projected net sales in the Greater China region as compared to the December 31, 2021 balance which was based upon projected world-wide net sales.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of June&#160;30, 2022, we reduced our deferred tax liabilities by $4.0 million as a result of intangibles impairment charge, driven by the decision to pause the development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. We recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. We recognize accrued interest and penalties related to uncertain tax positions as income tax expense in our condensed consolidated statements of operations. As of June&#160;30, 2022 and December&#160;31, 2021, we did not have any uncertain tax positions. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we are required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued accounting standards are discussed in &#8220;Item 1. Financial Statements - Notes to Condensed Consolidated Financial Statements - Note 4. Recent Accounting Pronouncements&#8221; of this Quarterly Report on Form 10-Q.</span></div><div id="i90488ba6460948abaea2097aabfb6299_103"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information under this item is not required to be provided by smaller reporting companies.</span></div><div id="i90488ba6460948abaea2097aabfb6299_106"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as defined in Exchange Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rules 13a-15(e) and 15d-15(e), that are designed to ensure information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as the end of the period covered by this Quarterly Report on Form 10-Q. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore, the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with the policies and procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of controls, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our system of controls to enhance, where necessary, our control policies and procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, there were no changes in our internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f), which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_109"></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i90488ba6460948abaea2097aabfb6299_112"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against us and certain of our officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. After the motion was fully briefed and before the court ruled on the motion, on June 3, 2022, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June 30, 2022 and July 6, 2022, the Company and the plaintiffs in the Securities Litigation engaged in in-person mediation sessions in an attempt to resolve the litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which is subject to court approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against our board of directors and certain of our officers (the &#8220;State Securities Litigation&#8221;). The three derivative complaints allege breach of fiduciary duties, waste of corporate assets and violations of federal securities laws, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in an in-person mediation session in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2002, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims. Pursuant to that agreement, the individual defendants will cause the Company to adopt certain enhancements to the Company&#8217;s corporate governance policies and procedures. In exchange, plaintiffs will dismiss the complaints and, on behalf of the Company, provide broad customary releases to the individual defendants. The agreement is subject to the execution of a definitive stipulation of settlement and, after notice to the Company&#8217;s stockholders, court approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation, the State Derivative Litigation and the Federal Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i90488ba6460948abaea2097aabfb6299_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, other than as set forth below, there were no material changes to the "Risk Factors" included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. You should carefully consider the information described therein and in this Quarterly Report on Form 10-Q, which could materially affect our financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our exploration of strategic alternatives may not result in entering into or completing a transaction, and the process of reviewing strategic alternatives or its conclusion could adversely affect our stock price.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this assessment process, which we believe will be complete by the end of 2022. On July 15, 2022, we made the strategic decision to voluntarily pause further development in the US of Vicineum. This decision enables us to conserve cash while we continue to assess potential strategic alternatives. Additionally, we intend to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance any transaction will result from the Company&#8217;s evaluation of strategic alternatives. Any potential transaction would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction with us, obtaining stockholder approval and the availability of financing to us or third parties in a potential transaction with us on reasonable terms. The process of reviewing strategic alternatives may be time consuming and may involve the dedication of significant resources and may require us to incur significant costs and expenses. It could negatively impact our ability to attract, retain and motivate key employees, and expose us to potential litigation in connection with this process or any resulting transaction. If we are unable to effectively manage the process, our financial condition and results of operations could be adversely affected. In addition, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to the future of our company could cause our stock price to fluctuate significantly. Further, any strategic alternative that may be pursued and completed ultimately may not deliver the anticipated benefits or enhance shareholder value. There can be no guarantee that the process of evaluating strategic alternatives will result in our company entering into or completing a potential transaction within the anticipated timing or at all.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we do not successfully complete a strategic transaction, our board of directors may decide to pursue a dissolution and liquidation of our company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no guarantee that the process to identify a strategic transaction will result in a successfully completed transaction. If no transaction is completed, our board of directors may decide that it is in the best interest of our stockholders to dissolve our company and liquidate our assets. In that event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as we fund our operations and evaluate our strategic alternatives. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution of our company, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation of our company. If a dissolution and liquidation were pursued, our board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a dissolution, liquidation or winding up of our company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to regain compliance with the listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market which could have a material adverse effect on our business and could make it more difficult for you to sell your shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders' equity, among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from the Nasdaq Capital Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2022, we received notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") that we were not currently in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had 180 calendar days, or until July 25, 2022, to regain compliance with the minimum bid price requirement by having the closing bid price of our common stock meet or exceed $1.00 per share for at least ten consecutive business days. On July 26, 2022, we received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of our common stock from the Nasdaq Global Market to the Nasdaq Capital Market. As a result, we were granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not regain compliance by January 23, 2023, we will receive notification from Nasdaq that our common stock is subject to delisting. At that time, we may then appeal the delisting determination to a Nasdaq hearings panel. Such notification will have no immediate effect on our listing on the Nasdaq Capital Market, nor will it have an immediate effect on the trading of our common stock pending such hearing. There can be no assurance, however, that we will be able to regain compliance with Nasdaq&#8217;s minimum bid price requirement. If we regain compliance with Nasdaq&#8217;s minimum bid price requirement, there can be no assurance that we will be able to maintain compliance with the continued listing requirements for the Nasdaq Capital Market or that our common stock will not be delisted from the Nasdaq Capital Market in the future. In addition, we may be unable to meet other applicable listing requirements of the Nasdaq Capital Market, including maintaining minimum levels of stockholders&#8217; equity or market values of our common stock in which case, our common stock could be delisted notwithstanding our ability to demonstrate compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delisting from the Nasdaq Capital Market may limit the range and attractiveness of strategic alternatives that we are able to consider, adversely affect our ability to raise additional financing through the public or private sale of equity securities, significantly affect the ability of investors to trade our securities, or negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are delisted from Nasdaq and we are not able to list our common stock on another exchange, our common stock could be quoted on the OTC Bulletin Board or in the &#8220;pink sheets.&#8221; As a result, we could face significant adverse consequences including, among others:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability of market quotations for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of news and little or no analyst coverage for us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we would no longer qualify for exemptions from state securities registration requirements, which may require us to comply with applicable state securities laws; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities (including pursuant to short-form Registration Statements on Form S-3) or obtain additional financing in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our restructuring plans and the associated headcount reductions may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). On July 15, 2022, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following our decision to pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2021 Restructuring Plan was substantially completed by the end of 2021. Execution of the 2022 Restructuring Plan is expected to be substantially completed by the end of 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital while the Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, the Company estimates that it will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $8 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also expects to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and is in the process of assessing the estimated impact.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. For example, we may incur unanticipated charges not currently contemplated as a result of the restructuring plans. If we are unable to realize the expected operational cost savings from the restructuring, our operating results and financial condition would be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_118"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any unregistered equity securities during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i90488ba6460948abaea2097aabfb6299_121"></div><div style="-sec-extract:summary;margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514056904/d679756dex31.htm">Restated Certificate of Incorporation of Eleven Biotherapeutics, Inc. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 18, 2014 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit31-ebioxcertificate.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000103/ex33-certificateofamendm.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q filed on May 10, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit32-elevenbiotherape.htm">Amended and Restated By-Laws. Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex41.htm">Specimen Stock Certificate evidencing the shares of common stock. Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A filed on January 23, 2014 (File No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514448885/d704357dex1023.htm">Form of Warrant issued to Silicon Valley Bank and Life Science Loans, LLC dated November 25, 2014. Incorporated by reference to Exhibit 10.23 to our Registration Statement on Form S-1 filed on December 19, 2014 (File No. 333-201176).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500317000132/ex41ebiopre-fundedwarrant1.htm">Form of Common Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on November 3, 2017 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit41.htm">Form of Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2017warrantamendmenta.htm">Form of 2017 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2018warrantamendmenta.htm">Form of 2018 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesenbio_minorirosales-e.htm">Employment </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesenbio_minorirosales-e.htm">Agreement, dated January 5, 2022, by and between Sesen Bio, Inc. and Minori Rosales.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-06302022x10qex311.htm">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-06302022x10qex312.htm">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-06302022x10qex321.htm">Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-06302022x10qex322.htm">Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data File (Form 10-Q for the Quarterly Period ended June 30, 2022 filed in XBRL). The financial information contained in the XBRL-related documents is "unaudited" and "unreviewed." The instance document does not appear in the interactive file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i90488ba6460948abaea2097aabfb6299_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:142.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:285.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SESEN BIO, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="margin-bottom:1pt;text-align:right"><span><br/></span></div><div style="margin-bottom:1pt;text-align:right"><span><br/></span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Monica Forbes&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>sesn-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2242ac9-1511-42db-a08a-ac050036e5da,g:27c8282b-5e55-4664-b4e1-3a6627cbab54-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sesn="http://www.sesenbio.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sesenbio.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sesenbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION">
        <link:definition>2103102 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPolicies" roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies">
        <link:definition>2204201 - Disclosure - BASIS OF PRESENTATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2105103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS">
        <link:definition>2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables">
        <link:definition>2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
        <link:definition>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLES" roleURI="http://www.sesenbio.com/role/RECEIVABLES">
        <link:definition>2112106 - Disclosure - RECEIVABLES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLESDetails" roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails">
        <link:definition>2413405 - Disclosure - RECEIVABLES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSES" roleURI="http://www.sesenbio.com/role/PREPAIDEXPENSES">
        <link:definition>2114107 - Disclosure - PREPAID EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESDetails" roleURI="http://www.sesenbio.com/role/PREPAIDEXPENSESDetails">
        <link:definition>2415406 - Disclosure - PREPAID EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWIL" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL">
        <link:definition>2116108 - Disclosure - INTANGIBLE ASSETS AND GOODWIL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILTables" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables">
        <link:definition>2317302 - Disclosure - INTANGIBLE ASSETS AND GOODWIL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails">
        <link:definition>2418407 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILNarrativeDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails">
        <link:definition>2419408 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails">
        <link:definition>2420409 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES">
        <link:definition>2121109 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2322303 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails">
        <link:definition>2423410 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2124110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2425411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.sesenbio.com/role/LEASES">
        <link:definition>2126111 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESDetails" roleURI="http://www.sesenbio.com/role/LEASESDetails">
        <link:definition>2427412 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2128112 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2329304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYEquityFinancingDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails">
        <link:definition>2430413 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYPreferredStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails">
        <link:definition>2431414 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYCommonStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails">
        <link:definition>2432415 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails">
        <link:definition>2433416 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYWarrantsDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails">
        <link:definition>2434417 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2135113 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2336305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>2437418 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2138114 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2339306 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
        <link:definition>2440419 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2441420 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>2442421 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
        <link:definition>2443422 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
        <link:definition>2444423 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2145115 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>2446424 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sesenbio.com/role/INCOMETAXES">
        <link:definition>2147116 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.sesenbio.com/role/INCOMETAXESTables">
        <link:definition>2348307 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofPretaxIncomeLossDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails">
        <link:definition>2449425 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofIncomeTaxProvisionsDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails">
        <link:definition>2450426 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails">
        <link:definition>2451427 - Disclosure - INCOME TAXES - Components of Deferred Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2452428 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTS" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS">
        <link:definition>2153117 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTSDetails" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails">
        <link:definition>2454429 - Disclosure - LICENSE AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIES" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES">
        <link:definition>2155118 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESTables" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables">
        <link:definition>2356308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails">
        <link:definition>2457430 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails">
        <link:definition>2458431 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS">
        <link:definition>2159119 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2460432 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_IncreaseDecreaseInDeferredTaxLiability" abstract="false" name="IncreaseDecreaseInDeferredTaxLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_MicrometAGMember" abstract="true" name="MicrometAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_GermanVATRecoveryMember" abstract="true" name="GermanVATRecoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" abstract="false" name="RightOfUseAssetRelatedToAdoptionOfAccountingStandard" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_FirstIndicationMember" abstract="true" name="FirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementUpfrontFee" abstract="false" name="LicenseAgreementUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantOrRightOutstandingRollForward" abstract="true" name="WarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" abstract="false" name="LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_QiluPharmaceuticalCoLtdMember" abstract="true" name="QiluPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_BusinessCombinationRoyaltyPaymentPercent" abstract="false" name="BusinessCombinationRoyaltyPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationTable" abstract="true" name="OrganizationAndBasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_OtherReceivableAssetPurchaseAgreement" abstract="false" name="OtherReceivableAssetPurchaseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CommonStockSharesIssuedAndReservedForFuture" abstract="false" name="CommonStockSharesIssuedAndReservedForFuture" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ExpensesPreviouslyClassifiedAsPrepaid" abstract="false" name="ExpensesPreviouslyClassifiedAsPrepaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementProceedsFromMilestoneAchieved" abstract="false" name="LicenseAgreementProceedsFromMilestoneAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchieved" abstract="false" name="LicenseAgreementMilestoneAchieved" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" abstract="false" name="ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" abstract="false" name="LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementOptionPeriods" abstract="false" name="LicenseAgreementOptionPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_BusinessCombinationMilestonePayments" abstract="false" name="BusinessCombinationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" abstract="false" name="SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" abstract="false" name="ProceedsFromExecutionOfAssetPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" abstract="false" name="LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_AccountsReceivablePaymentTerms" abstract="false" name="AccountsReceivablePaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" abstract="false" name="SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_WarrantsExpiringMarch2023Member" abstract="true" name="WarrantsExpiringMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" abstract="false" name="SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_AccruedRestructuringChargesRelatedCurrent" abstract="false" name="AccruedRestructuringChargesRelatedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SaleOfStockCommissionFixedRate" abstract="false" name="SaleOfStockCommissionFixedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedMay2015Member" abstract="true" name="WarrantsExpiringNovember2024IssuedMay2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RetentionProgramMember" abstract="true" name="RetentionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" abstract="true" name="EczacibasiPharmaceuticalsMarketingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" abstract="false" name="StockIssuedDuringPeriodExerciseOfWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" abstract="false" name="LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" abstract="true" name="CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharesOfCommonStockReservedForIssuanceAbstract" abstract="true" name="SharesOfCommonStockReservedForIssuanceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_StockIncentivePlanTwoThousandFourteenMember" abstract="true" name="StockIncentivePlanTwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_UniversityOfZurichMember" abstract="true" name="UniversityOfZurichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementAdditionalUpFrontFee" abstract="false" name="LicenseAgreementAdditionalUpFrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_XOMAIrelandLimitedMember" abstract="true" name="XOMAIrelandLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ATMFacilityMember" abstract="true" name="ATMFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_OperatingLeaseOtherMonthlyOperatingExpenses" abstract="false" name="OperatingLeaseOtherMonthlyOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" abstract="false" name="SaleOfStockMaximumAggregateSalesPriceInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_MENALicenseAgreementMember" abstract="true" name="MENALicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementTextBlock" abstract="false" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2022Member" abstract="true" name="WarrantsExpiringNovember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ViventiaBioInc.Member" abstract="true" name="ViventiaBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberofVotesEntitledForEachShare" abstract="false" name="NumberofVotesEntitledForEachShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyRate" abstract="false" name="LicenseAgreementRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ViciniumMember" abstract="true" name="ViciniumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" abstract="false" name="DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationLineItems" abstract="true" name="OrganizationAndBasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_RoyaltyRevenuePercentage" abstract="false" name="RoyaltyRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRoyaltyPeriod" abstract="false" name="CollaborativeArrangementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" abstract="false" name="SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" abstract="false" name="IncreaseDecreaseOfPrepaidExpensesNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseMaintenanceFees" abstract="false" name="LicenseMaintenanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_AccruedLegalFees" abstract="false" name="AccruedLegalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WeightedAverageCostOfCapital" abstract="false" name="WeightedAverageCostOfCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" abstract="true" name="WarrantsExpiringNovember2024IssuedNovember2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LitigationSettlementMember" abstract="true" name="LitigationSettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightIssuedDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_NumberOfLawsuits" abstract="false" name="NumberOfLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" abstract="false" name="BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" abstract="false" name="StockIssuedDuringPeriodNewIssuesIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OperatingLeaseMonthlyRent" abstract="false" name="OperatingLeaseMonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SecondIndicationMember" abstract="true" name="SecondIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_EBI031Member" abstract="true" name="EBI031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_StockIncentivePlan2009Member" abstract="true" name="StockIncentivePlan2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" abstract="false" name="SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchievementExpense" abstract="false" name="LicenseAgreementMilestoneAchievementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OperatingLeasesAreaOfOfficeSpace" abstract="false" name="OperatingLeasesAreaOfOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="sesn_A2014EmployeeStockPurchasePlanMember" abstract="true" name="A2014EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>sesn-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2242ac9-1511-42db-a08a-ac050036e5da,g:27c8282b-5e55-4664-b4e1-3a6627cbab54-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_8131ec89-133f-4e3c-8f4a-5e7411dd5bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_49b7efb5-172a-49e1-a673-26b8e6ef9a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8131ec89-133f-4e3c-8f4a-5e7411dd5bfd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_49b7efb5-172a-49e1-a673-26b8e6ef9a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1c6fb31c-7db8-47e1-8a39-0255945d90b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8131ec89-133f-4e3c-8f4a-5e7411dd5bfd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1c6fb31c-7db8-47e1-8a39-0255945d90b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f045087c-38bc-4ee8-9173-bcd571a2f51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8131ec89-133f-4e3c-8f4a-5e7411dd5bfd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f045087c-38bc-4ee8-9173-bcd571a2f51d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2f56456f-2fb5-46b8-b314-12d5ad129f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_412b6e6d-350e-4011-b7d2-ad153095ee40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2f56456f-2fb5-46b8-b314-12d5ad129f10" xlink:to="loc_us-gaap_AssetsNoncurrent_412b6e6d-350e-4011-b7d2-ad153095ee40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c8827f13-fea0-430a-83ed-bd0c09b2dae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2f56456f-2fb5-46b8-b314-12d5ad129f10" xlink:to="loc_us-gaap_AssetsCurrent_c8827f13-fea0-430a-83ed-bd0c09b2dae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dfe5d11b-91c3-4d68-8fa7-0c469d126854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_139d628c-ce58-4fdd-add6-185f21a833ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dfe5d11b-91c3-4d68-8fa7-0c469d126854" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_139d628c-ce58-4fdd-add6-185f21a833ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e5939947-d6ca-4d70-8a3c-bae659abea72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dfe5d11b-91c3-4d68-8fa7-0c469d126854" xlink:to="loc_us-gaap_LiabilitiesCurrent_e5939947-d6ca-4d70-8a3c-bae659abea72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e804d8ef-dbcb-44bf-a214-0e250b22d225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9deb7037-3103-4224-9b33-72392a51fbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e804d8ef-dbcb-44bf-a214-0e250b22d225" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9deb7037-3103-4224-9b33-72392a51fbe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f70e10a5-f07d-4a94-9471-d8bb7c418d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e804d8ef-dbcb-44bf-a214-0e250b22d225" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f70e10a5-f07d-4a94-9471-d8bb7c418d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_84e71082-a090-41e5-8c71-c0c598b1d7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e804d8ef-dbcb-44bf-a214-0e250b22d225" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_84e71082-a090-41e5-8c71-c0c598b1d7e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4afb5649-57a1-4c4a-91c8-f9dc426094ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e804d8ef-dbcb-44bf-a214-0e250b22d225" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4afb5649-57a1-4c4a-91c8-f9dc426094ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2edf4fcb-1566-41c1-a13a-2960ac751545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e804d8ef-dbcb-44bf-a214-0e250b22d225" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2edf4fcb-1566-41c1-a13a-2960ac751545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9c4f577e-bc3a-40bf-bb2b-0d41c004642e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2d885896-8fa6-4a24-8dac-4e0bdec78c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9c4f577e-bc3a-40bf-bb2b-0d41c004642e" xlink:to="loc_us-gaap_StockholdersEquity_2d885896-8fa6-4a24-8dac-4e0bdec78c0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_68aa14c9-6bca-4439-8fab-ec50d4e6e60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9c4f577e-bc3a-40bf-bb2b-0d41c004642e" xlink:to="loc_us-gaap_Liabilities_68aa14c9-6bca-4439-8fab-ec50d4e6e60c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_fb064e01-45a5-4569-9388-1691624d3f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0e748e5f-c9d5-461c-8966-611819c1dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb064e01-45a5-4569-9388-1691624d3f42" xlink:to="loc_us-gaap_Goodwill_0e748e5f-c9d5-461c-8966-611819c1dfdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_14794a0d-6aa0-4410-ae4e-465cf9ec5d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb064e01-45a5-4569-9388-1691624d3f42" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_14794a0d-6aa0-4410-ae4e-465cf9ec5d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ed82a79a-a3bf-464e-8447-dee157e78e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb064e01-45a5-4569-9388-1691624d3f42" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ed82a79a-a3bf-464e-8447-dee157e78e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ffc0cfdf-c550-4683-bd17-b47b37bea274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb064e01-45a5-4569-9388-1691624d3f42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ffc0cfdf-c550-4683-bd17-b47b37bea274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7111d10a-d78f-4d79-9ba2-eb3beaad3e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb064e01-45a5-4569-9388-1691624d3f42" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7111d10a-d78f-4d79-9ba2-eb3beaad3e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8a6ad3e6-6c00-4aaa-bb9f-073d3428e71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb064e01-45a5-4569-9388-1691624d3f42" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8a6ad3e6-6c00-4aaa-bb9f-073d3428e71a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_30e62d58-37c0-4fac-a7e0-7a3de4397686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb064e01-45a5-4569-9388-1691624d3f42" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_30e62d58-37c0-4fac-a7e0-7a3de4397686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_109691b9-be3c-45d3-b1f6-517c8ebc91c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2ab1b60a-e5bd-4abb-b895-af7572c98558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109691b9-be3c-45d3-b1f6-517c8ebc91c3" xlink:to="loc_us-gaap_AccountsPayableCurrent_2ab1b60a-e5bd-4abb-b895-af7572c98558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9598b361-0720-41fc-a5f4-8ffcc57164e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109691b9-be3c-45d3-b1f6-517c8ebc91c3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9598b361-0720-41fc-a5f4-8ffcc57164e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_98f1c29e-0f5f-43e5-9b24-78aa0eb90071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_109691b9-be3c-45d3-b1f6-517c8ebc91c3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_98f1c29e-0f5f-43e5-9b24-78aa0eb90071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8acf31c7-17f4-4d94-bda2-e8a3530c08e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_32511743-65b7-452c-9908-ee49ef433c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8acf31c7-17f4-4d94-bda2-e8a3530c08e3" xlink:to="loc_us-gaap_CommonStockValue_32511743-65b7-452c-9908-ee49ef433c98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b49eec00-7a12-46ec-a125-5dd51cc5a5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8acf31c7-17f4-4d94-bda2-e8a3530c08e3" xlink:to="loc_us-gaap_PreferredStockValue_b49eec00-7a12-46ec-a125-5dd51cc5a5d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf853dcc-735a-4783-af4b-97f5d122acb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8acf31c7-17f4-4d94-bda2-e8a3530c08e3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf853dcc-735a-4783-af4b-97f5d122acb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_25573a7b-ebd6-4a40-8b4f-edaf96ff77fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8acf31c7-17f4-4d94-bda2-e8a3530c08e3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_25573a7b-ebd6-4a40-8b4f-edaf96ff77fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba3eb176-e479-47e5-966c-1237770584c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8acf31c7-17f4-4d94-bda2-e8a3530c08e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba3eb176-e479-47e5-966c-1237770584c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_cfaa59f4-0cff-4f80-a869-c41a6fd4b533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b26f36df-53e5-48c8-b9c2-49aa994832c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cfaa59f4-0cff-4f80-a869-c41a6fd4b533" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b26f36df-53e5-48c8-b9c2-49aa994832c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9f570ae5-304f-4b7d-9c72-b4286c288192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cfaa59f4-0cff-4f80-a869-c41a6fd4b533" xlink:to="loc_us-gaap_OperatingIncomeLoss_9f570ae5-304f-4b7d-9c72-b4286c288192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_11e2c770-676f-455c-9017-d1f2c4eb9d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e75feb20-fba5-4a98-9889-da1e7632de8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_11e2c770-676f-455c-9017-d1f2c4eb9d9e" xlink:to="loc_us-gaap_NetIncomeLoss_e75feb20-fba5-4a98-9889-da1e7632de8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_41642ce7-fec1-4346-a805-a36f8acd2444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2d4fa05f-abe0-4563-a947-d313ea3d6e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41642ce7-fec1-4346-a805-a36f8acd2444" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2d4fa05f-abe0-4563-a947-d313ea3d6e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8e1d806a-6b8b-4b0e-995a-060998c32ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41642ce7-fec1-4346-a805-a36f8acd2444" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8e1d806a-6b8b-4b0e-995a-060998c32ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7a02db32-a5d6-41e4-b8a7-ef139a9b3a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41642ce7-fec1-4346-a805-a36f8acd2444" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7a02db32-a5d6-41e4-b8a7-ef139a9b3a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_386c5494-136e-4df9-a0dc-d19a4d893196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41642ce7-fec1-4346-a805-a36f8acd2444" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_386c5494-136e-4df9-a0dc-d19a4d893196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e633fe8-9bae-4f84-b88b-d23f88dd84e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_1207f3b2-6b83-49d2-8d70-560d90942346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e633fe8-9bae-4f84-b88b-d23f88dd84e8" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_1207f3b2-6b83-49d2-8d70-560d90942346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0286f586-7c4f-4275-a40f-ca3c63612bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e633fe8-9bae-4f84-b88b-d23f88dd84e8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0286f586-7c4f-4275-a40f-ca3c63612bc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69777fff-8eab-49c3-af02-5a20564aef01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_714bb4b1-2814-4bdf-aaf0-617d286506f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_69777fff-8eab-49c3-af02-5a20564aef01" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_714bb4b1-2814-4bdf-aaf0-617d286506f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f3b562d5-a8b9-45e1-b970-76360119aa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_69777fff-8eab-49c3-af02-5a20564aef01" xlink:to="loc_us-gaap_OperatingExpenses_f3b562d5-a8b9-45e1-b970-76360119aa18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4a6fc2d1-241f-4512-bc1c-64a75943f76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_306daa6b-c43f-49ed-9095-083b28ee9233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4a6fc2d1-241f-4512-bc1c-64a75943f76f" xlink:to="loc_us-gaap_NetIncomeLoss_306daa6b-c43f-49ed-9095-083b28ee9233" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c41b37e-8752-4ba6-b636-af5188c303d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_518c73f7-f39d-41f0-8aca-031652c1a7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c41b37e-8752-4ba6-b636-af5188c303d0" xlink:to="loc_us-gaap_NetIncomeLoss_518c73f7-f39d-41f0-8aca-031652c1a7be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5d839b52-0b45-42e8-8414-5f1bea26a7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c41b37e-8752-4ba6-b636-af5188c303d0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5d839b52-0b45-42e8-8414-5f1bea26a7e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0aef8beb-5f1c-46bc-bd17-16ce23283f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0aef8beb-5f1c-46bc-bd17-16ce23283f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_40973166-f0e7-400f-b208-0d5616cca08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_40973166-f0e7-400f-b208-0d5616cca08a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3d2e122c-d050-4a8a-928b-24013c1cf619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3d2e122c-d050-4a8a-928b-24013c1cf619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_f5a933ac-15b6-4b38-950f-cf48839647bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_f5a933ac-15b6-4b38-950f-cf48839647bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_361a11e9-f73d-47a7-b545-ac0e41144be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_NetIncomeLoss_361a11e9-f73d-47a7-b545-ac0e41144be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_068d3ad9-2be8-40bd-bbd8-e160dd6a175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_068d3ad9-2be8-40bd-bbd8-e160dd6a175b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6c4d6fdf-8c6c-4096-87d5-80d69eb8c229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6c4d6fdf-8c6c-4096-87d5-80d69eb8c229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_75628a08-e4dc-4cd2-a9bc-661448bdd0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_DepreciationAndAmortization_75628a08-e4dc-4cd2-a9bc-661448bdd0f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e6716b39-5505-49c7-85ad-a1c6daa42e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_ShareBasedCompensation_e6716b39-5505-49c7-85ad-a1c6daa42e8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_d1df384d-629d-4594-96d0-efeed4083b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_d1df384d-629d-4594-96d0-efeed4083b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_208396b1-5bd9-4f3f-b616-849ae9f79580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_208396b1-5bd9-4f3f-b616-849ae9f79580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b18e8cb9-d3e4-4405-ba42-ec70215d3dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_AssetImpairmentCharges_b18e8cb9-d3e4-4405-ba42-ec70215d3dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_99ab646c-872f-4b19-8d61-f9d8c9fa3e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_99ab646c-872f-4b19-8d61-f9d8c9fa3e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_47167d96-4a26-45d0-a45c-981a338c0a43" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9eca6a2-1e8d-4343-bf3d-abf29350802b" xlink:to="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_47167d96-4a26-45d0-a45c-981a338c0a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93a8b49e-2fae-4691-82ac-ebc5b1c5a602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_94f1c2d8-b345-444a-8fae-a16df790e945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93a8b49e-2fae-4691-82ac-ebc5b1c5a602" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_94f1c2d8-b345-444a-8fae-a16df790e945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_574466e5-5ce4-496f-a5c9-0b23c524e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93a8b49e-2fae-4691-82ac-ebc5b1c5a602" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_574466e5-5ce4-496f-a5c9-0b23c524e5cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ebe1938-14ae-45cb-8976-9bb18e09c3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93a8b49e-2fae-4691-82ac-ebc5b1c5a602" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ebe1938-14ae-45cb-8976-9bb18e09c3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40580ccc-9edb-427f-9bcf-a7c0f2edb89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_73a346c5-fefa-4acd-804d-76fc258bf0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40580ccc-9edb-427f-9bcf-a7c0f2edb89e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_73a346c5-fefa-4acd-804d-76fc258bf0ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_70a1dce9-d1db-4274-ab0a-dcbd23bc9563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40580ccc-9edb-427f-9bcf-a7c0f2edb89e" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_70a1dce9-d1db-4274-ab0a-dcbd23bc9563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9cc5537-8e75-4677-bd1e-38048b60f181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40580ccc-9edb-427f-9bcf-a7c0f2edb89e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9cc5537-8e75-4677-bd1e-38048b60f181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e73fd407-6580-4208-8804-74d5b51d8859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3ca9d499-e1e9-4409-91af-92e55287ae02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e73fd407-6580-4208-8804-74d5b51d8859" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3ca9d499-e1e9-4409-91af-92e55287ae02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_935a8009-2c6f-42c6-be1c-e8b2ef0c5062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e73fd407-6580-4208-8804-74d5b51d8859" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_935a8009-2c6f-42c6-be1c-e8b2ef0c5062" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_18b52bbe-e879-4028-878d-fb6fd7a846cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8c0ad06d-fa4a-4fa9-8ba8-2dc8bc9910a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_18b52bbe-e879-4028-878d-fb6fd7a846cb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8c0ad06d-fa4a-4fa9-8ba8-2dc8bc9910a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFees_73adee6b-3377-4176-ad5b-1d66c51ae423" xlink:href="sesn-20220630.xsd#sesn_AccruedLegalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_18b52bbe-e879-4028-878d-fb6fd7a846cb" xlink:to="loc_sesn_AccruedLegalFees_73adee6b-3377-4176-ad5b-1d66c51ae423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4b9af5ff-ded9-4475-a4f3-179983c9d542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_18b52bbe-e879-4028-878d-fb6fd7a846cb" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4b9af5ff-ded9-4475-a4f3-179983c9d542" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_2bb77c0c-c9a4-4c1e-88dd-2bcccb063def" xlink:href="sesn-20220630.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_18b52bbe-e879-4028-878d-fb6fd7a846cb" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_2bb77c0c-c9a4-4c1e-88dd-2bcccb063def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_d50edebc-3cb1-4064-a0de-ac5c3067437d" xlink:href="sesn-20220630.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_18b52bbe-e879-4028-878d-fb6fd7a846cb" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_d50edebc-3cb1-4064-a0de-ac5c3067437d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2a3a6810-730f-4e7d-ac3f-e1f266cbe03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_18b52bbe-e879-4028-878d-fb6fd7a846cb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2a3a6810-730f-4e7d-ac3f-e1f266cbe03e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_cfdb6560-6a7f-4d82-8302-cbde62f4f607" xlink:href="sesn-20220630.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e59324c2-72fa-48ed-bae4-83236d058461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_cfdb6560-6a7f-4d82-8302-cbde62f4f607" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e59324c2-72fa-48ed-bae4-83236d058461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7d48ebfa-a3fc-4995-a200-7d9c9812b949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_cfdb6560-6a7f-4d82-8302-cbde62f4f607" xlink:to="loc_us-gaap_CommonStockSharesIssued_7d48ebfa-a3fc-4995-a200-7d9c9812b949" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6806b-3095-4de7-9c78-1683a0705483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f815b0f9-f1f8-49ad-bf7f-8acdb40bd492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6806b-3095-4de7-9c78-1683a0705483" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f815b0f9-f1f8-49ad-bf7f-8acdb40bd492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bd6bc6cb-8087-4203-b14c-968a0d5b5ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6806b-3095-4de7-9c78-1683a0705483" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bd6bc6cb-8087-4203-b14c-968a0d5b5ee9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofIncomeTaxProvisionsDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27afed51-8586-4254-9542-42fa64edd0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3540e95e-1aae-45d4-aefe-ecffc139d534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27afed51-8586-4254-9542-42fa64edd0a1" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3540e95e-1aae-45d4-aefe-ecffc139d534" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0ecbbabe-5af4-4752-912a-8e0f17bb8dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_e59d0a60-4919-4641-9ffa-2170eb0434d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0ecbbabe-5af4-4752-912a-8e0f17bb8dc5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_e59d0a60-4919-4641-9ffa-2170eb0434d8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>sesn-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2242ac9-1511-42db-a08a-ac050036e5da,g:27c8282b-5e55-4664-b4e1-3a6627cbab54-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i55b1bc97e71e407c82ac94168631ab63_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_07c7dd68-4349-43ea-88fd-c586220532ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07c7dd68-4349-43ea-88fd-c586220532ae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0a6f88e2-7bd0-42c6-ae16-d748b7734479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_SharesOutstanding_0a6f88e2-7bd0-42c6-ae16-d748b7734479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26822c10-df2c-49dd-86dc-d3d3ebdef0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockholdersEquity_26822c10-df2c-49dd-86dc-d3d3ebdef0ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12195fbd-2dc3-4be2-af11-6da284103015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_NetIncomeLoss_12195fbd-2dc3-4be2-af11-6da284103015" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_31a7a16b-0e8d-4061-b7f3-55ea2cb387b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_31a7a16b-0e8d-4061-b7f3-55ea2cb387b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6f49fd6b-15ee-46a2-bc54-8164764a1ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6f49fd6b-15ee-46a2-bc54-8164764a1ba0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4d78059a-7c5a-4b47-bbe5-373b59510edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4d78059a-7c5a-4b47-bbe5-373b59510edc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1b97d150-6cbe-47a4-b18b-951fb52512c3" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1b97d150-6cbe-47a4-b18b-951fb52512c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_312b1f93-ce6b-4895-ab46-dd323f1bf880" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_312b1f93-ce6b-4895-ab46-dd323f1bf880" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e943f88e-0397-4d7d-8d63-c602eca4714e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e943f88e-0397-4d7d-8d63-c602eca4714e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30ea3180-8c5c-4bcd-b279-435ef100a2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30ea3180-8c5c-4bcd-b279-435ef100a2c8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8735149d-c1da-4f17-bf64-61a49e40b9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8735149d-c1da-4f17-bf64-61a49e40b9b1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_27b5612e-f632-453d-8a41-8ad2579fe7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c35d3c3e-3a4a-47b9-9e88-c00df1e3469e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_07c7dd68-4349-43ea-88fd-c586220532ae" xlink:to="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b2105c3e-2baa-445e-964f-0cbe6262504d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b2105c3e-2baa-445e-964f-0cbe6262504d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b2105c3e-2baa-445e-964f-0cbe6262504d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2105c3e-2baa-445e-964f-0cbe6262504d" xlink:to="loc_us-gaap_EquityComponentDomain_b2105c3e-2baa-445e-964f-0cbe6262504d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2105c3e-2baa-445e-964f-0cbe6262504d" xlink:to="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_215bf212-2b02-4bba-8d1c-e64a687f34f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:to="loc_us-gaap_CommonStockMember_215bf212-2b02-4bba-8d1c-e64a687f34f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0e0feca3-61d0-4116-b956-87c22ed768a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0e0feca3-61d0-4116-b956-87c22ed768a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_427e33e1-4012-45ea-8df2-2cbcb4416178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_427e33e1-4012-45ea-8df2-2cbcb4416178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1437a7b4-6e15-4c47-abd3-fbf1d014090d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:to="loc_us-gaap_RetainedEarningsMember_1437a7b4-6e15-4c47-abd3-fbf1d014090d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_024ae251-7f65-4b75-b327-bc9ca165472a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_024ae251-7f65-4b75-b327-bc9ca165472a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_5405ecaf-b193-43a2-ac8a-1bf7741e1366" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_024ae251-7f65-4b75-b327-bc9ca165472a" xlink:to="loc_sesn_ATMFacilityMember_5405ecaf-b193-43a2-ac8a-1bf7741e1366" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="i08151417ffca4badab452a8f496be94a_DESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_8618353d-0d25-4dc5-abf7-410f043e8718" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_8618353d-0d25-4dc5-abf7-410f043e8718" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e78fe5e6-cf77-413a-9c70-4a4083882ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e78fe5e6-cf77-413a-9c70-4a4083882ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_2d849085-5c16-4158-92ed-68011cfb4307" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_2d849085-5c16-4158-92ed-68011cfb4307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_8bdaa3c1-6b27-429d-b3ad-49b8c23d6224" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_8bdaa3c1-6b27-429d-b3ad-49b8c23d6224" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_09302830-867c-48fb-9711-8ee373dc2fcd" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_09302830-867c-48fb-9711-8ee373dc2fcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_aceca459-b0e8-4859-9d2a-55db5b0ff330" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_aceca459-b0e8-4859-9d2a-55db5b0ff330" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d13b3be-e596-4268-b079-2706e3c490e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d13b3be-e596-4268-b079-2706e3c490e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d13b3be-e596-4268-b079-2706e3c490e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d13b3be-e596-4268-b079-2706e3c490e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d13b3be-e596-4268-b079-2706e3c490e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fc7da43-6136-4e8d-a134-325179874ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d13b3be-e596-4268-b079-2706e3c490e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fc7da43-6136-4e8d-a134-325179874ca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_839d4e73-ae28-408f-a1bb-9ffc2f1509f8" xlink:href="sesn-20220630.xsd#sesn_ViventiaBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fc7da43-6136-4e8d-a134-325179874ca0" xlink:to="loc_sesn_ViventiaBioInc.Member_839d4e73-ae28-408f-a1bb-9ffc2f1509f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c5684973-4831-40f1-b313-ec924f35b83c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_srt_ProductOrServiceAxis_c5684973-4831-40f1-b313-ec924f35b83c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5684973-4831-40f1-b313-ec924f35b83c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c5684973-4831-40f1-b313-ec924f35b83c" xlink:to="loc_srt_ProductsAndServicesDomain_c5684973-4831-40f1-b313-ec924f35b83c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_491c46a5-2a55-4368-8fac-85ec92dcc0d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c5684973-4831-40f1-b313-ec924f35b83c" xlink:to="loc_srt_ProductsAndServicesDomain_491c46a5-2a55-4368-8fac-85ec92dcc0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_9b84761c-683d-4ba7-b459-d6bed32bacd8" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_491c46a5-2a55-4368-8fac-85ec92dcc0d6" xlink:to="loc_sesn_ViciniumMember_9b84761c-683d-4ba7-b459-d6bed32bacd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b267f456-7535-4377-876a-e58daba1d69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b267f456-7535-4377-876a-e58daba1d69a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b267f456-7535-4377-876a-e58daba1d69a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b267f456-7535-4377-876a-e58daba1d69a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b267f456-7535-4377-876a-e58daba1d69a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408661ff-98c6-4b79-8677-d650af043d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b267f456-7535-4377-876a-e58daba1d69a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408661ff-98c6-4b79-8677-d650af043d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_32abe8cc-6c0f-4290-a934-f5fc40f502f2" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408661ff-98c6-4b79-8677-d650af043d7f" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_32abe8cc-6c0f-4290-a934-f5fc40f502f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_srt_StatementGeographicalAxis_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4" xlink:to="loc_srt_SegmentGeographicalDomain_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4" xlink:to="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b859678f-c6f3-4dff-9f47-214b6745bc41" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:to="loc_country_US_b859678f-c6f3-4dff-9f47-214b6745bc41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2098e613-5e20-4f90-a20a-fb7a8f5b9823" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:to="loc_srt_EuropeMember_2098e613-5e20-4f90-a20a-fb7a8f5b9823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_fe2dfe85-fd68-4f98-a5fc-c53d04741ba6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:to="loc_country_JP_fe2dfe85-fd68-4f98-a5fc-c53d04741ba6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i2f676e485b2743108debd44ec19dcbab_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69ab8eb7-dbb7-4ccc-877a-6eda07538e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0a3b0-98af-4fda-b2d8-41925bf1e32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69ab8eb7-dbb7-4ccc-877a-6eda07538e72" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0a3b0-98af-4fda-b2d8-41925bf1e32d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d794919-7081-41ba-a342-e0312999087a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0a3b0-98af-4fda-b2d8-41925bf1e32d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d794919-7081-41ba-a342-e0312999087a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0dcc17f-c925-47b7-bbb8-5cf7dab90f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0a3b0-98af-4fda-b2d8-41925bf1e32d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0dcc17f-c925-47b7-bbb8-5cf7dab90f08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_835d4d81-34e5-4c79-b08b-8eb272c22c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69ab8eb7-dbb7-4ccc-877a-6eda07538e72" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_835d4d81-34e5-4c79-b08b-8eb272c22c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_55709023-cd38-414e-8087-d3a2635fee25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_835d4d81-34e5-4c79-b08b-8eb272c22c40" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_55709023-cd38-414e-8087-d3a2635fee25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69ab8eb7-dbb7-4ccc-877a-6eda07538e72" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_59e0237b-ef0d-4cb8-9ce0-838295e617d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_59e0237b-ef0d-4cb8-9ce0-838295e617d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_59e0237b-ef0d-4cb8-9ce0-838295e617d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_59e0237b-ef0d-4cb8-9ce0-838295e617d6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_59e0237b-ef0d-4cb8-9ce0-838295e617d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0cd440d4-79d9-4177-a10f-4c6e5ab66c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_59e0237b-ef0d-4cb8-9ce0-838295e617d6" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0cd440d4-79d9-4177-a10f-4c6e5ab66c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad6bbc46-d80b-480c-ad20-588b08aca90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0cd440d4-79d9-4177-a10f-4c6e5ab66c2f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad6bbc46-d80b-480c-ad20-588b08aca90b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_651ea30c-3fa2-409c-90bd-9f32cfeb0b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad6bbc46-d80b-480c-ad20-588b08aca90b" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_651ea30c-3fa2-409c-90bd-9f32cfeb0b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_744c5ad2-ff3b-4171-a99b-95e43e721c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad6bbc46-d80b-480c-ad20-588b08aca90b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_744c5ad2-ff3b-4171-a99b-95e43e721c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0fb692e-b25c-4b61-8705-495e3c2db4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0fb692e-b25c-4b61-8705-495e3c2db4ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0fb692e-b25c-4b61-8705-495e3c2db4ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0fb692e-b25c-4b61-8705-495e3c2db4ef" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0fb692e-b25c-4b61-8705-495e3c2db4ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_91782c7c-a58f-46c9-aecc-1952e26a6d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0fb692e-b25c-4b61-8705-495e3c2db4ef" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_91782c7c-a58f-46c9-aecc-1952e26a6d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_031d5310-45bd-4aaf-8aad-9e4655e5fb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_91782c7c-a58f-46c9-aecc-1952e26a6d4b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_031d5310-45bd-4aaf-8aad-9e4655e5fb96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef2d888-1b27-4996-a7d8-9c585a0756a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef2d888-1b27-4996-a7d8-9c585a0756a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ef2d888-1b27-4996-a7d8-9c585a0756a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef2d888-1b27-4996-a7d8-9c585a0756a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ef2d888-1b27-4996-a7d8-9c585a0756a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef2d888-1b27-4996-a7d8-9c585a0756a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fdc2a68b-21e2-449e-b8cd-5b77bd58017e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fdc2a68b-21e2-449e-b8cd-5b77bd58017e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9f079091-0ea6-4174-b6d9-47ea90474280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9f079091-0ea6-4174-b6d9-47ea90474280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_69af75ea-a49f-48f2-b33a-e47641f84a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_69af75ea-a49f-48f2-b33a-e47641f84a0f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="iba8b33ade1894116a208530a47a11a6d_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_abf93d9d-b350-4f2e-acb8-ed2db42a61a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_abf93d9d-b350-4f2e-acb8-ed2db42a61a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_33909d13-5468-45a2-94ca-958eef29bf1b" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_33909d13-5468-45a2-94ca-958eef29bf1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_6280de6b-b306-411c-a8c0-c5e2d863ca99" xlink:href="sesn-20220630.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_sesn_WeightedAverageCostOfCapital_6280de6b-b306-411c-a8c0-c5e2d863ca99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_16cd78fb-51a5-4199-b27e-db8243cc06ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_16cd78fb-51a5-4199-b27e-db8243cc06ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6674d1e6-ffb5-4162-a165-0af4320367d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6674d1e6-ffb5-4162-a165-0af4320367d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6674d1e6-ffb5-4162-a165-0af4320367d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6674d1e6-ffb5-4162-a165-0af4320367d1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6674d1e6-ffb5-4162-a165-0af4320367d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_71422714-0a8a-4a8d-a8e0-889946e02679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6674d1e6-ffb5-4162-a165-0af4320367d1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_71422714-0a8a-4a8d-a8e0-889946e02679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f00900ff-acca-4533-9611-7790014197be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_71422714-0a8a-4a8d-a8e0-889946e02679" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f00900ff-acca-4533-9611-7790014197be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c7fa96e-89bb-4a59-bebc-5cca8aabb345" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:to="loc_srt_RangeAxis_5c7fa96e-89bb-4a59-bebc-5cca8aabb345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5c7fa96e-89bb-4a59-bebc-5cca8aabb345_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5c7fa96e-89bb-4a59-bebc-5cca8aabb345" xlink:to="loc_srt_RangeMember_5c7fa96e-89bb-4a59-bebc-5cca8aabb345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7e88328-c083-4b46-937d-494bed388f64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5c7fa96e-89bb-4a59-bebc-5cca8aabb345" xlink:to="loc_srt_RangeMember_d7e88328-c083-4b46-937d-494bed388f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3b20c18-8386-4d8e-abcf-2a28f443e0dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d7e88328-c083-4b46-937d-494bed388f64" xlink:to="loc_srt_MinimumMember_b3b20c18-8386-4d8e-abcf-2a28f443e0dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b40643be-0f35-4151-b3e6-8dc436470b61" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d7e88328-c083-4b46-937d-494bed388f64" xlink:to="loc_srt_MaximumMember_b40643be-0f35-4151-b3e6-8dc436470b61" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended" id="i2496c50e23e34bfd8657c7959571c357_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_edf9852d-54fb-46dd-ae25-169892a6d98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_edf9852d-54fb-46dd-ae25-169892a6d98c" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6b4c28cd-4bc9-4052-a0aa-0c37228bd8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6b4c28cd-4bc9-4052-a0aa-0c37228bd8ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_e9f306d0-386f-4b0b-a8e9-0f6df623adec" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_e9f306d0-386f-4b0b-a8e9-0f6df623adec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cb37b85f-25f3-485a-8f52-69406e500111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c7a63f3-9a49-45aa-9c39-13eb2ebbd987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_edf9852d-54fb-46dd-ae25-169892a6d98c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c7a63f3-9a49-45aa-9c39-13eb2ebbd987" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b86a3bef-6e07-485e-a858-1511fff0490e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c7a63f3-9a49-45aa-9c39-13eb2ebbd987" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b86a3bef-6e07-485e-a858-1511fff0490e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b86a3bef-6e07-485e-a858-1511fff0490e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b86a3bef-6e07-485e-a858-1511fff0490e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b86a3bef-6e07-485e-a858-1511fff0490e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33ac412-27fa-491b-99b5-92f57b12480e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b86a3bef-6e07-485e-a858-1511fff0490e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33ac412-27fa-491b-99b5-92f57b12480e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5de3096b-6de0-471d-8b33-4f09e064352a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33ac412-27fa-491b-99b5-92f57b12480e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5de3096b-6de0-471d-8b33-4f09e064352a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#RECEIVABLESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended" id="i23aa6abfe926489f9309685c8b6c2e36_RECEIVABLESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f34e1ce6-add6-4771-bf28-705420ef40a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f34e1ce6-add6-4771-bf28-705420ef40a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_a440b30b-4f60-42f1-8661-df957fe59acc" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_a440b30b-4f60-42f1-8661-df957fe59acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_3e000c97-d99e-48fc-9376-23badb89ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_3e000c97-d99e-48fc-9376-23badb89ba62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_f57fc009-2262-46c2-a859-ca5054582804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_f57fc009-2262-46c2-a859-ca5054582804" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_abf5bd75-4499-407a-9b2c-fd8fa8f608d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:to="loc_srt_CounterpartyNameAxis_abf5bd75-4499-407a-9b2c-fd8fa8f608d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_abf5bd75-4499-407a-9b2c-fd8fa8f608d6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_abf5bd75-4499-407a-9b2c-fd8fa8f608d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_abf5bd75-4499-407a-9b2c-fd8fa8f608d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc0f36a-5a65-4289-b95a-b480602ea897" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_abf5bd75-4499-407a-9b2c-fd8fa8f608d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc0f36a-5a65-4289-b95a-b480602ea897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_69f537d8-0607-449a-b6be-98cebac0a0bc" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc0f36a-5a65-4289-b95a-b480602ea897" xlink:to="loc_sesn_RocheMember_69f537d8-0607-449a-b6be-98cebac0a0bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3632a46-1569-49c4-9aee-00f6d2d79be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3632a46-1569-49c4-9aee-00f6d2d79be2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_f3632a46-1569-49c4-9aee-00f6d2d79be2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3632a46-1569-49c4-9aee-00f6d2d79be2" xlink:to="loc_us-gaap_ReceivableTypeDomain_f3632a46-1569-49c4-9aee-00f6d2d79be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_6959f899-bbdb-4a9a-a33a-586cfced243c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3632a46-1569-49c4-9aee-00f6d2d79be2" xlink:to="loc_us-gaap_ReceivableTypeDomain_6959f899-bbdb-4a9a-a33a-586cfced243c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LitigationSettlementMember_2129e3a8-a71f-4224-8a68-bd055d8f3874" xlink:href="sesn-20220630.xsd#sesn_LitigationSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_6959f899-bbdb-4a9a-a33a-586cfced243c" xlink:to="loc_sesn_LitigationSettlementMember_2129e3a8-a71f-4224-8a68-bd055d8f3874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember_030ca3fd-dc23-4ba3-8f22-5d2377e8c8cc" xlink:href="sesn-20220630.xsd#sesn_GermanVATRecoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_6959f899-bbdb-4a9a-a33a-586cfced243c" xlink:to="loc_sesn_GermanVATRecoveryMember_030ca3fd-dc23-4ba3-8f22-5d2377e8c8cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" xlink:type="extended" id="i5efc66af80e04ac191875c63122853ea_INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fa1d7d21-38ac-4a61-9fb5-9f047945ca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_74f2e5cc-bf0c-4411-be96-8dbd9852372f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fa1d7d21-38ac-4a61-9fb5-9f047945ca4d" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_74f2e5cc-bf0c-4411-be96-8dbd9852372f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fa1d7d21-38ac-4a61-9fb5-9f047945ca4d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_822c602a-65f2-4ea7-8728-8ba625f30d4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:to="loc_srt_StatementGeographicalAxis_822c602a-65f2-4ea7-8728-8ba625f30d4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_822c602a-65f2-4ea7-8728-8ba625f30d4e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_822c602a-65f2-4ea7-8728-8ba625f30d4e" xlink:to="loc_srt_SegmentGeographicalDomain_822c602a-65f2-4ea7-8728-8ba625f30d4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e85ec7b6-a8b4-43ca-98a6-7074c420f1dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_822c602a-65f2-4ea7-8728-8ba625f30d4e" xlink:to="loc_srt_SegmentGeographicalDomain_e85ec7b6-a8b4-43ca-98a6-7074c420f1dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0d49f83a-133d-4191-950d-6f0d8fad5e05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e85ec7b6-a8b4-43ca-98a6-7074c420f1dd" xlink:to="loc_srt_EuropeMember_0d49f83a-133d-4191-950d-6f0d8fad5e05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc807bb6-a015-4b04-9bea-3f2228c4ad86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:to="loc_srt_ProductOrServiceAxis_fc807bb6-a015-4b04-9bea-3f2228c4ad86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc807bb6-a015-4b04-9bea-3f2228c4ad86_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fc807bb6-a015-4b04-9bea-3f2228c4ad86" xlink:to="loc_srt_ProductsAndServicesDomain_fc807bb6-a015-4b04-9bea-3f2228c4ad86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_403f25e0-da81-4a14-b1c6-00d86801ffea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fc807bb6-a015-4b04-9bea-3f2228c4ad86" xlink:to="loc_srt_ProductsAndServicesDomain_403f25e0-da81-4a14-b1c6-00d86801ffea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_9cf1786c-9d81-41df-84f1-0c2ee33293d9" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_403f25e0-da81-4a14-b1c6-00d86801ffea" xlink:to="loc_sesn_ViciniumMember_9cf1786c-9d81-41df-84f1-0c2ee33293d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f306c979-57b9-4417-9dd6-69c59dbe595a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f306c979-57b9-4417-9dd6-69c59dbe595a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_ee0fc28e-c6e4-4525-b919-bb3174554957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f306c979-57b9-4417-9dd6-69c59dbe595a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_ee0fc28e-c6e4-4525-b919-bb3174554957" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails" xlink:type="extended" id="i99f594603aad44ae8ae413d458267434_INTANGIBLEASSETSANDGOODWILNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d19a8945-e615-4b2f-b826-3cb4900cc29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d19a8945-e615-4b2f-b826-3cb4900cc29a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_95da9561-39cd-47b7-a647-3cf15a497a57" xlink:href="sesn-20220630.xsd#sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:to="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_95da9561-39cd-47b7-a647-3cf15a497a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7c463c48-e17d-4a81-ac5a-b1bcae1d442e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:to="loc_us-gaap_Goodwill_7c463c48-e17d-4a81-ac5a-b1bcae1d442e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3a2b7ae2-41ec-4f70-8853-00cbf22c1353" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:to="loc_srt_ProductOrServiceAxis_3a2b7ae2-41ec-4f70-8853-00cbf22c1353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3a2b7ae2-41ec-4f70-8853-00cbf22c1353_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3a2b7ae2-41ec-4f70-8853-00cbf22c1353" xlink:to="loc_srt_ProductsAndServicesDomain_3a2b7ae2-41ec-4f70-8853-00cbf22c1353_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_47b6f500-ec89-4ebc-b9a0-a7440057d5ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3a2b7ae2-41ec-4f70-8853-00cbf22c1353" xlink:to="loc_srt_ProductsAndServicesDomain_47b6f500-ec89-4ebc-b9a0-a7440057d5ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_65526d7e-3f29-4f05-8dc8-d175dc84cb5d" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_47b6f500-ec89-4ebc-b9a0-a7440057d5ef" xlink:to="loc_sesn_ViciniumMember_65526d7e-3f29-4f05-8dc8-d175dc84cb5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4c2c51d1-e2c9-4dea-86b1-74889243b194" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:to="loc_srt_StatementGeographicalAxis_4c2c51d1-e2c9-4dea-86b1-74889243b194" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4c2c51d1-e2c9-4dea-86b1-74889243b194_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4c2c51d1-e2c9-4dea-86b1-74889243b194" xlink:to="loc_srt_SegmentGeographicalDomain_4c2c51d1-e2c9-4dea-86b1-74889243b194_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6b63146f-796f-46d0-b751-65c41161af12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4c2c51d1-e2c9-4dea-86b1-74889243b194" xlink:to="loc_srt_SegmentGeographicalDomain_6b63146f-796f-46d0-b751-65c41161af12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c5ffd006-c5a9-48ae-a1d6-5e6de762ad9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6b63146f-796f-46d0-b751-65c41161af12" xlink:to="loc_srt_EuropeMember_c5ffd006-c5a9-48ae-a1d6-5e6de762ad9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5e624b1-2ea4-40fa-9645-374848561f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5e624b1-2ea4-40fa-9645-374848561f6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5e624b1-2ea4-40fa-9645-374848561f6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5e624b1-2ea4-40fa-9645-374848561f6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5e624b1-2ea4-40fa-9645-374848561f6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_923e9b15-a34d-445a-900b-66b55e46d77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5e624b1-2ea4-40fa-9645-374848561f6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_923e9b15-a34d-445a-900b-66b55e46d77f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_f5d999d0-c5ff-4cf5-bb96-e729ddd49962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_923e9b15-a34d-445a-900b-66b55e46d77f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_f5d999d0-c5ff-4cf5-bb96-e729ddd49962" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#LEASESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LEASESDetails" xlink:type="extended" id="iba612cbf07e5468788b2862885542aaf_LEASESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_cacd15ad-dc6e-4a0a-b714-298b890c844a" xlink:href="sesn-20220630.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_cacd15ad-dc6e-4a0a-b714-298b890c844a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5fb0b0ce-5b44-4e9d-afb3-619fce388365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5fb0b0ce-5b44-4e9d-afb3-619fce388365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_e6334c7b-940e-40ff-8ead-a7780c7d5ad8" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_e6334c7b-940e-40ff-8ead-a7780c7d5ad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_a39bb845-97b4-4fea-871d-effa3edd96dd" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_a39bb845-97b4-4fea-871d-effa3edd96dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1c4839b5-7d6c-4d37-8ee6-6fe785bc7bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseCost_1c4839b5-7d6c-4d37-8ee6-6fe785bc7bed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_539162a6-1919-4076-8292-af3629d7c4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_539162a6-1919-4076-8292-af3629d7c4f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0acbc9a1-8d4d-496b-9bfa-2e3769ff9b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0acbc9a1-8d4d-496b-9bfa-2e3769ff9b67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3339e9cb-a758-4e2b-a783-4ceb83768c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3339e9cb-a758-4e2b-a783-4ceb83768c10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c40574b8-6230-495a-9134-b5c5f7469000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c40574b8-6230-495a-9134-b5c5f7469000" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:to="loc_srt_StatementGeographicalAxis_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1" xlink:to="loc_srt_SegmentGeographicalDomain_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1" xlink:to="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_be3c28b4-7c6f-4951-aeb8-aa468c39feeb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:to="loc_country_CA_be3c28b4-7c6f-4951-aeb8-aa468c39feeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_5071bd06-db38-4cdc-98f2-eb58a757097c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:to="loc_stpr_MA_5071bd06-db38-4cdc-98f2-eb58a757097c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_b71977cd-c97c-46b5-942b-0e94f297714a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:to="loc_stpr_PA_b71977cd-c97c-46b5-942b-0e94f297714a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be76ec9b-8c13-4e22-9713-c4bd587a7e6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:to="loc_srt_RangeAxis_be76ec9b-8c13-4e22-9713-c4bd587a7e6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be76ec9b-8c13-4e22-9713-c4bd587a7e6c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_be76ec9b-8c13-4e22-9713-c4bd587a7e6c" xlink:to="loc_srt_RangeMember_be76ec9b-8c13-4e22-9713-c4bd587a7e6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d6889ef-51cd-415f-a12f-4a6b1e802977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_be76ec9b-8c13-4e22-9713-c4bd587a7e6c" xlink:to="loc_srt_RangeMember_0d6889ef-51cd-415f-a12f-4a6b1e802977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b55b1365-8166-4e6e-a951-1fd864091668" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d6889ef-51cd-415f-a12f-4a6b1e802977" xlink:to="loc_srt_MinimumMember_b55b1365-8166-4e6e-a951-1fd864091668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_95502e9a-d26e-4561-88fa-1b533c2c1ff2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d6889ef-51cd-415f-a12f-4a6b1e802977" xlink:to="loc_srt_MaximumMember_95502e9a-d26e-4561-88fa-1b533c2c1ff2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYEquityFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="extended" id="i664cb9718f7b4e4192aee984aadd3a0f_STOCKHOLDERSEQUITYEquityFinancingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1902a3f3-a3c3-42a9-860a-bc3cde1250c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1902a3f3-a3c3-42a9-860a-bc3cde1250c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_a81ae32d-e976-415d-b175-2d4eb9e33d9f" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_a81ae32d-e976-415d-b175-2d4eb9e33d9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_39e4e570-1c49-4e46-8b49-9074addb6ab5" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_39e4e570-1c49-4e46-8b49-9074addb6ab5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_3e474479-86c9-44e0-bee0-473a4320acde" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_3e474479-86c9-44e0-bee0-473a4320acde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d5be4a2a-f1fb-4c6b-b40b-0a64c123a54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d5be4a2a-f1fb-4c6b-b40b-0a64c123a54c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ead3fa2-cfdf-4bdd-8435-ab7d3100af69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ead3fa2-cfdf-4bdd-8435-ab7d3100af69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_7dee836b-705d-48f8-bdd2-593aa6f12ea9" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_7dee836b-705d-48f8-bdd2-593aa6f12ea9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_afa413bc-95fb-4b29-ba78-0bd586e1e424" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_afa413bc-95fb-4b29-ba78-0bd586e1e424" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9c9870bf-aa64-408f-8986-26025e0fa4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9c9870bf-aa64-408f-8986-26025e0fa4dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f507c555-9548-4e9d-bb2f-ff89f1225476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9c9870bf-aa64-408f-8986-26025e0fa4dd" xlink:to="loc_us-gaap_CreditFacilityAxis_f507c555-9548-4e9d-bb2f-ff89f1225476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f507c555-9548-4e9d-bb2f-ff89f1225476_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f507c555-9548-4e9d-bb2f-ff89f1225476" xlink:to="loc_us-gaap_CreditFacilityDomain_f507c555-9548-4e9d-bb2f-ff89f1225476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ca48e363-2fcf-402e-966a-8593d7082efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f507c555-9548-4e9d-bb2f-ff89f1225476" xlink:to="loc_us-gaap_CreditFacilityDomain_ca48e363-2fcf-402e-966a-8593d7082efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_acb1dd0c-dd4e-4e19-b897-5b0ae59e8b10" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ca48e363-2fcf-402e-966a-8593d7082efb" xlink:to="loc_sesn_ATMFacilityMember_acb1dd0c-dd4e-4e19-b897-5b0ae59e8b10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="extended" id="ic948c05922354c6f838c542b6eecb983_STOCKHOLDERSEQUITYCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ce28e8ab-64d7-4634-958f-8b464053be83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ce28e8ab-64d7-4634-958f-8b464053be83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ef90e071-1463-41e8-932e-9045d9ecdd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_us-gaap_CommonStockSharesIssued_ef90e071-1463-41e8-932e-9045d9ecdd3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9b5a1f3a-9eaa-443d-aa19-0fb5500fcfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9b5a1f3a-9eaa-443d-aa19-0fb5500fcfee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_29853980-ba12-48cb-ba8c-e0396ab4b060" xlink:href="sesn-20220630.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_29853980-ba12-48cb-ba8c-e0396ab4b060" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_82eb0150-ce8f-4e4f-ac90-2a52432bd4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_82eb0150-ce8f-4e4f-ac90-2a52432bd4b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_219f55cc-3fc9-490b-a720-01f0c2028faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_82eb0150-ce8f-4e4f-ac90-2a52432bd4b6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_219f55cc-3fc9-490b-a720-01f0c2028faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_219f55cc-3fc9-490b-a720-01f0c2028faa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_219f55cc-3fc9-490b-a720-01f0c2028faa" xlink:to="loc_us-gaap_EquityComponentDomain_219f55cc-3fc9-490b-a720-01f0c2028faa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b189b106-ccf9-40d4-a842-77a229981cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_219f55cc-3fc9-490b-a720-01f0c2028faa" xlink:to="loc_us-gaap_EquityComponentDomain_b189b106-ccf9-40d4-a842-77a229981cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5c9b467e-8f5f-41d3-8e97-fadd665e5fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b189b106-ccf9-40d4-a842-77a229981cac" xlink:to="loc_us-gaap_CommonStockMember_5c9b467e-8f5f-41d3-8e97-fadd665e5fdd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended" id="ia0e6d4b74c9144d9ba6495e9e50e229c_STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0a514bcf-074b-4ad5-b3ed-df41704b32da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cead00ee-dc15-47ad-8c67-dd7e834a7459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0a514bcf-074b-4ad5-b3ed-df41704b32da" xlink:to="loc_us-gaap_CommonStockSharesIssued_cead00ee-dc15-47ad-8c67-dd7e834a7459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f65fd03-7056-4f3e-a04f-759f9b89bad9" xlink:href="sesn-20220630.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0a514bcf-074b-4ad5-b3ed-df41704b32da" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f65fd03-7056-4f3e-a04f-759f9b89bad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ebdfde9e-cc08-41a6-8d1f-4a405e28ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f65fd03-7056-4f3e-a04f-759f9b89bad9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ebdfde9e-cc08-41a6-8d1f-4a405e28ac40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_42b6164d-893a-4f7b-ad1a-cf0790a2bfb3" xlink:href="sesn-20220630.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f65fd03-7056-4f3e-a04f-759f9b89bad9" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_42b6164d-893a-4f7b-ad1a-cf0790a2bfb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_dbdd7a82-34b1-4020-8559-47db806011e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0a514bcf-074b-4ad5-b3ed-df41704b32da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_dbdd7a82-34b1-4020-8559-47db806011e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8456b883-62c9-4fcf-abc3-bd9e26a76180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_dbdd7a82-34b1-4020-8559-47db806011e3" xlink:to="loc_us-gaap_AwardTypeAxis_8456b883-62c9-4fcf-abc3-bd9e26a76180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8456b883-62c9-4fcf-abc3-bd9e26a76180_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8456b883-62c9-4fcf-abc3-bd9e26a76180" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8456b883-62c9-4fcf-abc3-bd9e26a76180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8456b883-62c9-4fcf-abc3-bd9e26a76180" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e084e064-2801-4bf4-bd30-4ea4b447b6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_WarrantMember_e084e064-2801-4bf4-bd30-4ea4b447b6d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8b4cbbbc-61e6-4a0d-b2ab-1bac24176d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8b4cbbbc-61e6-4a0d-b2ab-1bac24176d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f6915914-7e4d-4b9b-ac7c-306a0e251e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f6915914-7e4d-4b9b-ac7c-306a0e251e39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_471e8adc-b7dc-4fc4-91df-a1619c6f67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_StockCompensationPlanMember_471e8adc-b7dc-4fc4-91df-a1619c6f67a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1c7a912f-7fa8-4ce0-87a3-0138f5e956a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_EmployeeStockMember_1c7a912f-7fa8-4ce0-87a3-0138f5e956a8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="extended" id="ic180ac61744b41e1abdcae88668be3c0_STOCKHOLDERSEQUITYWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_99cb493a-1d63-4c0c-abbe-06500a633811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_346a6a4f-9621-4bf3-8f86-bbe16a8dbc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_99cb493a-1d63-4c0c-abbe-06500a633811" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_346a6a4f-9621-4bf3-8f86-bbe16a8dbc8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:href="sesn-20220630.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_99cb493a-1d63-4c0c-abbe-06500a633811" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8b601edf-944b-4aef-8a73-2ffa6c6c355a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8b601edf-944b-4aef-8a73-2ffa6c6c355a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_3b41cb29-bddb-4b1c-ba56-66ad908fa63f" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_3b41cb29-bddb-4b1c-ba56-66ad908fa63f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e61e5020-ec31-493f-a5b1-6f406814264f" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e61e5020-ec31-493f-a5b1-6f406814264f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_85c4f5b5-6bc1-4919-9320-3da8709a4c1e" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_85c4f5b5-6bc1-4919-9320-3da8709a4c1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d7a20af4-89b3-44e3-9e3a-c55d0e327fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_704f8d79-be5e-409f-b157-33a1aef8913d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_99cb493a-1d63-4c0c-abbe-06500a633811" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_704f8d79-be5e-409f-b157-33a1aef8913d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_305caa94-b260-4fb8-9f36-800bdc61b35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_704f8d79-be5e-409f-b157-33a1aef8913d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_305caa94-b260-4fb8-9f36-800bdc61b35d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_305caa94-b260-4fb8-9f36-800bdc61b35d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_305caa94-b260-4fb8-9f36-800bdc61b35d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_305caa94-b260-4fb8-9f36-800bdc61b35d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_305caa94-b260-4fb8-9f36-800bdc61b35d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_7d2b3c3b-b484-475f-9080-dc00b1b45e89" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_7d2b3c3b-b484-475f-9080-dc00b1b45e89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_6e866ab1-35ea-4fb1-9e34-ff6d974a142b" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_6e866ab1-35ea-4fb1-9e34-ff6d974a142b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_cea01e62-87c6-44e7-9f4e-c87cc47b27b5" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_cea01e62-87c6-44e7-9f4e-c87cc47b27b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_2d6f6d67-0558-4de6-b616-7f56dcd92672" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_2d6f6d67-0558-4de6-b616-7f56dcd92672" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="i327bc7d989634c55afe9a8c0611f6f25_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eba846fd-0118-4856-b3df-ccafddc88305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a3ae52c7-0091-4f15-9ed0-cdc063187351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eba846fd-0118-4856-b3df-ccafddc88305" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a3ae52c7-0091-4f15-9ed0-cdc063187351" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_38875960-4442-4d91-a0d0-cc9ac9140034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eba846fd-0118-4856-b3df-ccafddc88305" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_38875960-4442-4d91-a0d0-cc9ac9140034" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_38875960-4442-4d91-a0d0-cc9ac9140034" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8908b37f-8e2b-4655-bb3e-8f67cffd6bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:to="loc_us-gaap_WarrantMember_8908b37f-8e2b-4655-bb3e-8f67cffd6bfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ed5e1ac-5194-40e5-a053-d60d6fce41f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ed5e1ac-5194-40e5-a053-d60d6fce41f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4b1a4d35-d442-44dc-a5a6-b7416d182fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4b1a4d35-d442-44dc-a5a6-b7416d182fe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_96ee1514-07d3-4706-b5d0-b043a41b14ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:to="loc_us-gaap_PerformanceSharesMember_96ee1514-07d3-4706-b5d0-b043a41b14ca" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended" id="i0eb0c422e57949ee87823e68c3166d7e_SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e52a4e0-a0ef-4148-9583-77f557c834f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_06271a4b-65ee-4122-a93d-39bb7d90b8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e52a4e0-a0ef-4148-9583-77f557c834f0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_06271a4b-65ee-4122-a93d-39bb7d90b8bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d01e3ff9-7f75-4d3a-8fe4-be726e017265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e52a4e0-a0ef-4148-9583-77f557c834f0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d01e3ff9-7f75-4d3a-8fe4-be726e017265" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d01e3ff9-7f75-4d3a-8fe4-be726e017265" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e957828d-db42-4107-9122-b57e7655b935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e957828d-db42-4107-9122-b57e7655b935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0c4a2c20-ef26-47c3-ba53-6d009c2c340e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e957828d-db42-4107-9122-b57e7655b935" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0c4a2c20-ef26-47c3-ba53-6d009c2c340e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3f734e07-f9b0-48f2-ab03-9f8ca81b4c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e957828d-db42-4107-9122-b57e7655b935" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3f734e07-f9b0-48f2-ab03-9f8ca81b4c1c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="ie2cb8dcd502542c6805075f01559b572_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_552ccd79-f60a-4fca-8832-c5df4fe43dbf" xlink:href="sesn-20220630.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_552ccd79-f60a-4fca-8832-c5df4fe43dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44e81662-40d7-4d77-93a6-ab403e983dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44e81662-40d7-4d77-93a6-ab403e983dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3b99a547-4d1b-4939-ad4c-061537549ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3b99a547-4d1b-4939-ad4c-061537549ae4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5eda35a2-d02a-4be2-bc97-7b5d984b4584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5eda35a2-d02a-4be2-bc97-7b5d984b4584" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e8a80963-7f89-4693-9cf2-b600b2bf8e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e8a80963-7f89-4693-9cf2-b600b2bf8e4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_699c47ad-3142-4374-ac33-5e6fb096f62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_699c47ad-3142-4374-ac33-5e6fb096f62c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_9ea01784-1225-4436-bacc-02a0112b9f22" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_9ea01784-1225-4436-bacc-02a0112b9f22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_94efaebc-a764-4152-8722-90b31945c6fe" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_94efaebc-a764-4152-8722-90b31945c6fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ee2cb9e2-0752-4415-b9d0-9a9d96540526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ee2cb9e2-0752-4415-b9d0-9a9d96540526" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_eaae50c2-64ee-4bae-9952-48a778c26feb" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_eaae50c2-64ee-4bae-9952-48a778c26feb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_db27ce44-f238-4f8c-ac5a-c5f03f804ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_db27ce44-f238-4f8c-ac5a-c5f03f804ac0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_44648d67-836a-4a5b-88e2-09e308e15a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_44648d67-836a-4a5b-88e2-09e308e15a4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d2e26151-e37b-42ee-94be-f79a3d1a783a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d2e26151-e37b-42ee-94be-f79a3d1a783a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8fe2588b-eff7-4ec4-8255-de28dcfa320e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8fe2588b-eff7-4ec4-8255-de28dcfa320e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1244983e-2b75-4cbd-a150-b60336854aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1244983e-2b75-4cbd-a150-b60336854aef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0cc088d8-d7f7-4f2c-b7a1-c6a7eaf93381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0cc088d8-d7f7-4f2c-b7a1-c6a7eaf93381" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_db68afe0-1602-4696-a505-91a23594e993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_db68afe0-1602-4696-a505-91a23594e993" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06735921-5597-4107-9aa6-3340501a4655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_AwardTypeAxis_06735921-5597-4107-9aa6-3340501a4655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06735921-5597-4107-9aa6-3340501a4655_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_06735921-5597-4107-9aa6-3340501a4655" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06735921-5597-4107-9aa6-3340501a4655_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_06735921-5597-4107-9aa6-3340501a4655" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7ca120e3-3e08-44bf-9e78-d8b5eb077c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7ca120e3-3e08-44bf-9e78-d8b5eb077c46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bf838c8b-520f-44c7-b9c7-8c2de4a4b712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bf838c8b-520f-44c7-b9c7-8c2de4a4b712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_06ff0106-3e24-4bc0-9cc9-e2d602d3dbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:to="loc_us-gaap_PerformanceSharesMember_06ff0106-3e24-4bc0-9cc9-e2d602d3dbd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a45bc5cf-d5b2-482b-a459-f33960c57e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_PlanNameAxis_a45bc5cf-d5b2-482b-a459-f33960c57e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a45bc5cf-d5b2-482b-a459-f33960c57e9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a45bc5cf-d5b2-482b-a459-f33960c57e9c" xlink:to="loc_us-gaap_PlanNameDomain_a45bc5cf-d5b2-482b-a459-f33960c57e9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a45bc5cf-d5b2-482b-a459-f33960c57e9c" xlink:to="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_64010cae-df4c-4b23-9bcd-f9e46fb4df46" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_64010cae-df4c-4b23-9bcd-f9e46fb4df46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_86dd0ed1-7b85-4499-b4d2-978015a56e0d" xlink:href="sesn-20220630.xsd#sesn_RetentionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:to="loc_sesn_RetentionProgramMember_86dd0ed1-7b85-4499-b4d2-978015a56e0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_55cf1841-b431-42ed-a972-465c5e745b56" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:to="loc_sesn_StockIncentivePlan2009Member_55cf1841-b431-42ed-a972-465c5e745b56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7614488f-c98c-433b-b894-a1bf871ca2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_VestingAxis_7614488f-c98c-433b-b894-a1bf871ca2a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7614488f-c98c-433b-b894-a1bf871ca2a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7614488f-c98c-433b-b894-a1bf871ca2a5" xlink:to="loc_us-gaap_VestingDomain_7614488f-c98c-433b-b894-a1bf871ca2a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_58167e4d-6dee-45b4-8419-eebf3bd1c8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7614488f-c98c-433b-b894-a1bf871ca2a5" xlink:to="loc_us-gaap_VestingDomain_58167e4d-6dee-45b4-8419-eebf3bd1c8e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4014bf0a-c5bc-4d47-b08b-6cb6d2938a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_58167e4d-6dee-45b4-8419-eebf3bd1c8e0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4014bf0a-c5bc-4d47-b08b-6cb6d2938a32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f5dede16-70ef-4e2a-88f5-fe49034f088e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_58167e4d-6dee-45b4-8419-eebf3bd1c8e0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f5dede16-70ef-4e2a-88f5-fe49034f088e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_6ff4006d-7131-4e4d-82d4-dbec98e12c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_GranteeStatusAxis_6ff4006d-7131-4e4d-82d4-dbec98e12c2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_6ff4006d-7131-4e4d-82d4-dbec98e12c2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_6ff4006d-7131-4e4d-82d4-dbec98e12c2f" xlink:to="loc_us-gaap_GranteeStatusDomain_6ff4006d-7131-4e4d-82d4-dbec98e12c2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_5bdca4ce-c2f0-4019-a8b1-729c403dcfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_6ff4006d-7131-4e4d-82d4-dbec98e12c2f" xlink:to="loc_us-gaap_GranteeStatusDomain_5bdca4ce-c2f0-4019-a8b1-729c403dcfeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_c837f3eb-d70b-4182-88b0-2792be1a9276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_5bdca4ce-c2f0-4019-a8b1-729c403dcfeb" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_c837f3eb-d70b-4182-88b0-2792be1a9276" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended" id="i018c085aef7544df8fb689c26e4edf53_SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_8b8182b3-6981-4d60-905a-a6fb02259a13" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_8b8182b3-6981-4d60-905a-a6fb02259a13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_039e6666-8ab4-4e94-8d76-06e6c7b76572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_039e6666-8ab4-4e94-8d76-06e6c7b76572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1fad74b-8fa8-465f-bd46-6db87c04d1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1fad74b-8fa8-465f-bd46-6db87c04d1d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d84315ef-55a9-4715-bf13-dd83b8b7a08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d84315ef-55a9-4715-bf13-dd83b8b7a08f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f3d6b553-0b13-4ffe-bcb2-29c86e9580f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f3d6b553-0b13-4ffe-bcb2-29c86e9580f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ca353199-f209-4dee-accb-bda8b66c828f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ca353199-f209-4dee-accb-bda8b66c828f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c278d56-7ec2-4027-9daf-c64f318e860c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c278d56-7ec2-4027-9daf-c64f318e860c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ccbe8b87-856b-4b9d-8321-5f1199227450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c278d56-7ec2-4027-9daf-c64f318e860c" xlink:to="loc_us-gaap_AwardTypeAxis_ccbe8b87-856b-4b9d-8321-5f1199227450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccbe8b87-856b-4b9d-8321-5f1199227450_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ccbe8b87-856b-4b9d-8321-5f1199227450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccbe8b87-856b-4b9d-8321-5f1199227450_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0988ab2e-0ce3-4d8e-a8e7-2065ed5a02ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ccbe8b87-856b-4b9d-8321-5f1199227450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0988ab2e-0ce3-4d8e-a8e7-2065ed5a02ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3e102855-11f8-4df8-b6a1-5dda15665c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0988ab2e-0ce3-4d8e-a8e7-2065ed5a02ae" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3e102855-11f8-4df8-b6a1-5dda15665c7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended" id="i0a69aae0846a4eaabf6ea9990399a0be_SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f8606d2-2dd4-4d57-a49c-db7e8ad0f726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f8606d2-2dd4-4d57-a49c-db7e8ad0f726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d5455e8-b508-402d-a3c1-697ae517e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d5455e8-b508-402d-a3c1-697ae517e4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a24736f7-7cfb-448c-a87f-e099277b9af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a24736f7-7cfb-448c-a87f-e099277b9af2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41b47ff0-52f1-4d25-b476-cf557df25117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41b47ff0-52f1-4d25-b476-cf557df25117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_23c15993-4d6c-43fa-9f75-932b9d3544df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f8606d2-2dd4-4d57-a49c-db7e8ad0f726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6c74a148-611b-4a57-b3e6-7ecf5f1bee71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6c74a148-611b-4a57-b3e6-7ecf5f1bee71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_171c9ce8-f91d-43e3-b5e7-0a201e65b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_171c9ce8-f91d-43e3-b5e7-0a201e65b5ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_757fe9ff-3b65-44fb-bdeb-6fc041c59f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_757fe9ff-3b65-44fb-bdeb-6fc041c59f53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2eccd7ab-7f01-4b08-8ec5-4dc45d715fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5c7b1926-d929-48ef-9d4e-f48a994d7895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f8606d2-2dd4-4d57-a49c-db7e8ad0f726" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5c7b1926-d929-48ef-9d4e-f48a994d7895" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_401132a2-8927-4bc8-a56f-38deb0261704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5c7b1926-d929-48ef-9d4e-f48a994d7895" xlink:to="loc_us-gaap_AwardTypeAxis_401132a2-8927-4bc8-a56f-38deb0261704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_401132a2-8927-4bc8-a56f-38deb0261704_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_401132a2-8927-4bc8-a56f-38deb0261704" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_401132a2-8927-4bc8-a56f-38deb0261704_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf043f81-9e6e-4b84-9e7d-d79e25f22c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_401132a2-8927-4bc8-a56f-38deb0261704" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf043f81-9e6e-4b84-9e7d-d79e25f22c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_40af4aa3-ca05-422f-a505-7c5eca2d77ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf043f81-9e6e-4b84-9e7d-d79e25f22c9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_40af4aa3-ca05-422f-a505-7c5eca2d77ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_2f2fe621-8489-46c1-b8a0-87e4bdecb19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf043f81-9e6e-4b84-9e7d-d79e25f22c9d" xlink:to="loc_us-gaap_PerformanceSharesMember_2f2fe621-8489-46c1-b8a0-87e4bdecb19e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="i0f576ee19b28485b83077ffab50e638a_EMPLOYEEBENEFITPLANSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f2571cfe-9c92-4423-9f70-10c877659a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f2571cfe-9c92-4423-9f70-10c877659a89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6b6e0a0f-5e9c-40fb-a0b2-49d0f8dcce03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6b6e0a0f-5e9c-40fb-a0b2-49d0f8dcce03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b3bbb92c-bb4e-4f9b-9eb4-99dd85cb2c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b3bbb92c-bb4e-4f9b-9eb4-99dd85cb2c80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_abbb11f3-9e1e-41df-b762-2e045af476e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_abbb11f3-9e1e-41df-b762-2e045af476e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0e22f2b7-aa3e-4b16-af05-f99b80def83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0e22f2b7-aa3e-4b16-af05-f99b80def83e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_fc53032a-2219-4e5e-b994-931be9122540" xlink:href="sesn-20220630.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_fc53032a-2219-4e5e-b994-931be9122540" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5d517545-7f37-4e3f-932e-4ba131852861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5d517545-7f37-4e3f-932e-4ba131852861" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_041dd9c1-7547-4d93-9e28-9d3daf9b8846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:to="loc_us-gaap_PlanNameAxis_041dd9c1-7547-4d93-9e28-9d3daf9b8846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_041dd9c1-7547-4d93-9e28-9d3daf9b8846_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_041dd9c1-7547-4d93-9e28-9d3daf9b8846" xlink:to="loc_us-gaap_PlanNameDomain_041dd9c1-7547-4d93-9e28-9d3daf9b8846_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5af5c0f0-31dc-43de-8fec-e444d8ca8f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_041dd9c1-7547-4d93-9e28-9d3daf9b8846" xlink:to="loc_us-gaap_PlanNameDomain_5af5c0f0-31dc-43de-8fec-e444d8ca8f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_8b15cb47-04f5-488c-be1b-fd8434afb144" xlink:href="sesn-20220630.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5af5c0f0-31dc-43de-8fec-e444d8ca8f27" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_8b15cb47-04f5-488c-be1b-fd8434afb144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a108d73-f57e-43e8-81b5-c585c506fca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a108d73-f57e-43e8-81b5-c585c506fca6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7a108d73-f57e-43e8-81b5-c585c506fca6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a108d73-f57e-43e8-81b5-c585c506fca6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7a108d73-f57e-43e8-81b5-c585c506fca6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed5fcf29-d7da-4644-b8a0-39a8593102dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a108d73-f57e-43e8-81b5-c585c506fca6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed5fcf29-d7da-4644-b8a0-39a8593102dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_93a2fedd-9de7-4a8a-9c75-2f9ca38955f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed5fcf29-d7da-4644-b8a0-39a8593102dc" xlink:to="loc_us-gaap_DomesticPlanMember_93a2fedd-9de7-4a8a-9c75-2f9ca38955f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0a48646b-c180-4fb4-91c5-bb538f5a3099" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_93a2fedd-9de7-4a8a-9c75-2f9ca38955f2" xlink:to="loc_country_US_0a48646b-c180-4fb4-91c5-bb538f5a3099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6a2e001e-5e0c-486a-8e8d-fd2c20f5a59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed5fcf29-d7da-4644-b8a0-39a8593102dc" xlink:to="loc_us-gaap_ForeignPlanMember_6a2e001e-5e0c-486a-8e8d-fd2c20f5a59e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_814328d9-3a88-4d25-bac2-2de07063a189" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_6a2e001e-5e0c-486a-8e8d-fd2c20f5a59e" xlink:to="loc_country_CA_814328d9-3a88-4d25-bac2-2de07063a189" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended" id="i85b541c6bc744c6eacdf480dfdf7dcc6_INCOMETAXESComponentsofPretaxIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_19139e2c-fdf3-4e59-a21e-52ed95503145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_19139e2c-fdf3-4e59-a21e-52ed95503145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1a246767-0682-41af-8c1c-892390cdac18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1a246767-0682-41af-8c1c-892390cdac18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_842f980f-8662-4634-8e84-651b96cf053c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_842f980f-8662-4634-8e84-651b96cf053c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_bb73bb18-d673-4c1f-9072-5afb395e4b83" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:to="loc_sesn_IncomeTaxesTable_bb73bb18-d673-4c1f-9072-5afb395e4b83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_57f5806b-e727-49a3-b507-0b959573ccdc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_bb73bb18-d673-4c1f-9072-5afb395e4b83" xlink:to="loc_srt_StatementGeographicalAxis_57f5806b-e727-49a3-b507-0b959573ccdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_57f5806b-e727-49a3-b507-0b959573ccdc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_57f5806b-e727-49a3-b507-0b959573ccdc" xlink:to="loc_srt_SegmentGeographicalDomain_57f5806b-e727-49a3-b507-0b959573ccdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a68d0891-3689-4e2d-8508-be020ac17d26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_57f5806b-e727-49a3-b507-0b959573ccdc" xlink:to="loc_srt_SegmentGeographicalDomain_a68d0891-3689-4e2d-8508-be020ac17d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6a114137-0f3b-4cb2-a0a1-dca19bf8fdbd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a68d0891-3689-4e2d-8508-be020ac17d26" xlink:to="loc_country_US_6a114137-0f3b-4cb2-a0a1-dca19bf8fdbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_f4f182e1-de4c-403f-a342-c34eb02d2694" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a68d0891-3689-4e2d-8508-be020ac17d26" xlink:to="loc_country_CA_f4f182e1-de4c-403f-a342-c34eb02d2694" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i3b7804960bfd4b37bc56c57418490922_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_93eabca2-9782-4e25-996e-b16b6c17cbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_93eabca2-9782-4e25-996e-b16b6c17cbba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_11509b0c-4b23-4b2f-a1b6-463564d1a652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_11509b0c-4b23-4b2f-a1b6-463564d1a652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_55886832-b397-472e-8469-f560887b4e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_55886832-b397-472e-8469-f560887b4e7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseInDeferredTaxLiability_6409c1b2-131a-4fc2-a569-83253c5ce021" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_sesn_IncreaseDecreaseInDeferredTaxLiability_6409c1b2-131a-4fc2-a569-83253c5ce021" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_d94e9f27-a460-4cc5-85ea-c8a41eb81315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_us-gaap_IncomeTaxesPaid_d94e9f27-a460-4cc5-85ea-c8a41eb81315" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:to="loc_srt_ProductOrServiceAxis_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d" xlink:to="loc_srt_ProductsAndServicesDomain_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85966262-bf07-45f2-9d24-e19cd9bc52b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d" xlink:to="loc_srt_ProductsAndServicesDomain_85966262-bf07-45f2-9d24-e19cd9bc52b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_9513aa3d-3fd6-4f19-aa8b-06c855fcaf7f" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85966262-bf07-45f2-9d24-e19cd9bc52b1" xlink:to="loc_sesn_ViciniumMember_9513aa3d-3fd6-4f19-aa8b-06c855fcaf7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_adc851d9-992a-48a2-8914-0ade2d9bd27d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:to="loc_srt_StatementGeographicalAxis_adc851d9-992a-48a2-8914-0ade2d9bd27d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_adc851d9-992a-48a2-8914-0ade2d9bd27d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_adc851d9-992a-48a2-8914-0ade2d9bd27d" xlink:to="loc_srt_SegmentGeographicalDomain_adc851d9-992a-48a2-8914-0ade2d9bd27d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46885cde-9b51-452f-933d-80d3746499fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_adc851d9-992a-48a2-8914-0ade2d9bd27d" xlink:to="loc_srt_SegmentGeographicalDomain_46885cde-9b51-452f-933d-80d3746499fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b6f16dc1-9396-40c5-b3f6-48958a83669b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_46885cde-9b51-452f-933d-80d3746499fc" xlink:to="loc_srt_EuropeMember_b6f16dc1-9396-40c5-b3f6-48958a83669b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ac6770-1e68-4c92-8d4d-3391847b42c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ac6770-1e68-4c92-8d4d-3391847b42c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65ac6770-1e68-4c92-8d4d-3391847b42c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ac6770-1e68-4c92-8d4d-3391847b42c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65ac6770-1e68-4c92-8d4d-3391847b42c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e194c6c-2b8e-4e2c-b255-b5950328cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ac6770-1e68-4c92-8d4d-3391847b42c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e194c6c-2b8e-4e2c-b255-b5950328cc30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_805f6448-0d4d-4d32-a26a-2c9a5f335858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e194c6c-2b8e-4e2c-b255-b5950328cc30" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_805f6448-0d4d-4d32-a26a-2c9a5f335858" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#LICENSEAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended" id="i831051894e17492a8c0a7db4e3864a30_LICENSEAGREEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_d07ada2c-ed2a-4a9d-af1e-999ad186384d" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_d07ada2c-ed2a-4a9d-af1e-999ad186384d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_873f41ce-4cf5-4377-be88-be3d74591b49" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_873f41ce-4cf5-4377-be88-be3d74591b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_a2148988-5b2e-4713-bf8f-8fa88afd2e1d" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_a2148988-5b2e-4713-bf8f-8fa88afd2e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_c5dfb043-7d44-4502-96de-95a5058f8b79" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_c5dfb043-7d44-4502-96de-95a5058f8b79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_41111bac-672f-47a3-9514-f283d0ecbe35" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_41111bac-672f-47a3-9514-f283d0ecbe35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_62afbad1-8296-4438-a0cd-8a8f57d09fac" xlink:href="sesn-20220630.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_62afbad1-8296-4438-a0cd-8a8f57d09fac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_642876b6-9687-4004-b80f-edaba3458a44" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_642876b6-9687-4004-b80f-edaba3458a44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_97262cd0-78ae-4d73-98f6-d8f7514926ea" xlink:href="sesn-20220630.xsd#sesn_LicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseMaintenanceFees_97262cd0-78ae-4d73-98f6-d8f7514926ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_b6584cd8-02f9-4fa3-a43c-620c6845b7c8" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_b6584cd8-02f9-4fa3-a43c-620c6845b7c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_581abac9-0ab8-466f-93c6-605402ca0abd" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_581abac9-0ab8-466f-93c6-605402ca0abd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_35dba5e0-a189-4f5c-a766-6a30a80b5e98" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_35dba5e0-a189-4f5c-a766-6a30a80b5e98" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_024e3759-9f28-4b56-80d8-64d226497d75" xlink:href="sesn-20220630.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_024e3759-9f28-4b56-80d8-64d226497d75" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_972fdde3-3ae0-4326-80cc-a75b3db51af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_972fdde3-3ae0-4326-80cc-a75b3db51af5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_4c9c638e-19ff-467b-928d-b89396d1c115" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_4c9c638e-19ff-467b-928d-b89396d1c115" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_36dad52c-da78-45bf-ab4b-7266069994ae" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_36dad52c-da78-45bf-ab4b-7266069994ae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_971f2ea4-7aef-4f2c-9c99-c539feb18527" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_971f2ea4-7aef-4f2c-9c99-c539feb18527" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_eece0761-5a33-45ba-950f-94cf66e3f5db" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_eece0761-5a33-45ba-950f-94cf66e3f5db" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_37d868e6-1a5c-4019-ab33-f49cf2625bd1" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_37d868e6-1a5c-4019-ab33-f49cf2625bd1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_f19dc8cf-841c-437c-ac34-a5a9a5032780" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_f19dc8cf-841c-437c-ac34-a5a9a5032780" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_4a2a6831-fac7-4e1e-91b2-548e49b57124" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_4a2a6831-fac7-4e1e-91b2-548e49b57124" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_a4ba7a95-c70a-4969-85d3-20f121d421b5" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_a4ba7a95-c70a-4969-85d3-20f121d421b5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_63112b07-5f96-454b-83a0-79dbd2dd9e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_PaymentsForRestructuring_63112b07-5f96-454b-83a0-79dbd2dd9e18" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9fe8a6b1-6dd7-4f7b-9d8f-6f3ddee10fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9fe8a6b1-6dd7-4f7b-9d8f-6f3ddee10fc3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_ef13414f-e700-404a-86fb-d3a97a434379" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_ef13414f-e700-404a-86fb-d3a97a434379" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_03b26862-6779-4397-a33c-1e12e1227850" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_03b26862-6779-4397-a33c-1e12e1227850" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod_1bd0c982-d91e-4624-9021-0ac9ba15e9cf" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_CollaborativeArrangementRoyaltyPeriod_1bd0c982-d91e-4624-9021-0ac9ba15e9cf" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e594252d-3fce-4dc7-aca7-75ba10035ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e594252d-3fce-4dc7-aca7-75ba10035ebe" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_14e4ac41-8516-4b78-885e-8efa1fc800e9" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_14e4ac41-8516-4b78-885e-8efa1fc800e9" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_ddcbf9ce-3b7b-4405-981f-1ac7fa7608f8" xlink:href="sesn-20220630.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_RoyaltyRevenuePercentage_ddcbf9ce-3b7b-4405-981f-1ac7fa7608f8" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_daffc814-da73-4943-88c7-250e5330b138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_DeferredRevenue_daffc814-da73-4943-88c7-250e5330b138" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_36f5348a-0de5-4db4-9fee-30a85dd03ea7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_srt_CounterpartyNameAxis_36f5348a-0de5-4db4-9fee-30a85dd03ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36f5348a-0de5-4db4-9fee-30a85dd03ea7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_36f5348a-0de5-4db4-9fee-30a85dd03ea7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36f5348a-0de5-4db4-9fee-30a85dd03ea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_36f5348a-0de5-4db4-9fee-30a85dd03ea7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_b66e704a-bf5f-4662-abe0-41fe7a3d1d71" xlink:href="sesn-20220630.xsd#sesn_UniversityOfZurichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_UniversityOfZurichMember_b66e704a-bf5f-4662-abe0-41fe7a3d1d71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_322ec8ce-451d-4753-9f32-1bef00b2884c" xlink:href="sesn-20220630.xsd#sesn_MicrometAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_MicrometAGMember_322ec8ce-451d-4753-9f32-1bef00b2884c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_7a92439a-e90a-492f-b072-159c568281c1" xlink:href="sesn-20220630.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_XOMAIrelandLimitedMember_7a92439a-e90a-492f-b072-159c568281c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_1842d948-743f-4cb5-a536-3053683e241f" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_RocheMember_1842d948-743f-4cb5-a536-3053683e241f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_c8264189-603c-4dd1-ba24-aca2ac6d383c" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_c8264189-603c-4dd1-ba24-aca2ac6d383c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_51d831f8-d485-480c-92f6-45cec43cc9c7" xlink:href="sesn-20220630.xsd#sesn_MENALicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_MENALicenseAgreementMember_51d831f8-d485-480c-92f6-45cec43cc9c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_8e07e640-beb6-44f1-9322-4ae97ca78d48" xlink:href="sesn-20220630.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_8e07e640-beb6-44f1-9322-4ae97ca78d48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3189f1c7-5c2c-4a56-9c45-ae9703683e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3189f1c7-5c2c-4a56-9c45-ae9703683e1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3189f1c7-5c2c-4a56-9c45-ae9703683e1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3189f1c7-5c2c-4a56-9c45-ae9703683e1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3189f1c7-5c2c-4a56-9c45-ae9703683e1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3189f1c7-5c2c-4a56-9c45-ae9703683e1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_211c21ff-9c37-4849-bef4-372878aeb185" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_211c21ff-9c37-4849-bef4-372878aeb185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_cdb0cc24-20c9-497a-8e11-8bcf00c43177" xlink:href="sesn-20220630.xsd#sesn_FirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_FirstIndicationMember_cdb0cc24-20c9-497a-8e11-8bcf00c43177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_fc6208e7-bafe-495a-adac-9a5b38815aac" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_fc6208e7-bafe-495a-adac-9a5b38815aac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_113d48d2-7fba-4732-a651-29d9c3ddea91" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_113d48d2-7fba-4732-a651-29d9c3ddea91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_57e9ae43-862c-472c-b216-756816543acb" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_57e9ae43-862c-472c-b216-756816543acb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_65c65564-1838-4977-a457-26c715b8673e" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_65c65564-1838-4977-a457-26c715b8673e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_f9a8542a-9d7b-4f0d-b08f-8467c9292df6" xlink:href="sesn-20220630.xsd#sesn_SecondIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_SecondIndicationMember_f9a8542a-9d7b-4f0d-b08f-8467c9292df6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4a7639e2-a2e4-4c3d-9b7d-2506b413195d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_srt_ProductOrServiceAxis_4a7639e2-a2e4-4c3d-9b7d-2506b413195d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4a7639e2-a2e4-4c3d-9b7d-2506b413195d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4a7639e2-a2e4-4c3d-9b7d-2506b413195d" xlink:to="loc_srt_ProductsAndServicesDomain_4a7639e2-a2e4-4c3d-9b7d-2506b413195d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe3f0f86-52e5-47c3-bb07-8113db2987ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4a7639e2-a2e4-4c3d-9b7d-2506b413195d" xlink:to="loc_srt_ProductsAndServicesDomain_fe3f0f86-52e5-47c3-bb07-8113db2987ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_8e860de9-89e6-465f-b9b9-dfd220a1bf43" xlink:href="sesn-20220630.xsd#sesn_EBI031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fe3f0f86-52e5-47c3-bb07-8113db2987ab" xlink:to="loc_sesn_EBI031Member_8e860de9-89e6-465f-b9b9-dfd220a1bf43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_srt_RangeAxis_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe" xlink:to="loc_srt_RangeMember_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ae56805-fa84-4e7b-a0ef-23b5999b21a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe" xlink:to="loc_srt_RangeMember_8ae56805-fa84-4e7b-a0ef-23b5999b21a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f816d520-ef7d-474f-9ff8-c358547086f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8ae56805-fa84-4e7b-a0ef-23b5999b21a9" xlink:to="loc_srt_MinimumMember_f816d520-ef7d-474f-9ff8-c358547086f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_04b01dcf-02b8-4c87-bb2d-17d9785ad6df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8ae56805-fa84-4e7b-a0ef-23b5999b21a9" xlink:to="loc_srt_MaximumMember_04b01dcf-02b8-4c87-bb2d-17d9785ad6df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cf136f5f-9b62-41b9-9a24-9974bf94d1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cf136f5f-9b62-41b9-9a24-9974bf94d1d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf136f5f-9b62-41b9-9a24-9974bf94d1d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf136f5f-9b62-41b9-9a24-9974bf94d1d5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf136f5f-9b62-41b9-9a24-9974bf94d1d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725bcb57-a595-4a1c-beee-8bb7b5463299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf136f5f-9b62-41b9-9a24-9974bf94d1d5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725bcb57-a595-4a1c-beee-8bb7b5463299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_7136893f-5452-436b-823f-60830737ff63" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725bcb57-a595-4a1c-beee-8bb7b5463299" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_7136893f-5452-436b-823f-60830737ff63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e452c30-88c1-461f-a4eb-a620426e4de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e452c30-88c1-461f-a4eb-a620426e4de2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e452c30-88c1-461f-a4eb-a620426e4de2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e452c30-88c1-461f-a4eb-a620426e4de2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e452c30-88c1-461f-a4eb-a620426e4de2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6406667-8586-43a8-9b5e-24f0f7ca8e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e452c30-88c1-461f-a4eb-a620426e4de2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6406667-8586-43a8-9b5e-24f0f7ca8e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_32bd40cd-8609-42a9-9f72-ba8408a44c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6406667-8586-43a8-9b5e-24f0f7ca8e92" xlink:to="loc_us-gaap_LicensingAgreementsMember_32bd40cd-8609-42a9-9f72-ba8408a44c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_84bec747-d0ff-4e12-b686-bfdbd3019980" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_srt_StatementGeographicalAxis_84bec747-d0ff-4e12-b686-bfdbd3019980" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_84bec747-d0ff-4e12-b686-bfdbd3019980_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_84bec747-d0ff-4e12-b686-bfdbd3019980" xlink:to="loc_srt_SegmentGeographicalDomain_84bec747-d0ff-4e12-b686-bfdbd3019980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_de96cdd1-dc35-4b00-87e4-3126e5258fde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_84bec747-d0ff-4e12-b686-bfdbd3019980" xlink:to="loc_srt_SegmentGeographicalDomain_de96cdd1-dc35-4b00-87e4-3126e5258fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_1d7e72dc-8d75-4773-9d23-ecca18c0bca1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_de96cdd1-dc35-4b00-87e4-3126e5258fde" xlink:to="loc_country_TR_1d7e72dc-8d75-4773-9d23-ecca18c0bca1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0bcbb470-651f-48bf-a503-a2e2e37511e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0bcbb470-651f-48bf-a503-a2e2e37511e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0bcbb470-651f-48bf-a503-a2e2e37511e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0bcbb470-651f-48bf-a503-a2e2e37511e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0bcbb470-651f-48bf-a503-a2e2e37511e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b6a72bb-035b-45b6-a896-d47ce61242bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0bcbb470-651f-48bf-a503-a2e2e37511e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b6a72bb-035b-45b6-a896-d47ce61242bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_53e11b07-724b-412d-920d-83be5e8c18ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4b6a72bb-035b-45b6-a896-d47ce61242bf" xlink:to="loc_us-gaap_SubsequentEventMember_53e11b07-724b-412d-920d-83be5e8c18ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="ibce0ab6549194baeb5eb3cdcd7b9ef2e_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_47c404a8-9735-4e7a-a332-24e0be0c28e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_47c404a8-9735-4e7a-a332-24e0be0c28e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_a3c3bdc3-8d65-449f-b931-82f96f5d5d3a" xlink:href="sesn-20220630.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:to="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_a3c3bdc3-8d65-449f-b931-82f96f5d5d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_357c9acb-0a23-424d-a96f-1290aa713f0a" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_357c9acb-0a23-424d-a96f-1290aa713f0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_cb1dc1ce-ba19-41de-baa1-0d5df7d35a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:to="loc_us-gaap_SubsequentEventTable_cb1dc1ce-ba19-41de-baa1-0d5df7d35a9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_03de3964-d570-41f7-b83c-6f9777ad586c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cb1dc1ce-ba19-41de-baa1-0d5df7d35a9a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_03de3964-d570-41f7-b83c-6f9777ad586c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_03de3964-d570-41f7-b83c-6f9777ad586c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03de3964-d570-41f7-b83c-6f9777ad586c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_03de3964-d570-41f7-b83c-6f9777ad586c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_20323912-9860-4c7b-b33d-86c7c749805d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03de3964-d570-41f7-b83c-6f9777ad586c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_20323912-9860-4c7b-b33d-86c7c749805d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bfb1433b-359d-4565-b478-a3708e4b8ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_20323912-9860-4c7b-b33d-86c7c749805d" xlink:to="loc_us-gaap_SubsequentEventMember_bfb1433b-359d-4565-b478-a3708e4b8ca0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>sesn-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2242ac9-1511-42db-a08a-ac050036e5da,g:27c8282b-5e55-4664-b4e1-3a6627cbab54-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e3bdabab-fc00-4469-80ca-401884861353_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_d2da86a4-1652-4fc6-8e38-8bdcd2b09d67_terseLabel_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_label_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_documentation_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember" xlink:href="sesn-20220630.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_XOMAIrelandLimitedMember" xlink:to="lab_sesn_XOMAIrelandLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23e6941c-bb5a-452b-8c05-a035401ecf00_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_a9a21831-bf88-4ea8-ba24-ba6362f8f276_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e9be40ec-316e-4ea2-a74c-df93b946e883_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6a0db315-7649-4daf-aaf8-6bd857a416d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_767c4d82-a3e5-4c06-845f-cf17ddaacbaf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_91d8ae2f-338e-4e03-bac0-bad98ed43965_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_6bc60c8b-8195-43a0-94c4-702457194ab7_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_7cc24828-a981-47f9-a439-e3f329411ad3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_5703055b-7701-4c49-899e-c7f1f8bef5cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_7652ea8f-eb98-471a-9e4e-e4ff982d1b48_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_12b5f6bc-6bac-4a97-a7ff-ab708cd895f9_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received per award (in shares)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_408f4b55-0a13-4bbf-8ecd-965652c99796_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_053c0dd1-64be-4358-a69b-4e8d2a56e3df_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LitigationSettlementMember_2b6ea3cf-42b2-442a-ba6a-4bf9c3cd4214_terseLabel_en-US" xlink:label="lab_sesn_LitigationSettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement</link:label>
    <link:label id="lab_sesn_LitigationSettlementMember_label_en-US" xlink:label="lab_sesn_LitigationSettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement [Member]</link:label>
    <link:label id="lab_sesn_LitigationSettlementMember_documentation_en-US" xlink:label="lab_sesn_LitigationSettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LitigationSettlementMember" xlink:href="sesn-20220630.xsd#sesn_LitigationSettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LitigationSettlementMember" xlink:to="lab_sesn_LitigationSettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_81518021-3343-45dc-984b-b73b7b2b0827_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_560f5e6b-69e5-4f18-be64-c859df551257_terseLabel_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue, percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_label_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_documentation_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage" xlink:href="sesn-20220630.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RoyaltyRevenuePercentage" xlink:to="lab_sesn_RoyaltyRevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3039d666-1c01-4179-8d84-0103e4b37609_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eefde763-78ac-4f24-96fa-18857920763e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c5d8a80-9d49-411a-bb6a-52b1e48cf880_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35c1f723-b0af-4720-92b9-d11932e770f9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_2ff4c8cd-1151-4ae4-ae30-ad986ade4f1c_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementUpfrontFee" xlink:to="lab_sesn_LicenseAgreementUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5597b22a-d7f5-4495-b913-ae1367264776_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_dfd3178f-6cba-4807-8f24-d71294729a65_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party minimum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_2cd534bb-0188-49d1-bffe-1bb88c38780b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5b0df4ac-9024-40a1-96e8-8a1c3d4ba68f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss After Taxes</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b99ba5b4-63d5-491f-9eea-0dacc9409832_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_55a15b8a-9b93-411c-839b-597885895323_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_88beed9d-2184-44d4-8fda-ce19dfaa385b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_26876270-c210-4d40-bf7b-c4030b9d036b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_758440f9-d450-4a26-a1e7-e18cb05c0ef2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dc43128f-f0f7-46c7-9102-f21b40a9788d_netLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3ee1c7a7-ae1f-4a91-9dfe-a65e939d7809_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9c63c9ca-295a-45a8-be36-09b15deb0313_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c90fe9fb-df97-4740-8a4a-4c98570e29ad_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_e81c80a8-7bd3-49a1-825a-212301c7e0e6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_913f33c6-4cee-438e-b92d-ebe26022069d_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space (in square feet)</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_label_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_documentation_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:href="sesn-20220630.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:to="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_449b0639-80d3-4ea5-92b8-498e1d5c63c1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original number of shares subject to the option vesting</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_4f6a7057-22be-4547-ac49-5297ad7614df_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_54baa754-92df-4be2-8ee5-c9cf438754bc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_dba2c756-e14a-4288-9c52-71826f512797_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_64d11840-3ac5-4242-b4cd-700319505b26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_46578bd8-39c4-4aa3-ad31-86b08791c968_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on regulatory milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5d88d452-8fce-4224-b973-b2a5a274b28e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eb47f519-e2f7-49a7-8d75-b37decececdb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2f8d1cea-b321-4fa3-8c40-b1fb4076800a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3445c560-dd79-4b9c-8a30-ec7cb8d0d54a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c5f2bef2-ac84-41cd-a5eb-d914c458d81c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cd2615b0-d07b-4e53-a156-3d35c174f4bf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_80ef4e8d-d2d1-4b33-b759-f3f08d28d206_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_dff36537-2736-48b7-88a6-3f0149f60315_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_GermanVATRecoveryMember_70f5a8fa-ce90-400f-9986-b4a99f6e3be1_terseLabel_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery</link:label>
    <link:label id="lab_sesn_GermanVATRecoveryMember_label_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery [Member]</link:label>
    <link:label id="lab_sesn_GermanVATRecoveryMember_documentation_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember" xlink:href="sesn-20220630.xsd#sesn_GermanVATRecoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_GermanVATRecoveryMember" xlink:to="lab_sesn_GermanVATRecoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_15dc385a-9711-4551-ae65-a31b2507d522_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5a570ccb-709a-432d-810e-c40cf025319b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e3f15f15-4df1-43af-ac7a-1d6d4cd54432_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_ac1882b4-b33c-4e31-8aaf-2e21b78f265c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for sale under 2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ba1bc1e0-9747-4004-93d5-ce75198d4467_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_51824b3d-fa8a-4ab0-a30f-3d9b3b65b239_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a63aa255-36d8-4c32-a778-3af1ac8a36df_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_74393598-2715-42f1-958e-fe2693e66a2e_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party maximum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:to="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0f809192-0281-44a6-8fb4-0ef9de9e6fd5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_dcf60bb1-ca20-42a4-92fd-820cf5523587_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_b11f4a68-05cf-4b7b-b48d-c7174706d878_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D intangible assets:</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f097fa42-c001-4fea-8512-913607fd5288_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_60923a15-1678-4b41-b533-c05e56d3b3ee_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution retirement plan, maximum employee contribution deferred</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_56b0d9ad-6d75-479a-8e7c-6c68fec507d0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d3d42720-cfd4-4d29-acfb-8d59a0ad1cbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_60c68171-7a49-43cc-9459-3f296f520bdb_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECEIVABLES</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_11c1c32c-a9ac-4cbe-822d-4b9b28f3ee47_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fca98f0a-f843-407b-a77e-8297bdb701dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_fe327161-06ab-4a35-9272-f02d7ed3c5ef_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_74caf742-7031-4853-8e44-5bf1c4eff3c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b37cc610-2ef2-4513-a4f8-fba215e16256_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_719bb8e0-21d0-4619-9006-9108a5fc8dbf_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment, percentage</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_label_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:to="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ee7b9ea3-031d-48c4-b1c7-f1731e3dc477_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_efa37c93-86df-44ec-96c3-c31e884bd937_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_6b1eb810-bcd5-479d-8911-cd7611b8ccae_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_df5e4d4f-1ce2-4dd5-88d0-caa7318e0a89_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_a02b6c01-fd34-46fc-944a-b32ce2e2d21e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_df613fca-4572-490f-aa3a-83fa4e2e8ad6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a8faf291-160b-420e-ad19-27c30ec6925b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f42c065-5567-4ea0-8af8-60e68e94c488_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45e97b43-3ffc-4969-897c-a1b88eb9fbb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_6aac6b5f-fa8b-41d6-824f-4dcec90ffacb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff4c67c3-d813-4e02-b2e4-d217d785710c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e706b708-085b-4a9c-b173-80af3dce249c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8460d922-8169-4b26-a2dd-8c36cf7e1a20_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_0152cd86-fcb8-4dd0-b849-1a2ab9eba816_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_88928852-d2bd-4856-a165-3ed40e9e1c1f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b5acf2cc-ed46-449a-a49f-a1a425427c74_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0f3c87ad-7e57-404f-8bf3-9f86b6eae428_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7db7e711-0ddc-4d34-8dfc-903380ef4a50_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_cc11ae3c-4d60-4df0-b3b8-90a4024d21c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_FirstIndicationMember_54e414dd-2a0d-40c4-b4f2-9c3e486d01d4_terseLabel_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_label_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_documentation_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember" xlink:href="sesn-20220630.xsd#sesn_FirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_FirstIndicationMember" xlink:to="lab_sesn_FirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_fe7ca334-5b82-4e15-a4c2-3d2a5a677c66_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_d4ba56b4-95d3-4f98-b1fc-be34ea7b9871_terseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_label_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009 [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlan2009Member" xlink:to="lab_sesn_StockIncentivePlan2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_8fc0f42c-6b9b-44fc-a1c0-a372cab7fed6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4996ae13-43d8-4d78-be16-f2ccd21ee29a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfLawsuits_d9d5c724-2e2b-4896-8d7e-b9d6d3fca8b7_terseLabel_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_label_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_documentation_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits" xlink:href="sesn-20220630.xsd#sesn_NumberOfLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfLawsuits" xlink:to="lab_sesn_NumberOfLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_25b45775-87e1-4873-8510-fd54a1438aef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting on the First Anniversary of Date of Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedLegalFees_9635f16b-efa2-4ee3-a57f-89d9018e7acb_terseLabel_en-US" xlink:label="lab_sesn_AccruedLegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses, including preliminary litigation settlement</link:label>
    <link:label id="lab_sesn_AccruedLegalFees_label_en-US" xlink:label="lab_sesn_AccruedLegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees</link:label>
    <link:label id="lab_sesn_AccruedLegalFees_documentation_en-US" xlink:label="lab_sesn_AccruedLegalFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFees" xlink:href="sesn-20220630.xsd#sesn_AccruedLegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedLegalFees" xlink:to="lab_sesn_AccruedLegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_712893d4-80a2-48df-bd3f-2396bd1dc655_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_5e9ec88a-ca56-4373-acd1-7917bfc4290d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_43f68edd-4da5-4833-8fbc-d640b69cbff9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a7c96ca2-7985-4a54-8ce2-46555cdc49aa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c75ff238-6eea-4e35-81bb-9fbc4e7fb32d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_3ba88de4-3e85-4b8f-9e0f-f3e8f16f3e5c_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_11a17baf-248d-4960-9bdd-981cd54cd0fc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_68382de1-554e-4a07-b0c6-18c9ae57a36c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_aa5c6b90-1254-47e7-aae9-af4bfa9dd729_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_4ed8010b-07e3-4a07-b25c-6c641f30a42e_terseLabel_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary match per participating employee, maximum</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_label_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_documentation_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:href="sesn-20220630.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:to="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0ba7d383-8044-4334-b9cc-cb2989318c1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9148d92-1341-49f9-9fbe-eddd92e51a95_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_19efa0e9-5cc0-4083-bb0e-8163eba44ffb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e9497c55-d2cb-40d3-86f7-d6d5c6b47973_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d2d7928-d7f8-491c-a4af-74c0c4ca6d39_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Loss before Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_231d9442-4cc0-4b03-aecb-5830b09c83e6_terseLabel_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:href="sesn-20220630.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:to="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_10129c6e-9d9b-4091-a9b2-9b66921e7407_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0ec02f43-0349-4c5b-ac78-29ace4bc2b6a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_fbfc1004-7da5-47d3-bdda-5b3769dfa0d2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d6f9fdee-0028-4148-92c0-071a4734ccd0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_6bb27af2-7828-45cd-be29-431df8054349_terseLabel_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to company upon execution of the Roche Asset Purchase Agreement</link:label>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_label_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Execution Of Asset Purchase Agreement</link:label>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Execution Of Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:href="sesn-20220630.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:to="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_de90798a-f99b-4990-b3ed-19591ed0fbf4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Benefit (Provision)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98c3836b-07bb-4824-ac96-7bd23e045914_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_4c2867ed-68f8-4ae2-83c9-884969addb47_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8943846d-19dc-4f45-82c4-8d2d1975bc58_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period unvested stock to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21eb9fe7-3ce9-46c3-bb8d-071c574985a0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_e67a5f93-00fe-4d59-9211-93599e69129f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_d20e3225-c744-43e5-bd48-d163650ba090_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sales price</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_label_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_documentation_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:to="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_91df74de-5ef7-4c59-8241-ad8f5bc2d0db_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_10c49ce0-04ba-45a0-98eb-d5132eea2be1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d47de6ca-462e-4ce9-bf30-4cddc69ab66c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6f164eb6-d40e-45e3-98b3-1b1e40ac358f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_01e4337c-037c-452e-bfa5-0e02f49dfda0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a10ebb3e-c75a-4743-9ee2-598294895261_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_066ce876-2d2b-40da-b1d1-ad10f7f0d213_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b8f7b1e-c51f-4112-a9ae-4cca0498dac7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_b2031cb4-2f52-4102-b9cc-517603092fd8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_290e7e4e-91cb-4db0-8ab5-1f837dd75e7c_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_e6a67a5d-e8ce-4759-a2cf-e33bfb70eae2_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, option periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_label_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementOptionPeriods" xlink:to="lab_sesn_LicenseAgreementOptionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e8f43d81-06b2-46d7-9014-d6c7632c0a29_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f2808755-fe7d-41db-a838-cc15b83833d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_a5da999c-9b70-4a79-928b-8f74b258dc10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_04a08a10-d918-4359-9fcb-eefd4ee94046_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_ce1b7da7-b913-48d0-adf7-302749b87c66_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_b8e24db2-b1b2-4ae3-bd48-e3de8f0bd8d7_terseLabel_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_label_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_documentation_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms" xlink:href="sesn-20220630.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccountsReceivablePaymentTerms" xlink:to="lab_sesn_AccountsReceivablePaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid_d4a4cdac-5ac9-4e8d-8062-922f910f181e_terseLabel_en-US" xlink:label="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses previously classified as prepaid</link:label>
    <link:label id="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid_label_en-US" xlink:label="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Previously Classified as Prepaid</link:label>
    <link:label id="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid_documentation_en-US" xlink:label="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Previously Classified as Prepaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:href="sesn-20220630.xsd#sesn_ExpensesPreviouslyClassifiedAsPrepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:to="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ef001584-44f7-4c8a-9734-23ef0d092121_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cb5fb0f2-2157-48c5-910b-7c071425ed66_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cce86098-4dd0-48cc-814a-2f4d40df7472_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b2169716-5d5f-476a-aed7-0cfcd90fcae7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4270e7e3-e11b-453e-a124-78ea67729049_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d04c563b-eebf-4b1d-a514-dba1cd78a9d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_59689c65-d801-4eea-bb17-4d07a9a38b3a_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:to="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_18ba69c5-9813-47e5-8bbc-1c1ef102f5af_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c8657021-d90c-4f5c-916a-ecd2fd72ddd0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f6a83dbd-728a-4315-813f-bfd1ec1f6d53_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6fdb2902-3141-46a6-8906-bea7a0db08d8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_d682afe9-fa03-452d-b2ab-7333c65d8cb1_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e650d25d-9576-47b2-a01a-29ee22465889_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested grant restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d8b20a79-cf34-4bb8-892e-cd6628f778fc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6b6a6efc-ad3b-4731-a08b-25a2a68c2c97_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9b537fe7-d3fc-476a-a7c0-49b511730df4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_ce3791d2-0056-4667-890b-4a9e337ecc7a_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fixed rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_label_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_documentation_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockCommissionFixedRate" xlink:to="lab_sesn_SaleOfStockCommissionFixedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_f13b1893-789a-4329-88c6-6e1a652804d0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_05836033-9bd0-4ac1-832d-198dc2ac69f7_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsCurrent" xlink:to="lab_us-gaap_IntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_600a1dcc-2885-46c9-9bd0-e563f3efaf2f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c267151-1624-4701-bf75-160a4c6b14a0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds (cash equivalents)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_72c1e148-b423-4f39-986f-bf2d86ce738e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_67f97c54-9a34-4430-9368-33d5a6ca57b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_f2791882-0cd5-4760-8315-9eacb2033e8a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_39ae6557-08f7-472d-85b6-4889990d6284_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91ea7e9a-5351-49c8-9941-93aca33354df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_dbd610d9-0b7e-4fde-923f-07478f08edd0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d7f5cf79-56ee-4103-9d3d-27fc42c2981f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_10e1b09d-cdc6-4741-84aa-1959167bb27b_terseLabel_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_label_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_documentation_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:href="sesn-20220630.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:to="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5b3c0445-e44f-4c53-b455-9dc17a3f8969_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3ef8e2c2-8c42-46f2-8876-7e5957bc8a75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f235abb9-7683-4642-8ab2-04d738272a8f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_f43ecbc4-8aa6-460a-a325-92f25c6b8bf8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_cb34dd90-4e7b-47d1-9341-e852d121b882_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_78bb0a48-6c29-4138-9f37-d659c66121f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_553d98e3-0093-44c8-8fed-eeb4e38f23ee_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a446a384-68a2-4fda-b5ae-cce536158597_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e50c2c9a-a5de-4472-b2e2-dd23d5d66d4f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a21cdc70-90c5-45cf-ae8b-59cbad1ffabd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled RSU (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_b5eee39b-4ad4-48cb-ac61-7a03495875e6_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_f779d09b-8c55-4058-850f-90ef4430d53b_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, period to pay buyout option once exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_label_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:to="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_8fdf3b7c-c11f-4aa4-8d7d-20f91549632e_totalLabel_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock issued and reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_label_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_documentation_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:href="sesn-20220630.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:to="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_533393dd-b1a4-4163-96a9-10e244de69a5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc60953b-7cd8-46db-8907-4aacb35d3120_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of units issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_4e79ea0a-72e0-4477-82e8-d3255044fa2b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_44a525b6-540d-4136-a6f7-56e959011a0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_d35052b5-c486-433f-8ef4-2b66e86dda43_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_64189b65-316c-49fb-a4de-138082e37158_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_198ad2a7-3b7f-444a-bb4c-0fe5996c00b0_verboseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_label_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseMonthlyRent" xlink:to="lab_sesn_OperatingLeaseMonthlyRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b02f7cef-f30b-400c-94f9-2f2d2cf8d285_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bf6ed7fb-f96e-4e6a-8bf5-e878ee55caf9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_63caec1c-2e34-4d4f-8fc6-fe99de92daf1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ad22258d-4a99-42ba-a9a2-096cce71d492_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for sale (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_08596d20-05d6-4d05-af09-3208fc51d799_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ef8f8178-d919-4cd1-b940-d1d43aa38c58_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_4ad62cd2-2968-4b35-8eb3-d80f6f4e57ff_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued to the selling shareholders (in shares)</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_label_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:to="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_744991ac-e019-489c-a5f7-00b084ed18be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Status of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ea64cf2f-df2d-4386-99b2-a536a058a108_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_b1a4d080-9445-46f7-a374-e1e57f1af62d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax benefit (provision)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_c0410394-c209-4c59-9465-179dbe4a6ccd_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_7542eb25-ce92-4f6c-ac54-15d1732ff3b5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_33949167-1507-4d02-a7aa-7368c7cd4055_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f2e3f33b-8fc4-43f9-8d70-d00cbf8a16ba_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_9495eab7-0760-4ffb-bb6e-e43be3a483a3_terseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_770e1a25-d7d1-41d0-9a25-f46ffe12f3d6_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4c640a64-de47-4433-8da4-2ec67b14eed5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5daa8046-28d3-4113-b782-3914068c3a21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_0fe94224-f9d3-4d71-b5a5-47a876f5bf3c_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_93421f30-7bf3-467d-afaa-1648da20f3e8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_6b956866-d3f0-485b-8f36-53ccae18df5c_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyRate" xlink:to="lab_sesn_LicenseAgreementRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c3f9f385-32b0-4506-88a9-dcf0495c3db4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b838f815-eb4c-4806-b0f5-a4e6d352e302_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2a00d431-de69-426a-b159-7fe593b36c81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_e64d1ccd-33bd-41b6-8e0a-8aa2ad5b6d9c_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_32b0ca77-006c-44ad-9576-55e4469ffae5_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance amount</link:label>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_label_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Shares Amount Available For Future Issuance</link:label>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Shares Amount Available For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:to="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d7c6c438-d98d-423a-ae81-0af8dd9617ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24a1c0ae-aa27-4d20-acc7-afc23a7585fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e7af4d16-a09e-45c3-ab43-452be980c80f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_4b812e18-898d-42bd-9bae-b512ee3d4f4e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_acddb699-7447-40d4-85a0-c07ae56e536c_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time milestone payment upon first sale of product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:to="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_70c36f52-7dce-4219-87b0-0e6e847e4b29_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_ea8d7776-e43a-439c-9591-6cdda137d8db_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of base salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_3ec636ee-495a-4bb8-84f6-85f86a0c9b38_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringMarch2023Member" xlink:to="lab_sesn_WarrantsExpiringMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_183a3eae-4598-4c25-9497-74279bdaa5f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_667d4d21-7ce6-4d7d-9cfb-51e3adc752a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74c21257-597a-4f93-9ae9-6a925df45647_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_57b44734-94ea-495e-aee8-5e29ec7eef90_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5982ba13-3a5c-4c70-92cc-548afbb375d2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ATMFacilityMember_43d3a165-c34a-41e0-9584-c6f10d0eff97_terseLabel_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_label_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_documentation_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ATMFacilityMember" xlink:to="lab_sesn_ATMFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a261004d-a9d3-4aef-a80a-f81c17fde2f6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8d5939d5-2ddc-40fb-bce3-44a5f7683ab3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in the fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_b37e5508-1028-403e-8975-c5c832f83c58_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current benefit (provision)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1e22a448-794b-45df-bfa7-4d2f91650a86_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_46fcb918-7eaf-4868-a4de-e3df3845cfc7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RetentionProgramMember_482304dc-cf93-41ca-8a15-f3a8db271b89_terseLabel_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_label_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_documentation_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember" xlink:href="sesn-20220630.xsd#sesn_RetentionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RetentionProgramMember" xlink:to="lab_sesn_RetentionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_98209600-36fd-4f74-85c9-0d7d1a54f611_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Period</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:to="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_23e92635-2100-44ac-91c3-ec58f8baa65c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ec47f578-0cd7-44db-b1ea-0e7cec8aa7b4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_93cc0b87-c164-4a2b-90b0-130ca1500527_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d0cd1ad7-7af9-43ab-b0e8-b2b89002196b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7467dbb6-dcf9-4415-a2bc-7a521427173b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6aff2255-6b9d-40ea-a22c-b16fbf4db53d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_292a3411-26b1-4e54-a32c-65e1476ef26e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9cf7ffdc-0dda-4c6f-8345-12d849663757_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_89c08768-e198-4990-98e6-7643234ed774_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_dc47a5b8-91fd-40ff-87bc-6c1d276a8c73_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_5c60f177-99cf-4614-a0f3-974ab796c0b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89cf68bc-09d8-4e14-a19a-ba1245f76f5e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d731eb55-678f-467d-8cc5-b97ee86b2255_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWIL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_431ba0e0-db39-40e8-81f4-d222eac3e558_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_1273d0a9-380c-4a5a-ba9d-868731bdcfe5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_9d7e27dc-98ee-40cc-a77a-43bb1c532788_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40260c61-db35-4bc6-bc4f-6eb4f974ed5f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5d849ec7-2bd4-4645-b199-d6c70420595e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ee9dd555-2540-421a-99ba-5b245ee8dde8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_cfeb7bc0-3fed-4f2f-b6a1-f3944cd0d476_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_147ea710-e03a-4ac8-817b-ae41e47ba6eb_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_186f5412-1470-42cc-ac3d-56b27791574b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_c22237f6-f779-480b-affc-b0d2b3efb2eb_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fddf10c-02a1-46c4-a31d-3633799f939c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_3d0f77be-fc25-4709-aef3-2c8217356f59_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, additional up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:to="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_b2f86e07-f2a7-45cf-8bcf-b0971b619653_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value (in dollars per share)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7bbc164b-33cf-4ac0-96ae-ad7a7bb1197a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da3cc533-1436-4cd7-9643-fb3a25ab3f81_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_576632e7-442f-43a8-a180-00d6a3558efc_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement deemed probable, percent</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_4c187e11-2e44-4d6b-be26-6de505fdda13_terseLabel_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_label_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_documentation_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare" xlink:href="sesn-20220630.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberofVotesEntitledForEachShare" xlink:to="lab_sesn_NumberofVotesEntitledForEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_241b0700-97a6-45a9-b710-c4d17a682907_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 400,000,000 shares authorized at June&#160;30, 2022 and December&#160;31, 2021; 199,463,645 shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_37330deb-a225-40f9-9c2a-4c3a157830e0_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5f1a520d-61e3-42ba-8d26-d529096ac98d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_652f39b7-c365-46d0-8f76-30cf1d452cf0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_311d4fdc-cd1d-4575-8f08-2ee24f400f77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8557b8b0-8c3e-483b-bfba-a23864357075_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7c9920b8-2b7a-48aa-a205-e0ef532a28dd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncreaseDecreaseInDeferredTaxLiability_7c22cb44-ae6b-4a48-a53d-21fb2b15e915_terseLabel_en-US" xlink:label="lab_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax liability</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseInDeferredTaxLiability_label_en-US" xlink:label="lab_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liability</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseInDeferredTaxLiability_documentation_en-US" xlink:label="lab_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:to="lab_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c7fd2696-c00a-4242-a361-515f32cbc1e5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_f2dbddee-3935-4c60-bb9f-e7ef5b505637_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0fddb4a5-8f0c-43a2-a05a-02cf0613c941_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a3cb4f0-5666-448f-88a5-f71f218d2d67_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_123301bb-44c0-4f25-b355-ff5d1d6e2f0d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income (loss) Canada</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_0901d3d5-4a9e-42a5-a687-7e4d317ee419_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e667f432-45f2-4952-918e-e521ba40b593_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_77f0eabc-ba92-421c-a4af-3934453781a3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d743f057-241e-4090-8354-c7f54130e223_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c169dd5a-59a6-4d2c-9cd9-dcfe9741e26c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c7ada21a-52df-41d9-bdaa-2fe67b855eb7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f1a84171-18ab-47f9-84fd-a42414bd487e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_74b3865b-022d-40f0-9bd8-c8dd50de49ee_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equipment included in accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e011cab4-76eb-4459-a0ec-bc2e0ecd6188_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' eligible compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a754ddb9-a23e-44ce-bf9c-b937cfbfcaac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a47bec62-9786-4f00-aaa2-37c8ea2dd0cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_b2d07438-e516-4f9e-8735-11eeea467947_negatedTerseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Cancelled (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_42360087-54d2-46b2-94eb-600a2765922a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_da995eca-70ee-49aa-814a-3ea75354268d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a9b9fff4-5468-4b80-a00a-3fee623ce2f6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost, including related operating cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_904b62c0-ffa7-4e51-a5c9-7f6da4d01ea6_terseLabel_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge related</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_label_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:href="sesn-20220630.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:to="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_e3d31d33-d183-4e69-b56a-40b6f45e9ac0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a9bb5840-8580-459f-9a47-e5f1495be24a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_07d0a25a-dcee-4ad0-a7c1-9f7e2b9ef1cd_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_9da188ba-835c-4cb9-9dd9-a915ed59bc30_terseLabel_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance for:</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_label_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_documentation_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:href="sesn-20220630.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:to="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3babaf70-ac80-4ee4-afa6-6b13bd637d4d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0ceb1cfc-43e3-4df1-9aba-994c8d442158_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_61d96f29-4021-4064-af35-cedfdec30960_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_de2b94e7-7e3a-4abb-9a99-a3ef8a31ce1b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for restructuring</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_f3f1d008-fb31-418f-a1fc-32d7a0180d0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c206e7bb-2b32-4152-8a64-dbe052aefd35_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_210dada9-c392-409f-b9d2-24c7985bd1bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_01d71139-dc69-4bbb-9dc2-20a7b441473a_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6f61a4ad-69f8-491c-bd3a-d1e76ecdc563_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SecondIndicationMember_c306ed8d-66ff-4a66-a2cc-e654a8376f39_terseLabel_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_label_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_documentation_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember" xlink:href="sesn-20220630.xsd#sesn_SecondIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SecondIndicationMember" xlink:to="lab_sesn_SecondIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a69756cd-7922-4235-8d8b-bab325017a0d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_7558fdbc-147c-4425-ad0b-b6f666faeca8_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_label_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationMilestonePayments" xlink:to="lab_sesn_BusinessCombinationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_567fda17-0cff-4a9a-89ba-f2c81b391399_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9575ebee-9110-4420-97bd-709b08abc036_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dca537d9-e611-46cf-8a5f-f49166fd96d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3ad814b8-f872-4d00-a903-73bae0281aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EBI031Member_c2ee4288-e3bf-417a-8959-ad2caf7d685a_terseLabel_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031</link:label>
    <link:label id="lab_sesn_EBI031Member_label_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:label id="lab_sesn_EBI031Member_documentation_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member" xlink:href="sesn-20220630.xsd#sesn_EBI031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EBI031Member" xlink:to="lab_sesn_EBI031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_421792df-af3e-41a2-8e47-bd78f7482c02_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_0253e0b2-8fad-446d-bb03-a95c6ed30831_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_62616e55-0bcc-4445-a920-34f84ac0e48f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_724c84ae-a901-4ba4-a85a-b79768ad8e75_negatedTerseLabel_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_label_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) of Prepaid Expenses, Noncurrent</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_documentation_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) of Prepaid Expenses, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:to="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cac98546-06d0-484a-b3e5-0074d1652327_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_55a481b8-f98c-47c6-a355-5e5c37bf6be1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_8a48d02c-f425-4332-aed6-c1d8cd4e930a_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_227c41a2-d0ea-49e1-9f53-6fa77b33620f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_69297de0-d5df-4f00-a610-39c742347acb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_dbfc469b-ea29-4bb5-854e-a339de3e98ac_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on development milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bcc7fbda-a875-4e98-90f0-7f2be65730da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled RSU (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_35000bae-eceb-4db0-9b5c-57f9c5b4a04f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2f3335ec-cf3f-45de-aba6-be983d30fd82_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING AND RELATED ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3e00020c-da8b-432c-bc4d-4cd87ca751e7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8a9a5c34-992c-4bc1-bd36-2fcca00d3f86_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cc59f357-e7f3-4b5b-92d2-3c5575060ff5_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_a73f0f32-b257-4fb5-ad7e-a381b15d1122_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_deea9d53-822e-463b-a113-bb5c3312c51d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8516510f-29bd-445f-a3c3-39ef0e28587e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_876ff2a8-40b8-410f-984c-fefddde168e4_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78287d3e-704e-46fb-b027-541d4e8ef3d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_a28f1e3d-431f-4746-8618-29a77f91e423_terseLabel_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable, asset purchase agreement</link:label>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_label_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivable, Asset Purchase Agreement</link:label>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivable, Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OtherReceivableAssetPurchaseAgreement" xlink:to="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_e896dcc8-931b-4955-b0a8-0cd55b030cf5_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant under 2014 Stock Incentive Plan</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_57f654a2-05fb-47bf-b0ed-8048de64f979_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8afd8c56-5734-4d9d-a24e-7f9f44891399_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_26d2d07c-d29e-45aa-bf22-98ee1afddd2b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncomeTaxesLineItems_c4354dd6-ad59-465b-aa52-2fd030e604f1_terseLabel_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sesn_IncomeTaxesLineItems_label_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sesn_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncomeTaxesLineItems" xlink:to="lab_sesn_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b119401a-ddea-49e1-9cbd-3afe2f1662f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cf84126f-05c1-4459-8702-b637930bbb09_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8e1167ca-38c2-421b-b200-fb855e7e450d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrants Outstanding and Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_2b9ea60a-11f9-4040-9827-7401c309dd37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e0e9c2f3-a7f6-4936-a408-bb302afa219c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_0dbfe174-6d72-459a-ba9d-34d96ca1be73_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3c04e050-28be-48a8-ae45-1738ec18c0b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4dcfb22f-4426-405d-86cc-bdec112f8107_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bd546372-fce9-4b1c-9d3d-def05b092aa0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1c63a1de-7899-48fb-ac56-986bf665a27a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_a4c40461-6fb6-4c8d-a728-99c9cb5e49fc_verboseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_ea433034-d12f-40c6-9950-2dcb6b3530e5_negatedTerseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9937d4c5-4d12-46da-8cda-5cf2e5582ebd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78882b51-ec14-4953-a513-e216c3c18be7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares under Option (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_1663f89e-079f-46f2-9e02-12d8a7ea9d9b_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales of quarterly earn-out payments during earn-out periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:to="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3b9bbf5f-481b-4000-87c4-0b71eb729947_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_d6421325-5754-4918-9262-d73dc0a95985_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1e8e3c88-e51a-4e02-bf44-398672757ee4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7dcb9840-8104-4db9-b0c9-1b9cc6b2d396_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c5eb344a-dc49-4997-918e-f441fe52b63f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_11dfbd70-092d-4b7a-9d53-acc95623037f_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_98482e22-dac2-4247-8059-0a05732b4e0a_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance cost</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:to="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_80d4a90b-e0d2-4442-8404-b802c3a874da_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_6c03feda-df0f-4cbc-9476-37377054cf49_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_bdb0feb1-5025-4c7e-ad49-fbe475e656d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_464fee37-515e-472e-ad4a-372c12dd7248_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:to="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_7e276ef4-27fe-444c-ac9b-ad427e1efd71_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_967e293d-8d86-42ee-aa36-b49301d95a6a_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_85383d3e-1959-40ec-8232-866e4786c596_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_41a3adbd-091f-4940-b644-d3e66c68e6ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_17776ab9-cad5-4805-8482-98a4df2a8c5d_terseLabel_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_label_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement [Member]</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_documentation_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:href="sesn-20220630.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:to="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2dea4c96-8d15-4fd9-943b-e9c1ed7990a9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_14a15fb6-796f-4cca-a14f-837c9425fb0d_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34f30348-d2e0-415d-a2d2-eb10dd8d141a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e460f6bd-5f2e-4fca-8fcb-eceff5b4f1e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4ac2edf2-f1f6-4a15-acb4-257f3400908f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1360b6e8-b7d1-47b4-abd3-6989d167ee8f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_21af166e-96ad-42d6-ae61-3e81d22dcaf9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_ff3e85e9-1eb6-4cb1-8b64-2c601fa46a49_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_dd84483b-c4c6-46d3-ba99-df648c8b96c9_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_825f6a5b-8366-4c1c-8677-cd5e6edb2728_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_36c5e7dd-6353-4bd0-ac0a-c76658edbd44_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_5e73a47f-e284-4279-8498-ef1d31d4d2fe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1a721aab-f40b-4e66-8489-31520819998f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_27838c2c-af17-486c-906e-dcd2834f35db_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_29bc58d6-ec80-4725-bed5-8ed30d491ca1_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to achievement of development milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:to="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_01f18794-bf2e-4cfd-ac83-c8d459f95de2_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_UniversityOfZurichMember_e97871f9-d165-4cd3-b8ae-ee7db8f90cd1_terseLabel_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_label_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich [Member]</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_documentation_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember" xlink:href="sesn-20220630.xsd#sesn_UniversityOfZurichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_UniversityOfZurichMember" xlink:to="lab_sesn_UniversityOfZurichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_f39b99a7-bd49-42e4-bc9f-e84827c939b4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d0d956a2-82db-4683-b472-5089d6c6f368_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Share Based Compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f3ef213c-929d-4a2c-8207-72ef120835fc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ce0040f7-a284-40a2-b820-9b94efc5495d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cf84c22-75a1-449e-965a-9def577a69fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c8a9de17-ec0a-415e-aeca-31bf0141bd48_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_1c6ed80e-5053-4bee-ae8d-9610b0f9b329_verboseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Stock Incentive Plan</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_label_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:to="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_ac55ef4a-8fa3-49f8-b105-70dac3590f2d_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_397cc16d-7b43-4491-9913-7349d141d54a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_c95f7a71-475d-4071-a581-8569560cc3a0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at June&#160;30, 2022 and December&#160;31, 2021; no shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_53c4b4ca-8303-4b91-a6f0-484dd73f429e_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RocheMember_0a7fc700-ae99-4aeb-8db5-6e3ad3477061_terseLabel_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_sesn_RocheMember_label_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_sesn_RocheMember_documentation_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RocheMember" xlink:to="lab_sesn_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_36aac0c4-3999-46d2-b28e-d4554b7f0911_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of common stock warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:to="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b7132572-06dd-4faf-bb55-0084c73570ff_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c1a30772-5ade-41ad-8495-b9fcac3f71ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_692e6e7c-9660-4055-b130-430731f980a8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_86f3ef60-598b-45ae-b994-2cecb40e3036_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_4b359419-89b6-44db-80eb-7342758f336a_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b4c1a25b-b4a1-407d-b70f-2367e6b344f4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_31c47099-cefc-4718-b03a-bca9474a757d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_d8d063b1-71ce-4e84-a407-395cbbe0dc0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_6b21ceea-e7a9-4de0-90e1-8776c667da19_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_e77427c1-62c0-47d4-93f6-a3cb81eedd2b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_83945505-a078-4051-a14b-15e73f6f7bb9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_6e2a6407-793e-4fe3-b293-e21b982d1bec_terseLabel_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:to="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_19293056-d7df-44de-9d7f-82522917ffee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_c27f9579-122f-4ee8-8b97-b4758a718d44_terseLabel_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average cost of capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_label_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital" xlink:href="sesn-20220630.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WeightedAverageCostOfCapital" xlink:to="lab_sesn_WeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_cd20df07-6edb-419c-af5b-1c97846f4ab5_terseLabel_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:href="sesn-20220630.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:to="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_831d494f-9d2b-4acc-9743-cc70ade64c39_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_28c0369a-8942-49a4-b7f2-2c2d4265011f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_009680a2-c97d-45fd-b42b-45956a2738c6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViventiaBioInc.Member_f9c4de5a-ec01-4ffc-9673-9b198da7e2d9_terseLabel_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio Inc.</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_label_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc. [Member]</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_documentation_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member" xlink:href="sesn-20220630.xsd#sesn_ViventiaBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViventiaBioInc.Member" xlink:to="lab_sesn_ViventiaBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_4668b76c-e130-4101-8e30-d51139bdd215_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_412be36c-c8a7-43f6-be8e-71b3856d2e79_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_0a3a8cc2-cf3d-41b4-b96e-4a5a555a76f6_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment obligation, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_f52f414d-ebd9-4fa3-bc0c-48a93843171f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Pre-tax Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_fc797ea3-b1b1-425b-b021-041059efd1c8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ec04297a-5c1d-4c7c-b810-6151107b3a76_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_dc4a4447-ea4d-446c-bbae-563ff5da3760_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_617760fc-2d5b-440f-9856-bb376f3846ee_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseMaintenanceFees_367a393a-3910-4c9b-b7f3-175e307a365a_terseLabel_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License maintenance fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_label_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_documentation_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees" xlink:href="sesn-20220630.xsd#sesn_LicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseMaintenanceFees" xlink:to="lab_sesn_LicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_d12d6d1a-3762-4e50-b2af-be32195b4fbb_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ca5fd4c-06b9-4044-a937-780a0618f5d2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5a788acf-4cc5-4cee-b32e-19e268fbdd1f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3f849657-1b62-4cf0-aefb-65ef97d47378_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c66df884-606c-4414-9a9d-65ee4ce3facf_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1c8af844-7a06-42d4-bc4f-30f198c52ce2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_92114231-125c-40fc-a8b8-f5bbd06854f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting at End of Each Successive Three-Month Period Thereafter</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38a65b86-8632-4f90-8c99-41211b9939ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_45d2f9a4-b26d-45cb-bc64-fc746c37ab91_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_a022b33e-b4a0-4f33-b2d7-7a4a42fb01c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2127cf40-7d64-40e9-8fac-e7b6973f98c9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_ace1a395-fed6-4b0d-aa5e-5ac86a1e96b2_terseLabel_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="sesn-20220630.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b8e90667-3f03-4155-9d1a-c18fb40da26c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_bcafc2b1-2525-4c28-a48b-e79bd6131d46_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_2ce748c4-b36f-4890-b096-b758b2ea932b_terseLabel_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_label_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_documentation_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:href="sesn-20220630.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:to="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_8ec2dfc6-20e2-4126-a287-e5ad24b2bcb6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6f482947-fa54-4243-9927-6be4433c6668_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income (loss) U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_87162e88-aed7-4381-b11a-f362b63e9524_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_746b4cd4-aee8-4dad-bb51-c9ef5958e4fd_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2022Member" xlink:to="lab_sesn_WarrantsExpiringNovember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0361c280-6e7d-4bae-a66b-44742fd3d764_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a55ee5ff-91c5-4a27-8245-6f9fd7693164_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_b862cbab-9a8c-4eaa-8615-0a66915c7b60_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under first option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_7db36699-1085-48ef-a047-a36134ec4ac9_terseLabel_en-US" xlink:label="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets risk adjusted</link:label>
    <link:label id="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_label_en-US" xlink:label="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Cost of Capital, Percentage</link:label>
    <link:label id="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_documentation_en-US" xlink:label="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Cost of Capital, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:href="sesn-20220630.xsd#sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:to="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_a3916f4b-86d9-4e89-8888-a7de51beb201_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_label_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementTextBlock" xlink:to="lab_sesn_LicenseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d890edb8-5e2b-448d-89c8-1d0dad81c36f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_1c399a6b-4c2a-4e3c-82fb-eb56f9a35fe4_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_8a4d4ff7-f1a1-4359-bcf5-95bc646c1bec_verboseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_dd1e7fc9-8cc2-47fc-9550-a0c8c8716ce7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1c786deb-427b-4e18-a699-07d080ed2289_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_50a25705-17fd-4aa0-9d32-a1632d0ec3f2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c79328cb-f463-463e-a372-7a971ce36a43_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss of investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e1483e44-e99b-4f2f-b185-1f215e5fb3f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_4d48c9e4-8c3c-49c9-8e9f-833dec8dbd08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_8124cd55-6dfb-4218-8f1e-114a7e5e13fc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_78c19a4b-f4f2-4542-a722-6026f1ebca24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_01a0c6b6-dd03-470a-af52-03bde5b30d54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d41bb7a8-5a78-4371-bc9c-9c4d3ea2f056_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_f1b49f20-1248-4ec1-907e-6c2144716c7a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_90d925dc-c8f1-4105-b0ae-dbb291992af5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price, discount rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_81e521d1-922e-40f3-8977-89946e891527_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average stock price per share (in dollars per share)</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_f32fee59-d61f-4b3e-bdd7-e6209b80c352_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncomeTaxesTable_15951288-e749-428f-bc91-9a2f8034d4a3_terseLabel_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sesn_IncomeTaxesTable_label_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sesn_IncomeTaxesTable_documentation_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncomeTaxesTable" xlink:to="lab_sesn_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MicrometAGMember_aec95ecf-9b7a-44e7-8f1d-65d2615d25f5_terseLabel_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG</link:label>
    <link:label id="lab_sesn_MicrometAGMember_label_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG [Member]</link:label>
    <link:label id="lab_sesn_MicrometAGMember_documentation_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember" xlink:href="sesn-20220630.xsd#sesn_MicrometAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MicrometAGMember" xlink:to="lab_sesn_MicrometAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_390fa144-aab1-4c93-8079-24ee65e08b03_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f6beb091-8da0-4b56-a43a-ab9f3adc85b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8ee81ea9-3343-471a-84b2-92feb6cbaef0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_c901b55b-67e7-4dbf-982f-bc77146ea6ff_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which quarterly earn-outs are payable after date of net sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:to="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ae3ca0f8-55ec-4abf-a55a-894e1eeb4641_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5c7bea68-ddbc-4c57-b5cb-7bfea3d0ecd2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a0c9746d-3c25-4a9e-a2f6-7672647591a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3e472663-ac9d-42a1-8d04-fa28305df5d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00edf326-6c36-4ae1-b07d-2ca267f9a9ed_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b81cdda-b6c2-4fbb-919f-48a384fe8b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_10d67a1a-f271-49ea-8646-461d7dc3691f_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, amount payable upon achievement of specified milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_label_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:to="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_2c5a680f-d96c-4f92-acb8-74cad25184cd_terseLabel_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_label_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_documentation_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:href="sesn-20220630.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:to="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViciniumMember_029682ad-e942-4d7e-b880-3854ee910a0c_terseLabel_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium</link:label>
    <link:label id="lab_sesn_ViciniumMember_label_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:label id="lab_sesn_ViciniumMember_documentation_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViciniumMember" xlink:to="lab_sesn_ViciniumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4f6c9bb4-2fac-44d7-b268-4a23b90b3809_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b2e5e14c-8bc5-4039-bd69-76f57c7b9ef3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_823bbda6-73fe-40ba-a4b7-906887abe790_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated litigation liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_f04d9ce1-0c2a-431e-955a-604bb6e116a8_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty payment, reduction, conditions not met</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:to="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_90a74aa3-50ea-4096-9948-b8b4e7c87547_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_69a467c2-c9aa-492a-a00b-39e27c08bb0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c6c05541-0c7a-45c3-9e58-bdf2d597a1cd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_efafc42b-f3ed-4282-9685-a1e77b7d90a6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d18e7ff4-20c6-45d1-aef5-dedb4f9b7820_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_1810a9cf-8b20-431d-89ba-c24cdf4845a0_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_226eb03e-e3a5-4375-8c59-193cb5df4886_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_39fdd5f5-783d-4da3-b7a0-5348e9b728e3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a2e49b82-7c8a-45c6-b5f5-216fa21e6676_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_227b5726-6edb-42bc-9292-d7daf45178c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c7863f19-4b84-48a4-87a5-aaeadfefb9e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_dfa3dc2b-a823-4faa-b48e-4153ca1814ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_79528db7-02e4-4c59-82b5-720abaf1d20f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MENALicenseAgreementMember_a2eec331-e774-4272-8443-1a460e109610_terseLabel_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_label_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement [Member]</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_documentation_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember" xlink:href="sesn-20220630.xsd#sesn_MENALicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MENALicenseAgreementMember" xlink:to="lab_sesn_MENALicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_631fb487-943c-45a1-b00e-dcbf553bc95c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_b5afb760-5e8e-4ad1-9f5c-3f323da07e0a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_faec295f-4b14-4b7c-a28f-c6d16ef80e11_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_label_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:to="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_74e0051b-bcc1-4bf9-8a74-4e42f6dd8cfc_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_04a5c974-3ac0-4f98-941e-b28828fb8f44_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on commercialization milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d5479e23-7ccb-46a1-a330-7c826b282028_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_7744773e-da06-400c-a217-976ad8c79484_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2a2b4ba2-a0b4-43e5-a997-c84f631848cc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated, period percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_35b253e7-14b5-430e-a29d-eb0ce2eec2c3_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related operating expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_label_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:to="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>sesn-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2242ac9-1511-42db-a08a-ac050036e5da,g:27c8282b-5e55-4664-b4e1-3a6627cbab54-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/Cover" xlink:type="simple" xlink:href="sesn-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_80719091-b1e8-4b8c-83c2-6daeaa66f92d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_DocumentType_80719091-b1e8-4b8c-83c2-6daeaa66f92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_69bf29d7-3e58-4fae-aa7d-05e6440647b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_DocumentQuarterlyReport_69bf29d7-3e58-4fae-aa7d-05e6440647b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5423cb0c-2fdd-44bf-89de-4373e09757fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_DocumentPeriodEndDate_5423cb0c-2fdd-44bf-89de-4373e09757fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b7e6029f-fe37-45a7-93d2-1174ec3d03d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_DocumentTransitionReport_b7e6029f-fe37-45a7-93d2-1174ec3d03d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bd1ee0e6-be38-416c-b666-3c04085541b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityFileNumber_bd1ee0e6-be38-416c-b666-3c04085541b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4f76b309-4223-4203-ab60-d086d328939c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityRegistrantName_4f76b309-4223-4203-ab60-d086d328939c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f68bd4d6-79ac-43bb-8606-6ff35496b1f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f68bd4d6-79ac-43bb-8606-6ff35496b1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_592da54b-3f63-4bab-967a-0971c9f3f743" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityTaxIdentificationNumber_592da54b-3f63-4bab-967a-0971c9f3f743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9d9fc846-4847-4125-b600-031f85ea5896" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityAddressAddressLine1_9d9fc846-4847-4125-b600-031f85ea5896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f9c12f36-337e-4e95-bb17-bfd4e2bb45be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityAddressAddressLine2_f9c12f36-337e-4e95-bb17-bfd4e2bb45be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_317ef8c2-9fd8-4428-980a-cc1767388745" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityAddressCityOrTown_317ef8c2-9fd8-4428-980a-cc1767388745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_80d4ab1a-4709-431c-a500-d221ec5d4925" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityAddressStateOrProvince_80d4ab1a-4709-431c-a500-d221ec5d4925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0aedde1f-b408-40cf-a7d6-d04d3ab87502" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityAddressPostalZipCode_0aedde1f-b408-40cf-a7d6-d04d3ab87502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1bab11f3-f42f-4de0-a423-2cc509aa5abb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_CityAreaCode_1bab11f3-f42f-4de0-a423-2cc509aa5abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1981cedf-8d51-4166-a281-8547aa17726a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_LocalPhoneNumber_1981cedf-8d51-4166-a281-8547aa17726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_16902c3c-5164-4848-8bf1-3e5d64a9871b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_Security12bTitle_16902c3c-5164-4848-8bf1-3e5d64a9871b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2e399231-7206-4d62-b8b2-5718ee257f0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_TradingSymbol_2e399231-7206-4d62-b8b2-5718ee257f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a766223a-0e2c-4b88-835e-ec2c9f0109b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_SecurityExchangeName_a766223a-0e2c-4b88-835e-ec2c9f0109b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_171b2b09-8ec2-42d0-8595-369eab8a2e0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityCurrentReportingStatus_171b2b09-8ec2-42d0-8595-369eab8a2e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ca09a47b-7997-46be-bb5f-0addb84dee29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityInteractiveDataCurrent_ca09a47b-7997-46be-bb5f-0addb84dee29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_854f0eb5-ac74-4899-a8dd-7bb34d4cec4e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityFilerCategory_854f0eb5-ac74-4899-a8dd-7bb34d4cec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8d22ee04-e8d7-4d30-94fc-e7e305c4eece" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntitySmallBusiness_8d22ee04-e8d7-4d30-94fc-e7e305c4eece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_82103568-616a-4bd8-b8af-e8e1a51bbe7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityEmergingGrowthCompany_82103568-616a-4bd8-b8af-e8e1a51bbe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_00bbb335-da8e-4d58-841f-9de3605dd11b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityShellCompany_00bbb335-da8e-4d58-841f-9de3605dd11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_08aaa9f4-9341-4f33-89b8-59460b413881" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_08aaa9f4-9341-4f33-89b8-59460b413881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_07fb4850-ebd6-4bfc-a0f7-4ed008165841" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_EntityCentralIndexKey_07fb4850-ebd6-4bfc-a0f7-4ed008165841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cefd3f50-c34c-4f29-b55e-ed53f7e90e63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_CurrentFiscalYearEndDate_cefd3f50-c34c-4f29-b55e-ed53f7e90e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_04c19faa-d549-4bff-9741-3638ada09fe9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_DocumentFiscalYearFocus_04c19faa-d549-4bff-9741-3638ada09fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a3c923a6-64d4-4746-b192-aa2e1df186a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a3c923a6-64d4-4746-b192-aa2e1df186a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_49be7179-bb02-4e9c-b248-b8c76b345221" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc2aed07-2bfb-4201-87f0-324e4f5f00b4" xlink:to="loc_dei_AmendmentFlag_49be7179-bb02-4e9c-b248-b8c76b345221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9a9a7e07-7359-4dac-a748-4c05b7561adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_30797d5c-6545-4084-ab58-9799f7aae010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9a9a7e07-7359-4dac-a748-4c05b7561adc" xlink:to="loc_us-gaap_AssetsAbstract_30797d5c-6545-4084-ab58-9799f7aae010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e667091b-e0cd-4e96-ba98-5a29f4d18b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30797d5c-6545-4084-ab58-9799f7aae010" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e667091b-e0cd-4e96-ba98-5a29f4d18b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bf911d2-0faf-4b24-9d2a-666086aa8088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e667091b-e0cd-4e96-ba98-5a29f4d18b32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bf911d2-0faf-4b24-9d2a-666086aa8088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_05d8b197-37e4-401f-be14-445861b0ef3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e667091b-e0cd-4e96-ba98-5a29f4d18b32" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_05d8b197-37e4-401f-be14-445861b0ef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a9206fa0-99df-450d-92db-d511a6fbeb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e667091b-e0cd-4e96-ba98-5a29f4d18b32" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a9206fa0-99df-450d-92db-d511a6fbeb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_24c84ebd-8a29-4668-b70b-023cfdbc5d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e667091b-e0cd-4e96-ba98-5a29f4d18b32" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_24c84ebd-8a29-4668-b70b-023cfdbc5d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_568c609f-883d-4bdb-83e6-1269c44c67a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e667091b-e0cd-4e96-ba98-5a29f4d18b32" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_568c609f-883d-4bdb-83e6-1269c44c67a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_525efe3a-d8d8-48b0-83cd-d54475b73e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e667091b-e0cd-4e96-ba98-5a29f4d18b32" xlink:to="loc_us-gaap_AssetsCurrent_525efe3a-d8d8-48b0-83cd-d54475b73e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30797d5c-6545-4084-ab58-9799f7aae010" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f556863d-d050-4128-8db5-4c79de6e5a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f556863d-d050-4128-8db5-4c79de6e5a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f8d8329d-80b6-4925-a389-b49bc45ae612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f8d8329d-80b6-4925-a389-b49bc45ae612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_087e2cca-4138-49c8-b65a-58cc90195cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_087e2cca-4138-49c8-b65a-58cc90195cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a0352d2d-6c63-43f1-bebf-550a35932d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a0352d2d-6c63-43f1-bebf-550a35932d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_23c1ba5e-3011-463f-ac6d-6521be5a0b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:to="loc_us-gaap_Goodwill_23c1ba5e-3011-463f-ac6d-6521be5a0b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_f939c1e6-1ac7-48b6-b60b-5a12a0a4a213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_f939c1e6-1ac7-48b6-b60b-5a12a0a4a213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0445ade8-6805-484e-a3c2-1b071f709ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0445ade8-6805-484e-a3c2-1b071f709ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_f387d050-f467-4865-9770-c32bbca4ff1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6c5ddf22-6b6e-4c5c-8f6a-3a5b4528ec3a" xlink:to="loc_us-gaap_AssetsNoncurrent_f387d050-f467-4865-9770-c32bbca4ff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cc2f5e4f-21f8-46c6-9146-12512a5f40f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30797d5c-6545-4084-ab58-9799f7aae010" xlink:to="loc_us-gaap_Assets_cc2f5e4f-21f8-46c6-9146-12512a5f40f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b3b0b14-d186-494f-9f35-965b515bb89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9a9a7e07-7359-4dac-a748-4c05b7561adc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b3b0b14-d186-494f-9f35-965b515bb89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1253098c-bcac-42ab-874f-7cc0acf0dbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b3b0b14-d186-494f-9f35-965b515bb89b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1253098c-bcac-42ab-874f-7cc0acf0dbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4155ddd3-5dad-4000-a9e9-d90d46b53a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1253098c-bcac-42ab-874f-7cc0acf0dbf2" xlink:to="loc_us-gaap_AccountsPayableCurrent_4155ddd3-5dad-4000-a9e9-d90d46b53a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7d17d670-38c7-42fc-b0b6-75206b9910fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1253098c-bcac-42ab-874f-7cc0acf0dbf2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7d17d670-38c7-42fc-b0b6-75206b9910fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_91dc962a-8121-473b-88fe-2df339416b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1253098c-bcac-42ab-874f-7cc0acf0dbf2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_91dc962a-8121-473b-88fe-2df339416b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2aee06a5-c817-4613-aaa7-b9e5275136f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1253098c-bcac-42ab-874f-7cc0acf0dbf2" xlink:to="loc_us-gaap_LiabilitiesCurrent_2aee06a5-c817-4613-aaa7-b9e5275136f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d295b1a-c7d9-45c1-bd2a-d4014812ec57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b3b0b14-d186-494f-9f35-965b515bb89b" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d295b1a-c7d9-45c1-bd2a-d4014812ec57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b5bdef4c-3d90-46e8-93ae-54f8180170d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d295b1a-c7d9-45c1-bd2a-d4014812ec57" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b5bdef4c-3d90-46e8-93ae-54f8180170d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fcb44bd7-66e9-4f3f-b6ed-c80b79e40f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d295b1a-c7d9-45c1-bd2a-d4014812ec57" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fcb44bd7-66e9-4f3f-b6ed-c80b79e40f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_81daeb83-ad6d-43a6-849a-0a5e36aa9e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d295b1a-c7d9-45c1-bd2a-d4014812ec57" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_81daeb83-ad6d-43a6-849a-0a5e36aa9e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_687c240c-fd20-4b23-b382-5405477e80a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d295b1a-c7d9-45c1-bd2a-d4014812ec57" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_687c240c-fd20-4b23-b382-5405477e80a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d623a193-b8be-4af9-93e7-1aedaecee9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b3b0b14-d186-494f-9f35-965b515bb89b" xlink:to="loc_us-gaap_Liabilities_d623a193-b8be-4af9-93e7-1aedaecee9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_831266ea-42fa-46ab-8bde-be026a9ed287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b3b0b14-d186-494f-9f35-965b515bb89b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_831266ea-42fa-46ab-8bde-be026a9ed287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1febc3bb-bc77-456c-ad54-221234824a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_831266ea-42fa-46ab-8bde-be026a9ed287" xlink:to="loc_us-gaap_PreferredStockValue_1febc3bb-bc77-456c-ad54-221234824a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_144aaf7b-9228-430f-89b7-3d00b1cacd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_831266ea-42fa-46ab-8bde-be026a9ed287" xlink:to="loc_us-gaap_CommonStockValue_144aaf7b-9228-430f-89b7-3d00b1cacd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cfad4e3d-7737-45f9-918f-2a6c626a19a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_831266ea-42fa-46ab-8bde-be026a9ed287" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cfad4e3d-7737-45f9-918f-2a6c626a19a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6e08c86d-eda3-496f-9600-ca8e0690c003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_831266ea-42fa-46ab-8bde-be026a9ed287" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6e08c86d-eda3-496f-9600-ca8e0690c003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_da6cf01b-b89c-4ac9-90ec-5557691b61cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_831266ea-42fa-46ab-8bde-be026a9ed287" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_da6cf01b-b89c-4ac9-90ec-5557691b61cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_254680cf-f774-4551-83b6-434a1b367e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_831266ea-42fa-46ab-8bde-be026a9ed287" xlink:to="loc_us-gaap_StockholdersEquity_254680cf-f774-4551-83b6-434a1b367e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_638ed32e-8d10-44cb-93dd-c158cf5b0742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b3b0b14-d186-494f-9f35-965b515bb89b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_638ed32e-8d10-44cb-93dd-c158cf5b0742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_74488834-45ae-48f2-a4a8-c518485cccfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_74488834-45ae-48f2-a4a8-c518485cccfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_23b55df6-3059-4507-aeee-73a3b4f73606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_23b55df6-3059-4507-aeee-73a3b4f73606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0d3549c1-2a71-4fe2-8891-6a13eb6f7fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0d3549c1-2a71-4fe2-8891-6a13eb6f7fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b7b17cb1-1cdd-478a-bee5-63b639f5a926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b7b17cb1-1cdd-478a-bee5-63b639f5a926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cced09ef-54b9-4355-9d03-2141fb557b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cced09ef-54b9-4355-9d03-2141fb557b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9ee6bcd3-b759-4541-8db1-dd36ed530b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9ee6bcd3-b759-4541-8db1-dd36ed530b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8a8ee9da-d906-4fa9-b5eb-14fc7e9f9552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:to="loc_us-gaap_CommonStockSharesIssued_8a8ee9da-d906-4fa9-b5eb-14fc7e9f9552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6fe89993-2c7b-49c4-9c89-e4669a4f6637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50dc2796-ccc3-488b-9196-277b55694c1f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6fe89993-2c7b-49c4-9c89-e4669a4f6637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c7ed7fa0-bc4c-4c98-9f54-5dbf77cba95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c7ed7fa0-bc4c-4c98-9f54-5dbf77cba95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f4c1322b-1ccf-40ae-a87a-6f278a2dfe66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f4c1322b-1ccf-40ae-a87a-6f278a2dfe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_60a7f1e3-a5cb-4a2b-86cf-824dc4469218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f4c1322b-1ccf-40ae-a87a-6f278a2dfe66" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_60a7f1e3-a5cb-4a2b-86cf-824dc4469218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fba15772-9770-46e8-a5a4-f386eded171e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f4c1322b-1ccf-40ae-a87a-6f278a2dfe66" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fba15772-9770-46e8-a5a4-f386eded171e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_49ae84eb-46c8-42ce-bd85-ad30dbb5c1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f4c1322b-1ccf-40ae-a87a-6f278a2dfe66" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_49ae84eb-46c8-42ce-bd85-ad30dbb5c1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_958dc5ba-6a04-4b7c-824d-aaae64b564a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f4c1322b-1ccf-40ae-a87a-6f278a2dfe66" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_958dc5ba-6a04-4b7c-824d-aaae64b564a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d4ea6660-52ba-4968-b819-5a061cfc0e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f4c1322b-1ccf-40ae-a87a-6f278a2dfe66" xlink:to="loc_us-gaap_OperatingExpenses_d4ea6660-52ba-4968-b819-5a061cfc0e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_482a483e-928e-49ca-911b-2cb0170368db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_OperatingIncomeLoss_482a483e-928e-49ca-911b-2cb0170368db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_352eed04-2f5b-4552-b536-ae23bd0e76f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_352eed04-2f5b-4552-b536-ae23bd0e76f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_c37b0276-7bbd-4d70-98c5-22442ecf3ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_c37b0276-7bbd-4d70-98c5-22442ecf3ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dc7122c9-ed96-4ca5-a665-1a7ed0224c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dc7122c9-ed96-4ca5-a665-1a7ed0224c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a8127b2-9010-4103-8b58-25dc8f79fdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_NetIncomeLoss_7a8127b2-9010-4103-8b58-25dc8f79fdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b63a31d9-d58b-4557-8520-e3048161627b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b63a31d9-d58b-4557-8520-e3048161627b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_60fb7959-02ce-4e5b-8898-0b521f97544e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_60fb7959-02ce-4e5b-8898-0b521f97544e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e25fdd89-0414-40f2-adfe-984ed53f0bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_EarningsPerShareBasic_e25fdd89-0414-40f2-adfe-984ed53f0bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5bfbcc3b-c643-47db-87a1-8b027c0340a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5bfbcc3b-c643-47db-87a1-8b027c0340a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6215f74c-0df2-46e1-88a1-77573b7b5beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6215f74c-0df2-46e1-88a1-77573b7b5beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_df9d12de-68f9-4e90-bf8e-55b3e4fe7a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_df9d12de-68f9-4e90-bf8e-55b3e4fe7a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_4624a633-68e5-4cc0-98d9-9db85e56adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f3c366f4-69c8-409a-a3cd-42aee23e1b3f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_4624a633-68e5-4cc0-98d9-9db85e56adb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_71834ee7-63eb-4bcd-b6ad-f68428121db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8978132a-55d2-408b-830f-0cf9c9ece7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_71834ee7-63eb-4bcd-b6ad-f68428121db4" xlink:to="loc_us-gaap_NetIncomeLoss_8978132a-55d2-408b-830f-0cf9c9ece7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7980b906-86e9-4707-ae59-396e3a24e289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_71834ee7-63eb-4bcd-b6ad-f68428121db4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7980b906-86e9-4707-ae59-396e3a24e289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0332cc92-9231-4eaf-9e02-bd767180bfac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_71834ee7-63eb-4bcd-b6ad-f68428121db4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0332cc92-9231-4eaf-9e02-bd767180bfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bc64ebb4-0a19-4319-abf2-016273ceb776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bc64ebb4-0a19-4319-abf2-016273ceb776" xlink:to="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b2105c3e-2baa-445e-964f-0cbe6262504d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b2105c3e-2baa-445e-964f-0cbe6262504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2105c3e-2baa-445e-964f-0cbe6262504d" xlink:to="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_215bf212-2b02-4bba-8d1c-e64a687f34f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:to="loc_us-gaap_CommonStockMember_215bf212-2b02-4bba-8d1c-e64a687f34f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0e0feca3-61d0-4116-b956-87c22ed768a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0e0feca3-61d0-4116-b956-87c22ed768a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_427e33e1-4012-45ea-8df2-2cbcb4416178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_427e33e1-4012-45ea-8df2-2cbcb4416178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1437a7b4-6e15-4c47-abd3-fbf1d014090d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_083f5271-34de-4b8c-8c79-d32b406424c3" xlink:to="loc_us-gaap_RetainedEarningsMember_1437a7b4-6e15-4c47-abd3-fbf1d014090d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_024ae251-7f65-4b75-b327-bc9ca165472a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1a9aacbd-e963-45e6-91d0-9c0bb7ca89c5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_024ae251-7f65-4b75-b327-bc9ca165472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_5405ecaf-b193-43a2-ac8a-1bf7741e1366" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_024ae251-7f65-4b75-b327-bc9ca165472a" xlink:to="loc_sesn_ATMFacilityMember_5405ecaf-b193-43a2-ac8a-1bf7741e1366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_07c7dd68-4349-43ea-88fd-c586220532ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33aab750-d1b4-454e-9412-cc2e5641888b" xlink:to="loc_us-gaap_StatementLineItems_07c7dd68-4349-43ea-88fd-c586220532ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07c7dd68-4349-43ea-88fd-c586220532ae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0a6f88e2-7bd0-42c6-ae16-d748b7734479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_SharesOutstanding_0a6f88e2-7bd0-42c6-ae16-d748b7734479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26822c10-df2c-49dd-86dc-d3d3ebdef0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockholdersEquity_26822c10-df2c-49dd-86dc-d3d3ebdef0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12195fbd-2dc3-4be2-af11-6da284103015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_NetIncomeLoss_12195fbd-2dc3-4be2-af11-6da284103015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_31a7a16b-0e8d-4061-b7f3-55ea2cb387b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_31a7a16b-0e8d-4061-b7f3-55ea2cb387b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6f49fd6b-15ee-46a2-bc54-8164764a1ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6f49fd6b-15ee-46a2-bc54-8164764a1ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4d78059a-7c5a-4b47-bbe5-373b59510edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4d78059a-7c5a-4b47-bbe5-373b59510edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1b97d150-6cbe-47a4-b18b-951fb52512c3" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1b97d150-6cbe-47a4-b18b-951fb52512c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_312b1f93-ce6b-4895-ab46-dd323f1bf880" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_312b1f93-ce6b-4895-ab46-dd323f1bf880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e943f88e-0397-4d7d-8d63-c602eca4714e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e943f88e-0397-4d7d-8d63-c602eca4714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30ea3180-8c5c-4bcd-b279-435ef100a2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30ea3180-8c5c-4bcd-b279-435ef100a2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8735149d-c1da-4f17-bf64-61a49e40b9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8735149d-c1da-4f17-bf64-61a49e40b9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_27b5612e-f632-453d-8a41-8ad2579fe7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_SharesOutstanding_27b5612e-f632-453d-8a41-8ad2579fe7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c35d3c3e-3a4a-47b9-9e88-c00df1e3469e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_572e1952-3f2a-4a51-8d69-1158f6ffeebd" xlink:to="loc_us-gaap_StockholdersEquity_c35d3c3e-3a4a-47b9-9e88-c00df1e3469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0ed61ee0-c7f2-4a0a-9926-2efd41dc72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_cdae66cc-1e2a-4748-9d57-c80a165b1bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0ed61ee0-c7f2-4a0a-9926-2efd41dc72f4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_cdae66cc-1e2a-4748-9d57-c80a165b1bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_67848dbf-6636-4561-b643-4faef254881f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_67848dbf-6636-4561-b643-4faef254881f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2447052d-132d-4e3c-9d39-3195f14ac7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_67848dbf-6636-4561-b643-4faef254881f" xlink:to="loc_us-gaap_NetIncomeLoss_2447052d-132d-4e3c-9d39-3195f14ac7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648518bc-6d17-4787-860b-1faa4217b0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_67848dbf-6636-4561-b643-4faef254881f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648518bc-6d17-4787-860b-1faa4217b0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_153968b3-3eda-4af7-a291-2752f184dd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648518bc-6d17-4787-860b-1faa4217b0b2" xlink:to="loc_us-gaap_DepreciationAndAmortization_153968b3-3eda-4af7-a291-2752f184dd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_83908610-ca83-46dc-a285-a6e8ccb3f085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648518bc-6d17-4787-860b-1faa4217b0b2" xlink:to="loc_us-gaap_ShareBasedCompensation_83908610-ca83-46dc-a285-a6e8ccb3f085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7e209f51-6189-4c99-97e7-f721b7db2b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648518bc-6d17-4787-860b-1faa4217b0b2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7e209f51-6189-4c99-97e7-f721b7db2b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9800c51a-081b-4e61-bb97-565ab342b45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648518bc-6d17-4787-860b-1faa4217b0b2" xlink:to="loc_us-gaap_AssetImpairmentCharges_9800c51a-081b-4e61-bb97-565ab342b45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648518bc-6d17-4787-860b-1faa4217b0b2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_83e06528-ef93-4bda-b268-8203a854f717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_83e06528-ef93-4bda-b268-8203a854f717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_a4be664a-c811-4947-ac5c-e326fde8ac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_a4be664a-c811-4947-ac5c-e326fde8ac4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_51a6416f-80d8-4109-b319-0e246394a605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_51a6416f-80d8-4109-b319-0e246394a605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_02d535a3-a772-4107-b5d7-450b4c930ccf" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_02d535a3-a772-4107-b5d7-450b4c930ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_c8957cb6-502c-48c1-baba-7f93e98c1aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_c8957cb6-502c-48c1-baba-7f93e98c1aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_35195467-a357-436f-878c-97623d0c9de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_35195467-a357-436f-878c-97623d0c9de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ab77e0b6-a6d8-4f5c-8574-93328369faa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ab77e0b6-a6d8-4f5c-8574-93328369faa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_da082c8e-a38c-4034-95c2-91ece66fccaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_da082c8e-a38c-4034-95c2-91ece66fccaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_31ae84a8-f164-4e44-8cb1-f26399742928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3793c783-e015-4cfe-b3cd-3f2e2131e930" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_31ae84a8-f164-4e44-8cb1-f26399742928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_496d0bb9-ae59-4f87-891f-d0ab31953c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_67848dbf-6636-4561-b643-4faef254881f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_496d0bb9-ae59-4f87-891f-d0ab31953c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_143e9ad4-0776-47b2-95b0-79800cfe5b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_143e9ad4-0776-47b2-95b0-79800cfe5b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a9777d2-4287-4d37-91fe-910fbf451080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_143e9ad4-0776-47b2-95b0-79800cfe5b1a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a9777d2-4287-4d37-91fe-910fbf451080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c6a765f4-badb-47e2-b6a8-2f7e3774c9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_143e9ad4-0776-47b2-95b0-79800cfe5b1a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c6a765f4-badb-47e2-b6a8-2f7e3774c9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97e0044f-b2f6-45c2-af71-f7ec803c550f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_143e9ad4-0776-47b2-95b0-79800cfe5b1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97e0044f-b2f6-45c2-af71-f7ec803c550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04aa1780-403d-4a87-8efc-aa3909589090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04aa1780-403d-4a87-8efc-aa3909589090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c2e2d7da-e5a9-480b-a4e6-9f8f98e399be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04aa1780-403d-4a87-8efc-aa3909589090" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c2e2d7da-e5a9-480b-a4e6-9f8f98e399be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_333ac43b-6b6e-45ba-8ff8-492472b61365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04aa1780-403d-4a87-8efc-aa3909589090" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_333ac43b-6b6e-45ba-8ff8-492472b61365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1437c30f-63f0-4efb-a3a2-4514c9bd0d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04aa1780-403d-4a87-8efc-aa3909589090" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1437c30f-63f0-4efb-a3a2-4514c9bd0d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ed305e6-70fb-4a49-b14b-4f59d8d172ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04aa1780-403d-4a87-8efc-aa3909589090" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ed305e6-70fb-4a49-b14b-4f59d8d172ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_20a924dd-178a-472d-b20e-9687638858bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_20a924dd-178a-472d-b20e-9687638858bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45f8f3c0-4444-4ae9-86e3-7346af340932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45f8f3c0-4444-4ae9-86e3-7346af340932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89816154-2e2b-44cb-9569-5c9b4e336b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89816154-2e2b-44cb-9569-5c9b4e336b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_755f6173-2bb2-4e65-ae74-0d8b39637fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_755f6173-2bb2-4e65-ae74-0d8b39637fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_dabcb2e4-faa0-4e57-885f-2b598899a49f" xlink:href="sesn-20220630.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_755f6173-2bb2-4e65-ae74-0d8b39637fa2" xlink:to="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_dabcb2e4-faa0-4e57-885f-2b598899a49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1f645a3a-7dec-4d5d-857e-4a8752858b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7c1210e-bd55-4689-a526-8933c2731e89" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1f645a3a-7dec-4d5d-857e-4a8752858b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c3860efa-4576-4f66-91cb-f726b17492e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1f645a3a-7dec-4d5d-857e-4a8752858b9f" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c3860efa-4576-4f66-91cb-f726b17492e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="sesn-20220630.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05dd1907-e1c8-4aae-a899-2f3c6702f9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_12a82620-bd7a-4cf6-a420-d2aa23e37461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05dd1907-e1c8-4aae-a899-2f3c6702f9c6" xlink:to="loc_us-gaap_NatureOfOperations_12a82620-bd7a-4cf6-a420-d2aa23e37461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a2bc835-7f17-448c-a823-5b24a49d4840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a2bc835-7f17-448c-a823-5b24a49d4840" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d13b3be-e596-4268-b079-2706e3c490e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d13b3be-e596-4268-b079-2706e3c490e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fc7da43-6136-4e8d-a134-325179874ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d13b3be-e596-4268-b079-2706e3c490e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fc7da43-6136-4e8d-a134-325179874ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_839d4e73-ae28-408f-a1bb-9ffc2f1509f8" xlink:href="sesn-20220630.xsd#sesn_ViventiaBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fc7da43-6136-4e8d-a134-325179874ca0" xlink:to="loc_sesn_ViventiaBioInc.Member_839d4e73-ae28-408f-a1bb-9ffc2f1509f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c5684973-4831-40f1-b313-ec924f35b83c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_srt_ProductOrServiceAxis_c5684973-4831-40f1-b313-ec924f35b83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_491c46a5-2a55-4368-8fac-85ec92dcc0d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c5684973-4831-40f1-b313-ec924f35b83c" xlink:to="loc_srt_ProductsAndServicesDomain_491c46a5-2a55-4368-8fac-85ec92dcc0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_9b84761c-683d-4ba7-b459-d6bed32bacd8" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_491c46a5-2a55-4368-8fac-85ec92dcc0d6" xlink:to="loc_sesn_ViciniumMember_9b84761c-683d-4ba7-b459-d6bed32bacd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b267f456-7535-4377-876a-e58daba1d69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b267f456-7535-4377-876a-e58daba1d69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408661ff-98c6-4b79-8677-d650af043d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b267f456-7535-4377-876a-e58daba1d69a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408661ff-98c6-4b79-8677-d650af043d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_32abe8cc-6c0f-4290-a934-f5fc40f502f2" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408661ff-98c6-4b79-8677-d650af043d7f" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_32abe8cc-6c0f-4290-a934-f5fc40f502f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_srt_StatementGeographicalAxis_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_98d3e3f2-9092-4afd-8d2d-072aa0de9fe4" xlink:to="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b859678f-c6f3-4dff-9f47-214b6745bc41" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:to="loc_country_US_b859678f-c6f3-4dff-9f47-214b6745bc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2098e613-5e20-4f90-a20a-fb7a8f5b9823" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:to="loc_srt_EuropeMember_2098e613-5e20-4f90-a20a-fb7a8f5b9823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_fe2dfe85-fd68-4f98-a5fc-c53d04741ba6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_60ba9084-c335-49a8-9796-c1e947c5b875" xlink:to="loc_country_JP_fe2dfe85-fd68-4f98-a5fc-c53d04741ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1c0927ed-d3d4-42b3-9cbf-e4f3c3d936ea" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_8618353d-0d25-4dc5-abf7-410f043e8718" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_8618353d-0d25-4dc5-abf7-410f043e8718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e78fe5e6-cf77-413a-9c70-4a4083882ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e78fe5e6-cf77-413a-9c70-4a4083882ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_2d849085-5c16-4158-92ed-68011cfb4307" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_2d849085-5c16-4158-92ed-68011cfb4307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_8bdaa3c1-6b27-429d-b3ad-49b8c23d6224" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_8bdaa3c1-6b27-429d-b3ad-49b8c23d6224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_09302830-867c-48fb-9711-8ee373dc2fcd" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_09302830-867c-48fb-9711-8ee373dc2fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_aceca459-b0e8-4859-9d2a-55db5b0ff330" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6321ebd5-c3c3-449b-b55a-38e0aea3fd2f" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_aceca459-b0e8-4859-9d2a-55db5b0ff330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="sesn-20220630.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2a64ba35-5272-4fc8-baac-c70f87c88c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_b22b132e-c22e-438f-9c50-6fc5ed69e245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a64ba35-5272-4fc8-baac-c70f87c88c74" xlink:to="loc_us-gaap_BasisOfAccounting_b22b132e-c22e-438f-9c50-6fc5ed69e245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies" xlink:type="simple" xlink:href="sesn-20220630.xsd#BASISOFPRESENTATIONPolicies"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_51926cb7-938c-42d8-9bc5-1fe7d824a8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3fb3d906-3e75-49c2-a82c-c3b3189fad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51926cb7-938c-42d8-9bc5-1fe7d824a8d9" xlink:to="loc_us-gaap_UseOfEstimates_3fb3d906-3e75-49c2-a82c-c3b3189fad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7d7af869-c281-45e0-b0a0-4efb3de71ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51926cb7-938c-42d8-9bc5-1fe7d824a8d9" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_7d7af869-c281-45e0-b0a0-4efb3de71ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fc209b9f-8cf8-4217-8df7-b847a38f86c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51926cb7-938c-42d8-9bc5-1fe7d824a8d9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fc209b9f-8cf8-4217-8df7-b847a38f86c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25a54ad5-0530-4806-a979-4cbe14ee9357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51926cb7-938c-42d8-9bc5-1fe7d824a8d9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25a54ad5-0530-4806-a979-4cbe14ee9357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e16cb134-1517-4d38-add9-997c511d9358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51926cb7-938c-42d8-9bc5-1fe7d824a8d9" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e16cb134-1517-4d38-add9-997c511d9358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sesn-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9b7035b7-f94b-4922-b2b1-ced829ed9664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2ccb4d49-5e45-4fdc-8268-8b118cb945b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b7035b7-f94b-4922-b2b1-ced829ed9664" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2ccb4d49-5e45-4fdc-8268-8b118cb945b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="sesn-20220630.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_249fafff-017b-48fb-801b-8ec03af365d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_dbbbc5c1-227f-450d-b924-226d97d4c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_249fafff-017b-48fb-801b-8ec03af365d7" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_dbbbc5c1-227f-450d-b924-226d97d4c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7a047f5b-b0ed-4b73-b5d2-c112a40d9fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_110217e3-cc64-47de-b0e3-37839bce9373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7a047f5b-b0ed-4b73-b5d2-c112a40d9fd1" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_110217e3-cc64-47de-b0e3-37839bce9373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_87542a18-addb-4c78-8c99-542407a6f27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_756a87ea-6fdd-4232-8e2e-62ce1d40427d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_87542a18-addb-4c78-8c99-542407a6f27f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_756a87ea-6fdd-4232-8e2e-62ce1d40427d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_8f5b3b43-f440-4af2-ad6b-df1918b7a027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_87542a18-addb-4c78-8c99-542407a6f27f" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_8f5b3b43-f440-4af2-ad6b-df1918b7a027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_881c71f3-cfed-44a7-baf8-32ae0d9c7476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_881c71f3-cfed-44a7-baf8-32ae0d9c7476" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_59e0237b-ef0d-4cb8-9ce0-838295e617d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_59e0237b-ef0d-4cb8-9ce0-838295e617d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0cd440d4-79d9-4177-a10f-4c6e5ab66c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_59e0237b-ef0d-4cb8-9ce0-838295e617d6" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0cd440d4-79d9-4177-a10f-4c6e5ab66c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad6bbc46-d80b-480c-ad20-588b08aca90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0cd440d4-79d9-4177-a10f-4c6e5ab66c2f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad6bbc46-d80b-480c-ad20-588b08aca90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_651ea30c-3fa2-409c-90bd-9f32cfeb0b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad6bbc46-d80b-480c-ad20-588b08aca90b" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_651ea30c-3fa2-409c-90bd-9f32cfeb0b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_744c5ad2-ff3b-4171-a99b-95e43e721c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad6bbc46-d80b-480c-ad20-588b08aca90b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_744c5ad2-ff3b-4171-a99b-95e43e721c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0fb692e-b25c-4b61-8705-495e3c2db4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0fb692e-b25c-4b61-8705-495e3c2db4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_91782c7c-a58f-46c9-aecc-1952e26a6d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0fb692e-b25c-4b61-8705-495e3c2db4ef" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_91782c7c-a58f-46c9-aecc-1952e26a6d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_031d5310-45bd-4aaf-8aad-9e4655e5fb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_91782c7c-a58f-46c9-aecc-1952e26a6d4b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_031d5310-45bd-4aaf-8aad-9e4655e5fb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef2d888-1b27-4996-a7d8-9c585a0756a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef2d888-1b27-4996-a7d8-9c585a0756a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef2d888-1b27-4996-a7d8-9c585a0756a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fdc2a68b-21e2-449e-b8cd-5b77bd58017e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fdc2a68b-21e2-449e-b8cd-5b77bd58017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9f079091-0ea6-4174-b6d9-47ea90474280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9f079091-0ea6-4174-b6d9-47ea90474280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_69af75ea-a49f-48f2-b33a-e47641f84a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ca7ac3f-7fd9-4554-8e37-c6da51a3f058" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_69af75ea-a49f-48f2-b33a-e47641f84a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69ab8eb7-dbb7-4ccc-877a-6eda07538e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a77bffe-2905-4b54-bd63-7375770866ec" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69ab8eb7-dbb7-4ccc-877a-6eda07538e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0a3b0-98af-4fda-b2d8-41925bf1e32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69ab8eb7-dbb7-4ccc-877a-6eda07538e72" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0a3b0-98af-4fda-b2d8-41925bf1e32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d794919-7081-41ba-a342-e0312999087a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0a3b0-98af-4fda-b2d8-41925bf1e32d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d794919-7081-41ba-a342-e0312999087a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0dcc17f-c925-47b7-bbb8-5cf7dab90f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0a3b0-98af-4fda-b2d8-41925bf1e32d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0dcc17f-c925-47b7-bbb8-5cf7dab90f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_835d4d81-34e5-4c79-b08b-8eb272c22c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69ab8eb7-dbb7-4ccc-877a-6eda07538e72" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_835d4d81-34e5-4c79-b08b-8eb272c22c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_55709023-cd38-414e-8087-d3a2635fee25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_835d4d81-34e5-4c79-b08b-8eb272c22c40" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_55709023-cd38-414e-8087-d3a2635fee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6b42ded9-0d21-4019-a41b-3cea45bf4b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6b42ded9-0d21-4019-a41b-3cea45bf4b5f" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6674d1e6-ffb5-4162-a165-0af4320367d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6674d1e6-ffb5-4162-a165-0af4320367d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_71422714-0a8a-4a8d-a8e0-889946e02679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6674d1e6-ffb5-4162-a165-0af4320367d1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_71422714-0a8a-4a8d-a8e0-889946e02679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f00900ff-acca-4533-9611-7790014197be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_71422714-0a8a-4a8d-a8e0-889946e02679" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f00900ff-acca-4533-9611-7790014197be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c7fa96e-89bb-4a59-bebc-5cca8aabb345" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:to="loc_srt_RangeAxis_5c7fa96e-89bb-4a59-bebc-5cca8aabb345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7e88328-c083-4b46-937d-494bed388f64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5c7fa96e-89bb-4a59-bebc-5cca8aabb345" xlink:to="loc_srt_RangeMember_d7e88328-c083-4b46-937d-494bed388f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3b20c18-8386-4d8e-abcf-2a28f443e0dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d7e88328-c083-4b46-937d-494bed388f64" xlink:to="loc_srt_MinimumMember_b3b20c18-8386-4d8e-abcf-2a28f443e0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b40643be-0f35-4151-b3e6-8dc436470b61" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d7e88328-c083-4b46-937d-494bed388f64" xlink:to="loc_srt_MaximumMember_b40643be-0f35-4151-b3e6-8dc436470b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_efce469e-da30-4acf-a5dd-17b3001073b6" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_abf93d9d-b350-4f2e-acb8-ed2db42a61a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_abf93d9d-b350-4f2e-acb8-ed2db42a61a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_33909d13-5468-45a2-94ca-958eef29bf1b" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_33909d13-5468-45a2-94ca-958eef29bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_6280de6b-b306-411c-a8c0-c5e2d863ca99" xlink:href="sesn-20220630.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_sesn_WeightedAverageCostOfCapital_6280de6b-b306-411c-a8c0-c5e2d863ca99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_16cd78fb-51a5-4199-b27e-db8243cc06ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_3c82f3fe-1042-4772-8971-88143e3c0171" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_16cd78fb-51a5-4199-b27e-db8243cc06ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9868ff0b-ea99-434c-91cb-185d3e2b5745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c7a63f3-9a49-45aa-9c39-13eb2ebbd987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9868ff0b-ea99-434c-91cb-185d3e2b5745" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c7a63f3-9a49-45aa-9c39-13eb2ebbd987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b86a3bef-6e07-485e-a858-1511fff0490e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c7a63f3-9a49-45aa-9c39-13eb2ebbd987" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b86a3bef-6e07-485e-a858-1511fff0490e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33ac412-27fa-491b-99b5-92f57b12480e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b86a3bef-6e07-485e-a858-1511fff0490e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33ac412-27fa-491b-99b5-92f57b12480e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5de3096b-6de0-471d-8b33-4f09e064352a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33ac412-27fa-491b-99b5-92f57b12480e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5de3096b-6de0-471d-8b33-4f09e064352a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_edf9852d-54fb-46dd-ae25-169892a6d98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c7a63f3-9a49-45aa-9c39-13eb2ebbd987" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_edf9852d-54fb-46dd-ae25-169892a6d98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_edf9852d-54fb-46dd-ae25-169892a6d98c" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6b4c28cd-4bc9-4052-a0aa-0c37228bd8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6b4c28cd-4bc9-4052-a0aa-0c37228bd8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_e9f306d0-386f-4b0b-a8e9-0f6df623adec" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_e9f306d0-386f-4b0b-a8e9-0f6df623adec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cb37b85f-25f3-485a-8f52-69406e500111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ed7dd0bf-591b-40fc-b282-f1f83ce86b00" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cb37b85f-25f3-485a-8f52-69406e500111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="simple" xlink:href="sesn-20220630.xsd#RECEIVABLES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_24f78bae-e0e5-474f-894b-0134e2ae5198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_fca710d1-621e-48bd-9de0-888ea787312a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_24f78bae-e0e5-474f-894b-0134e2ae5198" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_fca710d1-621e-48bd-9de0-888ea787312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#RECEIVABLESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_28f58339-1ccb-4e41-9ecf-c159d986b7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_28f58339-1ccb-4e41-9ecf-c159d986b7c7" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_abf5bd75-4499-407a-9b2c-fd8fa8f608d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:to="loc_srt_CounterpartyNameAxis_abf5bd75-4499-407a-9b2c-fd8fa8f608d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc0f36a-5a65-4289-b95a-b480602ea897" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_abf5bd75-4499-407a-9b2c-fd8fa8f608d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc0f36a-5a65-4289-b95a-b480602ea897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_69f537d8-0607-449a-b6be-98cebac0a0bc" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc0f36a-5a65-4289-b95a-b480602ea897" xlink:to="loc_sesn_RocheMember_69f537d8-0607-449a-b6be-98cebac0a0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3632a46-1569-49c4-9aee-00f6d2d79be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3632a46-1569-49c4-9aee-00f6d2d79be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_6959f899-bbdb-4a9a-a33a-586cfced243c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3632a46-1569-49c4-9aee-00f6d2d79be2" xlink:to="loc_us-gaap_ReceivableTypeDomain_6959f899-bbdb-4a9a-a33a-586cfced243c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LitigationSettlementMember_2129e3a8-a71f-4224-8a68-bd055d8f3874" xlink:href="sesn-20220630.xsd#sesn_LitigationSettlementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_6959f899-bbdb-4a9a-a33a-586cfced243c" xlink:to="loc_sesn_LitigationSettlementMember_2129e3a8-a71f-4224-8a68-bd055d8f3874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember_030ca3fd-dc23-4ba3-8f22-5d2377e8c8cc" xlink:href="sesn-20220630.xsd#sesn_GermanVATRecoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_6959f899-bbdb-4a9a-a33a-586cfced243c" xlink:to="loc_sesn_GermanVATRecoveryMember_030ca3fd-dc23-4ba3-8f22-5d2377e8c8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_77d436f3-ec2b-4ca5-81d6-0e6bcdbd2f37" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f34e1ce6-add6-4771-bf28-705420ef40a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f34e1ce6-add6-4771-bf28-705420ef40a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_a440b30b-4f60-42f1-8661-df957fe59acc" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_a440b30b-4f60-42f1-8661-df957fe59acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_3e000c97-d99e-48fc-9376-23badb89ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_3e000c97-d99e-48fc-9376-23badb89ba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_f57fc009-2262-46c2-a859-ca5054582804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a1dd9892-649a-4264-b36b-6a7e6b08e2b6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_f57fc009-2262-46c2-a859-ca5054582804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PREPAIDEXPENSES" xlink:type="simple" xlink:href="sesn-20220630.xsd#PREPAIDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PREPAIDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8211892b-e239-480c-ae8c-1de608f09d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_1a93df48-3d47-4280-8022-34a3032ca281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8211892b-e239-480c-ae8c-1de608f09d37" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_1a93df48-3d47-4280-8022-34a3032ca281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PREPAIDEXPENSESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#PREPAIDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PREPAIDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_496d3005-7a84-460a-a457-ee45b66517f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_f2d1de28-36ff-42d5-9bff-2fe99e197d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_496d3005-7a84-460a-a457-ee45b66517f4" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_f2d1de28-36ff-42d5-9bff-2fe99e197d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ExpensesPreviouslyClassifiedAsPrepaid_0ff6281a-4e42-46a7-bd8d-9b96487aaf4e" xlink:href="sesn-20220630.xsd#sesn_ExpensesPreviouslyClassifiedAsPrepaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_496d3005-7a84-460a-a457-ee45b66517f4" xlink:to="loc_sesn_ExpensesPreviouslyClassifiedAsPrepaid_0ff6281a-4e42-46a7-bd8d-9b96487aaf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWIL"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3db2d4e2-b9c6-472d-baef-c955f6ff4e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f5dcd6d5-cbee-475d-ba24-54b12584f6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3db2d4e2-b9c6-472d-baef-c955f6ff4e1a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f5dcd6d5-cbee-475d-ba24-54b12584f6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c529e278-e92e-4ac1-afbe-cc39b5597b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_473f37c8-5143-4d18-97e8-59ec16df72b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c529e278-e92e-4ac1-afbe-cc39b5597b66" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_473f37c8-5143-4d18-97e8-59ec16df72b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_df21cdc6-c7f0-4b51-8ece-1a414fbcbe16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c529e278-e92e-4ac1-afbe-cc39b5597b66" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_df21cdc6-c7f0-4b51-8ece-1a414fbcbe16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d240f62-834d-44f8-ba12-940ddf2dba59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d240f62-834d-44f8-ba12-940ddf2dba59" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_822c602a-65f2-4ea7-8728-8ba625f30d4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:to="loc_srt_StatementGeographicalAxis_822c602a-65f2-4ea7-8728-8ba625f30d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e85ec7b6-a8b4-43ca-98a6-7074c420f1dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_822c602a-65f2-4ea7-8728-8ba625f30d4e" xlink:to="loc_srt_SegmentGeographicalDomain_e85ec7b6-a8b4-43ca-98a6-7074c420f1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0d49f83a-133d-4191-950d-6f0d8fad5e05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e85ec7b6-a8b4-43ca-98a6-7074c420f1dd" xlink:to="loc_srt_EuropeMember_0d49f83a-133d-4191-950d-6f0d8fad5e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc807bb6-a015-4b04-9bea-3f2228c4ad86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:to="loc_srt_ProductOrServiceAxis_fc807bb6-a015-4b04-9bea-3f2228c4ad86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_403f25e0-da81-4a14-b1c6-00d86801ffea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fc807bb6-a015-4b04-9bea-3f2228c4ad86" xlink:to="loc_srt_ProductsAndServicesDomain_403f25e0-da81-4a14-b1c6-00d86801ffea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_9cf1786c-9d81-41df-84f1-0c2ee33293d9" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_403f25e0-da81-4a14-b1c6-00d86801ffea" xlink:to="loc_sesn_ViciniumMember_9cf1786c-9d81-41df-84f1-0c2ee33293d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f306c979-57b9-4417-9dd6-69c59dbe595a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d3bd1b8-98d0-4edc-b667-1bfcfa78fbd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f306c979-57b9-4417-9dd6-69c59dbe595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_ee0fc28e-c6e4-4525-b919-bb3174554957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f306c979-57b9-4417-9dd6-69c59dbe595a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_ee0fc28e-c6e4-4525-b919-bb3174554957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fa1d7d21-38ac-4a61-9fb5-9f047945ca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_225c90ea-5727-4d96-9f63-c58abcec1e4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fa1d7d21-38ac-4a61-9fb5-9f047945ca4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_74f2e5cc-bf0c-4411-be96-8dbd9852372f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fa1d7d21-38ac-4a61-9fb5-9f047945ca4d" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_74f2e5cc-bf0c-4411-be96-8dbd9852372f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_905714b7-7585-41aa-aa3d-57d7a00976c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_905714b7-7585-41aa-aa3d-57d7a00976c8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3a2b7ae2-41ec-4f70-8853-00cbf22c1353" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:to="loc_srt_ProductOrServiceAxis_3a2b7ae2-41ec-4f70-8853-00cbf22c1353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_47b6f500-ec89-4ebc-b9a0-a7440057d5ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3a2b7ae2-41ec-4f70-8853-00cbf22c1353" xlink:to="loc_srt_ProductsAndServicesDomain_47b6f500-ec89-4ebc-b9a0-a7440057d5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_65526d7e-3f29-4f05-8dc8-d175dc84cb5d" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_47b6f500-ec89-4ebc-b9a0-a7440057d5ef" xlink:to="loc_sesn_ViciniumMember_65526d7e-3f29-4f05-8dc8-d175dc84cb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4c2c51d1-e2c9-4dea-86b1-74889243b194" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:to="loc_srt_StatementGeographicalAxis_4c2c51d1-e2c9-4dea-86b1-74889243b194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6b63146f-796f-46d0-b751-65c41161af12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4c2c51d1-e2c9-4dea-86b1-74889243b194" xlink:to="loc_srt_SegmentGeographicalDomain_6b63146f-796f-46d0-b751-65c41161af12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c5ffd006-c5a9-48ae-a1d6-5e6de762ad9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6b63146f-796f-46d0-b751-65c41161af12" xlink:to="loc_srt_EuropeMember_c5ffd006-c5a9-48ae-a1d6-5e6de762ad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5e624b1-2ea4-40fa-9645-374848561f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5e624b1-2ea4-40fa-9645-374848561f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_923e9b15-a34d-445a-900b-66b55e46d77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5e624b1-2ea4-40fa-9645-374848561f6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_923e9b15-a34d-445a-900b-66b55e46d77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_f5d999d0-c5ff-4cf5-bb96-e729ddd49962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_923e9b15-a34d-445a-900b-66b55e46d77f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_f5d999d0-c5ff-4cf5-bb96-e729ddd49962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b2bcc31-8d59-4fa4-96ff-28905d1f268a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d19a8945-e615-4b2f-b826-3cb4900cc29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d19a8945-e615-4b2f-b826-3cb4900cc29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_95da9561-39cd-47b7-a647-3cf15a497a57" xlink:href="sesn-20220630.xsd#sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:to="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_95da9561-39cd-47b7-a647-3cf15a497a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7c463c48-e17d-4a81-ac5a-b1bcae1d442e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d1779904-b13b-49d5-912c-d3c14d824f63" xlink:to="loc_us-gaap_Goodwill_7c463c48-e17d-4a81-ac5a-b1bcae1d442e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41bdd99b-8b8f-43b5-a906-f3baf7a1ccdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4e67f7e9-c8b0-4efa-8c30-a435f0f751a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41bdd99b-8b8f-43b5-a906-f3baf7a1ccdc" xlink:to="loc_us-gaap_Goodwill_4e67f7e9-c8b0-4efa-8c30-a435f0f751a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_62c3e615-edda-4c5b-9453-0d93502e6f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41bdd99b-8b8f-43b5-a906-f3baf7a1ccdc" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_62c3e615-edda-4c5b-9453-0d93502e6f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_61c88ff7-343c-43fa-919d-da539d2c9abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41bdd99b-8b8f-43b5-a906-f3baf7a1ccdc" xlink:to="loc_us-gaap_Goodwill_61c88ff7-343c-43fa-919d-da539d2c9abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="sesn-20220630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2370f27a-d9ec-477e-afed-1130f2f67275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_002b1692-7273-4146-8d54-dade1e3fe627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2370f27a-d9ec-477e-afed-1130f2f67275" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_002b1692-7273-4146-8d54-dade1e3fe627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8042211b-1622-4ec3-af8b-4189ed6ce9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c81273fe-4d4c-420b-b39e-6e035a10921f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8042211b-1622-4ec3-af8b-4189ed6ce9e5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c81273fe-4d4c-420b-b39e-6e035a10921f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_688f006b-1c63-4259-83c0-f28ad497a1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_c32b0545-1972-4a7d-80b1-9b810171f4ec" xlink:href="sesn-20220630.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_688f006b-1c63-4259-83c0-f28ad497a1c1" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_c32b0545-1972-4a7d-80b1-9b810171f4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_34fe43c5-5cbd-4996-b656-7c16ab5cc862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_688f006b-1c63-4259-83c0-f28ad497a1c1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_34fe43c5-5cbd-4996-b656-7c16ab5cc862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_a69fe86f-ff77-4d1f-a8f2-fa04a9297e10" xlink:href="sesn-20220630.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_688f006b-1c63-4259-83c0-f28ad497a1c1" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_a69fe86f-ff77-4d1f-a8f2-fa04a9297e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_cf413b1a-df6b-45dd-96b4-1a2e03ea4018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_688f006b-1c63-4259-83c0-f28ad497a1c1" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_cf413b1a-df6b-45dd-96b4-1a2e03ea4018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFees_640dc4a6-cd4b-434e-a317-b97b4759cfcb" xlink:href="sesn-20220630.xsd#sesn_AccruedLegalFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_688f006b-1c63-4259-83c0-f28ad497a1c1" xlink:to="loc_sesn_AccruedLegalFees_640dc4a6-cd4b-434e-a317-b97b4759cfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f562a7e3-b662-4177-9431-9ce14168b1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_688f006b-1c63-4259-83c0-f28ad497a1c1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f562a7e3-b662-4177-9431-9ce14168b1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0cddc843-7e83-49b5-a24a-4da790227eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_688f006b-1c63-4259-83c0-f28ad497a1c1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0cddc843-7e83-49b5-a24a-4da790227eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sesn-20220630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68ca432c-fb9e-421f-a9b6-6279e9816004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e1141226-87a5-416a-bfc3-56f495686ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68ca432c-fb9e-421f-a9b6-6279e9816004" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e1141226-87a5-416a-bfc3-56f495686ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a13a01f4-581a-438b-bfd5-47f957493967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits_37811b03-4ed2-44d9-a938-63b5667b715e" xlink:href="sesn-20220630.xsd#sesn_NumberOfLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a13a01f4-581a-438b-bfd5-47f957493967" xlink:to="loc_sesn_NumberOfLawsuits_37811b03-4ed2-44d9-a938-63b5667b715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_0092dfa3-d3c4-403d-bb3d-840b0384494f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a13a01f4-581a-438b-bfd5-47f957493967" xlink:to="loc_us-gaap_LitigationReserve_0092dfa3-d3c4-403d-bb3d-840b0384494f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASES" xlink:type="simple" xlink:href="sesn-20220630.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0c0ea7ee-f37b-4fbc-8e76-42bba9d260d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_20b72234-92d5-42ea-b631-6ab1aed89451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c0ea7ee-f37b-4fbc-8e76-42bba9d260d0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_20b72234-92d5-42ea-b631-6ab1aed89451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#LEASESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6372b1b4-d456-4213-8644-374067d87473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6372b1b4-d456-4213-8644-374067d87473" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:to="loc_srt_StatementGeographicalAxis_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_73324fd5-8abe-4ec5-a2f9-bba7ae0423e1" xlink:to="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_be3c28b4-7c6f-4951-aeb8-aa468c39feeb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:to="loc_country_CA_be3c28b4-7c6f-4951-aeb8-aa468c39feeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_5071bd06-db38-4cdc-98f2-eb58a757097c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:to="loc_stpr_MA_5071bd06-db38-4cdc-98f2-eb58a757097c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_b71977cd-c97c-46b5-942b-0e94f297714a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_abecbfc2-749b-4c8a-8efd-a0bc24995914" xlink:to="loc_stpr_PA_b71977cd-c97c-46b5-942b-0e94f297714a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be76ec9b-8c13-4e22-9713-c4bd587a7e6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:to="loc_srt_RangeAxis_be76ec9b-8c13-4e22-9713-c4bd587a7e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d6889ef-51cd-415f-a12f-4a6b1e802977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_be76ec9b-8c13-4e22-9713-c4bd587a7e6c" xlink:to="loc_srt_RangeMember_0d6889ef-51cd-415f-a12f-4a6b1e802977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b55b1365-8166-4e6e-a951-1fd864091668" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d6889ef-51cd-415f-a12f-4a6b1e802977" xlink:to="loc_srt_MinimumMember_b55b1365-8166-4e6e-a951-1fd864091668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_95502e9a-d26e-4561-88fa-1b533c2c1ff2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d6889ef-51cd-415f-a12f-4a6b1e802977" xlink:to="loc_srt_MaximumMember_95502e9a-d26e-4561-88fa-1b533c2c1ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_becd3b40-23c4-4308-86be-58591ab2ca98" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_cacd15ad-dc6e-4a0a-b714-298b890c844a" xlink:href="sesn-20220630.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_cacd15ad-dc6e-4a0a-b714-298b890c844a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5fb0b0ce-5b44-4e9d-afb3-619fce388365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5fb0b0ce-5b44-4e9d-afb3-619fce388365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_e6334c7b-940e-40ff-8ead-a7780c7d5ad8" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_e6334c7b-940e-40ff-8ead-a7780c7d5ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_a39bb845-97b4-4fea-871d-effa3edd96dd" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_a39bb845-97b4-4fea-871d-effa3edd96dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1c4839b5-7d6c-4d37-8ee6-6fe785bc7bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseCost_1c4839b5-7d6c-4d37-8ee6-6fe785bc7bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_539162a6-1919-4076-8292-af3629d7c4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_539162a6-1919-4076-8292-af3629d7c4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0acbc9a1-8d4d-496b-9bfa-2e3769ff9b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0acbc9a1-8d4d-496b-9bfa-2e3769ff9b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3339e9cb-a758-4e2b-a783-4ceb83768c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3339e9cb-a758-4e2b-a783-4ceb83768c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c40574b8-6230-495a-9134-b5c5f7469000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9af2ba30-5ab7-4866-9ba5-2ac5ecf01bb2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c40574b8-6230-495a-9134-b5c5f7469000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_844c157e-d376-4dc4-b625-89cf8cc440e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8ad401a7-1ecc-4b5f-b36e-55f3896295aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_844c157e-d376-4dc4-b625-89cf8cc440e4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8ad401a7-1ecc-4b5f-b36e-55f3896295aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1095d301-8934-4914-a418-6049aa478767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_a5006cd7-d1ed-403d-90c2-321fa239ef40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1095d301-8934-4914-a418-6049aa478767" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_a5006cd7-d1ed-403d-90c2-321fa239ef40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_783b4d9d-9a88-4b10-a629-b50f77edc0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1095d301-8934-4914-a418-6049aa478767" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_783b4d9d-9a88-4b10-a629-b50f77edc0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYEquityFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c555d948-ce23-4019-8a4c-b878242d610b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9c9870bf-aa64-408f-8986-26025e0fa4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c555d948-ce23-4019-8a4c-b878242d610b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9c9870bf-aa64-408f-8986-26025e0fa4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f507c555-9548-4e9d-bb2f-ff89f1225476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9c9870bf-aa64-408f-8986-26025e0fa4dd" xlink:to="loc_us-gaap_CreditFacilityAxis_f507c555-9548-4e9d-bb2f-ff89f1225476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ca48e363-2fcf-402e-966a-8593d7082efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f507c555-9548-4e9d-bb2f-ff89f1225476" xlink:to="loc_us-gaap_CreditFacilityDomain_ca48e363-2fcf-402e-966a-8593d7082efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_acb1dd0c-dd4e-4e19-b897-5b0ae59e8b10" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ca48e363-2fcf-402e-966a-8593d7082efb" xlink:to="loc_sesn_ATMFacilityMember_acb1dd0c-dd4e-4e19-b897-5b0ae59e8b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9c9870bf-aa64-408f-8986-26025e0fa4dd" xlink:to="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1902a3f3-a3c3-42a9-860a-bc3cde1250c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1902a3f3-a3c3-42a9-860a-bc3cde1250c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_a81ae32d-e976-415d-b175-2d4eb9e33d9f" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_a81ae32d-e976-415d-b175-2d4eb9e33d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_39e4e570-1c49-4e46-8b49-9074addb6ab5" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_39e4e570-1c49-4e46-8b49-9074addb6ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_3e474479-86c9-44e0-bee0-473a4320acde" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_3e474479-86c9-44e0-bee0-473a4320acde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d5be4a2a-f1fb-4c6b-b40b-0a64c123a54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d5be4a2a-f1fb-4c6b-b40b-0a64c123a54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ead3fa2-cfdf-4bdd-8435-ab7d3100af69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ead3fa2-cfdf-4bdd-8435-ab7d3100af69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_7dee836b-705d-48f8-bdd2-593aa6f12ea9" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_7dee836b-705d-48f8-bdd2-593aa6f12ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_afa413bc-95fb-4b29-ba78-0bd586e1e424" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0c2d4cd-daf8-4740-ab8c-2b115d0f50ee" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_afa413bc-95fb-4b29-ba78-0bd586e1e424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fef7fa5a-d02b-478e-9323-3c337bd38cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e0f66db9-02d8-4098-87fb-d624afbc30a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fef7fa5a-d02b-478e-9323-3c337bd38cdb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e0f66db9-02d8-4098-87fb-d624afbc30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4d031bdc-83ea-4b01-a48e-25237e5a4489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fef7fa5a-d02b-478e-9323-3c337bd38cdb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4d031bdc-83ea-4b01-a48e-25237e5a4489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0de46837-37f6-4603-a389-f6e83df5ee14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fef7fa5a-d02b-478e-9323-3c337bd38cdb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0de46837-37f6-4603-a389-f6e83df5ee14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_86a0cb02-45b3-4bfc-a05d-b952c49f14a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fef7fa5a-d02b-478e-9323-3c337bd38cdb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_86a0cb02-45b3-4bfc-a05d-b952c49f14a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8aee46c6-d11e-4678-a286-1289111a4c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_82eb0150-ce8f-4e4f-ac90-2a52432bd4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8aee46c6-d11e-4678-a286-1289111a4c5a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_82eb0150-ce8f-4e4f-ac90-2a52432bd4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_219f55cc-3fc9-490b-a720-01f0c2028faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_82eb0150-ce8f-4e4f-ac90-2a52432bd4b6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_219f55cc-3fc9-490b-a720-01f0c2028faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b189b106-ccf9-40d4-a842-77a229981cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_219f55cc-3fc9-490b-a720-01f0c2028faa" xlink:to="loc_us-gaap_EquityComponentDomain_b189b106-ccf9-40d4-a842-77a229981cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5c9b467e-8f5f-41d3-8e97-fadd665e5fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b189b106-ccf9-40d4-a842-77a229981cac" xlink:to="loc_us-gaap_CommonStockMember_5c9b467e-8f5f-41d3-8e97-fadd665e5fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_82eb0150-ce8f-4e4f-ac90-2a52432bd4b6" xlink:to="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ce28e8ab-64d7-4634-958f-8b464053be83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ce28e8ab-64d7-4634-958f-8b464053be83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ef90e071-1463-41e8-932e-9045d9ecdd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_us-gaap_CommonStockSharesIssued_ef90e071-1463-41e8-932e-9045d9ecdd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9b5a1f3a-9eaa-443d-aa19-0fb5500fcfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9b5a1f3a-9eaa-443d-aa19-0fb5500fcfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_29853980-ba12-48cb-ba8c-e0396ab4b060" xlink:href="sesn-20220630.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b97c40e-c82f-4029-bb0f-b69ca6f5c894" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_29853980-ba12-48cb-ba8c-e0396ab4b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1d79daf6-95aa-4027-baaf-70e857618342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_dbdd7a82-34b1-4020-8559-47db806011e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1d79daf6-95aa-4027-baaf-70e857618342" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_dbdd7a82-34b1-4020-8559-47db806011e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8456b883-62c9-4fcf-abc3-bd9e26a76180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_dbdd7a82-34b1-4020-8559-47db806011e3" xlink:to="loc_us-gaap_AwardTypeAxis_8456b883-62c9-4fcf-abc3-bd9e26a76180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8456b883-62c9-4fcf-abc3-bd9e26a76180" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e084e064-2801-4bf4-bd30-4ea4b447b6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_WarrantMember_e084e064-2801-4bf4-bd30-4ea4b447b6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8b4cbbbc-61e6-4a0d-b2ab-1bac24176d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8b4cbbbc-61e6-4a0d-b2ab-1bac24176d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f6915914-7e4d-4b9b-ac7c-306a0e251e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f6915914-7e4d-4b9b-ac7c-306a0e251e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_471e8adc-b7dc-4fc4-91df-a1619c6f67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_StockCompensationPlanMember_471e8adc-b7dc-4fc4-91df-a1619c6f67a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1c7a912f-7fa8-4ce0-87a3-0138f5e956a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d322be-f40c-4e1f-a9ec-202536c48514" xlink:to="loc_us-gaap_EmployeeStockMember_1c7a912f-7fa8-4ce0-87a3-0138f5e956a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0a514bcf-074b-4ad5-b3ed-df41704b32da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_dbdd7a82-34b1-4020-8559-47db806011e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_0a514bcf-074b-4ad5-b3ed-df41704b32da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cead00ee-dc15-47ad-8c67-dd7e834a7459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0a514bcf-074b-4ad5-b3ed-df41704b32da" xlink:to="loc_us-gaap_CommonStockSharesIssued_cead00ee-dc15-47ad-8c67-dd7e834a7459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f65fd03-7056-4f3e-a04f-759f9b89bad9" xlink:href="sesn-20220630.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0a514bcf-074b-4ad5-b3ed-df41704b32da" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f65fd03-7056-4f3e-a04f-759f9b89bad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ebdfde9e-cc08-41a6-8d1f-4a405e28ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f65fd03-7056-4f3e-a04f-759f9b89bad9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ebdfde9e-cc08-41a6-8d1f-4a405e28ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_42b6164d-893a-4f7b-ad1a-cf0790a2bfb3" xlink:href="sesn-20220630.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f65fd03-7056-4f3e-a04f-759f9b89bad9" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_42b6164d-893a-4f7b-ad1a-cf0790a2bfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5ea52e50-f515-401a-9022-107352764530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_704f8d79-be5e-409f-b157-33a1aef8913d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5ea52e50-f515-401a-9022-107352764530" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_704f8d79-be5e-409f-b157-33a1aef8913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_305caa94-b260-4fb8-9f36-800bdc61b35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_704f8d79-be5e-409f-b157-33a1aef8913d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_305caa94-b260-4fb8-9f36-800bdc61b35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_305caa94-b260-4fb8-9f36-800bdc61b35d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_7d2b3c3b-b484-475f-9080-dc00b1b45e89" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_7d2b3c3b-b484-475f-9080-dc00b1b45e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_6e866ab1-35ea-4fb1-9e34-ff6d974a142b" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_6e866ab1-35ea-4fb1-9e34-ff6d974a142b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_cea01e62-87c6-44e7-9f4e-c87cc47b27b5" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_cea01e62-87c6-44e7-9f4e-c87cc47b27b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_2d6f6d67-0558-4de6-b616-7f56dcd92672" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34915b4a-94ac-4445-a8f2-b6930766c32a" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_2d6f6d67-0558-4de6-b616-7f56dcd92672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_99cb493a-1d63-4c0c-abbe-06500a633811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_704f8d79-be5e-409f-b157-33a1aef8913d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_99cb493a-1d63-4c0c-abbe-06500a633811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_346a6a4f-9621-4bf3-8f86-bbe16a8dbc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_99cb493a-1d63-4c0c-abbe-06500a633811" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_346a6a4f-9621-4bf3-8f86-bbe16a8dbc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:href="sesn-20220630.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_99cb493a-1d63-4c0c-abbe-06500a633811" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8b601edf-944b-4aef-8a73-2ffa6c6c355a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8b601edf-944b-4aef-8a73-2ffa6c6c355a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_3b41cb29-bddb-4b1c-ba56-66ad908fa63f" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_3b41cb29-bddb-4b1c-ba56-66ad908fa63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e61e5020-ec31-493f-a5b1-6f406814264f" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e61e5020-ec31-493f-a5b1-6f406814264f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_85c4f5b5-6bc1-4919-9320-3da8709a4c1e" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_85c4f5b5-6bc1-4919-9320-3da8709a4c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d7a20af4-89b3-44e3-9e3a-c55d0e327fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_98c07f46-6470-4775-a927-3686ab15fb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d7a20af4-89b3-44e3-9e3a-c55d0e327fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="sesn-20220630.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5a6ec947-c7dd-4c8c-8d0d-258b2c95ad82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0afb6bb1-bfc0-4cb1-8ec4-3f0a069b7291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a6ec947-c7dd-4c8c-8d0d-258b2c95ad82" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0afb6bb1-bfc0-4cb1-8ec4-3f0a069b7291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="sesn-20220630.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7525bc68-f711-4e43-922c-6d879679fe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7b624aff-b6fb-44f4-991e-47960cb584c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7525bc68-f711-4e43-922c-6d879679fe2c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7b624aff-b6fb-44f4-991e-47960cb584c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6785d9ba-6108-4ae1-911d-17bfe4d1e627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_38875960-4442-4d91-a0d0-cc9ac9140034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6785d9ba-6108-4ae1-911d-17bfe4d1e627" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_38875960-4442-4d91-a0d0-cc9ac9140034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_38875960-4442-4d91-a0d0-cc9ac9140034" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6c1bbb7-646f-4b16-a8ec-3bebfdabb8f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8908b37f-8e2b-4655-bb3e-8f67cffd6bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:to="loc_us-gaap_WarrantMember_8908b37f-8e2b-4655-bb3e-8f67cffd6bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ed5e1ac-5194-40e5-a053-d60d6fce41f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ed5e1ac-5194-40e5-a053-d60d6fce41f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4b1a4d35-d442-44dc-a5a6-b7416d182fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4b1a4d35-d442-44dc-a5a6-b7416d182fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_96ee1514-07d3-4706-b5d0-b043a41b14ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7c8ea40e-794a-41aa-9c0d-431c9a6d6dc1" xlink:to="loc_us-gaap_PerformanceSharesMember_96ee1514-07d3-4706-b5d0-b043a41b14ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eba846fd-0118-4856-b3df-ccafddc88305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_38875960-4442-4d91-a0d0-cc9ac9140034" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eba846fd-0118-4856-b3df-ccafddc88305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a3ae52c7-0091-4f15-9ed0-cdc063187351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eba846fd-0118-4856-b3df-ccafddc88305" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a3ae52c7-0091-4f15-9ed0-cdc063187351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ba4a743-7e85-4ad3-a5b6-e16aaaa6cef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8082b91b-86c2-4f9b-9460-001bc414cff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ba4a743-7e85-4ad3-a5b6-e16aaaa6cef5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8082b91b-86c2-4f9b-9460-001bc414cff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5820d813-c0f5-4a9b-88b9-2c4784a127b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b03de39c-add7-483c-962c-2f20ef761d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5820d813-c0f5-4a9b-88b9-2c4784a127b0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b03de39c-add7-483c-962c-2f20ef761d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c9ef3c36-6001-483d-8008-1ae9a4619f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5820d813-c0f5-4a9b-88b9-2c4784a127b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c9ef3c36-6001-483d-8008-1ae9a4619f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9cda794c-926c-49da-b2d7-4e672c383a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5820d813-c0f5-4a9b-88b9-2c4784a127b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9cda794c-926c-49da-b2d7-4e672c383a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_502933a1-1fdb-4585-984b-6ef8707c8f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5820d813-c0f5-4a9b-88b9-2c4784a127b0" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_502933a1-1fdb-4585-984b-6ef8707c8f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb3f07ea-387e-4cf1-8800-8d54f689a5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d01e3ff9-7f75-4d3a-8fe4-be726e017265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb3f07ea-387e-4cf1-8800-8d54f689a5ac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d01e3ff9-7f75-4d3a-8fe4-be726e017265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d01e3ff9-7f75-4d3a-8fe4-be726e017265" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e957828d-db42-4107-9122-b57e7655b935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd9dcebc-2698-4ca8-8fea-ed90a44e9c8c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e957828d-db42-4107-9122-b57e7655b935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0c4a2c20-ef26-47c3-ba53-6d009c2c340e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e957828d-db42-4107-9122-b57e7655b935" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0c4a2c20-ef26-47c3-ba53-6d009c2c340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3f734e07-f9b0-48f2-ab03-9f8ca81b4c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e957828d-db42-4107-9122-b57e7655b935" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3f734e07-f9b0-48f2-ab03-9f8ca81b4c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e52a4e0-a0ef-4148-9583-77f557c834f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d01e3ff9-7f75-4d3a-8fe4-be726e017265" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e52a4e0-a0ef-4148-9583-77f557c834f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_06271a4b-65ee-4122-a93d-39bb7d90b8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e52a4e0-a0ef-4148-9583-77f557c834f0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_06271a4b-65ee-4122-a93d-39bb7d90b8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4675096d-7316-42c6-ad02-f402401d57cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4675096d-7316-42c6-ad02-f402401d57cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06735921-5597-4107-9aa6-3340501a4655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_AwardTypeAxis_06735921-5597-4107-9aa6-3340501a4655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_06735921-5597-4107-9aa6-3340501a4655" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7ca120e3-3e08-44bf-9e78-d8b5eb077c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7ca120e3-3e08-44bf-9e78-d8b5eb077c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bf838c8b-520f-44c7-b9c7-8c2de4a4b712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bf838c8b-520f-44c7-b9c7-8c2de4a4b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_06ff0106-3e24-4bc0-9cc9-e2d602d3dbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ca40af4-3a9c-4d50-817a-0f85e83a540c" xlink:to="loc_us-gaap_PerformanceSharesMember_06ff0106-3e24-4bc0-9cc9-e2d602d3dbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a45bc5cf-d5b2-482b-a459-f33960c57e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_PlanNameAxis_a45bc5cf-d5b2-482b-a459-f33960c57e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a45bc5cf-d5b2-482b-a459-f33960c57e9c" xlink:to="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_64010cae-df4c-4b23-9bcd-f9e46fb4df46" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_64010cae-df4c-4b23-9bcd-f9e46fb4df46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_86dd0ed1-7b85-4499-b4d2-978015a56e0d" xlink:href="sesn-20220630.xsd#sesn_RetentionProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:to="loc_sesn_RetentionProgramMember_86dd0ed1-7b85-4499-b4d2-978015a56e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_55cf1841-b431-42ed-a972-465c5e745b56" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_65195315-5214-4382-a425-c6154d6eb0a3" xlink:to="loc_sesn_StockIncentivePlan2009Member_55cf1841-b431-42ed-a972-465c5e745b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7614488f-c98c-433b-b894-a1bf871ca2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_VestingAxis_7614488f-c98c-433b-b894-a1bf871ca2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_58167e4d-6dee-45b4-8419-eebf3bd1c8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7614488f-c98c-433b-b894-a1bf871ca2a5" xlink:to="loc_us-gaap_VestingDomain_58167e4d-6dee-45b4-8419-eebf3bd1c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4014bf0a-c5bc-4d47-b08b-6cb6d2938a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_58167e4d-6dee-45b4-8419-eebf3bd1c8e0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4014bf0a-c5bc-4d47-b08b-6cb6d2938a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f5dede16-70ef-4e2a-88f5-fe49034f088e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_58167e4d-6dee-45b4-8419-eebf3bd1c8e0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f5dede16-70ef-4e2a-88f5-fe49034f088e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_6ff4006d-7131-4e4d-82d4-dbec98e12c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_GranteeStatusAxis_6ff4006d-7131-4e4d-82d4-dbec98e12c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_5bdca4ce-c2f0-4019-a8b1-729c403dcfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_6ff4006d-7131-4e4d-82d4-dbec98e12c2f" xlink:to="loc_us-gaap_GranteeStatusDomain_5bdca4ce-c2f0-4019-a8b1-729c403dcfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_c837f3eb-d70b-4182-88b0-2792be1a9276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_5bdca4ce-c2f0-4019-a8b1-729c403dcfeb" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_c837f3eb-d70b-4182-88b0-2792be1a9276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0beb642-106e-418e-b93a-60489ac90e8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_552ccd79-f60a-4fca-8832-c5df4fe43dbf" xlink:href="sesn-20220630.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_552ccd79-f60a-4fca-8832-c5df4fe43dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44e81662-40d7-4d77-93a6-ab403e983dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44e81662-40d7-4d77-93a6-ab403e983dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3b99a547-4d1b-4939-ad4c-061537549ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3b99a547-4d1b-4939-ad4c-061537549ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5eda35a2-d02a-4be2-bc97-7b5d984b4584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5eda35a2-d02a-4be2-bc97-7b5d984b4584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e8a80963-7f89-4693-9cf2-b600b2bf8e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e8a80963-7f89-4693-9cf2-b600b2bf8e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_699c47ad-3142-4374-ac33-5e6fb096f62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_699c47ad-3142-4374-ac33-5e6fb096f62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_9ea01784-1225-4436-bacc-02a0112b9f22" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_9ea01784-1225-4436-bacc-02a0112b9f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_94efaebc-a764-4152-8722-90b31945c6fe" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_94efaebc-a764-4152-8722-90b31945c6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ee2cb9e2-0752-4415-b9d0-9a9d96540526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ee2cb9e2-0752-4415-b9d0-9a9d96540526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_eaae50c2-64ee-4bae-9952-48a778c26feb" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_eaae50c2-64ee-4bae-9952-48a778c26feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_db27ce44-f238-4f8c-ac5a-c5f03f804ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_db27ce44-f238-4f8c-ac5a-c5f03f804ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_44648d67-836a-4a5b-88e2-09e308e15a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_44648d67-836a-4a5b-88e2-09e308e15a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d2e26151-e37b-42ee-94be-f79a3d1a783a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d2e26151-e37b-42ee-94be-f79a3d1a783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8fe2588b-eff7-4ec4-8255-de28dcfa320e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8fe2588b-eff7-4ec4-8255-de28dcfa320e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1244983e-2b75-4cbd-a150-b60336854aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1244983e-2b75-4cbd-a150-b60336854aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0cc088d8-d7f7-4f2c-b7a1-c6a7eaf93381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0cc088d8-d7f7-4f2c-b7a1-c6a7eaf93381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_db68afe0-1602-4696-a505-91a23594e993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_654c48a1-87bf-4e23-aa25-334a92f9b32f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_db68afe0-1602-4696-a505-91a23594e993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31bdfe81-bfcc-4bdd-aca9-70e22ef1c84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fdde18a9-f89b-42c0-a85f-f86c0ef5f53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31bdfe81-bfcc-4bdd-aca9-70e22ef1c84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fdde18a9-f89b-42c0-a85f-f86c0ef5f53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b4f24422-fb85-47b2-9454-139767acb28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fdde18a9-f89b-42c0-a85f-f86c0ef5f53a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b4f24422-fb85-47b2-9454-139767acb28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_64dd3100-8852-4ea2-9754-0105b83861d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fdde18a9-f89b-42c0-a85f-f86c0ef5f53a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_64dd3100-8852-4ea2-9754-0105b83861d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c0213469-a427-4398-b719-2af35f7e08fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fdde18a9-f89b-42c0-a85f-f86c0ef5f53a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c0213469-a427-4398-b719-2af35f7e08fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b747d553-3877-49c8-a61a-8c11ddb7a01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fdde18a9-f89b-42c0-a85f-f86c0ef5f53a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b747d553-3877-49c8-a61a-8c11ddb7a01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc5220f8-7bb9-4228-add4-e8caaaa5b291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fdde18a9-f89b-42c0-a85f-f86c0ef5f53a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc5220f8-7bb9-4228-add4-e8caaaa5b291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_75350c3b-8014-4fbb-852c-843145a7a27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31bdfe81-bfcc-4bdd-aca9-70e22ef1c84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_75350c3b-8014-4fbb-852c-843145a7a27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a614970e-3598-4112-ac31-4084ffc596b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31bdfe81-bfcc-4bdd-aca9-70e22ef1c84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a614970e-3598-4112-ac31-4084ffc596b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_118cd2df-ebea-4832-b8fe-85afa9050e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a614970e-3598-4112-ac31-4084ffc596b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_118cd2df-ebea-4832-b8fe-85afa9050e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ff58993b-499d-48b6-9b07-f5f96972e920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a614970e-3598-4112-ac31-4084ffc596b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ff58993b-499d-48b6-9b07-f5f96972e920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_071a5e88-7d72-43d4-8e3f-ecbd997e3244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a614970e-3598-4112-ac31-4084ffc596b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_071a5e88-7d72-43d4-8e3f-ecbd997e3244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ec24943f-58b2-4f42-9582-372eab7eeb46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a614970e-3598-4112-ac31-4084ffc596b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ec24943f-58b2-4f42-9582-372eab7eeb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44ded68c-7ce2-4dc8-baf7-854ce416ac9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a614970e-3598-4112-ac31-4084ffc596b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44ded68c-7ce2-4dc8-baf7-854ce416ac9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_84ba8906-e6e5-4208-ab8f-cd12b47ed417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31bdfe81-bfcc-4bdd-aca9-70e22ef1c84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_84ba8906-e6e5-4208-ab8f-cd12b47ed417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d90ec0f5-9c7d-4570-8632-094447dc6733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31bdfe81-bfcc-4bdd-aca9-70e22ef1c84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d90ec0f5-9c7d-4570-8632-094447dc6733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_989647e0-9965-473c-a8ff-d5dfe8ba073b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d90ec0f5-9c7d-4570-8632-094447dc6733" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_989647e0-9965-473c-a8ff-d5dfe8ba073b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f3e70801-4c74-4cca-ab09-552cd2e0a631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d90ec0f5-9c7d-4570-8632-094447dc6733" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f3e70801-4c74-4cca-ab09-552cd2e0a631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17bb03e3-d12b-4184-af28-4c58218fdaae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d90ec0f5-9c7d-4570-8632-094447dc6733" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17bb03e3-d12b-4184-af28-4c58218fdaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_209e0148-65ed-4627-baf6-c440461b0beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d90ec0f5-9c7d-4570-8632-094447dc6733" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_209e0148-65ed-4627-baf6-c440461b0beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cdc1c3a-095e-4f80-8526-39c3357e1fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c278d56-7ec2-4027-9daf-c64f318e860c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cdc1c3a-095e-4f80-8526-39c3357e1fdf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c278d56-7ec2-4027-9daf-c64f318e860c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ccbe8b87-856b-4b9d-8321-5f1199227450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c278d56-7ec2-4027-9daf-c64f318e860c" xlink:to="loc_us-gaap_AwardTypeAxis_ccbe8b87-856b-4b9d-8321-5f1199227450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0988ab2e-0ce3-4d8e-a8e7-2065ed5a02ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ccbe8b87-856b-4b9d-8321-5f1199227450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0988ab2e-0ce3-4d8e-a8e7-2065ed5a02ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3e102855-11f8-4df8-b6a1-5dda15665c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0988ab2e-0ce3-4d8e-a8e7-2065ed5a02ae" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3e102855-11f8-4df8-b6a1-5dda15665c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c278d56-7ec2-4027-9daf-c64f318e860c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_8b8182b3-6981-4d60-905a-a6fb02259a13" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_8b8182b3-6981-4d60-905a-a6fb02259a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_039e6666-8ab4-4e94-8d76-06e6c7b76572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_039e6666-8ab4-4e94-8d76-06e6c7b76572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1fad74b-8fa8-465f-bd46-6db87c04d1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1fad74b-8fa8-465f-bd46-6db87c04d1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d84315ef-55a9-4715-bf13-dd83b8b7a08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d84315ef-55a9-4715-bf13-dd83b8b7a08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f3d6b553-0b13-4ffe-bcb2-29c86e9580f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f3d6b553-0b13-4ffe-bcb2-29c86e9580f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ca353199-f209-4dee-accb-bda8b66c828f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_025bc9b3-5abc-4274-9592-f72bafd58a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ca353199-f209-4dee-accb-bda8b66c828f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_abba0ba0-af16-46c7-b5f4-0130ac36df7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5c7b1926-d929-48ef-9d4e-f48a994d7895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_abba0ba0-af16-46c7-b5f4-0130ac36df7e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5c7b1926-d929-48ef-9d4e-f48a994d7895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_401132a2-8927-4bc8-a56f-38deb0261704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5c7b1926-d929-48ef-9d4e-f48a994d7895" xlink:to="loc_us-gaap_AwardTypeAxis_401132a2-8927-4bc8-a56f-38deb0261704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf043f81-9e6e-4b84-9e7d-d79e25f22c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_401132a2-8927-4bc8-a56f-38deb0261704" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf043f81-9e6e-4b84-9e7d-d79e25f22c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_40af4aa3-ca05-422f-a505-7c5eca2d77ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf043f81-9e6e-4b84-9e7d-d79e25f22c9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_40af4aa3-ca05-422f-a505-7c5eca2d77ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_2f2fe621-8489-46c1-b8a0-87e4bdecb19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf043f81-9e6e-4b84-9e7d-d79e25f22c9d" xlink:to="loc_us-gaap_PerformanceSharesMember_2f2fe621-8489-46c1-b8a0-87e4bdecb19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f8606d2-2dd4-4d57-a49c-db7e8ad0f726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5c7b1926-d929-48ef-9d4e-f48a994d7895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f8606d2-2dd4-4d57-a49c-db7e8ad0f726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f8606d2-2dd4-4d57-a49c-db7e8ad0f726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d5455e8-b508-402d-a3c1-697ae517e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d5455e8-b508-402d-a3c1-697ae517e4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a24736f7-7cfb-448c-a87f-e099277b9af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a24736f7-7cfb-448c-a87f-e099277b9af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41b47ff0-52f1-4d25-b476-cf557df25117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41b47ff0-52f1-4d25-b476-cf557df25117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_23c15993-4d6c-43fa-9f75-932b9d3544df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9009cbc1-aeaf-4f52-80b3-e2abee8498e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_23c15993-4d6c-43fa-9f75-932b9d3544df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f8606d2-2dd4-4d57-a49c-db7e8ad0f726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6c74a148-611b-4a57-b3e6-7ecf5f1bee71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6c74a148-611b-4a57-b3e6-7ecf5f1bee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_171c9ce8-f91d-43e3-b5e7-0a201e65b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_171c9ce8-f91d-43e3-b5e7-0a201e65b5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_757fe9ff-3b65-44fb-bdeb-6fc041c59f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_757fe9ff-3b65-44fb-bdeb-6fc041c59f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2eccd7ab-7f01-4b08-8ec5-4dc45d715fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42fe2c02-18a3-4da8-b518-6b605ff2c178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2eccd7ab-7f01-4b08-8ec5-4dc45d715fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="sesn-20220630.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c79d8f01-8398-407e-9a11-b210685e8485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_cddccc52-65e7-49df-85ee-3b75c917add0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c79d8f01-8398-407e-9a11-b210685e8485" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_cddccc52-65e7-49df-85ee-3b75c917add0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e4309b15-d770-49ff-be5e-6f7b358913a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e4309b15-d770-49ff-be5e-6f7b358913a8" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_041dd9c1-7547-4d93-9e28-9d3daf9b8846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:to="loc_us-gaap_PlanNameAxis_041dd9c1-7547-4d93-9e28-9d3daf9b8846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5af5c0f0-31dc-43de-8fec-e444d8ca8f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_041dd9c1-7547-4d93-9e28-9d3daf9b8846" xlink:to="loc_us-gaap_PlanNameDomain_5af5c0f0-31dc-43de-8fec-e444d8ca8f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_8b15cb47-04f5-488c-be1b-fd8434afb144" xlink:href="sesn-20220630.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5af5c0f0-31dc-43de-8fec-e444d8ca8f27" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_8b15cb47-04f5-488c-be1b-fd8434afb144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a108d73-f57e-43e8-81b5-c585c506fca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a108d73-f57e-43e8-81b5-c585c506fca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed5fcf29-d7da-4644-b8a0-39a8593102dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a108d73-f57e-43e8-81b5-c585c506fca6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed5fcf29-d7da-4644-b8a0-39a8593102dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_93a2fedd-9de7-4a8a-9c75-2f9ca38955f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed5fcf29-d7da-4644-b8a0-39a8593102dc" xlink:to="loc_us-gaap_DomesticPlanMember_93a2fedd-9de7-4a8a-9c75-2f9ca38955f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0a48646b-c180-4fb4-91c5-bb538f5a3099" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_93a2fedd-9de7-4a8a-9c75-2f9ca38955f2" xlink:to="loc_country_US_0a48646b-c180-4fb4-91c5-bb538f5a3099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6a2e001e-5e0c-486a-8e8d-fd2c20f5a59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed5fcf29-d7da-4644-b8a0-39a8593102dc" xlink:to="loc_us-gaap_ForeignPlanMember_6a2e001e-5e0c-486a-8e8d-fd2c20f5a59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_814328d9-3a88-4d25-bac2-2de07063a189" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_6a2e001e-5e0c-486a-8e8d-fd2c20f5a59e" xlink:to="loc_country_CA_814328d9-3a88-4d25-bac2-2de07063a189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef9097-583c-4a66-af05-39a17c336f0a" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f2571cfe-9c92-4423-9f70-10c877659a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f2571cfe-9c92-4423-9f70-10c877659a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6b6e0a0f-5e9c-40fb-a0b2-49d0f8dcce03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6b6e0a0f-5e9c-40fb-a0b2-49d0f8dcce03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b3bbb92c-bb4e-4f9b-9eb4-99dd85cb2c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b3bbb92c-bb4e-4f9b-9eb4-99dd85cb2c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_abbb11f3-9e1e-41df-b762-2e045af476e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_abbb11f3-9e1e-41df-b762-2e045af476e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0e22f2b7-aa3e-4b16-af05-f99b80def83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0e22f2b7-aa3e-4b16-af05-f99b80def83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_fc53032a-2219-4e5e-b994-931be9122540" xlink:href="sesn-20220630.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_fc53032a-2219-4e5e-b994-931be9122540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5d517545-7f37-4e3f-932e-4ba131852861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b55a7b3-648e-4f6b-a853-8c3676c2aae5" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5d517545-7f37-4e3f-932e-4ba131852861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1a434e2e-9580-41b8-9fca-516a976dfd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3c934643-039b-4184-8f1b-473835a8703d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1a434e2e-9580-41b8-9fca-516a976dfd9c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3c934643-039b-4184-8f1b-473835a8703d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f0ef2b11-1190-43b7-a0b8-ec9dda4c82ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a9286a19-f11a-4c1b-aa07-082f6c388c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0ef2b11-1190-43b7-a0b8-ec9dda4c82ec" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a9286a19-f11a-4c1b-aa07-082f6c388c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1155788a-27fa-4b39-9c8d-14c8db1f97b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0ef2b11-1190-43b7-a0b8-ec9dda4c82ec" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1155788a-27fa-4b39-9c8d-14c8db1f97b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_fcb2a04e-f0f8-4fee-90a7-6d1a0496a276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0ef2b11-1190-43b7-a0b8-ec9dda4c82ec" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_fcb2a04e-f0f8-4fee-90a7-6d1a0496a276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_20548a4c-74d8-47f8-b226-13d49ea2f1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_bb73bb18-d673-4c1f-9072-5afb395e4b83" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_20548a4c-74d8-47f8-b226-13d49ea2f1bf" xlink:to="loc_sesn_IncomeTaxesTable_bb73bb18-d673-4c1f-9072-5afb395e4b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_57f5806b-e727-49a3-b507-0b959573ccdc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_bb73bb18-d673-4c1f-9072-5afb395e4b83" xlink:to="loc_srt_StatementGeographicalAxis_57f5806b-e727-49a3-b507-0b959573ccdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a68d0891-3689-4e2d-8508-be020ac17d26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_57f5806b-e727-49a3-b507-0b959573ccdc" xlink:to="loc_srt_SegmentGeographicalDomain_a68d0891-3689-4e2d-8508-be020ac17d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6a114137-0f3b-4cb2-a0a1-dca19bf8fdbd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a68d0891-3689-4e2d-8508-be020ac17d26" xlink:to="loc_country_US_6a114137-0f3b-4cb2-a0a1-dca19bf8fdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_f4f182e1-de4c-403f-a342-c34eb02d2694" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a68d0891-3689-4e2d-8508-be020ac17d26" xlink:to="loc_country_CA_f4f182e1-de4c-403f-a342-c34eb02d2694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_bb73bb18-d673-4c1f-9072-5afb395e4b83" xlink:to="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_19139e2c-fdf3-4e59-a21e-52ed95503145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_19139e2c-fdf3-4e59-a21e-52ed95503145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1a246767-0682-41af-8c1c-892390cdac18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1a246767-0682-41af-8c1c-892390cdac18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_842f980f-8662-4634-8e84-651b96cf053c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_02f3d9d1-dbf3-42b7-8eb9-7ee636bf9187" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_842f980f-8662-4634-8e84-651b96cf053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofIncomeTaxProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_62574df8-d0e3-4a7b-a6d8-0c0d7d469d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_281b8713-2da6-43a9-920b-dbd4f119bbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62574df8-d0e3-4a7b-a6d8-0c0d7d469d68" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_281b8713-2da6-43a9-920b-dbd4f119bbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_497aa669-9d8c-4e4e-ba19-b6769d7a710e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_281b8713-2da6-43a9-920b-dbd4f119bbdd" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_497aa669-9d8c-4e4e-ba19-b6769d7a710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_422e7449-0284-488f-a693-bc8295044e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_281b8713-2da6-43a9-920b-dbd4f119bbdd" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_422e7449-0284-488f-a693-bc8295044e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ddbe6c5e-1b47-46b1-a31f-c24a7c7e5f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_52e7ede2-ef37-46e0-ae7f-f42b9625c260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddbe6c5e-1b47-46b1-a31f-c24a7c7e5f64" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_52e7ede2-ef37-46e0-ae7f-f42b9625c260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_8789375c-90dc-481f-9ecd-0bab990ba6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_52e7ede2-ef37-46e0-ae7f-f42b9625c260" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_8789375c-90dc-481f-9ecd-0bab990ba6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2062c468-7768-48ef-9d43-68e6daedfaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_52e7ede2-ef37-46e0-ae7f-f42b9625c260" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2062c468-7768-48ef-9d43-68e6daedfaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3367e927-2de6-49a6-818f-c56a56945720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3367e927-2de6-49a6-818f-c56a56945720" xlink:to="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:to="loc_srt_ProductOrServiceAxis_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85966262-bf07-45f2-9d24-e19cd9bc52b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_329c0e1e-c7b4-44ef-87af-5b46d4f7f59d" xlink:to="loc_srt_ProductsAndServicesDomain_85966262-bf07-45f2-9d24-e19cd9bc52b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_9513aa3d-3fd6-4f19-aa8b-06c855fcaf7f" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85966262-bf07-45f2-9d24-e19cd9bc52b1" xlink:to="loc_sesn_ViciniumMember_9513aa3d-3fd6-4f19-aa8b-06c855fcaf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_adc851d9-992a-48a2-8914-0ade2d9bd27d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:to="loc_srt_StatementGeographicalAxis_adc851d9-992a-48a2-8914-0ade2d9bd27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46885cde-9b51-452f-933d-80d3746499fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_adc851d9-992a-48a2-8914-0ade2d9bd27d" xlink:to="loc_srt_SegmentGeographicalDomain_46885cde-9b51-452f-933d-80d3746499fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b6f16dc1-9396-40c5-b3f6-48958a83669b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_46885cde-9b51-452f-933d-80d3746499fc" xlink:to="loc_srt_EuropeMember_b6f16dc1-9396-40c5-b3f6-48958a83669b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ac6770-1e68-4c92-8d4d-3391847b42c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ac6770-1e68-4c92-8d4d-3391847b42c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e194c6c-2b8e-4e2c-b255-b5950328cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ac6770-1e68-4c92-8d4d-3391847b42c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e194c6c-2b8e-4e2c-b255-b5950328cc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_805f6448-0d4d-4d32-a26a-2c9a5f335858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e194c6c-2b8e-4e2c-b255-b5950328cc30" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_805f6448-0d4d-4d32-a26a-2c9a5f335858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_4510a02c-9ffa-4ea5-9f77-d8d51af1d8fc" xlink:to="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_93eabca2-9782-4e25-996e-b16b6c17cbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_93eabca2-9782-4e25-996e-b16b6c17cbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_11509b0c-4b23-4b2f-a1b6-463564d1a652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_11509b0c-4b23-4b2f-a1b6-463564d1a652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_55886832-b397-472e-8469-f560887b4e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_55886832-b397-472e-8469-f560887b4e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseInDeferredTaxLiability_6409c1b2-131a-4fc2-a569-83253c5ce021" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_sesn_IncreaseDecreaseInDeferredTaxLiability_6409c1b2-131a-4fc2-a569-83253c5ce021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_d94e9f27-a460-4cc5-85ea-c8a41eb81315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_d7c819b3-5830-437e-8efd-93f9d68904bb" xlink:to="loc_us-gaap_IncomeTaxesPaid_d94e9f27-a460-4cc5-85ea-c8a41eb81315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="simple" xlink:href="sesn-20220630.xsd#LICENSEAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4f4235d-f780-44f5-9278-55cf486d60e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock_bcd9fb00-dd7d-4a9d-94e0-6fd2d4ac0a51" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4f4235d-f780-44f5-9278-55cf486d60e5" xlink:to="loc_sesn_LicenseAgreementTextBlock_bcd9fb00-dd7d-4a9d-94e0-6fd2d4ac0a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#LICENSEAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f23ee47d-4a16-4af6-8def-286ee406ec64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f23ee47d-4a16-4af6-8def-286ee406ec64" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_36f5348a-0de5-4db4-9fee-30a85dd03ea7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_srt_CounterpartyNameAxis_36f5348a-0de5-4db4-9fee-30a85dd03ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_36f5348a-0de5-4db4-9fee-30a85dd03ea7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_b66e704a-bf5f-4662-abe0-41fe7a3d1d71" xlink:href="sesn-20220630.xsd#sesn_UniversityOfZurichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_UniversityOfZurichMember_b66e704a-bf5f-4662-abe0-41fe7a3d1d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_322ec8ce-451d-4753-9f32-1bef00b2884c" xlink:href="sesn-20220630.xsd#sesn_MicrometAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_MicrometAGMember_322ec8ce-451d-4753-9f32-1bef00b2884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_7a92439a-e90a-492f-b072-159c568281c1" xlink:href="sesn-20220630.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_XOMAIrelandLimitedMember_7a92439a-e90a-492f-b072-159c568281c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_1842d948-743f-4cb5-a536-3053683e241f" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_RocheMember_1842d948-743f-4cb5-a536-3053683e241f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_c8264189-603c-4dd1-ba24-aca2ac6d383c" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_c8264189-603c-4dd1-ba24-aca2ac6d383c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_51d831f8-d485-480c-92f6-45cec43cc9c7" xlink:href="sesn-20220630.xsd#sesn_MENALicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_MENALicenseAgreementMember_51d831f8-d485-480c-92f6-45cec43cc9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_8e07e640-beb6-44f1-9322-4ae97ca78d48" xlink:href="sesn-20220630.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e017d0-43f3-43ce-b43d-fa2746c4659a" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_8e07e640-beb6-44f1-9322-4ae97ca78d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3189f1c7-5c2c-4a56-9c45-ae9703683e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3189f1c7-5c2c-4a56-9c45-ae9703683e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3189f1c7-5c2c-4a56-9c45-ae9703683e1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_211c21ff-9c37-4849-bef4-372878aeb185" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_211c21ff-9c37-4849-bef4-372878aeb185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_cdb0cc24-20c9-497a-8e11-8bcf00c43177" xlink:href="sesn-20220630.xsd#sesn_FirstIndicationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_FirstIndicationMember_cdb0cc24-20c9-497a-8e11-8bcf00c43177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_fc6208e7-bafe-495a-adac-9a5b38815aac" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_fc6208e7-bafe-495a-adac-9a5b38815aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_113d48d2-7fba-4732-a651-29d9c3ddea91" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_113d48d2-7fba-4732-a651-29d9c3ddea91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_57e9ae43-862c-472c-b216-756816543acb" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_57e9ae43-862c-472c-b216-756816543acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_65c65564-1838-4977-a457-26c715b8673e" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_65c65564-1838-4977-a457-26c715b8673e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_f9a8542a-9d7b-4f0d-b08f-8467c9292df6" xlink:href="sesn-20220630.xsd#sesn_SecondIndicationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e5b007-9e03-42f2-99e6-eb51eb886ae8" xlink:to="loc_sesn_SecondIndicationMember_f9a8542a-9d7b-4f0d-b08f-8467c9292df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4a7639e2-a2e4-4c3d-9b7d-2506b413195d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_srt_ProductOrServiceAxis_4a7639e2-a2e4-4c3d-9b7d-2506b413195d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe3f0f86-52e5-47c3-bb07-8113db2987ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4a7639e2-a2e4-4c3d-9b7d-2506b413195d" xlink:to="loc_srt_ProductsAndServicesDomain_fe3f0f86-52e5-47c3-bb07-8113db2987ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_8e860de9-89e6-465f-b9b9-dfd220a1bf43" xlink:href="sesn-20220630.xsd#sesn_EBI031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fe3f0f86-52e5-47c3-bb07-8113db2987ab" xlink:to="loc_sesn_EBI031Member_8e860de9-89e6-465f-b9b9-dfd220a1bf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_srt_RangeAxis_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ae56805-fa84-4e7b-a0ef-23b5999b21a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ce0dbbb0-f5a5-4be7-8950-bfe6830592fe" xlink:to="loc_srt_RangeMember_8ae56805-fa84-4e7b-a0ef-23b5999b21a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f816d520-ef7d-474f-9ff8-c358547086f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8ae56805-fa84-4e7b-a0ef-23b5999b21a9" xlink:to="loc_srt_MinimumMember_f816d520-ef7d-474f-9ff8-c358547086f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_04b01dcf-02b8-4c87-bb2d-17d9785ad6df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8ae56805-fa84-4e7b-a0ef-23b5999b21a9" xlink:to="loc_srt_MaximumMember_04b01dcf-02b8-4c87-bb2d-17d9785ad6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cf136f5f-9b62-41b9-9a24-9974bf94d1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cf136f5f-9b62-41b9-9a24-9974bf94d1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725bcb57-a595-4a1c-beee-8bb7b5463299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf136f5f-9b62-41b9-9a24-9974bf94d1d5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725bcb57-a595-4a1c-beee-8bb7b5463299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_7136893f-5452-436b-823f-60830737ff63" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725bcb57-a595-4a1c-beee-8bb7b5463299" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_7136893f-5452-436b-823f-60830737ff63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e452c30-88c1-461f-a4eb-a620426e4de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e452c30-88c1-461f-a4eb-a620426e4de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6406667-8586-43a8-9b5e-24f0f7ca8e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e452c30-88c1-461f-a4eb-a620426e4de2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6406667-8586-43a8-9b5e-24f0f7ca8e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_32bd40cd-8609-42a9-9f72-ba8408a44c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6406667-8586-43a8-9b5e-24f0f7ca8e92" xlink:to="loc_us-gaap_LicensingAgreementsMember_32bd40cd-8609-42a9-9f72-ba8408a44c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_84bec747-d0ff-4e12-b686-bfdbd3019980" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_srt_StatementGeographicalAxis_84bec747-d0ff-4e12-b686-bfdbd3019980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_de96cdd1-dc35-4b00-87e4-3126e5258fde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_84bec747-d0ff-4e12-b686-bfdbd3019980" xlink:to="loc_srt_SegmentGeographicalDomain_de96cdd1-dc35-4b00-87e4-3126e5258fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_1d7e72dc-8d75-4773-9d23-ecca18c0bca1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_de96cdd1-dc35-4b00-87e4-3126e5258fde" xlink:to="loc_country_TR_1d7e72dc-8d75-4773-9d23-ecca18c0bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0bcbb470-651f-48bf-a503-a2e2e37511e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0bcbb470-651f-48bf-a503-a2e2e37511e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b6a72bb-035b-45b6-a896-d47ce61242bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0bcbb470-651f-48bf-a503-a2e2e37511e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b6a72bb-035b-45b6-a896-d47ce61242bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_53e11b07-724b-412d-920d-83be5e8c18ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4b6a72bb-035b-45b6-a896-d47ce61242bf" xlink:to="loc_us-gaap_SubsequentEventMember_53e11b07-724b-412d-920d-83be5e8c18ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_65639579-b7ea-44b7-afb8-975d5969a27b" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_d07ada2c-ed2a-4a9d-af1e-999ad186384d" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_d07ada2c-ed2a-4a9d-af1e-999ad186384d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_873f41ce-4cf5-4377-be88-be3d74591b49" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_873f41ce-4cf5-4377-be88-be3d74591b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_a2148988-5b2e-4713-bf8f-8fa88afd2e1d" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_a2148988-5b2e-4713-bf8f-8fa88afd2e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_c5dfb043-7d44-4502-96de-95a5058f8b79" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_c5dfb043-7d44-4502-96de-95a5058f8b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_41111bac-672f-47a3-9514-f283d0ecbe35" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_41111bac-672f-47a3-9514-f283d0ecbe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_62afbad1-8296-4438-a0cd-8a8f57d09fac" xlink:href="sesn-20220630.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_62afbad1-8296-4438-a0cd-8a8f57d09fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_642876b6-9687-4004-b80f-edaba3458a44" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_642876b6-9687-4004-b80f-edaba3458a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_97262cd0-78ae-4d73-98f6-d8f7514926ea" xlink:href="sesn-20220630.xsd#sesn_LicenseMaintenanceFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseMaintenanceFees_97262cd0-78ae-4d73-98f6-d8f7514926ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_b6584cd8-02f9-4fa3-a43c-620c6845b7c8" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_b6584cd8-02f9-4fa3-a43c-620c6845b7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_581abac9-0ab8-466f-93c6-605402ca0abd" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_581abac9-0ab8-466f-93c6-605402ca0abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_35dba5e0-a189-4f5c-a766-6a30a80b5e98" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_35dba5e0-a189-4f5c-a766-6a30a80b5e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_024e3759-9f28-4b56-80d8-64d226497d75" xlink:href="sesn-20220630.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_024e3759-9f28-4b56-80d8-64d226497d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_972fdde3-3ae0-4326-80cc-a75b3db51af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_972fdde3-3ae0-4326-80cc-a75b3db51af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_4c9c638e-19ff-467b-928d-b89396d1c115" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_4c9c638e-19ff-467b-928d-b89396d1c115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_36dad52c-da78-45bf-ab4b-7266069994ae" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_36dad52c-da78-45bf-ab4b-7266069994ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_971f2ea4-7aef-4f2c-9c99-c539feb18527" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_971f2ea4-7aef-4f2c-9c99-c539feb18527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_eece0761-5a33-45ba-950f-94cf66e3f5db" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_eece0761-5a33-45ba-950f-94cf66e3f5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_37d868e6-1a5c-4019-ab33-f49cf2625bd1" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_37d868e6-1a5c-4019-ab33-f49cf2625bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_f19dc8cf-841c-437c-ac34-a5a9a5032780" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_f19dc8cf-841c-437c-ac34-a5a9a5032780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_4a2a6831-fac7-4e1e-91b2-548e49b57124" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_4a2a6831-fac7-4e1e-91b2-548e49b57124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_a4ba7a95-c70a-4969-85d3-20f121d421b5" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_a4ba7a95-c70a-4969-85d3-20f121d421b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_63112b07-5f96-454b-83a0-79dbd2dd9e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_PaymentsForRestructuring_63112b07-5f96-454b-83a0-79dbd2dd9e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9fe8a6b1-6dd7-4f7b-9d8f-6f3ddee10fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9fe8a6b1-6dd7-4f7b-9d8f-6f3ddee10fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_ef13414f-e700-404a-86fb-d3a97a434379" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_ef13414f-e700-404a-86fb-d3a97a434379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_03b26862-6779-4397-a33c-1e12e1227850" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_03b26862-6779-4397-a33c-1e12e1227850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod_1bd0c982-d91e-4624-9021-0ac9ba15e9cf" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_CollaborativeArrangementRoyaltyPeriod_1bd0c982-d91e-4624-9021-0ac9ba15e9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e594252d-3fce-4dc7-aca7-75ba10035ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e594252d-3fce-4dc7-aca7-75ba10035ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_14e4ac41-8516-4b78-885e-8efa1fc800e9" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_14e4ac41-8516-4b78-885e-8efa1fc800e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_ddcbf9ce-3b7b-4405-981f-1ac7fa7608f8" xlink:href="sesn-20220630.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_sesn_RoyaltyRevenuePercentage_ddcbf9ce-3b7b-4405-981f-1ac7fa7608f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_daffc814-da73-4943-88c7-250e5330b138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_4361ae4e-8168-4732-bd19-17cfb3abc5ea" xlink:to="loc_us-gaap_DeferredRevenue_daffc814-da73-4943-88c7-250e5330b138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="simple" xlink:href="sesn-20220630.xsd#RESTRUCTURINGANDRELATEDACTIVITIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a164497a-769c-446d-b6ff-0a317b6c8162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_e47e11db-c803-4819-a697-02382f893d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a164497a-769c-446d-b6ff-0a317b6c8162" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_e47e11db-c803-4819-a697-02382f893d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#RESTRUCTURINGANDRELATEDACTIVITIESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3f54bd0a-8bc3-4d26-ac8c-5ec06b14630e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_2850f8ae-e0c2-44e4-98e2-97e43d767ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3f54bd0a-8bc3-4d26-ac8c-5ec06b14630e" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_2850f8ae-e0c2-44e4-98e2-97e43d767ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_72beac09-d8c5-4b23-a900-8f63f7c3b2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b19cf9cc-0a26-4f67-8d7c-2b026a3284ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_72beac09-d8c5-4b23-a900-8f63f7c3b2e0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b19cf9cc-0a26-4f67-8d7c-2b026a3284ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_287cf2cf-143a-4fbf-ae16-04b5a325931a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_72beac09-d8c5-4b23-a900-8f63f7c3b2e0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_287cf2cf-143a-4fbf-ae16-04b5a325931a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#RESTRUCTURINGANDRELATEDACTIVITIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9a5470c3-d08d-4176-99c1-c23a389e51ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_0e9a1887-809f-4555-8bf5-52909ab01f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9a5470c3-d08d-4176-99c1-c23a389e51ef" xlink:to="loc_us-gaap_RestructuringReserveRollForward_0e9a1887-809f-4555-8bf5-52909ab01f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_607fb1f5-0174-482e-adaa-9ea7085bcda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0e9a1887-809f-4555-8bf5-52909ab01f39" xlink:to="loc_us-gaap_RestructuringReserve_607fb1f5-0174-482e-adaa-9ea7085bcda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_8f6c6a09-3ee3-4b2b-877d-bd98a38158c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0e9a1887-809f-4555-8bf5-52909ab01f39" xlink:to="loc_us-gaap_PaymentsForRestructuring_8f6c6a09-3ee3-4b2b-877d-bd98a38158c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_5e2d1842-0126-41f6-8c79-647dd43dff57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0e9a1887-809f-4555-8bf5-52909ab01f39" xlink:to="loc_us-gaap_RestructuringReserve_5e2d1842-0126-41f6-8c79-647dd43dff57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sesn-20220630.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_be02e5bf-e438-4eaf-add9-8835c18e9559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3bb6a72b-39b1-4489-930c-218131c20fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_be02e5bf-e438-4eaf-add9-8835c18e9559" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3bb6a72b-39b1-4489-930c-218131c20fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6b86916e-0851-4bf6-9f60-d872a6149664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_cb1dc1ce-ba19-41de-baa1-0d5df7d35a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6b86916e-0851-4bf6-9f60-d872a6149664" xlink:to="loc_us-gaap_SubsequentEventTable_cb1dc1ce-ba19-41de-baa1-0d5df7d35a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_03de3964-d570-41f7-b83c-6f9777ad586c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cb1dc1ce-ba19-41de-baa1-0d5df7d35a9a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_03de3964-d570-41f7-b83c-6f9777ad586c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_20323912-9860-4c7b-b33d-86c7c749805d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03de3964-d570-41f7-b83c-6f9777ad586c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_20323912-9860-4c7b-b33d-86c7c749805d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bfb1433b-359d-4565-b478-a3708e4b8ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_20323912-9860-4c7b-b33d-86c7c749805d" xlink:to="loc_us-gaap_SubsequentEventMember_bfb1433b-359d-4565-b478-a3708e4b8ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cb1dc1ce-ba19-41de-baa1-0d5df7d35a9a" xlink:to="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_47c404a8-9735-4e7a-a332-24e0be0c28e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_47c404a8-9735-4e7a-a332-24e0be0c28e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_a3c3bdc3-8d65-449f-b931-82f96f5d5d3a" xlink:href="sesn-20220630.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:to="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_a3c3bdc3-8d65-449f-b931-82f96f5d5d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_357c9acb-0a23-424d-a96f-1290aa713f0a" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fa6fb78c-d46b-46b7-8219-ca47afd12901" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_357c9acb-0a23-424d-a96f-1290aa713f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458651648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sesen Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">444-8550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SESN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458269072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,090<span></span>
</td>
<td class="nump">$ 162,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short term marketable securities</a></td>
<td class="nump">69,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">21,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">14,046<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">18,476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">156,420<span></span>
</td>
<td class="nump">205,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">19,641<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">19,743<span></span>
</td>
<td class="nump">35,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">176,163<span></span>
</td>
<td class="nump">240,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">29,851<span></span>
</td>
<td class="nump">8,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,005<span></span>
</td>
<td class="nump">11,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">57,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">33,805<span></span>
</td>
<td class="nump">69,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at June&#160;30, 2022 and December&#160;31, 2021; no shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 400,000,000 shares authorized at June&#160;30, 2022 and December&#160;31, 2021; 199,463,645 shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">491,464<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(349,024)<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">142,358<span></span>
</td>
<td class="nump">171,710<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 176,163<span></span>
</td>
<td class="nump">$ 240,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646457974160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 03, 2021</div></th>
<th class="th"><div>May 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646457700544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,234<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,944<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">34,705<span></span>
</td>
<td class="nump">13,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,589<span></span>
</td>
<td class="nump">6,805<span></span>
</td>
<td class="nump">24,564<span></span>
</td>
<td class="nump">12,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(37,300)<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="num">(50,200)<span></span>
</td>
<td class="nump">61,760<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">35,997<span></span>
</td>
<td class="nump">27,633<span></span>
</td>
<td class="nump">36,833<span></span>
</td>
<td class="nump">87,164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(35,997)<span></span>
</td>
<td class="num">(25,399)<span></span>
</td>
<td class="num">(36,833)<span></span>
</td>
<td class="num">(80,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">162<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss Before Taxes</a></td>
<td class="num">(35,835)<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
<td class="num">(36,642)<span></span>
</td>
<td class="num">(80,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">3,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,875<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss After Taxes</a></td>
<td class="num">(31,960)<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
<td class="num">(32,767)<span></span>
</td>
<td class="num">(80,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - basic</a></td>
<td class="num">(31,960)<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
<td class="num">(32,767)<span></span>
</td>
<td class="num">(80,954)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders - diluted</a></td>
<td class="num">$ (31,960)<span></span>
</td>
<td class="num">$ (25,442)<span></span>
</td>
<td class="num">$ (32,767)<span></span>
</td>
<td class="num">$ (80,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">175,393<span></span>
</td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">166,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">175,393<span></span>
</td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">166,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458606752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 31,960<span></span>
</td>
<td class="nump">$ 25,442<span></span>
</td>
<td class="nump">$ 32,767<span></span>
</td>
<td class="nump">$ 80,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (32,241)<span></span>
</td>
<td class="num">$ (25,442)<span></span>
</td>
<td class="num">$ (33,048)<span></span>
</td>
<td class="num">$ (80,954)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646454524592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM Facility</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss Investments</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (9,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (315,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercises of common stock warrants</a></td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,645,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants</a></td>
<td class="nump">72,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,978,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">9,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(371,433)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(9,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,460,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">49,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(396,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,978,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">9,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(371,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,482,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,460,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">49,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(396,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">171,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">172,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(317,064)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">171,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss of investments</a></td>
<td class="num">$ (281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">142,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="num">(349,024)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">172,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(317,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss of investments</a></td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 142,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (281)<span></span>
</td>
<td class="num">$ (349,024)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Exercise Of Warrants, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646464466992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458680336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,767)<span></span>
</td>
<td class="num">$ (80,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(50,200)<span></span>
</td>
<td class="nump">61,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Intangibles impairment charge</a></td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable (net)</a></td>
<td class="nump">20,939<span></span>
</td>
<td class="num">(2,303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(10,565)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,719<span></span>
</td>
<td class="num">(20,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">7,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,186)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">17,654<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,441)<span></span>
</td>
<td class="num">(41,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(89,095)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(89,095)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">137,312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(90,536)<span></span>
</td>
<td class="nump">95,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of period</a></td>
<td class="nump">162,656<span></span>
</td>
<td class="nump">55,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end of period</a></td>
<td class="nump">72,120<span></span>
</td>
<td class="nump">151,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of equipment included in accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) of Prepaid Expenses, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Related To Adoption of Accounting Standard</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463472688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA, which are further described below. The Company has turned its primary focus to the careful assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022. Additionally, the Company intends to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with bacillus Calmette-Gu&#233;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#8220;CMC&#8221;) issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, </span></div>United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of June&#160;30, 2022, none of these individuals are active employees of the Company or members of the Company's board of directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646465361248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646545503248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463523504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463679488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 10.2% as of June&#160;30, 2022 to 8.0% and 9.3% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development in the US of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Additionally, the Company intends to seek a partner for the further development of Vicineum. The Company expects that any partner who acquires Vicineum from the Company will be obligated to make any payments that become payable to the former shareholders of Viventia under the Share Purchase Agreement. Accordingly, as of June&#160;30, 2022, the Company no longer expects to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights have already been out-licensed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the balance as of June&#160;30, 2022 relates to contingent consideration for projected net sales in the Greater China region as compared to the balance as of December&#160;31, 2021 which was based upon projected world-wide net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s contingent consideration was determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from the Company&#8217;s weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021 to 10.2% as of June&#160;30, 2022. As of December&#160;31, 2021, the balance also reflected potential milestone payments which constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $50.2&#160;million for the six months ended June 30, 2022 was driven by the Company's decision to voluntarily pause further development of Vicineum.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463505104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">RECEIVABLES</a></td>
<td class="text">RECEIVABLES <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of June&#160;30, 2022 is $0.1&#160;million compared to $21.0&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $20.0&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of June&#160;30, 2022 is $14.0&#160;million compared to $3.5&#160;million as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase is driven by expected insurance recovery of $13.0&#160;million related to the preliminary settlements of the securities and derivative litigation. This was partially offset by the receipt of $2.4&#160;million for German value-added tax ("VAT") recovery in the first half of 2022, related to drug substance sent to Baxter in 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463448608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses</a></td>
<td class="text">PREPAID EXPENSES The prepaid expenses balance as of June&#160;30, 2022 is $0.8&#160;million compared to $25.7&#160;million as of December&#160;31, 2021. In light of the Company's decision to voluntarily pause further development of Vicineum, the Company evaluated prepaid balances and determined that the prepayments for the manufacturing of Vicineum, including consumables, had no future economic benefit or value. Pursuant to ASC Topic 730, Certain Nonrefundable Advance Payment, the Company expensed $25.2&#160;million of prepaids during the three months ended June 30, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463534592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWIL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the European Union ("EU") rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#8217;s former lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum&#8482; for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there was more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the EU. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $31.7&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the current range of commercialization timelines and probability of success assumptions. This was primarily due to the fact that the EU asset was burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan was to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in its share price and a resulting decrease in our market capitalization. On July 15, 2022 the Company made the strategic decision to voluntarily pause further development in the US of Vicineum and intends to seek a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of a potential partnering deal to conclude the fair value of EU asset. The Company concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum EU rights of $14.7&#160;million was fully impaired and written off as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#8217;s most recent impairment test, which was 24.5%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. During the second quarter of 2022 the Company observed continued trends in the Company&#8217;s market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, length and cost of a clinical study, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis, in advance of the Company's typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both the US and outside the US ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. Management also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#8217;s most recent impairment test, which was 24.5%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458650384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including preliminary litigation settlement </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463679488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. After the motion was fully briefed and before the court ruled on the motion, on June 3, 2022, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. The parties engaged in mediation on June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers (the &#8220;State Derivative Litigation&#8221;). The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company deemed the settlements of the Securities Litigation, the State Derivative Litigation, the Federal Derivative Litigation, and other potential related derivative claims, probable and amounts reasonably estimable as of June 30, 2022 and accrued $21.6&#160;million to litigation related liability. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation, the State Derivative Litigation and the Federal Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463463728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,000 at exchange rates in effect on June&#160;30, 2022). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,100 at exchange rates in effect on June&#160;30, 2022). Operating lease cost under this lease, including the related operating costs, were $83,000 and $165,000 for the three and six months ended June&#160;30, 2022, respectively, and $84,000 and $166,000 for the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_7413172c-d3a5-4068-a39f-148f182a4c0b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_ea5c27f0-7ff4-4a17-899a-400e6d9e6d97">other assets</span></span> on the Company's condensed consolidated balance sheets. The right of use asset total was $41,700 as of June&#160;30, 2022 and $123,300 as of December&#160;31, 2021. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_0bf1b90e-c07f-46a0-9567-ec2c0325b103"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_1319265b-1386-40c8-9f75-781056e69617">other current liabilities</span></span> and the long-term lease liability is recorded in other liabilities on the Company&#8217;s condensed consolidated balance sheets. The short-term lease liability was $41,700 as of June&#160;30, 2022 and $123,300 as of December&#160;31, 2021. There was no long-term operating lease liability as of June&#160;30, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases are renewed on a month-to-month basis. The minimum monthly rent for these office spaces is $2,200 and $21,000, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463448608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS' EQUITY <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time through Jefferies (the &#8220;ATM Offering&#8221;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement of which $97.8&#160;million of common stock remain available for future issuance as of June&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June&#160;30, 2022. The Company raised $136.8&#160;million of net proceeds from the sale of 47.1&#160;million shares of common stock at a weighted-average price of $2.99 per share during the six months ended June 30, 2021. The Company raised $64.3&#160;million of net proceeds from the sale of 16.5&#160;million shares of common stock at a weighted-average price of $4.02 per share during the three months ended June 30, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0&#160;million and $4.2&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of June&#160;30, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 199&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">230,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity. The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463503872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,743</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,743</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463448608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"/><td style="width:238.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 3.1&#160;million shares of common stock available for issuance under the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 13.6 million stock options outstanding under the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty percent of then-current base salary. The fair value of PSUs at the grant date was $0.4&#160;million. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of June&#160;30, 2022 achievement was deemed probable for only the cash management milestone, representing $87,000, 20% of the PSU awards. Therefore, $11,000 and $33,000 have been expensed during the three and six months ended June 30, 2022, respectively and $54,000 remains measured but unrecognized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of June&#160;30, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately 3.5 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense, related to stock options, of $1.2 million and $2.5 million for the three and six months ended June&#160;30, 2022, respectively and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June&#160;30, 2021, respectively. As of June&#160;30, 2022, there was $8.6 million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of 2.36 years. The weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2022 and 2021 were $0.46 and $2.17, respectively. No stock options were exercised during the six months ended June 30, 2022. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:64.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.34</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"/><td style="width:60.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.68</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled RSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any RSUs or PSUs during the six months ended June 30, 2021. </span></div>The share-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2022 was $0.6 million and $1.2 million, respectively. There was no shared-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2021. As of June&#160;30, 2022, there was $3.0&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463436448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of June&#160;30, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP during the six months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div>The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463448608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:63.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,666)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:63.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,875</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(288)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, the Company recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, the Company determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7&#160;million. In connection with this impairment charge, the Company reversed the associated deferred tax liability by $4.0 million as an income tax benefit, partially offset by $0.1 million income tax paid to foreign jurisdictions pursuant to the exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) (the &#8220;Qilu License Agreement&#8221;). Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the six months ended June 30, 2021, the Company recorded a provision for income taxes of $0.3 million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the Qilu License Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463523504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text">LICENSE AGREEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $0.5&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to meeting a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of June&#160;30, 2022, the Company may be obligated to pay up to &#8364;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.5&#160;million at exchange rates in effect on June&#160;30, 2022). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;50,000 (approximately $52,148 at exchange rates in effect as of June&#160;30, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $7.5&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase III clinical trial, (ii) $50&#160;million in regulatory milestones and (iii) $75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification 606, Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606&#8221;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in previous periods. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for two &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30 days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the Roche License Agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the Company executed an asset purchase agreement with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. See further discussion in Note 19. "Subsequent Events".</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of VAT, which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Qilu Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020. As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained within the stated timeline and was initially recorded as deferred revenue. During the second quarter of 2022, the Company changed assumptions in the clinical study design which resulted in longer clinical trial and further delay in regulatory approval in the MENA region. Therefore, the Company reclassed $1.5&#160;million of deferred revenue to short-term accrued liability as of June 30, 2022. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million was recognized in the first quarter of 2021. Additional variable consideration, determined to be </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022, the Company terminated the MENA License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events."</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of June&#160;30, 2022, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price was estimated by management;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therefore, no revenue was recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30</span>, 2022, the Company terminated the EIP License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646457711424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING AND RELATED ACTIVITIES</a></td>
<td class="text">RESTRUCTURING AND RELATED ACTIVITIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Restructuring Plan included a reduction in the Company&#8217;s workforce by 18 positions (or approximately 35% of the Company&#8217;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that substantially all of the accrued restructuring costs as of June&#160;30, 2022 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div>Subsequent to June 30, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646454503984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vicineum</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA. The Company has turned its primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, the Company intends to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our manufacturing operations by terminating the Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A. and the Commercial Manufacturing and Supply Agreement with Baxter on July 17, 2022 and July 20, 2022, respectively. We requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, we have the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. The Company is in the process of assessing the estimated impact of the termination of the Fujifilm MSA and the Baxter CMSA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, the Company terminated its Cooperative Research and Development Agreement with the National Cancer Institute for the development of Vicineum in combination with AstraZeneca&#8217;s immune checkpoint inhibitor durvalumab for the treatment of BCG-unresponsive NMIBC.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Development Partnerships</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s decision to voluntarily pause further development of Vicineum in the US, the Company has commenced the process to wind down its OUS business development partnerships in MENA and Turkey by providing notice of termination for the MENA License Agreement and EIP License Agreement on July 20, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Restructuring Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially complete by the end of the fourth quarter of 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital while the Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, the Company estimates that it will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $8&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also expects to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and is in the process of assessing the estimated impact.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale of Legacy Technology to Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company executed an asset purchase agreement (the &#8220;Roche Asset Purchase Agreement&#8221;) with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30&#160;million payment to the Company upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and Derivative Litigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022 and July 6, 2022, the Company and the plaintiffs in the Securities Litigation engaged in in-person mediation sessions in an attempt to resolve the litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which is subject to court approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in an in-person mediation session in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims. Pursuant to that agreement, the individual defendants </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will cause the Company to adopt certain enhancements to the Company&#8217;s corporate governance policies and procedures. In exchange, the plaintiffs will dismiss the complaints and, on behalf of the Company, provide broad customary releases to the individual defendants. The agreement is subject to the execution of a definitive stipulation of settlement and, after notice to the Company&#8217;s stockholders, court approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer to Nasdaq Capital Market </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2022, the Company received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) to transfer the listing of the Company&#8217;s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the &#8220;Approval&#8221;). As a result of the Approval, the Company has been granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, the Company received written notice from Nasdaq indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Company was given until July 25, 2022, to regain compliance with the minimum bid price requirement. In response, the Company submitted an application to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock was transferred to the Nasdaq Capital Market effective at the opening of business on July 28, 2022 and will continue to trade under the symbol &#8220;SESN&#8221;. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market and requires that listed companies meet certain financial and liquidity requirements and comply with Nasdaq&#8217;s corporate governance requirements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company&#8217;s common stock must be at least $1.00 for at least ten consecutive business days during the second 180-day grace period. If the Company does not regain compliance during this second grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that if its stock price does not recover sufficiently during the second grace period, it would implement a reverse stock split, if necessary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646457736080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div>Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463644448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Summary of Contingent Consideration Liability</a></td>
<td class="text">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463454080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Composition of Intangible Assets</a></td>
<td class="text">The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463665120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including preliminary litigation settlement </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463533760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Common Stock</a></td>
<td class="text">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">230,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Outstanding and Warrant Activity</a></td>
<td class="text">The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):<div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463608352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,743</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,743</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458637072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"/><td style="width:238.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:64.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.34</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of the Status of Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"/><td style="width:60.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.68</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled RSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463473248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of Pre-tax Income (Loss)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:63.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,666)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Benefit (Provision)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:63.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,875</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(288)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463598112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text">The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646452312592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details) - Viventia Bio Inc.<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare', window );">Shares of common stock issued to the selling shareholders (in shares) | shares</a></td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="nump">19.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales', window );">Period during which quarterly earn-outs are payable after date of net sales</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations', window );">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods', window );">Percentage of net sales of quarterly earn-out payments during earn-out periods</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646455470752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">40,765<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">89,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">40,765<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">89,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">40,765<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">89,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646452329872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Decrease in the fair value of contingent consideration</a></td>
<td class="num">$ (37,300)<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="num">$ (50,200)<span></span>
</td>
<td class="nump">$ 61,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WeightedAverageCostOfCapital', window );">Weighted-average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="nump">0.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Cost of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646461120432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details) - Significant Unobservable Inputs (Level&#160;3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(50,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646457813776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,565)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_LitigationSettlementMember', window );">Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember', window );">German VAT recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_LitigationSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_LitigationSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646461267952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ExpensesPreviouslyClassifiedAsPrepaid', window );">Expenses previously classified as prepaid</a></td>
<td class="nump">$ 25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ExpensesPreviouslyClassifiedAsPrepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses Previously Classified as Prepaid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ExpensesPreviouslyClassifiedAsPrepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646455428144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details) - IPR&amp;D intangible assets: - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">European Union | Vicinium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646457790816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">$ 27,764<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,764<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | Europe | IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage', window );">Impairment of intangible assets risk adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of Intangible Assets, Cost of Capital, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458034192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 13,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="num">(13,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458883264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Components of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 1,847<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll-related expenses</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedRestructuringChargesRelatedCurrent', window );">Restructuring charge related</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedLegalFees', window );">Legal expenses, including preliminary litigation settlement</a></td>
<td class="nump">22,477<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 29,851<span></span>
</td>
<td class="nump">$ 8,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedRestructuringChargesRelatedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Restructuring Charges Related, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedRestructuringChargesRelatedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646457971472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberOfLawsuits', window );">Number of lawsuits | lawsuit</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated litigation liability | $</a></td>
<td class="nump">$ 21.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458342752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CAD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost, including related operating cost</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short term lease liability</a></td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeasesAreaOfOfficeSpace', window );">Office space (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses', window );">Related operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Other Monthly Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseOtherMonthlyOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeasesAreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Area Of Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeasesAreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646455386704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Equity Financing (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 29, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance', window );">Shares reserved for future issuance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockCommissionFixedRate', window );">Commission fixed rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.3<span></span>
</td>
<td class="nump">$ 136.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of units issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts', window );">Issuance of common stock, issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockCommissionFixedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Fixed Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockCommissionFixedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Sales Price In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Shares Amount Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Issues, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646455426944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458722368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 03, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberofVotesEntitledForEachShare', window );">Number of votes | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberofVotesEntitledForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Entitled For Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberofVotesEntitledForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458330288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockSharesIssuedAndReservedForFuture', window );">Total shares of common stock issued and reserved for issuance (in shares)</a></td>
<td class="nump">230,263,000<span></span>
</td>
<td class="nump">229,640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">17,161,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">8,063,000<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares available for grant under 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">3,076,000<span></span>
</td>
<td class="nump">8,933,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for sale under 2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockSharesIssuedAndReservedForFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Issued And Reserved For Future</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockSharesIssuedAndReservedForFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Of Common Stock Reserved For Issuance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharesOfCommonStockReservedForIssuanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646455560224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Warrants (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">Warrants, Expiring March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">Warrants, Expiring November 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member', window );">Warrants, Expiring November 2024, Issued May 2015</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member', window );">Warrants, Expiring November 2024, Issued November 2014</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued During The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Number Of Expirations During The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646459406640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">25,423<span></span>
</td>
<td class="nump">18,743<span></span>
</td>
<td class="nump">25,423<span></span>
</td>
<td class="nump">18,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">17,161<span></span>
</td>
<td class="nump">17,349<span></span>
</td>
<td class="nump">17,161<span></span>
</td>
<td class="nump">17,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458429696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 1,802<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="nump">$ 3,696<span></span>
</td>
<td class="nump">$ 2,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 1,329<span></span>
</td>
<td class="nump">$ 1,052<span></span>
</td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">$ 1,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646453764816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,802,000<span></span>
</td>
<td class="nump">$ 1,259,000<span></span>
</td>
<td class="nump">$ 3,696,000<span></span>
</td>
<td class="nump">$ 2,217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unvested stock to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan | Vesting on the First Anniversary of Date of Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan | Vesting at End of Each Successive Three-Month Period Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Stock Incentive Plan 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested grant restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,161,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU | Retention Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested grant restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Retention Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary', window );">Percent of base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent', window );">Achievement deemed probable, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_RetentionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458411584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares under Option (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(53,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">17,161,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">9,555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">1.83<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Life (in years), Outstanding</a></td>
<td class="text">7 years 8 months 19 days<span></span>
</td>
<td class="text">8 years 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Life (in years), Exercisable</a></td>
<td class="text">7 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458330064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue', window );">Fair market value (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.80%<span></span>
</td>
<td class="nump">74.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646455479424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares)</a></td>
<td class="nump">3,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares)</a></td>
<td class="nump">8,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested ending balance (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,161,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled RSU (in shares)</a></td>
<td class="num">(143,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled RSU (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646459777504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution retirement plan, maximum employee contribution deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee', window );">Discretionary match per participating employee, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Common stock purchase price, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for sale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646457748368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Pre-tax Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Pre-tax income (loss) U.S.</a></td>
<td class="num">$ (55,939)<span></span>
</td>
<td class="num">$ (21,210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Pre-tax income (loss) Canada</a></td>
<td class="nump">19,297<span></span>
</td>
<td class="num">(59,456)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total Loss before Income Taxes</a></td>
<td class="num">$ (36,642)<span></span>
</td>
<td class="num">$ (80,666)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646463515232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Income Tax Provisions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current tax benefit (provision)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">$ 3,875<span></span>
</td>
<td class="num">$ (288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current benefit (provision)</a></td>
<td class="num">$ (3,875)<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458852112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">IPR&amp;D</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,969<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458809584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">$ 3,875<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,875<span></span>
</td>
<td class="num">$ (288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncreaseDecreaseInDeferredTaxLiability', window );">Increase (decrease) in deferred tax liability</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | Europe | IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncreaseDecreaseInDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncreaseDecreaseInDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646445580528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>period</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OtherReceivableAssetPurchaseAgreement', window );">Other receivable, asset purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationRoyaltyPaymentPercent', window );">Royalty payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationMilestonePayments', window );">Business combination, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember', window );">Micromet AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent', window );">License agreement, royalty payment, reduction, conditions not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,148<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember', window );">XOMA Ireland Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementUpfrontFee', window );">License agreement, up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAdditionalUpFrontFee', window );">License agreement, additional up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementOptionPeriods', window );">License agreement, option periods | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod', window );">License agreement, buyout amount under first option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised', window );">License agreement, period to pay buyout option once exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod', window );">License agreement, buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct', window );">Buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | First Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on development milestone | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on commercialization milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Second Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CollaborativeArrangementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember', window );">MENA License Agreement | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccountsReceivablePaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccountsReceivablePaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Long-term Purchase Commitment, Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationRoyaltyPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Royalty Payment Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationRoyaltyPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CollaborativeArrangementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CollaborativeArrangementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAdditionalUpFrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Additional Up-Front Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAdditionalUpFrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Amount Payable Upon Achievement of Specified Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under First Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchievementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achievement Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchievementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementOptionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Option Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementOptionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty On Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty on Net Product Sales, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Period to Pay Buyout Option Once Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Proceeds From Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementProceedsFromMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Up-front Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Basis Of Presentation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OtherReceivableAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Receivable, Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OtherReceivableAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RoyaltyRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Revenue, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RoyaltyRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MicrometAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_EBI031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_EBI031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646464384048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Aug. 30, 2021 </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of positions eliminated</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, period percent</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646454425872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(1,103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139646458685328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement', window );">Payments to company upon execution of the Roche Asset Purchase Agreement</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OtherReceivableAssetPurchaseAgreement', window );">Other receivable, asset purchase agreement</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OtherReceivableAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Receivable, Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OtherReceivableAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Execution Of Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProceedsFromExecutionOfAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>sesn-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sesn="http://www.sesenbio.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sesn-20220630.xsd" xlink:type="simple"/>
    <context id="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia29b4bcc98fb446586c8d0938f7a6cdf_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i09ec16c102264bf888a63583634b10b9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iee48bd4076a144b6bcecb0df8e12665f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae6d8077dece4a95940087e255f75bc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i345971d52bde416886e88795d548811c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i677b1480fd064f218483dcf37f0aa72c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i084e153e02ad4c0fbdaeba8fea7f0792_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i814ff665c79642eb9c63201f9f6aa4c3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie970ce934b1e4c17b1f8e5435783799b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ba13d9d0682407bb0b32862ba63462c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6c99c9b6effb411d93633cf284df66a8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic6ecaf1deb82450595375aa26194263c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8643db175ec94af8835005bd348c2a15_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8d91c72b3c9a48f698faa963f06f6585_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i788239f286ce4a7aaf34d9b6448f7b19_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idbdee19feaf04f8eb7b2e7516c8272ba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0cbf3dbf085a4f5aa6d333be0b69cc50_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5331cf0a882c45b18c3f7c5cdd34d580_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1ba7a3599765459e9e5050731fd4dcd0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0ea6d35dc5474aa581a55e2b57ae57c6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i212d6b0e7fc04d0bb334aee4c3d885fb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic90e014d0d0846a6a6300ee56057382d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if0b29b8876ac49d4ada09cbcefec48ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbb5504ef7a4410cbd3d49b7bc9eac22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7b04bc3e3454a688ae44dcb39bfc41e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e8644b1d6b1492195108a81bd629611_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0208600fe4024d29a9aa9d6917193edb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50a087530030427d9767a04597f4120d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iee2d58ed494f4424abbfc10d0ab04193_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8f839115e09747288556177ec1208f7c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie063900bace246ea9ac9229220ed605a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie5a952d29209497aa9e963b66ddf48ba_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id06576b00b094f1a849c81ba939934c9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i691732dc107c4eb19beb797b845714a5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1e1c1185b384bb9b9a302d5f694d2b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i84f292f26d18474a88618593f2028cde_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4548660807654ebfad44b93c626bb154_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if1e1083313744230858402ce1024fb35_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iedc68b87db60469baad7a2624334af31_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ca4bd64eb504b02826a9652e4a84714_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id6a7b16d33054ed2bb2f3e95123e6d0c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ddf69ac8bf84700b67bf4be374a19f5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i791f0580873d401f8150577ee2f295da_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i927224fa40114d4e9fa1b0f9ea67129d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibaf9ab52935a412db213d105924c9a17_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id1375cc14b49437b91d5bbba570298c2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia3dde4b5cd0247c48f35a95c8521f4b9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i7f8bfc830bc347e7ba385a21bc092a5d_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="i0e3fdec0c73b4a429111263d24db668c_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i6e0b5fa857364bf4a51985aa66895ef9_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="idded2fb700664bad9763afed64edafd0_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i4937ec1ad1154d88925e0cabccbc0017_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="idddfae85f074434a95d80a49f60b90a8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia5c7832156a94fdeb7e233a110f7b809_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id7c2028a693348b8951ec9bd0156057c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibe177cf9141643909f6abc3b8fa7d37d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9372277261a1442382a0a57cd6b64879_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86a276b795564af5900e3ccde170c211_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93597cbef52346f8bf33793b3445c748_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0c6a63221e74f49a77225cfd89d52e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c6ff544a1cd473cb1b5466e70e8581d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic13e854370344e64955121ce52f8efd8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i077703176cde4f50813269c0d4bc4948_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i086d18af784f4ef89dd43b1a93d419d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id227aede38f346d295f8bb264c9c69d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2830d319d1ee4478869015d679421f00_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i60aca7f4595d416dac4c7c3f1aed4ccb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if7f36ed152cc4886975102feb1d3dcf2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa3364e01f0e4f3e8b9b4b9e879f7cda_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie9e6014176bb47daa77e93b8e95c92eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68913e68ad7b4a54a86589572b03f916_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:LitigationSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i22e566e4a4b842db8188c3f55dbff512_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:GermanVATRecoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaafbcb1be87d432d8ded324e6ed76889_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i99b037e30ee240a693feec6491f28390_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i043a889ad00d41bcbc065be28275a745_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia31cefc9e53e4fdea0146b38e97b9152_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75f8be7fd9a44548a385a47a21fdcbfa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id5bc92acb0454bdeb25962fc1d1aef23_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i148c02076fb6482087594002227223b6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i54a5e53888604de7b9eccc5f75d78406_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia060ccaf4f3043ab8f16a7a015f9e80e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if8a99add6a0641b5ab55bf3282467a0d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i84bae78e3b8749b39293629af79a1b2a_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="ib2f7003911044ca29a413fb1818f5c6c_D20210601-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i1ce363488c7540a6a587912208af7e0f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i35961c53b42e43cbb0b81da04777d408_D20211129-20211129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-29</startDate>
            <endDate>2021-11-29</endDate>
        </period>
    </context>
    <context id="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7960c58d87094e0aafb92767a535f891_I20210502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-05-02</instant>
        </period>
    </context>
    <context id="ifc8cab4c047e42a1993c113f9407d7c0_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i0e690f5ae31c41b7a191fa0ff85bf14a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4e430eedf22b467aac65cdb1b465bb18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if12ac6d811ab49fea4ae767cff635f67_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i879f338421144cd692f89c4e9f0c73c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf83b58ca25c49e192a0c8602c5b4cf2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iccc92bb70d08454e949c18da6144865f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9bd2cea79e94911a9584a49e07abbb3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3787aa8d02ce4f859f8c5f466f0d274a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab2fae56c82b4d01a53b53d0d8ad8169_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i018c376ae85743729c4cc85b9d0082c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0aa49d50600f4d809f73a21b67293288_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if3f5defe37004a80beffaabe3c084441_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i40c5616a1e704030a81402b94effbad5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69cb4439e7f34192bda24252ab0db0d6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i95be96bc66a447e49b2e6b3eb139bb61_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4361a004833c45998527402787d53315_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c9b9934bd1f4b4a87e74584ffe44869_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i364de02410824f29aef894a8c443af3b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5f346e6310724b48be23ba52453dfd1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib269223dc4c241d2ab59180afde39e5e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3afe3a9ad2a74fa9a621bbc8ca349720_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i65a150a7d69f42ab95bb4eebf536a4eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd894f48683d467eade7ea10a3423375_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i69d2c5c201c146a29dc3f4aaab1fa94b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if89d59ad112c41c1a5e5e4945e45b3a0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia1832afd10f54cc791caad58fb173350_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia2b6f3706013458ab5961aa0a088fa40_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6362c9affd304cba8c070c705be6dd77_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i369610441fa049a9b3af81518e15d50d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i831e2ac854704d1aae0e81436d368ad4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic013dea044994c0b9999755d2814f233_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i95d8a6c363c94c7ebb181ec0e4902d6d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3a5c4a87f8a04b809066ca30fe8adea9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if7a6d05611034f0cbfbdc965d1641901_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5b119b75001e4eb591c83a48aca8ad9e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibdffcc8e474644f1a7bc79d73e44c345_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1c426ecc6b6e483ab968812e43898fb8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i371ff9f9dd74484bbb7af64395b59cb2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf3d53abab674300a3e66f4bbf777a4d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30153c69f900480b8a7b0d198d30b92d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i70c58c1e89d74a42975680f91f9ea952_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7184f2bd1645489a8e93fd75f730b37a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifb927ed78cfd4508b0462135a3c2436f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2701137d4d3d4c4e8e5113cfb9b9bf7d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib379188f80ee457e82a023166eab9d6d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3bd5ecb234e84849a3ef40071493ded8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c124cc8b22a40b89b467199316812d8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie611da9814584f9980040a27dfc0cff0_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if40d7dc2760c4b73a1bf0f58cb0cea20_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i67dda89a221d455f9646b0da9c4929bc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifa54545585df44e4b7d3a89233f8dfaf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2df208e090e4403eb77e13ead4f86d17_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id9d2c51fc9d34a20a514bea566541f46_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i015ea6430d994fbc8697ad17d12ffea0_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i8e3af4b7d2cd45f48969782be08ae91a_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ice9190fd4c5e4b23a2cfa99f52b8d06e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i316721534e954709ac4ca98fac589f21_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i92ebc00eafc24ccc9dfc43c74893c366_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idd52d29ba82b4fc3a132c9324d52f501_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i03957233ce864a5a98dacdf6ed5a459b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1d5814f76b2747c3bb68d3ded24afaba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i734f190a8be94ab0a3e93a4104c4affb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4286168bb23741ed8ede08217b5079cd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i278e1922f5954901947c7da7b025ffda_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idddc6e09a127406fb21bab2cff01e6a3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i40d49584882e49c39b789667e1aa8b9a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5887d0c8af474b9da60db574f802c013_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idd2fc190c9bb4eac8b5f0a896433b557_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ided647db41004402b85556f36c1a5a6a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib5a0f88a3ce248ca80278fd875407820_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75f185aabf3c422eb49cc6accab9e6cd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i517f238357944a0796854ba08409d69f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0ad270b4c89440e0821ae038d2cb2389_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic9b0b2106a50498eb917274f3a68063a_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="i665443501e7f49ecae379e80a026aa5e_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i5f79c7546bc741bfb209ea4731a1b39f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i72b00192c39e430cbe5b0b12c9d8d89c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie820aa9d32f54e368d97eb79949bb246_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i877a2547d28941a6974c361f55d0df05_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id9d33e85d61e44c4bfd117e7d31fe670_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18a706cafcaf41aab0bf2bbae702174f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1d04fb2cb1d2410b8938ae078b9fd516_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic6f9d2a8d9b34e2ea5321b0774bc4cd3_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a026aa3a4334726bbd5d5b4169de5ac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i21cd86819fc94d60888b84c9fbec1cd9_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec3b8c8266c54149935b053a4854e949_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i01807f2cd89e4e9d84b0e1ec13338d5f_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="ic7f3a1555672448da4256c36f647a2ea_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="icedd019379624203beb6559637b67e52_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i71e7893a75ac4fcdbb28b05eddc7e79e_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i56d94eda0f1e46ba9ba00a785398fb15_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i87cb0e785fa74c60b27360b6bae115b5_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i8afbb1e24e95451fb3040230f72e3eea_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie0efda518e014299bbb43462ac3cc850_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i3d81161a92ef494db5814266170b94b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida7114209f954433a73b2aa4e6273e7f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaebb9ac802f4499ab5d494233003436d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c1ee3d4b0ed4b6d81693a3b78436a98_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a23e83ac0484f0bbab51200be62df4c_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i6542b5648ea045f58f4c69b28422077a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifd055427f2ee4af697e38e23fd5f01bc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6822798f98d34751ae079338ed021602_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="ia2e62709d9af4f339539c651a584c514_I20220715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-15</instant>
        </period>
    </context>
    <context id="i0492cdffd25d4cf78dc20d704adfe705_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="id40d181b700547bea2d9b69343d99848_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i60749fcbb0ad4615afcf10b65d11d107_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b2ff8e61fcd46c299eab19b8098175a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id4b71a855e3048d9a5e32abd82f7ed34_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib96799ba5a814f0c8caad764cfa9b749_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8ff51dfb75a942b18163f303609e9cf2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1922ec39f2664925917602d82aac09b7_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i166f7d51c9a04607804af70090d9f047_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33b6c64b39074311ba0d20d253292de1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibd9b4c5e3f1a4695a42133604689308c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5aa9628d22de45f283290aaf3f3b037b_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="id693de1f894a4b41bfff465cc3f75051_D20210805-20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="i8e4b88050bd14031af553100cd13d2ae_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="i224d2937076040b695691239c9bdd50d_D20210830-20210830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="i924d818132a640e4bbf0b520aa8af43a_D20220715-20220715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-15</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="ibd7f6776eada4e709a71593d6e50e7c4_I20220808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lawsuit">
        <measure>sesn:lawsuit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="vote">
        <measure>sesn:vote</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="period">
        <measure>sesn:period</measure>
    </unit>
    <unit id="position">
        <measure>sesn:position</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M181LTEtMS0xLTcwMDYw_664c11a5-68da-44fa-a701-29e28b496b8c">0001485003</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M182LTEtMS0xLTcwMDYw_fe6624ba-fb11-4a46-8bed-307b2b806bfb">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M183LTEtMS0xLTcwMDYw_0d43ff09-2b56-414c-9b4b-d1bfd1eeb547">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M184LTEtMS0xLTcwMDYw_b28f3007-ed44-4aca-8b31-32ff84122a99">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80L2ZyYWc6NDUwMGNiMWE3OTZiNDg2YzllMDRlYzk4YjIxYmFjNjMvdGFibGU6NWEyMmJkYzIxNGIyNDJjZjhkMzcwOTA5M2QzZDk5NDMvdGFibGVyYW5nZTo1YTIyYmRjMjE0YjI0MmNmOGQzNzA5MDkzZDNkOTk0M185LTEtMS0xLTcwMDYw_835f8a9c-ac37-48a6-a4c6-08cee8e45425">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_12b4d2e7-50cf-486e-9f55-531f61e9b030">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_31abd46a-5b00-4492-b73c-c6d432a04ad5">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_481dba29-3a20-4f06-a044-73c8436545ee">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0wLTEtMS03MDA2MA_897ed270-6cb7-4b09-83f1-a713e11dbc4b">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_7413172c-d3a5-4068-a39f-148f182a4c0b">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_ea5c27f0-7ff4-4a17-899a-400e6d9e6d97">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_0bf1b90e-c07f-46a0-9567-ec2c0325b103">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_1319265b-1386-40c8-9f75-781056e69617">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg3_c2c83ef4-1795-47bc-a72d-3e590f1a7b6f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6NDJiNWRhYWEyMzczNGVkZWEwMTJjM2FkZmVkMGY3MDAvdGFibGVyYW5nZTo0MmI1ZGFhYTIzNzM0ZWRlYTAxMmMzYWRmZWQwZjcwMF8wLTAtMS0xLTcwMDYw_070370d1-b7c3-4526-9e13-7eefc14a01f4">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xMzY_e35130b5-f828-49ba-9cca-61491bc92709">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6NmQ5NzMzYjg4NzdjNDRjOTk4NTdlZDY0MTRlNjU1NTAvdGFibGVyYW5nZTo2ZDk3MzNiODg3N2M0NGM5OTg1N2VkNjQxNGU2NTU1MF8wLTAtMS0xLTcwMDYw_2a9401fd-e869-48c0-a486-a9f9a405b295">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTgz_09fe0734-2692-4281-a71c-1cea123274cd">001-36296</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg4_038b90b8-277e-4238-a7c9-068a95489130">Sesen Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6MWFlYTI4M2Q3NTQ3NGI2YThiZDZhYzQ5Mzg1ZTY2NjMvdGFibGVyYW5nZToxYWVhMjgzZDc1NDc0YjZhOGJkNmFjNDkzODVlNjY2M18wLTAtMS0xLTcwMDYw_95f68828-ba34-4e37-bd4a-8ccafc793bf5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6MWFlYTI4M2Q3NTQ3NGI2YThiZDZhYzQ5Mzg1ZTY2NjMvdGFibGVyYW5nZToxYWVhMjgzZDc1NDc0YjZhOGJkNmFjNDkzODVlNjY2M18wLTEtMS0xLTcwMDYw_b9336f1b-283b-445a-9211-9112fcf6e75d">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTAtMS0xLTcwMDYwL3RleHRyZWdpb246OThlODkyOGQ4MmZjNDU2MzkwMjk4NDg5MDEwNGViM2FfNA_16061b1d-bfae-4ad8-8d65-890dd1a725e8">245 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTAtMS0xLTcwMDYwL3RleHRyZWdpb246OThlODkyOGQ4MmZjNDU2MzkwMjk4NDg5MDEwNGViM2FfOA_424d16d6-1aae-4e01-acd1-3713bdc67c3b">Suite 1800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTAtMS0xLTcwMDYwL3RleHRyZWdpb246OThlODkyOGQ4MmZjNDU2MzkwMjk4NDg5MDEwNGViM2FfMTE_53852441-c8b5-4445-bc4a-277d9e60974f">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTAtMS0xLTcwMDYwL3RleHRyZWdpb246OThlODkyOGQ4MmZjNDU2MzkwMjk4NDg5MDEwNGViM2FfMTU_1b8712f6-9d51-4f4a-a814-c80b80540b21">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YzgyMjc4MzVmYjNjNDIwNmIyNDlhYWVjMzllYjMyYTIvdGFibGVyYW5nZTpjODIyNzgzNWZiM2M0MjA2YjI0OWFhZWMzOWViMzJhMl8wLTEtMS0xLTcwMDYw_4eb7b64a-24d4-4e2b-b0d5-aea4f562a86f">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8zNTY_208d6176-4974-4c37-88b1-0ea3b7fd5ca0">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg5_9839d3a3-142b-4f3d-92bb-d52542b28bc2">444-8550</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6OWJlZTBhMzJhYWEyNGU2YTk5ZDM5ODM0MDgzODRhYzkvdGFibGVyYW5nZTo5YmVlMGEzMmFhYTI0ZTZhOTlkMzk4MzQwODM4NGFjOV8xLTAtMS0xLTcwMDYw_c4ef3a0f-1feb-4831-9b8b-d1dc49ccff05">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6OWJlZTBhMzJhYWEyNGU2YTk5ZDM5ODM0MDgzODRhYzkvdGFibGVyYW5nZTo5YmVlMGEzMmFhYTI0ZTZhOTlkMzk4MzQwODM4NGFjOV8xLTEtMS0xLTcwMDYw_e88b67ef-e090-414a-8e3c-c91baf7dc28f">SESN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6OWJlZTBhMzJhYWEyNGU2YTk5ZDM5ODM0MDgzODRhYzkvdGFibGVyYW5nZTo5YmVlMGEzMmFhYTI0ZTZhOTlkMzk4MzQwODM4NGFjOV8xLTItMS0xLTcwMDYw_53654ff6-2c2a-464f-9597-e901db2a2153">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg0_1e8dc16a-514a-47c6-b167-e33f3cb123fb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTg1_126974ed-8841-45d0-9279-eff044643ed1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YmEzMDNiODA4NzRiNDQ1NmIyNjdmZjI4MGFlNTViNjkvdGFibGVyYW5nZTpiYTMwM2I4MDg3NGI0NDU2YjI2N2ZmMjgwYWU1NWI2OV8wLTAtMS0xLTcwMDYw_371fe01e-f228-47fd-a4a9-3e95dce3ff2c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YmEzMDNiODA4NzRiNDQ1NmIyNjdmZjI4MGFlNTViNjkvdGFibGVyYW5nZTpiYTMwM2I4MDg3NGI0NDU2YjI2N2ZmMjgwYWU1NWI2OV8wLTMtMS0xLTcwMDYw_edc56ada-a9d7-4777-8aed-8b2a6050ab86">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGFibGU6YmEzMDNiODA4NzRiNDQ1NmIyNjdmZjI4MGFlNTViNjkvdGFibGVyYW5nZTpiYTMwM2I4MDg3NGI0NDU2YjI2N2ZmMjgwYWU1NWI2OV8xLTMtMS0xLTcwMDYw_615994a7-24d3-4950-a29a-bd6c3667f505">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTkx_b10542f8-9336-46d6-af57-c5b81260c99d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia29b4bcc98fb446586c8d0938f7a6cdf_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xL2ZyYWc6YTcwNjJiOWI0NzU0NDI1Zjk2OTZiZWIyYjhkZGYzOWQvdGV4dHJlZ2lvbjphNzA2MmI5YjQ3NTQ0MjVmOTY5NmJlYjJiOGRkZjM5ZF8xOTE4_b97523c4-8b2f-4c64-948d-a11d4a2d8313"
      unitRef="shares">199463645</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMy0xLTEtMS03MDA2MA_3dafca32-0f32-4b30-a799-d122a1c9bbe9"
      unitRef="usd">72090000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMy0zLTEtMS03MDA2MA_5bbce7e2-d4d7-487a-94a2-6c5e4eed910a"
      unitRef="usd">162636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNC0xLTEtMS03Njk0Ng_8d11abd3-5470-4aaa-bd10-300f0f1ad3a0"
      unitRef="usd">69454000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNC0zLTEtMS03Njk0Ng_63a8efc2-8da9-47a2-a7ca-d6d2066b22c8"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNC0xLTEtMS03MDA2MA_0f317f1d-beb0-4537-bd58-e65659a6efa1"
      unitRef="usd">73000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNC0zLTEtMS03MDA2MA_b9944da8-9646-4aae-b412-9972f91c917e"
      unitRef="usd">21011000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNS0xLTEtMS03MDA2MA_72d62aa7-5a0e-476a-a7f7-e22da2f83d46"
      unitRef="usd">14046000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNS0zLTEtMS03MDA2MA_d8ca2ce1-933c-4019-81b2-14e898f84c45"
      unitRef="usd">3482000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNi0xLTEtMS03MDA2MA_5bf177ec-b02c-4b5a-b59d-6349dad78a2e"
      unitRef="usd">757000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNi0zLTEtMS03MDA2MA_a29e7a13-1e5a-4f3f-a42b-fb5b84474ba0"
      unitRef="usd">18476000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfOC0xLTEtMS03MDA2MA_5f3514b4-6e9b-43cf-ba43-a23de3f75708"
      unitRef="usd">156420000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfOC0zLTEtMS03MDA2MA_2d04c6df-5377-417b-8f92-4c17ae479212"
      unitRef="usd">205605000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTEtMS0xLTEtNzAwNjA_3e79bb3e-9b6c-43b0-ab47-06bf7aa36586"
      unitRef="usd">30000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTEtMy0xLTEtNzAwNjA_a89cd406-0136-4696-9ed6-bf1834903f2f"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTItMS0xLTEtNzQwNTA_6986f132-8153-40d1-b718-b39c63a15d71"
      unitRef="usd">19641000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTItMy0xLTEtNzQwNTM_e9599499-9bfa-4026-b3a4-d922bb18c894"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTItMS0xLTEtNzAwNjA_b4869669-e7ae-47ac-8011-79ad650b4241"
      unitRef="usd">30000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTItMy0xLTEtNzAwNjA_6c15b82c-8287-45b6-af9e-314419edfe98"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTMtMS0xLTEtNzAwNjA_f8af27a0-7afa-475f-8ab6-fbb07e5dfbf1"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTMtMy0xLTEtNzAwNjA_473e1204-d2cd-4300-9a78-fe8388d8fd97"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTQtMS0xLTEtNzAwNjA_db1a6657-223a-4af9-b287-85b26ff75bc0"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTQtMy0xLTEtNzAwNjA_823635d4-e80e-4e7f-ab7a-277062277ad6"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTUtMS0xLTEtNzAwNjA_fd472c4e-9127-4f67-9ed3-deb93a18af10"
      unitRef="usd">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTUtMy0xLTEtNzAwNjA_d7a30136-1ebc-4f11-a853-81ad0039a6b9"
      unitRef="usd">7192000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTYtMS0xLTEtNzAwNjA_33f64a72-03d1-4e7f-83bc-95090d368003"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTYtMy0xLTEtNzAwNjA_04759891-8688-4e26-b2f9-8582f73fb165"
      unitRef="usd">123000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTctMS0xLTEtNzAwNjA_f3bc0116-205c-44e9-9829-1f291eb04d58"
      unitRef="usd">19743000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTctMy0xLTEtNzAwNjA_0fc44751-229d-42fd-add7-b19708297a94"
      unitRef="usd">35142000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTgtMS0xLTEtNzAwNjA_eb190a55-f8ef-4da4-9cd5-f40b8200db4c"
      unitRef="usd">176163000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMTgtMy0xLTEtNzAwNjA_cebb7f8c-fe16-4578-900f-1957b5ceb1f9"
      unitRef="usd">240747000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjItMS0xLTEtNzAwNjA_3427aa13-320c-40df-9eed-5db8a3088a69"
      unitRef="usd">1667000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjItMy0xLTEtNzAwNjA_684ccd0d-9222-4338-8fc8-f898322010f2"
      unitRef="usd">2853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjMtMS0xLTEtNzAwNjA_aef5b72c-3daa-450e-bbc9-a6ac76f668a5"
      unitRef="usd">29851000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjMtMy0xLTEtNzAwNjA_e4c06892-3874-4286-8c00-303fc79005ad"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjYtMS0xLTEtNzAwNjA_d5c81e3e-d367-47c1-bdcf-98da0640a53a"
      unitRef="usd">487000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjYtMy0xLTEtNzAwNjA_d096286b-2f83-43eb-bd9d-fde1cf793b4d"
      unitRef="usd">460000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjctMS0xLTEtNzAwNjA_024ee76c-2267-47c1-8fe6-ee911d3e1a32"
      unitRef="usd">32005000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMjctMy0xLTEtNzAwNjA_bad692fe-88a9-4ae2-a946-4fd2c5c36375"
      unitRef="usd">11568000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzAtMS0xLTEtNzAwNjA_dc501500-e130-4c11-9e82-79fb9cbcd0e8"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzAtMy0xLTEtNzAwNjA_c3e178e9-6b15-4d09-8f14-0a7d4f7941e0"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzEtMS0xLTEtNzAwNjA_773685a0-c74c-40e4-9018-25968d9dcd7f"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzEtMy0xLTEtNzAwNjA_84e86509-9800-4cad-95f6-e4feba822d7b"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzItMS0xLTEtNzAwNjA_831a6262-b720-4d3e-a163-be31bdcf1cec"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzItMy0xLTEtNzAwNjA_70a58daf-2e72-48af-a251-4a48acafd15f"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzQtMS0xLTEtNzAwNjA_0ed5fc48-0f7c-4675-82e9-579b1991b463"
      unitRef="usd">1800000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzQtMy0xLTEtNzAwNjA_c188ac02-d038-4f2f-9996-d519fe7f29c0"
      unitRef="usd">57469000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzUtMS0xLTEtNzAwNjA_4a552dad-38b7-4fd0-8d7f-bf9ac17f756a"
      unitRef="usd">33805000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzUtMy0xLTEtNzAwNjA_be5e9844-2328-4b40-9d53-6f05b5027f36"
      unitRef="usd">69037000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl8yMQ_511139a2-0427-46d9-a451-1740cdeda5df"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl8yMQ_6c3ef609-086a-483e-9853-756874251500"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl80NQ_a31a2599-3f6a-4bdf-8954-43a9aca359e5"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl80NQ_c464c08f-f0f7-4caa-a1ad-0bc80d0a319c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl84MA_200c48fc-023d-4818-a05b-e13077bae98a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl84MA_643fc72a-867a-4bd5-8ceb-5c0dbb259631"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl84MA_bcb3137d-32b2-47e6-a889-dc316ba79d96"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo1NmY0ZGQ4Nzk5ZGY0ZmFkYmI3NTQ4NzdiY2U2ZTJhNl84MA_c012d034-1b5f-43ff-a7be-80e1b8c5ef5a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMS0xLTEtNzAwNjA_02a06a2e-41a0-42ae-9cf0-f6a2bfa969ae"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzgtMy0xLTEtNzAwNjA_a98ce850-1cf1-4180-8731-1628ff5d4cc1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml8xOA_3042d888-9b2d-486f-912d-b3fe6dcedeb4"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml8xOA_8766cef8-23cf-420d-92f0-2a94b61fc1fb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml80Mg_66245f72-8839-4e3e-baef-cbb0f7410e3e"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml80Mg_856d25df-0abe-4581-af72-1d8b6f3e6713"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml83Nw_752b67a1-ecc2-458b-812d-77b5a2033449"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml83Nw_a5ea1609-cf54-4be7-b3cd-00fc2593415d"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml83Nw_b0162653-31f5-45e7-958d-c100ffe24751"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjo2Y2M4OGZiZWRkYzg0ZGU1ODAwMTY3MmE3NWUxNGU4Ml83Nw_e05c1f29-3c13-4029-adce-9bd77ab4565d"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMS0xLTEtNzAwNjA_8e67d72e-db7d-4c72-a7a9-ac8d2a66564d"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfMzktMy0xLTEtNzAwNjA_6f69f6f8-61bc-4c83-8ae6-fffcdf318207"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDAtMS0xLTEtNzAwNjA_ab0a0c39-6f8d-4e08-9182-fbd51bf4166a"
      unitRef="usd">491464000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDAtMy0xLTEtNzAwNjA_cc185670-815b-43d2-89e8-4ba4015b2a04"
      unitRef="usd">487768000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDMtMS0xLTEtNzg0NDY_b6536bc5-41c2-4152-8edc-8bf2ba60e6e8"
      unitRef="usd">-281000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDMtMy0xLTEtNzg0NDY_b203e266-cfca-4a8a-b9eb-351f35f360be"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDEtMS0xLTEtNzAwNjA_11e5ae41-8348-48a5-8394-d21132593ad0"
      unitRef="usd">-349024000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDEtMy0xLTEtNzAwNjA_54795ca4-2746-487b-ae2c-2099e48a8ca7"
      unitRef="usd">-316257000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDItMS0xLTEtNzAwNjA_4833c746-b21a-42f0-a093-d7015a2d8409"
      unitRef="usd">142358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDItMy0xLTEtNzAwNjA_3b052a93-c051-4d08-bbf2-1526e2756cff"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDMtMS0xLTEtNzAwNjA_ef24a8ef-603d-48f3-afba-0f19b537badb"
      unitRef="usd">176163000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xNi9mcmFnOjljMTNlOTMzYmExYTQwYmQ5Y2U5ZDBjN2E5NWQxOTg3L3RhYmxlOjIzM2VkMmY1YTk2MjRjZDFhYzU0NDRhMDkyM2JkMzkyL3RhYmxlcmFuZ2U6MjMzZWQyZjVhOTYyNGNkMWFjNTQ0NGEwOTIzYmQzOTJfNDMtMy0xLTEtNzAwNjA_287796d0-04d5-473c-9593-fa16f2b0544f"
      unitRef="usd">240747000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0xLTEtMS03MDA2MA_959d152a-6ede-4add-a2fa-76d8bb10b616"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC0zLTEtMS03MDA2MA_70ea6784-40c3-49a7-b831-2badecc3e3d6"
      unitRef="usd">2234000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC01LTEtMS03MDkyNQ_b75350d5-b2f4-4b77-9de3-24277a43ce3f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNC03LTEtMS03MDkyNQ_ae74f260-b467-415b-ae9a-55cce06f8361"
      unitRef="usd">6544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNS0xLTEtMS03MDA2MA_2ad50d83-60c7-4b6b-b6de-d866403401e4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNS0zLTEtMS03MDA2MA_31672ca6-8776-4828-92e2-1ecd8540a23f"
      unitRef="usd">2234000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNS01LTEtMS03MjUwMA_8e5f5cb9-0d57-4821-a274-ed780a39bcf2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfNS03LTEtMS03MjUwMA_02f6fbcd-5fca-4a0c-9c66-4093b6387805"
      unitRef="usd">6544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOC0xLTEtMS03MDA2MA_b8bdd652-6ebe-47da-942c-3dc70729c7b0"
      unitRef="usd">29944000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOC0zLTEtMS03MDA2MA_a562fe03-dd69-42f4-9673-6405561e252e"
      unitRef="usd">7228000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOC01LTEtMS03MDkzNA_180ff0bd-dfa2-4182-b9b2-194952aefd2a"
      unitRef="usd">34705000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOC03LTEtMS03MDkzNA_aca34931-382b-48dc-88bf-fd85803cb8ad"
      unitRef="usd">13306000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOS0xLTEtMS03MDA2MA_50f02178-cd97-45a4-962b-99977b7f5785"
      unitRef="usd">15589000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOS0zLTEtMS03MDA2MA_c02d4b04-c2e3-4ef7-8257-5cd248794e7b"
      unitRef="usd">6805000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOS01LTEtMS03MDkzNA_7ea578f9-8fbb-439d-bd2f-6443c79a6415"
      unitRef="usd">24564000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfOS03LTEtMS03MDkzNA_393080f5-e85f-4bf9-9bcd-04e7261a3fa8"
      unitRef="usd">12098000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTEtMS0xLTEtNzAwNjA_2e8afabf-f029-4d4d-89cd-900e598d70da"
      unitRef="usd">27764000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTEtMy0xLTEtNzAwNjA_05043c3a-e292-4bd2-aa60-c14ee952c208"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTEtNS0xLTEtNzUyMjM_b14f5220-5153-42e0-bbe6-79cb8589be34"
      unitRef="usd">27764000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTEtNy0xLTEtNzUyMjM_21cccc07-0cdd-49d4-bea4-5809114b6e3d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTItMS0xLTEtNzAwNjA_6e46e45a-5b61-4a94-aa23-337aaebad46d"
      unitRef="usd">-37300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTItMy0xLTEtNzAwNjA_d84769e4-d0a6-4682-a6a4-114faee01fa8"
      unitRef="usd">13600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTItNS0xLTEtNzA5NDE_279280c2-eb4e-44d9-8aac-50b3c97f0b4e"
      unitRef="usd">-50200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTItNy0xLTEtNzA5NDE_ad2bbe31-97f1-4eb7-bda0-0f56c01c7ea7"
      unitRef="usd">61760000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTMtMS0xLTEtNzAwNjA_1d154794-2d38-44d2-a90d-1aaaa0bbb54d"
      unitRef="usd">35997000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTMtMy0xLTEtNzAwNjA_e626511c-40f1-4f21-9986-cd0fa1200e90"
      unitRef="usd">27633000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTMtNS0xLTEtNzI1MDA_feba90a9-9a11-4a7d-be86-2e27602a0d0b"
      unitRef="usd">36833000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTMtNy0xLTEtNzI1MDA_6980c24a-d3d5-418d-90f6-9bfd42f0ef04"
      unitRef="usd">87164000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTUtMS0xLTEtNzAwNjA_c30f46e0-36c2-438e-b77b-62d0d6415be4"
      unitRef="usd">-35997000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTUtMy0xLTEtNzAwNjA_9c347fe0-c4c2-4fe0-9374-4eb07c7ffe70"
      unitRef="usd">-25399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTUtNS0xLTEtNzA5NDY_c1230777-9d48-429f-8900-ad4dcd16eca8"
      unitRef="usd">-36833000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTUtNy0xLTEtNzA5NDY_44b09389-5020-47ae-9255-3e62711e3960"
      unitRef="usd">-80620000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTYtMS0xLTEtNzAwNjA_bf1a9eb3-ec8a-4670-aa02-25b17e10423e"
      unitRef="usd">162000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTYtMy0xLTEtNzAwNjA_cb735712-d192-4cde-8316-43977982a315"
      unitRef="usd">-43000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTYtNS0xLTEtNzA5NDY_174a2b8c-91c8-40a9-be00-dcd5f224f248"
      unitRef="usd">191000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTYtNy0xLTEtNzA5NDY_f8bf3ef5-80eb-49b7-98e7-3559f278ab20"
      unitRef="usd">-46000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTctMS0xLTEtNzAwNjA_4a8226a1-02f7-4d79-8818-ffddc0af247a"
      unitRef="usd">-35835000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTctMy0xLTEtNzAwNjA_0e2aa015-774f-4c7b-9e18-9a82dbd3fa55"
      unitRef="usd">-25442000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTctNS0xLTEtNzI1MDA_64e3a29e-6915-4183-b4d8-337f91c2b8d8"
      unitRef="usd">-36642000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTctNy0xLTEtNzI1MDA_98da88d2-3ebf-4a94-a601-d30ea1125429"
      unitRef="usd">-80666000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTgtMS0xLTEtNzAwNjA_6a063a21-d3cc-4f22-805b-f2236810de4f"
      unitRef="usd">-3875000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTgtMy0xLTEtNzAwNjA_a625607d-d989-46db-af4f-f147edf0b923"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTgtNS0xLTEtNzA5NTY_0bf0c043-6ed1-4030-b423-bcdbbd528eb5"
      unitRef="usd">-3875000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTgtNy0xLTEtNzA5NTY_00e3d02c-6833-4bf9-bd48-e3e56b0f692f"
      unitRef="usd">288000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTktMS0xLTEtNzAwNjA_79c4cb55-8cf8-4437-badf-08d6432ce31b"
      unitRef="usd">-31960000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTktMy0xLTEtNzAwNjA_35633ca1-cfa6-4e20-9fbd-3a0b027f386e"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTktNS0xLTEtNzI1MDI_aa40bf07-3af3-4403-bee0-b9eacc4fd57b"
      unitRef="usd">-32767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMTktNy0xLTEtNzI1MDI_00191262-547e-44a0-bd18-2d3f7daa26d1"
      unitRef="usd">-80954000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtMS0xLTEtNzAwNjA_baf60690-574d-461a-b8a5-1be0f3ac83a2"
      unitRef="usd">-31960000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtMS0xLTEtNzAwNjA_d0e58ffa-94ec-4040-905e-3f35cbd8d298"
      unitRef="usd">-31960000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtMy0xLTEtNzAwNjA_0b4daf31-d484-45f2-a0c7-2b394b7a79c1"
      unitRef="usd">-25442000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtMy0xLTEtNzAwNjA_a30cace2-2f67-425a-b617-5eec4d9dc945"
      unitRef="usd">-25442000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtNS0xLTEtNzA5NzA_00e13b88-4e62-47c1-b3c4-6efd17d91bfd"
      unitRef="usd">-32767000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtNS0xLTEtNzA5NzA_b029def3-f78e-4a5c-9b49-58979b050607"
      unitRef="usd">-32767000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtNy0xLTEtNzA5NzA_162e0c5a-8572-4544-b59d-b38378abeaa0"
      unitRef="usd">-80954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjMtNy0xLTEtNzA5NzA_675b5b70-8467-4972-9cd8-de59c772509f"
      unitRef="usd">-80954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtMS0xLTEtNzAwNjA_034a56f4-a697-4e34-bc19-9f43b1802dd2"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtMS0xLTEtNzAwNjA_bed63fad-41b6-4bde-a35b-dc2537481970"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtMy0xLTEtNzAwNjA_88ef3fbe-eaf2-4cc5-9749-b30bc0e727cb"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtMy0xLTEtNzAwNjA_d13e9da2-4eee-42c6-8153-3c762280ae9a"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtNS0xLTEtNzI1MDI_cfb30eaf-0adb-4dbc-a712-1e72c2ed88dd"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtNS0xLTEtNzI1MDI_fa687fc9-a361-4c17-b850-bf1339c7a06d"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtNy0xLTEtNzI1MDI_8c0793d7-61b0-4163-b3ec-a62e6c141eb8"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjQtNy0xLTEtNzI1MDI_bb1bbac7-3a8f-467d-8911-bfa0aea2efe0"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtMS0xLTEtNzAwNjA_6d44f531-0b23-48a3-88cb-ba433933e791"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtMS0xLTEtNzAwNjA_d8ba8be1-9dca-49c8-8d83-35a141b5949a"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtMy0xLTEtNzAwNjA_0bc76b6b-e26a-4ffd-8914-a5c4c4dd243c"
      unitRef="shares">175393000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtMy0xLTEtNzAwNjA_0d238d41-0ff9-4841-a5f4-cc162d35de79"
      unitRef="shares">175393000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtNS0xLTEtNzA5OTA_a3850f09-ba38-40e4-be36-107af52d9f46"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtNS0xLTEtNzA5OTA_d840cf2d-0031-4b0b-bdba-1a45136f67a4"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtNy0xLTEtNzA5OTA_00cb87b0-408f-46d6-bb5a-32506801615a"
      unitRef="shares">166264000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8xOS9mcmFnOjUwZGJkOTA2YjQ1NzRjN2FhN2Y1OTQ4MjdlZGQ4ZGExL3RhYmxlOjU1MTVmMGNkNGFhYTRlZjJhMWYwZjM5YzM1YjkyNDQ3L3RhYmxlcmFuZ2U6NTUxNWYwY2Q0YWFhNGVmMmExZjBmMzljMzViOTI0NDdfMjUtNy0xLTEtNzA5OTA_d427fe75-f57c-43c2-8686-17be12918159"
      unitRef="shares">166264000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzMtMS0xLTEtNzk3NTU_92daea97-f122-4fe2-9ed0-febe0ef3c17e"
      unitRef="usd">-31960000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzMtMy0xLTEtNzk3NTU_6b7bd309-4842-4c1d-b9a3-a28ade3157e1"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzMtNS0xLTEtNzk3NTU_2686909f-c359-4746-9706-7259c6347bec"
      unitRef="usd">-32767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzMtNy0xLTEtNzk3NTU_7ccaabe1-a510-4852-97ff-971e2f63ba78"
      unitRef="usd">-80954000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzQtMS0xLTEtNzk3NTU_775fb7a8-301d-4993-9aa8-ac9216951503"
      unitRef="usd">-281000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzQtMy0xLTEtNzk3NTU_12a37321-c025-42a9-81a3-3b10b9971afd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzQtNS0xLTEtNzk3NTU_eddde06a-bb32-4192-bc8e-9343825df878"
      unitRef="usd">-281000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzQtNy0xLTEtNzk3NTU_c9531cc8-9e6b-4c3e-9703-0deca8637dde"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzUtMS0xLTEtNzk3NTU_5a626cdb-b77d-4f8a-9b5f-3d83e39c0743"
      unitRef="usd">-32241000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzUtMy0xLTEtNzk3NTU_603447ae-93e0-4883-b923-b0ae931429ab"
      unitRef="usd">-25442000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzUtNS0xLTEtNzk3NTU_144e8fb3-0aad-4a80-bbd1-a556fa5152b2"
      unitRef="usd">-33048000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85ODUvZnJhZzpkMDRhYmZlYjBlZTM0ODVlYWQ5MmViYjVjNTBlYTZmYi90YWJsZTplNzg3MDQ3ZTNhYTg0NTc0YTNjMjQwNWVjZWJhZTI4ZS90YWJsZXJhbmdlOmU3ODcwNDdlM2FhODQ1NzRhM2MyNDA1ZWNlYmFlMjhlXzUtNy0xLTEtNzk3NTU_6a660a93-740b-4070-9e50-8e195bb16561"
      unitRef="usd">-80954000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="iae6d8077dece4a95940087e255f75bc6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi0xLTEtMS03MDA2MA_e0f5e36a-d69f-41ed-8ba0-77d57d7fbf75"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iae6d8077dece4a95940087e255f75bc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi0zLTEtMS03MDA2MA_2daf1b5e-961d-4b65-b3ce-353ec3502f2f"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i345971d52bde416886e88795d548811c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi01LTEtMS03MDA2MA_67566b37-86d9-4796-9b93-e2f250642be9"
      unitRef="usd">487768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i677b1480fd064f218483dcf37f0aa72c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi03LTEtMS03NDY1NA_bf399817-56d6-4f7b-9dce-c4db962776d5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i084e153e02ad4c0fbdaeba8fea7f0792_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi03LTEtMS03MDA2MA_ed31d187-62df-4d97-9512-feb61a4a55d1"
      unitRef="usd">-316257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMi05LTEtMS03MDA2MA_5d0147f6-c4c3-4d5f-a774-b44bc4c221e7"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i814ff665c79642eb9c63201f9f6aa4c3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMy03LTEtMS03MDA2MA_94b6692f-fd49-4ad4-907a-a9b08dfd0bd9"
      unitRef="usd">-807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie970ce934b1e4c17b1f8e5435783799b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMy05LTEtMS03MDA2MA_c9b30e32-95e2-4694-9b64-369dd00b480d"
      unitRef="usd">-807000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0ba13d9d0682407bb0b32862ba63462c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfNC01LTEtMS03MDA2MA_78b0fe6e-b035-4929-8ac1-c8607958ebcb"
      unitRef="usd">1894000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie970ce934b1e4c17b1f8e5435783799b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfNC05LTEtMS03MDA2MA_205923e5-83d0-4d02-8eb0-afcb9446acbb"
      unitRef="usd">1894000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i6c99c9b6effb411d93633cf284df66a8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtMS0xLTEtNzAwNjA_003d34e5-f7bf-41d9-b25b-7224c05a0185"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6c99c9b6effb411d93633cf284df66a8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtMy0xLTEtNzAwNjA_2f31a680-5134-4072-80e9-67fdffda15e3"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6ecaf1deb82450595375aa26194263c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtNS0xLTEtNzAwNjA_5b3d98f4-17f0-4500-be29-9aeb32e4adfd"
      unitRef="usd">489662000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8643db175ec94af8835005bd348c2a15_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtNy0xLTEtNzU3NjE_799aca37-47a8-47e0-a16a-bdc289af3a37"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d91c72b3c9a48f698faa963f06f6585_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtNy0xLTEtNzAwNjA_fc33628a-7d31-46bd-8d16-5551acedcd28"
      unitRef="usd">-317064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i788239f286ce4a7aaf34d9b6448f7b19_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTAtOS0xLTEtNzAwNjA_2828ab42-c157-4502-8869-26a6b75abfe8"
      unitRef="usd">172797000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="idbdee19feaf04f8eb7b2e7516c8272ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTEtNy0xLTEtNzEwMzc_769864db-5462-4807-a93c-981054ed97a3"
      unitRef="usd">-31960000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTEtOS0xLTEtNzI1MTQ_22f1d6eb-1988-4fee-8082-34a8ae5decb5"
      unitRef="usd">-31960000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0cbf3dbf085a4f5aa6d333be0b69cc50_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTItNS0xLTEtNzEwMzc_643efa1b-d837-45e5-bdf0-3362680c2245"
      unitRef="usd">1802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTItOS0xLTEtNzI1MTQ_a33c04b0-84d2-4718-a646-384e8d0d32da"
      unitRef="usd">1802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5331cf0a882c45b18c3f7c5cdd34d580_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNy0xLTEtNzYyNjI_cf427b31-63a6-4f1e-8cd8-eaf6be64804d"
      unitRef="usd">-281000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMTEtMS0xLTc2NjQ5_ad5cf1c6-39b9-43f8-9ed7-0b38c331d9fb"
      unitRef="usd">-281000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i1ba7a3599765459e9e5050731fd4dcd0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMS0xLTEtNzI1MjI_cfc6a47d-f346-4a38-86dd-b04259de3001"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1ba7a3599765459e9e5050731fd4dcd0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMy0xLTEtNzI1MjI_289cfdfa-b2c0-41c5-9abe-ef6ebeb66c30"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ea6d35dc5474aa581a55e2b57ae57c6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNS0xLTEtNzI1MjI_0c33c49f-1cf4-4f81-a01d-c7583b965330"
      unitRef="usd">491464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i212d6b0e7fc04d0bb334aee4c3d885fb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNy0xLTEtNzQ2NjA_6d965c66-3579-4b3d-a37e-9dbe628907c6"
      unitRef="usd">-281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic90e014d0d0846a6a6300ee56057382d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNy0xLTEtNzI1MjI_49204c58-dc79-4fa6-b417-98177de6b2c9"
      unitRef="usd">-349024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtOS0xLTEtNzI1MjI_e7e3bbfc-34f8-4bad-bb8e-f51f5d67108f"
      unitRef="usd">142358000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if0b29b8876ac49d4ada09cbcefec48ec_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMS0xLTEtNzAwNjA_d02bab12-fd69-4673-9c00-f983f3cf85b3"
      unitRef="shares">140449647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if0b29b8876ac49d4ada09cbcefec48ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtMy0xLTEtNzAwNjA_2fa2e163-17e9-4ca3-9dba-6fed97f6368b"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbb5504ef7a4410cbd3d49b7bc9eac22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNS0xLTEtNzAwNjA_4f3e070b-5a0d-4812-9b7b-5ddcc15e6b5e"
      unitRef="usd">306554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7b04bc3e3454a688ae44dcb39bfc41e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTgtNy0xLTEtNzQ3MTg_38389b96-ccd2-486f-8752-3b19656e6af9"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e8644b1d6b1492195108a81bd629611_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtNy0xLTEtNzAwNjA_0cdc2c4e-d89e-4eee-803c-9bb83f3cdc11"
      unitRef="usd">-315921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0208600fe4024d29a9aa9d6917193edb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTQtOS0xLTEtNzAwNjA_903d3f30-e2fb-44fa-990e-88e78be48070"
      unitRef="usd">-9227000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i50a087530030427d9767a04597f4120d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTUtNy0xLTEtNzAwNjA_00c704bf-bb45-4785-b827-340414ad97f2"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTUtOS0xLTEtNzAwNjA_c91726b9-2a18-4638-87fa-d4c9c9e4ef2c"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iee2d58ed494f4424abbfc10d0ab04193_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTYtNS0xLTEtNzAwNjA_2fd4ad69-69e4-4b97-a850-8b4867a1cf3f"
      unitRef="usd">958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTYtOS0xLTEtNzAwNjA_e9cb5872-8739-4c3c-b29c-503fed6e44fb"
      unitRef="usd">958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8f839115e09747288556177ec1208f7c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTctMS0xLTEtNzAwNjA_6fc255a1-a806-43c6-a185-461f306454a7"
      unitRef="shares">30610</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iee2d58ed494f4424abbfc10d0ab04193_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTctNS0xLTEtNzAwNjA_4d2ea9bc-ba04-49a7-8c67-e4d468d119a0"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTctOS0xLTEtNzAwNjA_7f9e2b0a-0ebf-4a3a-a6f7-d85325341e4d"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i8f839115e09747288556177ec1208f7c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTktMS0xLTEtNzAwNjA_be7d1544-d7eb-46ef-b48d-ada93af9d6e6"
      unitRef="shares">852840</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i8f839115e09747288556177ec1208f7c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTktMy0xLTEtNzAwNjA_be6c051b-433a-4a0e-9410-7a7b0eb7e10e"
      unitRef="usd">1000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="iee2d58ed494f4424abbfc10d0ab04193_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTktNS0xLTEtNzAwNjA_77ee5fff-8d0f-41fd-bf9a-8a7ce637dff5"
      unitRef="usd">468000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMTktOS0xLTEtNzAwNjA_3707dab1-e349-4ee6-8969-04ac4ac1f305"
      unitRef="usd">469000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtMC0xLTEtNzAwNjAvdGV4dHJlZ2lvbjpjY2Y0NjU0OWFlZjk0OGY2OWFkYWE1YzI5OTIxZDk1Ml8xMDk5NTExNjI3ODYx_02129dc6-dfa9-443f-a5bc-504db2fb5849"
      unitRef="usd">2200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie063900bace246ea9ac9229220ed605a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtMS0xLTEtNzAwNjA_abf168d4-dd1b-41b8-90f5-bae5a04610b2"
      unitRef="shares">30645702</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie063900bace246ea9ac9229220ed605a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtMy0xLTEtNzAwNjA_2d72f29b-3526-4c72-b69e-a0f8bbeeaa2c"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie5a952d29209497aa9e963b66ddf48ba_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtNS0xLTEtNzAwNjA_c3fd49da-ab37-4f0f-ba4b-2aa9c4410729"
      unitRef="usd">72512000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9c26b15915554ec2a74edbfd12020a15_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjAtOS0xLTEtNzAwNjA_998497db-c5b5-41d0-9e3e-2577010039aa"
      unitRef="usd">72543000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="id06576b00b094f1a849c81ba939934c9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtMS0xLTEtNzAwNjA_f3f541dd-283c-4201-a1f8-784cabec3fc3"
      unitRef="shares">171978799</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id06576b00b094f1a849c81ba939934c9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtMy0xLTEtNzAwNjA_1c2df08a-cd33-40e4-a10f-afd3407784f4"
      unitRef="usd">172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i691732dc107c4eb19beb797b845714a5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtNS0xLTEtNzAwNjA_002b5bc0-bc17-4ef8-a426-c7f4d2806a18"
      unitRef="usd">380531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1e1c1185b384bb9b9a302d5f694d2b8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjUtNy0xLTEtNzU3NjQ_950ed899-2701-47bf-9800-54af478fa409"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84f292f26d18474a88618593f2028cde_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtNy0xLTEtNzAwNjA_6e563804-6bc7-4ff7-9512-d35e164590b4"
      unitRef="usd">-371433000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4548660807654ebfad44b93c626bb154_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjEtOS0xLTEtNzAwNjA_6a06e793-25c8-4dc6-ad71-f4964412dbd4"
      unitRef="usd">9270000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if1e1083313744230858402ce1024fb35_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjYtNy0xLTEtNzExMDA_7a61ba20-5e1d-40ad-a159-cc585d708060"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjYtOS0xLTEtNzI1MTc_6b7683fe-5c1e-46bb-b813-ebb03d5a9577"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iedc68b87db60469baad7a2624334af31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjctNS0xLTEtNzExMDA_08832eb7-4976-47cf-a81a-7d667dbc6f24"
      unitRef="usd">1260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjctOS0xLTEtNzI1MTc_616d0efa-2179-42f6-9b7e-ab36172ad711"
      unitRef="usd">1260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtMC0xLTEtNzEwOTMvdGV4dHJlZ2lvbjpiZWVkMGM5YmM0Yzc0MDAzYjNhNDljM2ViNWY2NzBiYV8xMDk5NTExNjI4MDMz_d993b6d3-8387-43b3-9a42-bc0f1bc3c72b"
      unitRef="usd">2000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3ca4bd64eb504b02826a9652e4a84714_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtMS0xLTEtNzExMDA_27395baa-4916-4533-a878-1cceb20ce1e9"
      unitRef="shares">16482152</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3ca4bd64eb504b02826a9652e4a84714_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtMy0xLTEtNzExMDA_4372b299-0378-469a-bc52-1a2562a986fc"
      unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id6a7b16d33054ed2bb2f3e95123e6d0c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtNS0xLTEtNzExMDA_80010d2c-df90-4aa2-b65e-19f5e231660f"
      unitRef="usd">64245000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7ddf69ac8bf84700b67bf4be374a19f5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjgtOS0xLTEtNzI1MjA_6cda305e-79ec-4ee0-a497-d41ca1f164c3"
      unitRef="usd">64261000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i791f0580873d401f8150577ee2f295da_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktMS0xLTEtNzI1MjA_2ba5a1c9-d849-45b2-bd59-1db801a6a7d6"
      unitRef="shares">188460951</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i791f0580873d401f8150577ee2f295da_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktMy0xLTEtNzI1MjA_745c02e0-7970-42ee-b254-6cdabc4bd091"
      unitRef="usd">188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i927224fa40114d4e9fa1b0f9ea67129d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktNS0xLTEtNzI1MjA_cbeafb36-3fa1-4985-a860-b3dd567d3503"
      unitRef="usd">446036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibaf9ab52935a412db213d105924c9a17_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktNy0xLTEtNzU3NjQ_2668d847-5f7b-498e-b501-558b41228ea8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1375cc14b49437b91d5bbba570298c2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktNy0xLTEtNzI1MjA_6834822d-3eab-49b4-ab50-dc59ea22a533"
      unitRef="usd">-396875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3dde4b5cd0247c48f35a95c8521f4b9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yMi9mcmFnOjAyYjBjYTg4ZjMyNTQ5NDhhOTk4MjkzOTQzMzI4MGU1L3RhYmxlOjhkYzdmZjI4OGNiNDQ0OGJhNzcyMzI4OWFmZWY1YjU4L3RhYmxlcmFuZ2U6OGRjN2ZmMjg4Y2I0NDQ4YmE3NzIzMjg5YWZlZjViNThfMjktOS0xLTEtNzI1MjA_4963352c-2901-462a-8e44-a2cc67338fb5"
      unitRef="usd">49349000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMy0xLTEtMS03MDA2MA_b6d33bcf-e74e-45d0-846e-257dcb254899"
      unitRef="usd">-32767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMy0zLTEtMS03MDA2MA_58ffa1d0-67bd-4c45-a022-22b23dcba7af"
      unitRef="usd">-80954000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNS0xLTEtMS03MDA2MA_66e1e7cc-bfb3-4256-967c-ca175646cf63"
      unitRef="usd">13000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNS0zLTEtMS03MDA2MA_073f8ecf-e261-4fa9-8128-1d0858d71849"
      unitRef="usd">64000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNi0xLTEtMS03MDA2MA_59beb4d2-1f4d-457d-90d1-503fb92c90fe"
      unitRef="usd">3696000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNi0zLTEtMS03MDA2MA_a6ee63d8-b948-40eb-bbc5-fc91b78a6512"
      unitRef="usd">2217000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNy0xLTEtMS03MDA2MA_279280c2-eb4e-44d9-8aac-50b3c97f0b4e"
      unitRef="usd">-50200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNy0zLTEtMS03MDA2MA_ad2bbe31-97f1-4eb7-bda0-0f56c01c7ea7"
      unitRef="usd">61760000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AssetImpairmentCharges
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfOS0xLTEtMS03MDA2MA_e556a6a2-152a-4064-a202-cb98f3382dc5"
      unitRef="usd">27764000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfOS0zLTEtMS03MDA2MA_f294d89a-ff8b-4cc7-8219-acd6b8af0053"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTEtMS0xLTEtNzAwNjA_bc1672a0-c790-49a1-a700-b3cd45df92d5"
      unitRef="usd">-20939000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTEtMy0xLTEtNzAwNjA_677ae23d-6866-4ad2-a8d8-3d27420eaf59"
      unitRef="usd">2303000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTItMS0xLTEtNzAwNjA_7af36498-4bfc-4931-bdaa-9004cc362446"
      unitRef="usd">10565000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTItMy0xLTEtNzAwNjA_9c556a55-e5fb-4eb7-97ea-5125e927bb93"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTMtMS0xLTEtNzAwNjA_f2656187-c99c-4756-a668-b77ef9a4f56b"
      unitRef="usd">-17719000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTMtMy0xLTEtNzAwNjA_fed439b9-1225-405a-9138-4778941496d1"
      unitRef="usd">20287000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTQtMS0xLTEtNzAwNjA_59b98267-8eb3-41f0-8614-956884cf852e"
      unitRef="usd">-7192000</sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent>
    <sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTQtMy0xLTEtNzAwNjA_648f54ea-f515-414c-94af-396c8991cad6"
      unitRef="usd">0</sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTUtMS0xLTEtNzAwNjA_9c22230d-d96f-4ac3-897c-11d52fc92bb5"
      unitRef="usd">281000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTUtMy0xLTEtNzAwNjA_17a47bd4-d9a5-4e25-b80a-0443da8086e5"
      unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTYtMS0xLTEtNzQ1Mzk_a098ca98-3e9a-4e9c-85e0-fdb51b8c4f45"
      unitRef="usd">-81000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTYtMy0xLTEtNzQ1Mzk_0204e2ab-e063-463b-b089-40ee02a74ff0"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTctMS0xLTEtNzAwNjA_613b5474-c794-4564-bfbd-9f50e2133bf2"
      unitRef="usd">-1186000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTctMy0xLTEtNzAwNjA_831d6beb-1b15-41a0-b51c-135d502054a7"
      unitRef="usd">-1875000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTgtMS0xLTEtNzAwNjA_d8452813-e961-4bbd-a69c-b879751914e1"
      unitRef="usd">17654000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTgtMy0xLTEtNzAwNjA_7a723ea0-8a24-40bf-a67d-c411e6926f34"
      unitRef="usd">1262000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTktMS0xLTEtNzAwNjA_1d7e6fcc-b246-4545-8ca5-15c7d66e0f48"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMTktMy0xLTEtNzAwNjA_40ba5e98-cb2f-47b2-8e3a-27bae0eb81f8"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjAtMS0xLTEtNzAwNjA_efdf25c9-0afd-4bee-8e5e-5a2c78084e6a"
      unitRef="usd">-1441000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjAtMy0xLTEtNzAwNjA_cd0a6af1-83fe-4a52-a00f-abf8c4b45100"
      unitRef="usd">-41616000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjMtMS0xLTEtODAwNDM_59df365f-5e4c-405f-9908-8b0640f32b4d"
      unitRef="usd">89095000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjMtMy0xLTEtODAwNDM_8face984-6365-47af-867a-00c3b7458cc3"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjItMS0xLTEtNzAwNjA_9ca10c8f-ffa9-432c-ae0f-5e65826ae827"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjItMy0xLTEtNzAwNjA_2cb7d95e-8cdd-4019-b34e-e7b59cb50552"
      unitRef="usd">49000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjMtMS0xLTEtNzAwNjA_cf1df462-ef5c-47ed-b07d-347692fb11a4"
      unitRef="usd">-89095000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjMtMy0xLTEtNzAwNjA_1da10b99-d68c-4a60-b807-dd947a51f5ae"
      unitRef="usd">-49000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjYtMS0xLTEtNzAwNjA_66c447d2-1a14-4d31-b71f-bc892f425e71"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjYtMy0xLTEtNzAwNjA_30691f16-f005-481d-a845-7bca134e8371"
      unitRef="usd">136804000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjctMS0xLTEtNzAwNjA_2d90bdd9-d506-4ecf-b360-3e441fe38484"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjctMy0xLTEtNzAwNjA_f8138acd-3120-4a8f-a615-9a643f8d790c"
      unitRef="usd">39000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjgtMS0xLTEtNzAwNjA_e15561b1-c9e5-477f-a76e-8022111810ef"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMjgtMy0xLTEtNzAwNjA_1ec870f6-2cb1-4846-83c8-0898e2b01b04"
      unitRef="usd">469000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzAtMS0xLTEtNzAwNjA_e33ab4dd-3e19-4955-b6af-a91b968c12e0"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzAtMy0xLTEtNzAwNjA_0bbdd6c1-7d6d-4fdd-a025-1c37c5681718"
      unitRef="usd">137312000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzEtMS0xLTEtNzAwNjA_fe5f4950-1792-48a7-b405-5d142276855d"
      unitRef="usd">-90536000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzEtMy0xLTEtNzAwNjA_f818fab4-1eee-413e-a474-bec7ad56e4bf"
      unitRef="usd">95647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzItMS0xLTEtNzAwNjA_b7305d25-11b5-416c-b110-d5ad7ecf0a32"
      unitRef="usd">162656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0208600fe4024d29a9aa9d6917193edb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzItMy0xLTEtNzAwNjA_9408ba98-bc19-4bec-b104-940104d5fd56"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzMtMS0xLTEtNzAwNjA_d3cb76e0-f333-4a17-9a57-36c39f66ce75"
      unitRef="usd">72120000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia3dde4b5cd0247c48f35a95c8521f4b9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzMtMy0xLTEtNzAwNjA_ca2f95a9-bad0-48cc-8dab-84ca736d4d7d"
      unitRef="usd">151056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzYtMS0xLTEtNzAwNjA_9fea9eb1-1f2a-43e2-8b42-6c141d7d8868"
      unitRef="usd">86000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfMzYtMy0xLTEtNzAwNjA_f095e2dd-cf97-4dd5-b94a-6efb97c6eb8d"
      unitRef="usd">87000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNDAtMS0xLTEtNzAwNjA_b67ef5d1-caed-4417-a0b4-e63debe7afbf"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8yOC9mcmFnOmU0NWM3NzFkYWFiMzQ0YmZiODhjMDVlODhhNjQ5YjNhL3RhYmxlOjI1ZDcwNzEzZTQ2ODRkYWY4MmQwZmE4YTExYjlmYmVlL3RhYmxlcmFuZ2U6MjVkNzA3MTNlNDY4NGRhZjgyZDBmYThhMTFiOWZiZWVfNDAtMy0xLTEtNzAwNjA_fae91113-c423-4ae0-a183-2a1ee3a7ba66"
      unitRef="usd">27000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNTQ1Mg_c27ff4be-8c4b-4c46-9c20-0cf85d4f1a86">DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sesen Bio, Inc. ("Sesen" or the &#x201c;Company&#x201d;), a Delaware corporation formed in February 2008, is a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company&#x2019;s most advanced product candidate, Vicineum&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#x201c;NMIBC&#x201d;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA, which are further described below. The Company has turned its primary focus to the careful assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022. Additionally, the Company intends to seek a partner for the further development of Vicineum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has completed the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with bacillus Calmette-Gu&#xe9;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#x201c;CRL&#x201d;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#x201c;CMC&#x201d;) issues pertaining to a recent pre-approval inspection and product quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#x2019;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#x2019;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Viventia Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#x201c;Selling Shareholders&#x201d;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#x201c;Clairmark&#x201d;) (the &#x201c;Share Purchase Agreement&#x201d;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#x201c;Viventia Acquisition&#x201d;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#x201c;Purchased Product&#x201d;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, &lt;/span&gt;&lt;/div&gt;United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of June&#160;30, 2022, none of these individuals are active employees of the Company or members of the Company's board of directors.</us-gaap:NatureOfOperations>
    <sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare
      contextRef="i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfMzM2Mw_6eee6eb6-0920-4cb0-b9b7-f22ecd2c23d0"
      unitRef="shares">4000000</sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i7f8bfc830bc347e7ba385a21bc092a5d_I20160930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfMzQ2Nw_1aa0f47f-f15a-4fae-8e4b-e03b60526897"
      unitRef="number">0.199</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i0e3fdec0c73b4a429111263d24db668c_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfMzkyNg_048ffeb4-6432-431f-9cc8-5c9fbaf89ee9"
      unitRef="usd">12500000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i6e0b5fa857364bf4a51985aa66895ef9_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDA1NQ_b67b687d-0b0a-4952-8bdc-77f4edb3e825"
      unitRef="usd">7000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="idded2fb700664bad9763afed64edafd0_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDIwMQ_71ae952b-d58b-4df7-8dad-8e8c200f7b07"
      unitRef="usd">3000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods
      contextRef="i4937ec1ad1154d88925e0cabccbc0017_D20160901-20160930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDMxMw_a23a260a-ad32-45f7-8551-c2fe0daaf830"
      unitRef="number">0.02</sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods>
    <sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales
      contextRef="i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDU4MA_bef220c6-067c-4fd0-9874-326c7e588bcb">P15Y</sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales>
    <sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations
      contextRef="i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNC9mcmFnOmU4NzI5OGJhMDU0MjRlOTg4ZmVkM2UxYTcyY2I3MjlkL3RleHRyZWdpb246ZTg3Mjk4YmEwNTQyNGU5ODhmZWQzZTFhNzJjYjcyOWRfNDg5NQ_4678b1c3-f1f5-4efe-a10d-66ccec52c658">P7Y</sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations>
    <us-gaap:BasisOfAccounting
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNy9mcmFnOjA3OGFmNjBmMTg2NzRkNjRiYTA4OTA1NWRhNDNkZmZlL3RleHRyZWdpb246MDc4YWY2MGYxODY3NGQ2NGJhMDg5MDU1ZGE0M2RmZmVfMzg5NQ_20f549a7-1cdd-4c74-a913-116c6efdcec1">BASIS OF PRESENTATION&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interim Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#x2019; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the US dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNy9mcmFnOjA3OGFmNjBmMTg2NzRkNjRiYTA4OTA1NWRhNDNkZmZlL3RleHRyZWdpb246MDc4YWY2MGYxODY3NGQ2NGJhMDg5MDU1ZGE0M2RmZmVfMzg5Mg_f4d86a16-59ea-4f11-8934-1fdcc4727f9f">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNy9mcmFnOjA3OGFmNjBmMTg2NzRkNjRiYTA4OTA1NWRhNDNkZmZlL3RleHRyZWdpb246MDc4YWY2MGYxODY3NGQ2NGJhMDg5MDU1ZGE0M2RmZmVfMzg5Mw_69c004aa-abf9-4f95-9ecd-7ab784d4a0c9">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV8zNy9mcmFnOjA3OGFmNjBmMTg2NzRkNjRiYTA4OTA1NWRhNDNkZmZlL3RleHRyZWdpb246MDc4YWY2MGYxODY3NGQ2NGJhMDg5MDU1ZGE0M2RmZmVfMzg5NA_cc38149b-7016-4cec-b3be-1b5a5c206adf">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the US dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80MC9mcmFnOmY2ZGM2MTg5Yjc1NzRmZDg5ZjBmMzhmNzk4YzUxNmUzL3RleHRyZWdpb246ZjZkYzYxODliNzU3NGZkODlmMGYzOGY3OThjNTE2ZTNfMzYw_19733c2d-5737-4664-abfd-63e9ba61344f">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80My9mcmFnOjdiN2UzNzg0N2NjZjRjOGE5MDVkNzQ1NDIyN2QxYTQ4L3RleHRyZWdpb246N2I3ZTM3ODQ3Y2NmNGM4YTkwNWQ3NDU0MjI3ZDFhNDhfMjQ3Nw_297b6c65-42e9-4120-8b7a-2dd3eb8f0d2e">RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#x2019;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2021-04")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-04 clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80My9mcmFnOjdiN2UzNzg0N2NjZjRjOGE5MDVkNzQ1NDIyN2QxYTQ4L3RleHRyZWdpb246N2I3ZTM3ODQ3Y2NmNGM4YTkwNWQ3NDU0MjI3ZDFhNDhfMjQ3OA_3aac6355-f6e3-499b-9d0b-d0d662d00f58">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#x2019;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2021-04")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-04 clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNzAyNw_a5fbae29-c1ae-4ab6-960d-bdc0d8608c28">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 10.2% as of June&#160;30, 2022 to 8.0% and 9.3% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company made the strategic decision to voluntarily pause further development in the US of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Additionally, the Company intends to seek a partner for the further development of Vicineum. The Company expects that any partner who acquires Vicineum from the Company will be obligated to make any payments that become payable to the former shareholders of Viventia under the Share Purchase Agreement. Accordingly, as of June&#160;30, 2022, the Company no longer expects to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights have already been out-licensed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore, the balance as of June&#160;30, 2022 relates to contingent consideration for projected net sales in the Greater China region as compared to the balance as of December&#160;31, 2021 which was based upon projected world-wide net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s contingent consideration was determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from the Company&#x2019;s weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021 to 10.2% as of June&#160;30, 2022. As of December&#160;31, 2021, the balance also reflected potential milestone payments which constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $50.2&#160;million for the six months ended June 30, 2022 was driven by the Company's decision to voluntarily pause further development of Vicineum.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNzAyOA_67654f55-7a9f-4fc5-abc6-9c9383beea68">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNzAyOQ_1a39565e-bb0b-4dc7-a724-e29c026debd7">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idddfae85f074434a95d80a49f60b90a8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC0xLTEtMS03MDA2MA_9b1ffaef-fb92-4125-9daa-ddaaed15b5ad"
      unitRef="usd">40765000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia5c7832156a94fdeb7e233a110f7b809_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC0zLTEtMS03MDA2MA_903af906-1f59-4fed-bd11-19609d3efe9d"
      unitRef="usd">40765000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC01LTEtMS03MDA2MA_f4433f1f-3527-4845-8c8f-c04f8ef3299a"
      unitRef="usd">40765000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id7c2028a693348b8951ec9bd0156057c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC03LTEtMS03MDA2MA_bee888d5-73ad-4294-8aa1-7a5eba5d5ba9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibe177cf9141643909f6abc3b8fa7d37d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNC05LTEtMS03MDA2MA_bbee6e55-2b99-478f-998c-df32183eb2db"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idddfae85f074434a95d80a49f60b90a8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi0xLTEtMS03NDIzMw_99d7f39c-d730-4cb6-8cb1-f025236f2cc9"
      unitRef="usd">89095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5c7832156a94fdeb7e233a110f7b809_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi0zLTEtMS03NDIzMw_826abd20-4bab-492a-a03e-ece93a9f93db"
      unitRef="usd">89095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi01LTEtMS03NDIzMw_936bf8be-271c-4467-a1e4-e87801e3dc57"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7c2028a693348b8951ec9bd0156057c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi03LTEtMS03NDIzMw_3bd857c6-e9cb-4143-adc1-5514d2001439"
      unitRef="usd">89095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe177cf9141643909f6abc3b8fa7d37d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNi05LTEtMS03NDIzMw_48cb915a-6ac5-4449-94ac-8708d29c2f04"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="idddfae85f074434a95d80a49f60b90a8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy0xLTEtMS03MDA2MA_c1d6a48c-7055-4af4-9144-07a9d9b4635a"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia5c7832156a94fdeb7e233a110f7b809_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy0zLTEtMS03MDA2MA_43d5ee5f-eb72-4438-82c2-f2ada802dc3b"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy01LTEtMS03MDA2MA_07f440a9-104b-4210-969c-41fff902ff49"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id7c2028a693348b8951ec9bd0156057c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy03LTEtMS03MDA2MA_1a9c141c-015c-485d-9f58-993b689018d4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ibe177cf9141643909f6abc3b8fa7d37d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjNmZWQ3YTg1ZGFkOTRkM2U4MzJmNTdlMWQ5N2VjMjFlL3RhYmxlcmFuZ2U6M2ZlZDdhODVkYWQ5NGQzZTgzMmY1N2UxZDk3ZWMyMWVfNy05LTEtMS03MDA2MA_edc96e78-fc28-4cbc-9248-61a0ecc7a91a"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9372277261a1442382a0a57cd6b64879_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC0xLTEtMS03MDA2MA_af41636c-fd8b-4eeb-b597-4f29499f80c5"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i86a276b795564af5900e3ccde170c211_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC0zLTEtMS03MDA2MA_c5dae4bf-f159-47d9-a03b-e0b06279f1aa"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i93597cbef52346f8bf33793b3445c748_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC01LTEtMS03MDA2MA_49629f33-98a2-4257-978f-cd9ea9eded26"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if0c6a63221e74f49a77225cfd89d52e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC03LTEtMS03MDA2MA_22455369-7564-44eb-81cb-05e2412cec8a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2c6ff544a1cd473cb1b5466e70e8581d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNC05LTEtMS03MDA2MA_ec10833d-c4ae-4dda-99d9-9c38c6761fbb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i9372277261a1442382a0a57cd6b64879_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy0xLTEtMS03MDA2MA_4ad5b0c2-654f-4cc8-8d95-a7a2a8ce3e86"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i86a276b795564af5900e3ccde170c211_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy0zLTEtMS03MDA2MA_05e085d7-10d4-405c-b849-5af8db4f09ae"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i93597cbef52346f8bf33793b3445c748_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy01LTEtMS03MDA2MA_7c2f87e4-6ff6-4f4e-9bea-af7401722f0e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if0c6a63221e74f49a77225cfd89d52e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy03LTEtMS03MDA2MA_658b3fc6-6cfe-45ff-bdda-91d8506d727a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2c6ff544a1cd473cb1b5466e70e8581d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOjM1NGY3ZDc5MzUyNDRjMTNiZTEyODZmYWI1MDlhNWFmL3RhYmxlcmFuZ2U6MzU0ZjdkNzkzNTI0NGMxM2JlMTI4NmZhYjUwOWE1YWZfNy05LTEtMS03MDA2MA_5b943f66-22d1-4b97-badd-daa147d83e44"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic13e854370344e64955121ce52f8efd8_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfODc5NjA5MzA0NDk3Mw_006ca314-d2f3-4ed0-adb1-4e46c10d6bf7"
      unitRef="number">0.102</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i077703176cde4f50813269c0d4bc4948_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfMzU4Mg_aac6f89b-3e6b-46bc-a361-f2176e424812"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i086d18af784f4ef89dd43b1a93d419d2_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfMzU4OA_005ee2e9-481f-4ffe-b4c9-8f1afba02280"
      unitRef="number">0.093</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNjA0NzMxMzk3OTU5OQ_afdcc93b-406c-47a3-bdf3-0fd9898aa8ed"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNzAzMA_457680fb-8ed4-4249-a9b7-cedc4177ad87">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id227aede38f346d295f8bb264c9c69d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOmVmMWI1MWIxYWQ4ODQwMDlhODYyYmJhZTNlNDU0YTAyL3RhYmxlcmFuZ2U6ZWYxYjUxYjFhZDg4NDAwOWE4NjJiYmFlM2U0NTRhMDJfMC0xLTEtMS03MDA2MA_a6d063e6-11e9-463a-ae0a-223c94903d74"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent
      contextRef="i2830d319d1ee4478869015d679421f00_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOmVmMWI1MWIxYWQ4ODQwMDlhODYyYmJhZTNlNDU0YTAyL3RhYmxlcmFuZ2U6ZWYxYjUxYjFhZDg4NDAwOWE4NjJiYmFlM2U0NTRhMDJfMi0xLTEtMS03MDA2MA_1fdcccc5-78e4-47bc-9f81-f20c94639583"
      unitRef="usd">-50200000</sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i60aca7f4595d416dac4c7c3f1aed4ccb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RhYmxlOmVmMWI1MWIxYWQ4ODQwMDlhODYyYmJhZTNlNDU0YTAyL3RhYmxlcmFuZ2U6ZWYxYjUxYjFhZDg4NDAwOWE4NjJiYmFlM2U0NTRhMDJfMy0xLTEtMS03MDA2MA_c1e7c30d-1cca-403c-b914-b2f46061c14e"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNDI0Mw_f1234538-7dce-446a-b592-93222eaec270"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNDM0Mg_c21476ef-c1e3-4659-9fb7-fbcb98b4c884"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="if7f36ed152cc4886975102feb1d3dcf2_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNDQ1Mg_0220f68f-bcb1-48f8-aa3d-a05cc39921c1"
      unitRef="number">0.093</sesn:WeightedAverageCostOfCapital>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic13e854370344e64955121ce52f8efd8_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfODc5NjA5MzA0NTYxMQ_006ca314-d2f3-4ed0-adb1-4e46c10d6bf7"
      unitRef="number">0.102</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfNDY4Mg_d1bd6ef4-2381-4f46-b619-7089865d4110"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80Ni9mcmFnOjZiMDRkYzM4Mjc2NDQ0NDE4MGEyOTAzMjVhMTZjNTIwL3RleHRyZWdpb246NmIwNGRjMzgyNzY0NDQ0MTgwYTI5MDMyNWExNmM1MjBfMTA5OTUxMTY0NjA5Ng_279280c2-eb4e-44d9-8aac-50b3c97f0b4e"
      unitRef="usd">-50200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfNTE1_ba85157f-0e14-4687-9c28-f2f5d8ef518d">RECEIVABLES &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounts receivable balance as of June&#160;30, 2022 is $0.1&#160;million compared to $21.0&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $20.0&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#x201c;Roche&#x201d;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other receivable balance as of June&#160;30, 2022 is $14.0&#160;million compared to $3.5&#160;million as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The increase is driven by expected insurance recovery of $13.0&#160;million related to the preliminary settlements of the securities and derivative litigation. This was partially offset by the receipt of $2.4&#160;million for German value-added tax ("VAT") recovery in the first half of 2022, related to drug substance sent to Baxter in 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifa3364e01f0e4f3e8b9b4b9e879f7cda_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfNjU_2b8ea801-4bad-4510-ad9e-d8e8e6eb29b8"
      unitRef="usd">100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfODA_7fd90a46-923e-4dae-b42e-7fdb719a2dbc"
      unitRef="usd">21000000</us-gaap:AccountsReceivableNetCurrent>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="ie9e6014176bb47daa77e93b8e95c92eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfMTM4_08adc5d8-25ea-4469-bb4d-13799b6fcb0e"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfMzUy_436fa8be-4052-4349-b967-10d8244b9cbb"
      unitRef="usd">14000000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfMzY3_ff333a7a-2506-4ac2-917d-daedae55082a"
      unitRef="usd">3500000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i68913e68ad7b4a54a86589572b03f916_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfNDk0NzgwMjMyNTg4NA_0a396c59-3088-45ef-889e-0ca6535b9a85"
      unitRef="usd">-13000000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i22e566e4a4b842db8188c3f55dbff512_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV80OS9mcmFnOjlhMTE5NDdiODM4ODQxMmJhZThmZmM0ZWJlMWVmNDc1L3RleHRyZWdpb246OWExMTk0N2I4Mzg4NDEyYmFlOGZmYzRlYmUxZWY0NzVfNjA0NzMxMzk1MzY3NQ_49b08ef0-872c-4f5c-b898-d73879ab1889"
      unitRef="usd">-2400000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NjQvZnJhZzozMzMwZTY1ZTIxNjk0NzgxYTFmN2FkNTQ4MGVmYTc5Ny90ZXh0cmVnaW9uOjMzMzBlNjVlMjE2OTQ3ODFhMWY3YWQ1NDgwZWZhNzk3XzYwNDczMTM5NTY1MjA_1f63bc32-c67e-442f-b549-4830a739b5c2">PREPAID EXPENSES The prepaid expenses balance as of June&#160;30, 2022 is $0.8&#160;million compared to $25.7&#160;million as of December&#160;31, 2021. In light of the Company's decision to voluntarily pause further development of Vicineum, the Company evaluated prepaid balances and determined that the prepayments for the manufacturing of Vicineum, including consumables, had no future economic benefit or value. Pursuant to ASC Topic 730, Certain Nonrefundable Advance Payment, the Company expensed $25.2&#160;million of prepaids during the three months ended June 30, 2022.</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NjQvZnJhZzozMzMwZTY1ZTIxNjk0NzgxYTFmN2FkNTQ4MGVmYTc5Ny90ZXh0cmVnaW9uOjMzMzBlNjVlMjE2OTQ3ODFhMWY3YWQ1NDgwZWZhNzk3XzQ5NDc4MDIzMjk4NDQ_63da4698-3732-452f-8752-e0b5614e0a20"
      unitRef="usd">800000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NjQvZnJhZzozMzMwZTY1ZTIxNjk0NzgxYTFmN2FkNTQ4MGVmYTc5Ny90ZXh0cmVnaW9uOjMzMzBlNjVlMjE2OTQ3ODFhMWY3YWQ1NDgwZWZhNzk3XzQ5NDc4MDIzMjk3NjE_46983600-f753-41f8-b142-62a0ba0668c5"
      unitRef="usd">25700000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <sesn:ExpensesPreviouslyClassifiedAsPrepaid
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NjQvZnJhZzozMzMwZTY1ZTIxNjk0NzgxYTFmN2FkNTQ4MGVmYTc5Ny90ZXh0cmVnaW9uOjMzMzBlNjVlMjE2OTQ3ODFhMWY3YWQ1NDgwZWZhNzk3XzE2NDkyNjc0NDY0NzY_3a67bc44-33b1-47e0-b035-e63596b3d793"
      unitRef="usd">25200000</sesn:ExpensesPreviouslyClassifiedAsPrepaid>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNjkxOQ_3ac1e7cf-a43a-4ef9-b8d0-56556f2ab2a2">INTANGIBLE ASSETS AND GOODWILL&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the acquired intangible assets for the European Union ("EU") rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#x2019;s former lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its marketing authorization application (&#x201c;MAA&#x201d;) to the European Medicines Agency (the &#x201c;EMA&#x201d;) for Vysyneum&#x2122; for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there was more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the EU. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#x2019;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $31.7&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the current range of commercialization timelines and probability of success assumptions. This was primarily due to the fact that the EU asset was burdened with significantly less expense than the US asset, as the Company&#x2019;s strategic operating plan was to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in its share price and a resulting decrease in our market capitalization. On July 15, 2022 the Company made the strategic decision to voluntarily pause further development in the US of Vicineum and intends to seek a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of a potential partnering deal to conclude the fair value of EU asset. The Company concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum EU rights of $14.7&#160;million was fully impaired and written off as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#x2019;s most recent impairment test, which was 24.5%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. During the second quarter of 2022 the Company observed continued trends in the Company&#x2019;s market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, length and cost of a clinical study, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis, in advance of the Company's typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both the US and outside the US ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. Management also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#x2019;s most recent impairment test, which was 24.5%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNjkyMA_9ec8fc02-3d1d-4fbf-adea-b11c7cd9e452">The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="iaafbcb1be87d432d8ded324e6ed76889_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOjU4OTkyZWQyMTZiYzRiOTNiYTRiYWNhN2Y0MzhhZGU0L3RhYmxlcmFuZ2U6NTg5OTJlZDIxNmJjNGI5M2JhNGJhY2E3ZjQzOGFkZTRfMy0xLTEtMS03MDA2MA_f8e39180-326f-40f3-bdf3-6fc1d2de0ce0"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i99b037e30ee240a693feec6491f28390_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOjU4OTkyZWQyMTZiYzRiOTNiYTRiYWNhN2Y0MzhhZGU0L3RhYmxlcmFuZ2U6NTg5OTJlZDIxNmJjNGI5M2JhNGJhY2E3ZjQzOGFkZTRfMy0zLTEtMS03MDA2MA_54686371-b954-41a7-b87e-20b788990b6d"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i043a889ad00d41bcbc065be28275a745_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOjU4OTkyZWQyMTZiYzRiOTNiYTRiYWNhN2Y0MzhhZGU0L3RhYmxlcmFuZ2U6NTg5OTJlZDIxNmJjNGI5M2JhNGJhY2E3ZjQzOGFkZTRfNC0xLTEtMS03MDA2MA_24f55546-eefd-4863-b290-5c2b27dbb582"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ia31cefc9e53e4fdea0146b38e97b9152_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOjU4OTkyZWQyMTZiYzRiOTNiYTRiYWNhN2Y0MzhhZGU0L3RhYmxlcmFuZ2U6NTg5OTJlZDIxNmJjNGI5M2JhNGJhY2E3ZjQzOGFkZTRfNC0zLTEtMS03MDA2MA_b1f498ea-5ef8-49b7-ae06-2f3d4e49ced9"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i75f8be7fd9a44548a385a47a21fdcbfa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfMTc2Nw_fea722a3-b2ed-40d3-a9e4-12dd1c310da7"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="id5bc92acb0454bdeb25962fc1d1aef23_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNDk0NzgwMjM1NjIxOQ_8dad634f-f57c-4178-8ccd-84a3470cfb10"
      unitRef="usd">14700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage
      contextRef="id5bc92acb0454bdeb25962fc1d1aef23_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNjA0NzMxMzk5NjQxNA_fb801dcc-4392-479a-9571-9f62e8e6c4e6"
      unitRef="number">0.245</sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage>
    <us-gaap:Goodwill
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNTYzNQ_e1c134a7-3c0e-4f4d-900c-3813de6e88b1"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage
      contextRef="id5bc92acb0454bdeb25962fc1d1aef23_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNDk0NzgwMjM2ODYzMA_06704022-b98e-463d-b233-c96c665120a0"
      unitRef="number">0.245</sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RleHRyZWdpb246NDA3MjM2NTgzNDZjNDY2NDhiZDBmMzM5MGNmY2I2MjNfNjA0NzMxMzk5MzAzNg_675e18d5-c339-4a5e-a368-585913276118">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOmJhZThjZmExMzMxMzRlNmRhMmM5NjMxZjQ3YTkzYmI5L3RhYmxlcmFuZ2U6YmFlOGNmYTEzMzEzNGU2ZGEyYzk2MzFmNDdhOTNiYjlfMC0xLTEtMS03ODY5Mg_61a60c28-3e2a-4f45-8674-f89394c9e7a0"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOmJhZThjZmExMzMxMzRlNmRhMmM5NjMxZjQ3YTkzYmI5L3RhYmxlcmFuZ2U6YmFlOGNmYTEzMzEzNGU2ZGEyYzk2MzFmNDdhOTNiYjlfMS0xLTEtMS03ODY5Mg_4cde8446-da80-47ad-8c7b-d01f859d5b9a"
      unitRef="usd">13064000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81Mi9mcmFnOjQwNzIzNjU4MzQ2YzQ2NjQ4YmQwZjMzOTBjZmNiNjIzL3RhYmxlOmJhZThjZmExMzMxMzRlNmRhMmM5NjMxZjQ3YTkzYmI5L3RhYmxlcmFuZ2U6YmFlOGNmYTEzMzEzNGU2ZGEyYzk2MzFmNDdhOTNiYjlfMi0xLTEtMS03ODcyNA_5e6a32a8-8541-48f2-9164-f003ab2efa16"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RleHRyZWdpb246ZGI0MDQ5OTBkODI5NDJmNjkzZmJjNzMwOGQ5YjEwMWFfMTI1_62e4594a-ce43-43d3-a80e-f213712bc9d6">ACCRUED EXPENSES&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal expenses, including preliminary litigation settlement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RleHRyZWdpb246ZGI0MDQ5OTBkODI5NDJmNjkzZmJjNzMwOGQ5YjEwMWFfMTM1_07094331-9945-4eda-a660-0baa6ac64c27">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal expenses, including preliminary litigation settlement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMS0xLTEtMS03MDA2MA_2405bb6a-8d41-4cc0-ab23-cdc4725d1b8f"
      unitRef="usd">1847000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMS0zLTEtMS03MDA2MA_81d095ae-c8ed-4584-b62f-0cf76b529780"
      unitRef="usd">1841000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMi0xLTEtMS03MDA2MA_34893809-4254-42eb-b26c-3fbd23f5727b"
      unitRef="usd">3099000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMi0zLTEtMS03MDA2MA_687d91db-d5b5-4654-8e07-1b44bb1b571c"
      unitRef="usd">2967000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMy0xLTEtMS03MDA2MA_bec83797-cc6c-45a7-8dbd-bb44d5728213"
      unitRef="usd">394000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfMy0zLTEtMS03MDA2MA_6854d87e-8991-41c1-8740-67731ddad937"
      unitRef="usd">1497000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNC0xLTEtMS03MDA2MA_ad8d41ab-2027-43eb-b308-eac3dc240d66"
      unitRef="usd">507000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNC0zLTEtMS03MDA2MA_5e9b9f78-a525-4051-a711-dfbfb78bd5fa"
      unitRef="usd">597000</us-gaap:AccruedProfessionalFeesCurrent>
    <sesn:AccruedLegalFees
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNS0xLTEtMS03NjQxNQ_7bfc20d7-0ed9-497b-a84b-16ddb23e24bb"
      unitRef="usd">22477000</sesn:AccruedLegalFees>
    <sesn:AccruedLegalFees
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNS0zLTEtMS03NjQxNQ_87715d0e-f557-436b-a5ee-7845757537e2"
      unitRef="usd">1344000</sesn:AccruedLegalFees>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNS0xLTEtMS03MDA2MA_3528b125-7e19-47b1-bdbc-dbdb84bce0fe"
      unitRef="usd">1527000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNS0zLTEtMS03MDA2MA_1ed81c95-1cc5-47e6-a3f3-1419c13a5f96"
      unitRef="usd">9000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNi0xLTEtMS03MDA2MA_54ee9fcd-6b9c-4785-a7cb-c2ad428ab536"
      unitRef="usd">29851000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81NS9mcmFnOmRiNDA0OTkwZDgyOTQyZjY5M2ZiYzczMDhkOWIxMDFhL3RhYmxlOmMxNGY1ZTBlNDE0NzQ0OGE4NDAxM2U1NDA0OTlkYTcyL3RhYmxlcmFuZ2U6YzE0ZjVlMGU0MTQ3NDQ4YTg0MDEzZTU0MDQ5OWRhNzJfNi0zLTEtMS03MDA2MA_af47f4d7-3b28-4a06-be2a-b871c79e324f"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfNTcxMQ_1a544a7c-f225-44f8-a85f-700a42753105">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#x2019;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#x2019; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#x201c;Securities Litigation&#x201d;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#x201c;Lead Plaintiffs&#x201d;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#x201c;Amended Complaint&#x201d;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. After the motion was fully briefed and before the court ruled on the motion, on June 3, 2022, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. The parties engaged in mediation on June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#x2019;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#x2019;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#x2019;s board of directors and certain of its officers (the &#x201c;State Derivative Litigation&#x201d;). The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treatment of BCG-unresponsive NMIBC. The D&#x2019;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#x2019; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#x201c;Federal Derivative Litigation&#x201d;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company deemed the settlements of the Securities Litigation, the State Derivative Litigation, the Federal Derivative Litigation, and other potential related derivative claims, probable and amounts reasonably estimable as of June 30, 2022 and accrued $21.6&#160;million to litigation related liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation, the State Derivative Litigation and the Federal Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sesn:NumberOfLawsuits
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTIxNA_bd70f977-365d-482f-ae84-963cf1641734"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTU5MA_ae7c94e9-bcb5-481f-8cca-c0204c2ca082"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTgzMA_ba564895-9c65-4bce-949e-a008efb4143d"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTk3MQ_2cce167b-285d-4879-8fde-b47fafa46119"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfMTY0OTI2NzQ3Mjg0NA_f25e2eb0-1686-4be3-b9ad-0935ec9bcb04"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <us-gaap:LitigationReserve
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV81OC9mcmFnOmE4OTQzNTBlYmQ1ODRhM2I4ZGEyNTJjNmY2ODBkNjQ4L3RleHRyZWdpb246YTg5NDM1MGViZDU4NGEzYjhkYTI1MmM2ZjY4MGQ2NDhfNjA0NzMxMzk3NTIwNw_e9c36a82-1c35-4583-a04f-860d314af3a0"
      unitRef="usd">21600000</us-gaap:LitigationReserve>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk1OQ_222e4539-f39d-45e4-94dd-d2c6e3e8973b">LEASES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,000 at exchange rates in effect on June&#160;30, 2022). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,100 at exchange rates in effect on June&#160;30, 2022). Operating lease cost under this lease, including the related operating costs, were $83,000 and $165,000 for the three and six months ended June&#160;30, 2022, respectively, and $84,000 and $166,000 for the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The asset component of the Company&#x2019;s operating leases is recorded as operating lease right-of-use assets and reported within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_7413172c-d3a5-4068-a39f-148f182a4c0b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2MQ_ea5c27f0-7ff4-4a17-899a-400e6d9e6d97"&gt;other assets&lt;/span&gt;&lt;/span&gt; on the Company's condensed consolidated balance sheets. The right of use asset total was $41,700 as of June&#160;30, 2022 and $123,300 as of December&#160;31, 2021. The short-term lease liability is recorded in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_0bf1b90e-c07f-46a0-9567-ec2c0325b103"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTk2Mg_1319265b-1386-40c8-9f75-781056e69617"&gt;other current liabilities&lt;/span&gt;&lt;/span&gt; and the long-term lease liability is recorded in other liabilities on the Company&#x2019;s condensed consolidated balance sheets. The short-term lease liability was $41,700 as of June&#160;30, 2022 and $123,300 as of December&#160;31, 2021. There was no long-term operating lease liability as of June&#160;30, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases are renewed on a month-to-month basis. The minimum monthly rent for these office spaces is $2,200 and $21,000, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sesn:OperatingLeasesAreaOfOfficeSpace
      contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTUz_36537782-5bb5-43dd-a561-f340791c3427"
      unitRef="sqft">31100</sesn:OperatingLeasesAreaOfOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i54a5e53888604de7b9eccc5f75d78406_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMzYx_a84ea351-1b07-4a7f-a29a-52c665516aef">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNTAz_09cb2396-a0b8-4401-a2e2-c826078887d8"
      unitRef="cad">18100</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNTIx_dc977c63-2ab9-4e96-a910-2fede064ed9b"
      unitRef="usd">14000</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNjIy_c5c91cec-7781-4bdf-8836-a530ab058f21"
      unitRef="cad">18200</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="i148c02076fb6482087594002227223b6_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNjgw_3a87d668-8f5f-47aa-976f-98938259ca29"
      unitRef="usd">14100</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <us-gaap:OperatingLeaseCost
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNjk3Nw_68fa94b4-0e8d-4f4a-b46f-46ee6ea96ac0"
      unitRef="usd">83000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzAwNg_99a2527a-a4c0-42e4-8a44-4ac16d3f4386"
      unitRef="usd">165000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzAzOA_00aedfec-fdef-4007-8077-8dd411c2fbf3"
      unitRef="usd">84000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzA0Ng_20fc79c3-7ea9-4f29-be10-cd4d20cec9d3"
      unitRef="usd">166000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTA3MA_e88e5eba-46ee-4974-8435-2f20244fed88"
      unitRef="usd">41700</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzA5MQ_389b8c3d-3e20-438c-8374-73978b773d8a"
      unitRef="usd">123300</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTMyMA_72acc189-ad8c-40ce-bbd4-64a74a85ef82"
      unitRef="usd">41700</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfNDk0NzgwMjMyNzEwNw_a2798717-5e5e-4599-9cfe-8809a0cfb459"
      unitRef="usd">123300</us-gaap:OperatingLeaseLiabilityCurrent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="ia060ccaf4f3043ab8f16a7a015f9e80e_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTgzOQ_1770da8d-6093-400f-a736-72dc9d4e9e3d"
      unitRef="usd">2200</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="if8a99add6a0641b5ab55bf3282467a0d_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82MS9mcmFnOjQ4YjZiNGI1NTIxNzRhYTE5NWIyMzZhMjRjNjdjYTQ1L3RleHRyZWdpb246NDhiNmI0YjU1MjE3NGFhMTk1YjIzNmEyNGM2N2NhNDVfMTg0Ng_d02348fb-be55-421a-92e4-5fe68092cf13"
      unitRef="usd">21000</sesn:OperatingLeaseMonthlyRent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNTU0OQ_125e302d-5624-4c08-9203-d8d23c12eb84">STOCKHOLDERS' EQUITY &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into an Open Market Sale Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time through Jefferies (the &#x201c;ATM Offering&#x201d;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement of which $97.8&#160;million of common stock remain available for future issuance as of June&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#x2019;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and six months ended June&#160;30, 2022. The Company raised $136.8&#160;million of net proceeds from the sale of 47.1&#160;million shares of common stock at a weighted-average price of $2.99 per share during the six months ended June 30, 2021. The Company raised $64.3&#160;million of net proceeds from the sale of 16.5&#160;million shares of common stock at a weighted-average price of $4.02 per share during the three months ended June 30, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.0&#160;million and $4.2&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following approval by the Company&#x2019;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately 199&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares were issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;230,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#x2019;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity. The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#x201c;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#x2019; Equity (Deficit)&#x201d; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i84bae78e3b8749b39293629af79a1b2a_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNDM0_9b618529-7cf4-48d1-be91-25a2dbc4f3d0"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="ib2f7003911044ca29a413fb1818f5c6c_D20210601-20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNjQ2_10564a4f-e879-4398-aed7-f38897a03cc0"
      unitRef="usd">200000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance
      contextRef="i1ce363488c7540a6a587912208af7e0f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNzA1_8c146640-34d1-4385-8c57-227e2ae34a15"
      unitRef="usd">97800000</sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance>
    <sesn:SaleOfStockCommissionFixedRate
      contextRef="i35961c53b42e43cbb0b81da04777d408_D20211129-20211129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTc4Mw_a810b89e-ac51-4d88-b35e-ba4c45fcbe4f"
      unitRef="number">0.030</sesn:SaleOfStockCommissionFixedRate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTA5OTUxMTYzMzYwOQ_26f32e97-7607-49fd-a8d2-58b7086bc49e"
      unitRef="usd">136800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTA5OTUxMTYzMzYxNQ_8aa496bf-421d-4894-a81d-cb0135410029"
      unitRef="shares">47100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTA5OTUxMTYzMzYyMg_adc123bd-b63b-43b8-bda9-4effc0cd1c20"
      unitRef="usdPerShare">2.99</sesn:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTk4MQ_43e3f88d-bd16-49d7-920d-6a91ce798e35"
      unitRef="usd">64300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjAxNw_a4547292-bca4-4c31-b085-27334dd76216"
      unitRef="shares">16500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjA3NA_ea0f883b-0d32-436a-8526-fc3af327e910"
      unitRef="usdPerShare">4.02</sesn:SaleOfStockWeightedAveragePricePerShare>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i7039a531f1094443b868fa0e3e79c797_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjE5Ng_5e890395-2caf-4ba2-ba32-d93867250339"
      unitRef="usd">2000000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i209e4095505046c0951d8fa01c03e6d9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMTA5OTUxMTYzMzYzNQ_c4315d61-de54-4494-b7d5-a7ba2420bfd3"
      unitRef="usd">4200000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjM2OQ_0a2af373-d65f-438b-af6e-374c7ae26dc7"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjQxMw_4ea48921-fa6e-48e9-9f1e-648ac45b4b5a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjg1Nw_742df77a-f3f0-4ed0-9b06-54526007b3f2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjg1Nw_89e6d50f-da0f-497d-b91e-1a78df6e5f3d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjg1Nw_90d3a98f-67d8-435d-b922-bd6465f78f6a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMjg1Nw_96d8ef3f-db90-47b8-b885-5ae9169cadb4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7960c58d87094e0aafb92767a535f891_I20210502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzEyOA_0e6c07ad-7350-48e6-92c0-a60e40995643"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifc8cab4c047e42a1993c113f9407d7c0_I20210503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzEzNA_7b9662f4-40f4-4823-b27b-7eb08a1a44c1"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzE0Nw_20581a02-8464-4747-8bf3-bb165bdfce8f"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzE0Nw_58a8dde9-b10e-4aac-b3c7-b02d3bd0e82b"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzE0Nw_b4274d56-7a8a-4c4f-bf63-ea28c4aacfae"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzE0Nw_e58be635-05aa-4109-a17c-c5b4ea8f6680"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNTU0Mw_4c254857-9e82-46df-86a0-eef3bf57a457">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;230,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfMS0xLTEtMS03MDA2MA_bd59b38b-66f3-424c-b10a-a2b9783d6f76"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfMS0zLTEtMS03MDA2MA_eca42b8a-fe77-4a68-bbf1-50bca6665390"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0e690f5ae31c41b7a191fa0ff85bf14a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfMy0xLTEtMS03MDA2MA_15e533d8-e86f-45c0-82fb-d5aae8c48d2f"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4e430eedf22b467aac65cdb1b465bb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfMy0zLTEtMS03MDA2MA_170f300a-e879-43e0-ac45-078cab84f160"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if12ac6d811ab49fea4ae767cff635f67_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNC0xLTEtMS03MDA2MA_301fdae9-35f1-49eb-b5d6-4686fb33c393"
      unitRef="shares">17161000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i879f338421144cd692f89c4e9f0c73c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNC0zLTEtMS03MDA2MA_000ac105-cb62-49cf-a8a1-e26c0378fe64"
      unitRef="shares">15703000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="idf83b58ca25c49e192a0c8602c5b4cf2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNS0xLTEtMS03MDA2MA_e7a1df98-6623-4c7f-97cf-fa7bc1e1500c"
      unitRef="shares">8063000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iccc92bb70d08454e949c18da6144865f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNS0zLTEtMS03MDA2MA_5b532874-b00b-4798-8db3-d44b8cf1c629"
      unitRef="shares">3041000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie9bd2cea79e94911a9584a49e07abbb3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNi0xLTEtMS03MDA2MA_e3f46eaf-82cc-4f94-a259-ed6cec405c6a"
      unitRef="shares">3076000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3787aa8d02ce4f859f8c5f466f0d274a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNi0zLTEtMS03MDA2MA_f7aa461a-4fd0-430a-947b-30fc268f5213"
      unitRef="shares">8933000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iab2fae56c82b4d01a53b53d0d8ad8169_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNy0xLTEtMS03MDA2MA_2dc3f314-8d0a-4dfd-b5b9-da8c0950a4e6"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i018c376ae85743729c4cc85b9d0082c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfNy0zLTEtMS03MDA2MA_360997d3-fafc-452d-b784-f9a268128cbd"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfOC0xLTEtMS03MDA2MA_ca7a9570-ba30-4ea7-981f-61e9f44fdfc1"
      unitRef="shares">230263000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOjlkZjFhY2QzYjZlMTRmNDhiYzU2OWFjM2E5NDk1NWI5L3RhYmxlcmFuZ2U6OWRmMWFjZDNiNmUxNGY0OGJjNTY5YWMzYTk0OTU1YjlfOC0zLTEtMS03MDA2MA_b673691c-0c24-432b-842d-89aae603c5bd"
      unitRef="shares">229640000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:NumberofVotesEntitledForEachShare
      contextRef="i0aa49d50600f4d809f73a21b67293288_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfMzYxMQ_03b62481-d2e5-4e15-988c-55c67106df77"
      unitRef="vote">1</sesn:NumberofVotesEntitledForEachShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RleHRyZWdpb246ZWYwMTZmNDdmYzNkNDNmNWJhZjI1NjdiNjhiMWU0NDhfNTU0NA_90c03324-810a-4890-8d9c-0d7797ded20b">The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#x201c;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#x2019; Equity (Deficit)&#x201d; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if3f5defe37004a80beffaabe3c084441_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS0yLTEtMS03MDA2MA_b4f3e198-b21f-418f-a6c9-863dee6a65b2"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i40c5616a1e704030a81402b94effbad5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS02LTEtMS03MDA2MA_58eaa896-eb17-4b69-a135-78f573712cf1"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i69cb4439e7f34192bda24252ab0db0d6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS04LTEtMS03MDA2MA_0564f2e0-49c6-41a8-aae4-1fbb4a7395a1"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i69cb4439e7f34192bda24252ab0db0d6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS0xMC0xLTEtNzAwNjA_fd3d20a7-8382-4163-9fef-2c59a656d04b"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i69cb4439e7f34192bda24252ab0db0d6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS0xMi0xLTEtNzAwNjA_706d56f4-5323-4568-ac31-05818ce44134"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if3f5defe37004a80beffaabe3c084441_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMS0xNC0xLTEtNzAwNjA_b5f9134e-c3ed-4b62-b425-5f5e476f59be"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i95be96bc66a447e49b2e6b3eb139bb61_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi0yLTEtMS03MDA2MA_6fc40324-4bd2-424e-97e1-d511912e9359"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4361a004833c45998527402787d53315_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi02LTEtMS03MDA2MA_edeb76e3-e1bf-437c-abd3-aa10e6c64eab"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i5c9b9934bd1f4b4a87e74584ffe44869_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi04LTEtMS03MDA2MA_05ff1b2f-198c-42fd-b8fc-d3b354d39b1c"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i5c9b9934bd1f4b4a87e74584ffe44869_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi0xMC0xLTEtNzAwNjA_22160fca-b176-4a5e-a418-d899e69fae48"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i5c9b9934bd1f4b4a87e74584ffe44869_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi0xMi0xLTEtNzAwNjA_a0444988-5da0-4b6b-9420-c9b4577335e3"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i95be96bc66a447e49b2e6b3eb139bb61_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMi0xNC0xLTEtNzAwNjA_457d83ba-ed77-4962-9831-f16f5029c2c9"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i364de02410824f29aef894a8c443af3b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy0yLTEtMS03MDA2MA_8d279ca4-1d39-4512-b1e4-7c46e7446262"
      unitRef="usdPerShare">11.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5f346e6310724b48be23ba52453dfd1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy02LTEtMS03MDA2MA_d3e2fb57-130a-47bd-bf76-aaf7c5dab799"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="ib269223dc4c241d2ab59180afde39e5e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy04LTEtMS03MDA2MA_b523c48d-48b9-4331-b6e5-217f82eae191"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ib269223dc4c241d2ab59180afde39e5e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy0xMC0xLTEtNzAwNjA_201c28f0-e720-466e-b789-364b5c8f1600"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="ib269223dc4c241d2ab59180afde39e5e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy0xMi0xLTEtNzAwNjA_9c0ba542-fbbe-45c3-8738-1334357cd070"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i364de02410824f29aef894a8c443af3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfMy0xNC0xLTEtNzAwNjA_01b5db97-2e15-43c9-a1e7-4110d427c067"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3afe3a9ad2a74fa9a621bbc8ca349720_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC0yLTEtMS03MDA2MA_2bbf16c3-ecc2-4544-aefb-d82415ffb656"
      unitRef="usdPerShare">11.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i65a150a7d69f42ab95bb4eebf536a4eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC02LTEtMS03MDA2MA_2ed9aee8-d219-477d-83d5-5670ced7cb0e"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="icd894f48683d467eade7ea10a3423375_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC04LTEtMS03MDA2MA_1036f754-0a26-476e-8146-611b549268ff"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="icd894f48683d467eade7ea10a3423375_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC0xMC0xLTEtNzAwNjA_6b6b0877-9a3b-4867-8e8e-3e41f0f80a62"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="icd894f48683d467eade7ea10a3423375_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC0xMi0xLTEtNzAwNjA_7f49d4c3-bf6d-4b1f-95fc-cb5ec780e094"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3afe3a9ad2a74fa9a621bbc8ca349720_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNC0xNC0xLTEtNzAwNjA_d8bdc8de-8ec8-42f0-aa7e-15002236b180"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS02LTEtMS03MDA2MA_10cee008-8058-4bf2-a861-b37678e51690"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS04LTEtMS03MDA2MA_cd51f334-05e2-452c-81ce-9ef497daa69d"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS0xMC0xLTEtNzAwNjA_f74f2d5a-bfd4-48fa-94b3-0c5bf54d84d8"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS0xMi0xLTEtNzAwNjA_5add3671-3e04-45ff-a4f5-c1d4068101f6"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82NC9mcmFnOmVmMDE2ZjQ3ZmMzZDQzZjViYWYyNTY3YjY4YjFlNDQ4L3RhYmxlOmZkZTMyZTM1MzBhNTQ5NWJhYTRhNzg3ZWU1NjViNmUyL3RhYmxlcmFuZ2U6ZmRlMzJlMzUzMGE1NDk1YmFhNGE3ODdlZTU2NWI2ZTJfNS0xNC0xLTEtNzAwNjA_6f909496-af9b-4661-aaa1-23c2398fbc73"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RleHRyZWdpb246ZGI5Yzc0NTljMWNjNGMzMDkyODU2MmJhNTM3NDJhZTNfMTM4OA_6af94a48-fe3e-4335-ad3e-87a9e8c311d9">EARNINGS (LOSS) PER SHARE&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#x2019;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RleHRyZWdpb246ZGI5Yzc0NTljMWNjNGMzMDkyODU2MmJhNTM3NDJhZTNfMTM4OQ_82219234-81b4-4c70-a4a9-fb94d03e9c74">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i69d2c5c201c146a29dc3f4aaab1fa94b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMi0xLTEtMS03MDA2MA_96a5f33f-6fb1-463d-9142-85f4b1013da4"
      unitRef="shares">199000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if89d59ad112c41c1a5e5e4945e45b3a0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMi0zLTEtMS03MDA2MA_83991747-9a62-43f9-9a36-287e86809662"
      unitRef="shares">1394000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1832afd10f54cc791caad58fb173350_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMi01LTEtMS03MTc2MQ_2137c497-36f9-4cc4-b11a-32554868a7c2"
      unitRef="shares">199000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia2b6f3706013458ab5961aa0a088fa40_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMi03LTEtMS03MTc2MQ_b63dfc19-ca64-4a51-9b17-1a0cbf989ce2"
      unitRef="shares">1394000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6362c9affd304cba8c070c705be6dd77_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMy0xLTEtMS03MDA2MA_d038aeee-07f7-44c7-bade-90aa25a79def"
      unitRef="shares">17161000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i369610441fa049a9b3af81518e15d50d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMy0zLTEtMS03MDA2MA_0fbbf7d5-a018-49f6-81e9-dfbc9feac102"
      unitRef="shares">17349000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i831e2ac854704d1aae0e81436d368ad4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMy01LTEtMS03MTc2MQ_d2f32e65-14a1-4b53-910c-573d14e12d84"
      unitRef="shares">17161000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic013dea044994c0b9999755d2814f233_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfMy03LTEtMS03MTc2MQ_9c1484fc-7443-4063-bcb0-9d3f4aa7b6b6"
      unitRef="shares">17349000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i95d8a6c363c94c7ebb181ec0e4902d6d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC0xLTEtMS03MDA2MA_2906ce16-dbde-4600-9199-bfede13f56ac"
      unitRef="shares">8063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3a5c4a87f8a04b809066ca30fe8adea9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC0xLTEtMS03MDA2MA_c0cc2daf-c33f-433a-b911-27c7cbc2b805"
      unitRef="shares">8063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if7a6d05611034f0cbfbdc965d1641901_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC0zLTEtMS03MDA2MA_e346bfad-f56e-4f31-8eac-9aaeb3a6a60e"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5b119b75001e4eb591c83a48aca8ad9e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC0zLTEtMS03MDA2MA_ef7e05ff-9cde-4d18-9206-eeb1c8ea1f66"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibdffcc8e474644f1a7bc79d73e44c345_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC01LTEtMS03MTc2MQ_1bcfcd7c-eb4a-415e-b03a-0ea3b650a1b3"
      unitRef="shares">8063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1c426ecc6b6e483ab968812e43898fb8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC01LTEtMS03MTc2MQ_f716397c-ce53-47dc-96e1-4f468c1a529f"
      unitRef="shares">8063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i371ff9f9dd74484bbb7af64395b59cb2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC03LTEtMS03MTc2MQ_66a8dd27-9aa7-45e2-b3a2-6ecd1740339c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf3d53abab674300a3e66f4bbf777a4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNC03LTEtMS03MTc2MQ_e2cbf525-410b-4f47-9619-db1e278caac2"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNS0xLTEtMS03MDA2MA_621fb7aa-ac8a-4f62-b67d-3bbff4ecf6f0"
      unitRef="shares">25423000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNS0zLTEtMS03MDA2MA_d62c48d5-9b12-47d9-ba3c-c8ba0f5c427a"
      unitRef="shares">18743000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNS01LTEtMS03MjUzNg_094c2dea-0bb5-4250-a1e7-639c5729caef"
      unitRef="shares">25423000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV82Ny9mcmFnOmRiOWM3NDU5YzFjYzRjMzA5Mjg1NjJiYTUzNzQyYWUzL3RhYmxlOjgyOGI4MjViNzQ0NzRhNjc5YTRiM2VjMDMyZjM3MmZhL3RhYmxlcmFuZ2U6ODI4YjgyNWI3NDQ3NGE2NzlhNGIzZWMwMzJmMzcyZmFfNS03LTEtMS03MjUzNg_9a785620-239f-4bd6-b9ca-9fcf84f110d5"
      unitRef="shares">18743000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk0OQ_bb14078c-32f3-422c-a254-f5be8e903634">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:238.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,696&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#x201c;evergreen&#x201d; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#x2019;s stockholders in May 2021, the Company&#x2019;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 3.1&#160;million shares of common stock available for issuance under the 2014 Plan as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 13.6 million stock options outstanding under the 2014 Plan as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#x201c;Retention Program&#x201d;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#x201c;PSU&#x201d;) award equal to the value of approximately fifty percent of then-current base salary. The fair value of PSUs at the grant date was $0.4&#160;million. Each PSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of June&#160;30, 2022 achievement was deemed probable for only the cash management milestone, representing $87,000, 20% of the PSU awards. Therefore, $11,000 and $33,000 have been expensed during the three and six months ended June 30, 2022, respectively and $54,000 remains measured but unrecognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2009 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of June&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-of-Plan Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;here were approximately 3.5 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense, related to stock options, of $1.2 million and $2.5 million for the three and six months ended June&#160;30, 2022, respectively and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.3 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.2 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and six months ended June&#160;30, 2021, respectively. As of June&#160;30, 2022, there was $8.6 million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of 2.36 years. The weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2022 and 2021 were $0.46 and $2.17, respectively. No stock options were exercised during the six months ended June 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units and Performance Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not grant any RSUs or PSUs during the six months ended June 30, 2021. &lt;/span&gt;&lt;/div&gt;The share-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2022 was $0.6 million and $1.2 million, respectively. There was no shared-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2021. As of June&#160;30, 2022, there was $3.0&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk1MA_b07b57d9-d84d-4e17-8453-0315d7310852">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:238.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,696&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i30153c69f900480b8a7b0d198d30b92d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMi0xLTEtMS03MDA2MA_e352acd1-52e8-4f5c-aae6-a5b5db65ca38"
      unitRef="usd">473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i70c58c1e89d74a42975680f91f9ea952_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMi0zLTEtMS03MDA2MA_840c1cc7-92b1-4cae-a39c-f3a69dd861a7"
      unitRef="usd">207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7184f2bd1645489a8e93fd75f730b37a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMi01LTEtMS03MTU0Mg_bafff51a-b97b-428b-ad2d-baa7a4f0749a"
      unitRef="usd">975000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifb927ed78cfd4508b0462135a3c2436f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMi03LTEtMS03MTU1MA_9d7b709b-e08b-4fd2-9cd8-d4d49a532ec9"
      unitRef="usd">386000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2701137d4d3d4c4e8e5113cfb9b9bf7d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMy0xLTEtMS03MDA2MA_e97825f7-4437-4cda-ba46-e20a56a7d471"
      unitRef="usd">1329000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib379188f80ee457e82a023166eab9d6d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMy0zLTEtMS03MDA2MA_790d6cb2-2e02-4eb2-ac68-ec8b44206bb7"
      unitRef="usd">1052000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3bd5ecb234e84849a3ef40071493ded8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMy01LTEtMS03MTU0Mg_b52cfc78-d42a-42e6-b6fb-b24b199ea91b"
      unitRef="usd">2721000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c124cc8b22a40b89b467199316812d8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfMy03LTEtMS03MTU1MA_9712802f-d5d0-492f-a888-149f97081ad3"
      unitRef="usd">1831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfNC0xLTEtMS03MDA2MA_1482d817-cdd7-484b-82cb-715f52faef2a"
      unitRef="usd">1802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfNC0zLTEtMS03MDA2MA_6497be89-ddcb-4cb9-84b9-5e457b1a533b"
      unitRef="usd">1259000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfNC01LTEtMS03MjU0NQ_4a347a83-8e02-4135-8c4a-23d9a58c9d10"
      unitRef="usd">3696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmM2ZGUyMWM3ZWI2MzRhODY4YTMyYTg2MTU0MmFlMDE4L3RhYmxlcmFuZ2U6YzZkZTIxYzdlYjYzNGE4NjhhMzJhODYxNTQyYWUwMThfNC03LTEtMS03MjU0NQ_bb4c9a67-961c-4938-8291-b9b532a120fd"
      unitRef="usd">2217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="ie611da9814584f9980040a27dfc0cff0_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5NQ_9e7c5dcb-38df-446a-aa34-3d012faad728"
      unitRef="shares">7900000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="if40d7dc2760c4b73a1bf0f58cb0cea20_D20210501-20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTU2NA_f4bf573a-5c17-4494-b42d-faa2cd81b57f"
      unitRef="shares">12000000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i67dda89a221d455f9646b0da9c4929bc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTY3Mg_1fd7bb29-f210-4a41-a6b7-1443dc676425"
      unitRef="shares">3100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifa54545585df44e4b7d3a89233f8dfaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk0Nw_2aa1bedf-9097-409c-a1ef-6243cff49a31">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2df208e090e4403eb77e13ead4f86d17_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTg0OQ_5e81fd83-27a8-4093-92e4-026f37eb5d35"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id9d2c51fc9d34a20a514bea566541f46_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTkyMw_ff201e03-1bc2-4c7b-b31a-af74245f1a83"
      unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifa54545585df44e4b7d3a89233f8dfaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTY0OTI2NzQ0OTU4NQ_fd69c6f2-21a2-4f07-8b2f-173a92078721">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i67dda89a221d455f9646b0da9c4929bc_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjYzNw_c08f7597-861d-4fbe-9e01-a8a1f2877e8c"
      unitRef="shares">13600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="i015ea6430d994fbc8697ad17d12ffea0_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMjg0Ng_0abf78a3-5cb3-4f4d-bf3b-59eda65cfb9d"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary
      contextRef="i8e3af4b7d2cd45f48969782be08ae91a_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMzE1MQ_b6ca2668-651b-422d-9a39-af41a97fd2de"
      unitRef="number">0.50</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i8e3af4b7d2cd45f48969782be08ae91a_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTgzOA_7abe3a35-2b7e-4e4b-af4e-a7694d226052"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="i8e3af4b7d2cd45f48969782be08ae91a_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMzIzNg_f5420bcb-ffaa-4a6f-be56-534db429e727"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ice9190fd4c5e4b23a2cfa99f52b8d06e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTkyNQ_8e832fc8-f79c-4364-a947-25be25d71491"
      unitRef="usd">87000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent
      contextRef="i316721534e954709ac4ca98fac589f21_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMzcxNw_25894d21-3599-4af7-9b43-6cf956eec774"
      unitRef="number">0.20</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92ebc00eafc24ccc9dfc43c74893c366_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTg5MA_02ed793b-f626-4600-a95a-9716ac57e00c"
      unitRef="usd">11000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd52d29ba82b4fc3a132c9324d52f501_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTg5OQ_0cbc24f7-aee3-4bce-b670-22b4b9fb43a5"
      unitRef="usd">33000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i316721534e954709ac4ca98fac589f21_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0NzMxMzk2MTg4MQ_8a1f0271-002e-45dc-9c02-0bb9a2ffe0e0"
      unitRef="usd">54000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i03957233ce864a5a98dacdf6ed5a459b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDY3MQ_114f0cb4-d1c1-4f93-896e-761d1c3527ac">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i03957233ce864a5a98dacdf6ed5a459b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDcyMw_3f376f56-8c17-4c51-91d4-c88c95216592"
      unitRef="shares">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1d5814f76b2747c3bb68d3ded24afaba_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNTIzMQ_fceab105-4edc-4561-a99c-0a77e860675e"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk2Mw_62ad3cc0-4858-46bf-a6fb-b81c3feaaff8">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMS0xLTEtMS03MDA2MA_b074117c-265a-4cfb-8309-9cdc26f05c9d"
      unitRef="shares">15703000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMS0zLTEtMS03MDA2MA_d2e3a15f-5101-4368-8469-7b8cc1002841"
      unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i734f190a8be94ab0a3e93a4104c4affb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMS01LTEtMS03MDA2MA_dbc2f835-4c9f-4031-ac51-524902eb43fa">P8Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMS03LTEtMS03MDA2MA_932d40d4-67b2-43ac-8dd8-a3d0b64e1213"
      unitRef="usd">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMi0xLTEtMS03MDA2MA_c0bcf819-55a9-40fd-8fc4-f8b211103d86"
      unitRef="shares">1511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMi0zLTEtMS03MDA2MA_2b365ee3-1ed4-4424-a569-cd71f190f075"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMy0xLTEtMS03MDA2MA_3a0ea5e2-22e3-4282-99c5-e56e2da01db9"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfMy0zLTEtMS03MDA2MA_28b44aff-e9de-4b5a-aa48-e0671b95dc19"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNC0xLTEtMS03MDA2MA_3674e18e-629c-47d3-acc0-96b87703d3a8"
      unitRef="shares">53000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNC0zLTEtMS03MDA2MA_8f563fc9-30ef-4cc7-a4a2-bf418215bfbf"
      unitRef="usdPerShare">1.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNS0xLTEtMS03MDA2MA_670fe141-2fe7-4902-85be-87c74e643cdc"
      unitRef="shares">17161000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNS0zLTEtMS03MDA2MA_dee752fe-b4c5-4a5b-b16c-e67e7c35e212"
      unitRef="usdPerShare">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNS01LTEtMS03MDA2MA_502f4cd6-4461-4cf1-9dab-4c4a7e118df8">P7Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNS03LTEtMS03MDA2MA_e9d3f204-45ec-4507-b0d4-292f717e1347"
      unitRef="usd">218000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNi0xLTEtMS03MDA2MA_ef753b66-8532-4524-802c-90df3d1a5dbb"
      unitRef="shares">9555000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNi0zLTEtMS03MDA2MA_f749e7b3-2553-42af-86bd-28c5200ac8d1"
      unitRef="usdPerShare">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNi01LTEtMS03MDA2MA_83c70437-c703-4ad4-a6b5-d8be4161a3e1">P7Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOmJhNTY5ZjY0ZjU2YTRjZDE4MzA1MTVhMTBlZmQ3N2ViL3RhYmxlcmFuZ2U6YmE1NjlmNjRmNTZhNGNkMTgzMDUxNWExMGVmZDc3ZWJfNi03LTEtMS03MDA2MA_59b36cb2-82cd-443a-8c2f-f7d434fe69a5"
      unitRef="usd">64000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4286168bb23741ed8ede08217b5079cd_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5OTUxMTYzNTA3MQ_d6d34b88-246f-4781-aa5a-f3a927bff6cd"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5OTUxMTYzNTA3Nw_f72e93fe-57c9-406e-958e-14773eb6bfc1"
      unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idddc6e09a127406fb21bab2cff01e6a3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5OTUxMTYzNTA4Ng_5ad73616-6f67-4d1f-b284-1d9c2181f4ce"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfMTA5OTUxMTYzNTA5Mw_f6270821-f4dc-4cb5-b1db-f8105c5c8ae7"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjUyOA_8427e53d-35d2-4c66-b4c5-cca2e7ec7444"
      unitRef="usd">8600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjUzOA_85afafa3-0cdf-48fc-b2ab-306e19717b01">P2Y4M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjAxNg_15b91abd-3696-4a6f-a5de-98f9573dd711"
      unitRef="usdPerShare">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjAyMw_3aa259e7-3b05-499f-956f-6f0de92e55ff"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjA0MQ_a1fda340-a876-41b8-b043-c093bc1c04e8"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk1NA_e5b87275-4da7-4767-8188-5dd2ae131035">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfMi0xLTEtMS03MDA2MA_8b602c4e-ed57-4447-91fa-9930bc72dede"
      unitRef="usdPerShare">0.72</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfMi0zLTEtMS03MDA2MA_12c9d98d-f686-4d46-ad0b-86673654a67e"
      unitRef="usdPerShare">3.34</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="if12ac6d811ab49fea4ae767cff635f67_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfMy0xLTEtMS03MDA2MA_a2210ebc-432c-4683-bffe-f129a456a464"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i40d49584882e49c39b789667e1aa8b9a_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfMy0zLTEtMS03MDA2MA_7bd2b1e5-0d27-4b1d-984d-cdac9c3f50e9"
      unitRef="usdPerShare">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNC0xLTEtMS03MDA2MA_c6a4c827-37b3-429a-b964-11c1e0224aff">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNC0zLTEtMS03MDA2MA_24216456-70d2-4f0b-974e-7cbee099e687">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNS0xLTEtMS03MDA2MA_6df5ac39-3d1b-462c-96ed-8052825e9230"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNS0zLTEtMS03MDA2MA_1e567020-e862-479c-adeb-4e7fbd00db41"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNi0xLTEtMS03MDA2MA_ca745a92-f0db-4694-ae61-5a157767f2fa"
      unitRef="number">0.718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNi0zLTEtMS03MDA2MA_6c97ddce-8d9a-4d2e-ad25-22c9287b7b93"
      unitRef="number">0.747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i278e1922f5954901947c7da7b025ffda_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNy0xLTEtMS03MDA2MA_d2c519b9-bfa1-46cd-8588-c6baf83281c6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ifab6b1200b524cc5998a727ec8f25f35_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjk4ZjU4ZmJlOWVhMDRkMDU5MGNiMzk5NTc4NDhkMmRlL3RhYmxlcmFuZ2U6OThmNThmYmU5ZWEwNGQwNTkwY2IzOTk1Nzg0OGQyZGVfNy0zLTEtMS03MDA2MA_a50636e3-8ec7-4769-9ca5-713218b28256"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjk1NQ_ffc132c2-79b6-4e9e-90ad-82de41763e43">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMS0xLTEtMS03MDA2MA_f42e0fb7-59df-4d89-8f21-b556dcd74dff"
      unitRef="shares">3041000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMS0zLTEtMS03MDA2MA_b1566b51-f392-4bd9-8794-47187b2c45e0"
      unitRef="usdPerShare">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMi0xLTEtMS03MDA2MA_5181800f-6171-464f-99ab-0bea6a0c302e"
      unitRef="shares">4161000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMi0zLTEtMS03MDA2MA_299997ff-c49b-4ba0-9214-6faddfd6f6b9"
      unitRef="usdPerShare">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMy0xLTEtMS03NjY5Ng_93ca7ba8-8ecb-4c72-a745-84bb1ea69a89"
      unitRef="shares">143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMy0zLTEtMS03NjY5OA_13929d6d-7652-47ea-aef6-ef0172599dc8"
      unitRef="usdPerShare">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idd2fc190c9bb4eac8b5f0a896433b557_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMy0xLTEtMS03MDA2MA_2ac07c39-0891-43b6-b4c5-5924f40990a2"
      unitRef="shares">1004000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd2fc190c9bb4eac8b5f0a896433b557_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfMy0zLTEtMS03MDA2MA_fe8ba43a-5ab2-4a7b-857d-a1bdb7ffb508"
      unitRef="usdPerShare">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfNC0xLTEtMS03MDA2MA_3819d022-d7b2-49d7-8e2e-fe17670ea0a8"
      unitRef="shares">8063000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RhYmxlOjRiY2ZmNGQ0ZTQ1ZjQwZGRiOGQxNWJmODIzN2RjMzMxL3RhYmxlcmFuZ2U6NGJjZmY0ZDRlNDVmNDBkZGI4ZDE1YmY4MjM3ZGMzMzFfNC0zLTEtMS03MDA2MA_6af85260-19ba-4e7e-9bdf-3c4b75d64c42"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ided647db41004402b85556f36c1a5a6a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjU0OA_2df8fed1-09b0-4281-8eae-0e79e616ad60"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib5a0f88a3ce248ca80278fd875407820_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjU0OA_4d0104cf-5c44-4311-88a6-c35f8184e6b7"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i75f185aabf3c422eb49cc6accab9e6cd_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjY4NA_12c62753-5cf0-4b30-ba56-f0ca67a4cc9a"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i517f238357944a0796854ba08409d69f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjY4NA_7d983bbe-6aab-4967-8360-5f385630c96a"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5887d0c8af474b9da60db574f802c013_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjY3Nw_18aff027-aa93-42be-acea-5282b9964be5"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd2fc190c9bb4eac8b5f0a896433b557_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNDk0NzgwMjMzMjY3Nw_8288e0da-2109-4a30-a467-9b2251bd66e4"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib5a0f88a3ce248ca80278fd875407820_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjY4Mg_01ae3446-d5aa-4c40-bec5-8feb1a65fdd5"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ided647db41004402b85556f36c1a5a6a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjY4Mg_33787c68-bdce-4a1b-8404-7c3f83294dac"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="idf83b58ca25c49e192a0c8602c5b4cf2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjc4OA_c7676eb5-199b-4959-8172-4d07c54a0f05"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i0ad270b4c89440e0821ae038d2cb2389_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83MC9mcmFnOmUxYTk5Zjk1N2U5OTRjMWE5NDVmOWI4OTU1YjNlNTY2L3RleHRyZWdpb246ZTFhOTlmOTU3ZTk5NGMxYTk0NWY5Yjg5NTViM2U1NjZfNjc4OA_d741d720-9d0f-4bdc-a026-b3b154ce42a9"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMjYzNQ_306845c1-1aab-4f90-af09-22e6e9fe0236">EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of June&#160;30, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP during the six months ended June 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States - 401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canada - Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic9b0b2106a50498eb917274f3a68063a_I20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMzg2_2897de74-3603-4a5c-8baf-4c6fb5691e79"
      unitRef="shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i665443501e7f49ecae379e80a026aa5e_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfNjE2_a9e81df5-8257-4fae-9a63-ab957f65a7d4"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i5f79c7546bc741bfb209ea4731a1b39f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfOTYz_9567e95e-d9a1-43a3-89b6-5a628ff16915"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i72b00192c39e430cbe5b0b12c9d8d89c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMTM4Ng_938f5541-401a-445a-9b96-e44f918c98d5"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ie820aa9d32f54e368d97eb79949bb246_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMTg0MA_54f60d7a-f37f-4caf-a460-30a9e66de85e"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee
      contextRef="ie820aa9d32f54e368d97eb79949bb246_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMjAzOQ_44b50922-14ca-41c9-941b-86823c64414b"
      unitRef="usd">4000</sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i877a2547d28941a6974c361f55d0df05_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83My9mcmFnOmRlZGQ3MTExZGExYzQxODY5ZGFlYmE1OGNjMDk0ZTJhL3RleHRyZWdpb246ZGVkZDcxMTFkYTFjNDE4NjlkYWViYTU4Y2MwOTRlMmFfMjQzNg_7f651a88-7c1d-4a3c-8934-01923bfed032"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzYwNDczMTM5NTYyMDM_e15a0e11-db0e-4d90-b35a-fa6ea1e58bc0">INCOME TAXES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Loss before Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(80,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,875&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred tax liability is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2022, the Company recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, the Company determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7&#160;million. In connection with this impairment charge, the Company reversed the associated deferred tax liability by $4.0 million as an income tax benefit, partially offset by $0.1 million income tax paid to foreign jurisdictions pursuant to the exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#x201c;Qilu&#x201d;) (the &#x201c;Qilu License Agreement&#x201d;). Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the six months ended June 30, 2021, the Company recorded a provision for income taxes of $0.3 million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the Qilu License Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzYwNDczMTM5NTYyMDQ_3194015a-2b41-4134-88a4-ed8a24ceeb25">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Loss before Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(80,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzMtMS0xLTEtNzYwNTY_22f0ac6d-c9fb-4041-beba-9403ec2d7b40"
      unitRef="usd">-55939000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzMtMy0xLTEtNzYwNTY_64c924c4-3a41-46d2-a43f-6fd0aa3082e4"
      unitRef="usd">-21210000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzQtMS0xLTEtNzYwNTY_66104dae-f1e5-4ed8-aea9-5466d76a371b"
      unitRef="usd">19297000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzQtMy0xLTEtNzYwNTY_f377e6c8-b15a-4cdb-be0f-2bb0dd0bbb32"
      unitRef="usd">-59456000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzUtMS0xLTEtNzcwNjc_931f8d5b-7b8c-4125-981d-cae0481b43ad"
      unitRef="usd">-36642000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpiNDdjZGE4ZjM4OWQ0ODFmOWQ2NDMyMTRmZTNkZTkwMC90YWJsZXJhbmdlOmI0N2NkYThmMzg5ZDQ4MWY5ZDY0MzIxNGZlM2RlOTAwXzUtMy0xLTEtNzcwNjc_02706232-b989-4536-add7-7842b80636cf"
      unitRef="usd">-80666000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzYwNDczMTM5NTYyMDU_b6844e5b-e75f-4e00-b1f5-64a203ff9aec">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,875&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpjNGU0ZWIzYWJhN2M0YzcwYTc4ZjE4YjhjN2IwMTMzYy90YWJsZXJhbmdlOmM0ZTRlYjNhYmE3YzRjNzBhNzhmMThiOGM3YjAxMzNjXzUtMS0xLTEtNzYxMDM_7f74b6ea-4ccd-4823-b727-f52d7db213a0"
      unitRef="usd">3875000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpjNGU0ZWIzYWJhN2M0YzcwYTc4ZjE4YjhjN2IwMTMzYy90YWJsZXJhbmdlOmM0ZTRlYjNhYmE3YzRjNzBhNzhmMThiOGM3YjAxMzNjXzUtMy0xLTEtNzYxMDM_9ecfef74-162e-4f4a-ad61-204c419e0e11"
      unitRef="usd">-288000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpjNGU0ZWIzYWJhN2M0YzcwYTc4ZjE4YjhjN2IwMTMzYy90YWJsZXJhbmdlOmM0ZTRlYjNhYmE3YzRjNzBhNzhmMThiOGM3YjAxMzNjXzYtMS0xLTEtNzcwNzA_d0999a9e-69e1-4526-a257-7f6806063f2d"
      unitRef="usd">3875000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZTpjNGU0ZWIzYWJhN2M0YzcwYTc4ZjE4YjhjN2IwMTMzYy90YWJsZXJhbmdlOmM0ZTRlYjNhYmE3YzRjNzBhNzhmMThiOGM3YjAxMzNjXzYtMy0xLTEtNzcwNzA_73525a5e-ca9f-4203-829b-b58a2395a966"
      unitRef="usd">-288000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzYwNDczMTM5NTYyMDY_600a3948-98b9-402e-bb55-b0d73357155a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred tax liability is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZToxZmViNThhMWYzMDc0NjMzYWI1NGE4NzYwYzBkMDg4NC90YWJsZXJhbmdlOjFmZWI1OGExZjMwNzQ2MzNhYjU0YTg3NjBjMGQwODg0XzItMS0xLTEtNzYwNTY_9cd3b1f6-c690-4fa0-837d-d9b793ce0e00"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZToxZmViNThhMWYzMDc0NjMzYWI1NGE4NzYwYzBkMDg4NC90YWJsZXJhbmdlOjFmZWI1OGExZjMwNzQ2MzNhYjU0YTg3NjBjMGQwODg0XzItMy0xLTEtNzYwNTY_d0a862ef-7f24-4306-a973-dba8e021991f"
      unitRef="usd">3969000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZToxZmViNThhMWYzMDc0NjMzYWI1NGE4NzYwYzBkMDg4NC90YWJsZXJhbmdlOjFmZWI1OGExZjMwNzQ2MzNhYjU0YTg3NjBjMGQwODg0XzQtMS0xLTEtNzcwNzM_d12e26d3-9e93-4c1b-af7a-e5838650be2e"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90YWJsZToxZmViNThhMWYzMDc0NjMzYWI1NGE4NzYwYzBkMDg4NC90YWJsZXJhbmdlOjFmZWI1OGExZjMwNzQ2MzNhYjU0YTg3NjBjMGQwODg0XzQtMy0xLTEtNzYwNTY_6b691747-5119-454e-9a0c-997b4bf43ea4"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjY5MDc_5dd07100-4a60-4837-b68b-ba69557d0adf"
      unitRef="usd">-3900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="iaafbcb1be87d432d8ded324e6ed76889_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzE2NDkyNjc0NDY3NzU_d456cea5-0416-4a55-9d4e-bde8cfe0955a"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="id9d33e85d61e44c4bfd117e7d31fe670_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjg0Mzc_920f04dc-848c-4c04-812e-c62b30a94e67"
      unitRef="usd">14700000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <sesn:IncreaseDecreaseInDeferredTaxLiability
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjcyMTU_34f2bd16-489b-48ab-b02f-dfeff22ed4dc"
      unitRef="usd">-4000000</sesn:IncreaseDecreaseInDeferredTaxLiability>
    <us-gaap:IncomeTaxesPaid
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjcyNTM_ca8fb875-989e-4b6a-b601-24c5af0a7429"
      unitRef="usd">100000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i55c60928f9134240b98ed2262bfac61c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV85NTEvZnJhZzo5ODFhYmQ5MTUyZjE0ZGQ3YWNiMTQwY2Y4ZTg0ODQ3Ny90ZXh0cmVnaW9uOjk4MWFiZDkxNTJmMTRkZDdhY2IxNDBjZjhlODQ4NDc3XzQ5NDc4MDIzMjg0NDU_1cdb2aec-d571-49bc-addb-5043875cf12b"
      unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <sesn:LicenseAgreementTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjA4MTQ_c1c504c4-79a7-4922-b7b4-bda4bc3fc667">LICENSE AGREEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Zurich&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#x201c;Zurich License Agreement&#x201d;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $0.5&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to meeting a development milestone, (the submission of the Company&#x2019;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#x2019;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Micromet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#x201c;Micromet License Agreement&#x201d;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of June&#160;30, 2022, the Company may be obligated to pay up to &#x20ac;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.5&#160;million at exchange rates in effect on June&#160;30, 2022). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#x20ac;50,000 (approximately $52,148 at exchange rates in effect as of June&#160;30, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#x20ac;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ecember 2020. The Company recorded an expense of &#x20ac;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#x2122; in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with XOMA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#x201c;XOMA License Agreement&#x201d;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#x2019;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Roche License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into the license agreement with Roche (the &#x201c;Roche License Agreement&#x201d;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#x2019;s monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#x201c;Roche Licensed Product&#x201d;) and pursue ongoing patent prosecution, at its cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received from Roche an upfront license fee of $7.5&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase III clinical trial, (ii) $50&#160;million in regulatory milestones and (iii) $75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provisions of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Codification 606, Revenue from Contracts with Customers ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606&#x201d;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in previous periods. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Buy-Out Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche License Agreement provides for two &#x201c;option periods&#x201d; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#x201c;Initiation&#x201d;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30 days after Roche&#x2019;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#x2019;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the Roche License Agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to June 30, 2022, the Company executed an asset purchase agreement with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. See further discussion in Note 19. "Subsequent Events".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OUS Business Development Partnership Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qilu License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2020, the Company and its wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to develop, manufacture and commercialize&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Vicineum (the &#x201c;Qilu Licensed Product&#x201d;) for the treatment of NMIBC and other types of cancer (the &#x201c;Field&#x201d;) in China, Hong Kong, Macau and Taiwan ("Greater China&#x201d;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#x201d;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of VAT, which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Qilu Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#x201c;Royalty Terms&#x201d;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#x2019;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020. As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MENA License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained within the stated timeline and was initially recorded as deferred revenue. During the second quarter of 2022, the Company changed assumptions in the clinical study design which resulted in longer clinical trial and further delay in regulatory approval in the MENA region. Therefore, the Company reclassed $1.5&#160;million of deferred revenue to short-term accrued liability as of June 30, 2022. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million was recognized in the first quarter of 2021. Additional variable consideration, determined to be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2022, the Company terminated the MENA License Agreement as a result of the Company&#x2019;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;EIP License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2021, the Company entered into an exclusive license agreement with E&#x130;P Eczac&#x131;ba&#x15f;&#x131; &#x130;la&#xe7; Pazarlama A.&#x15e;., (&#x201c;EIP&#x201d;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#x201c;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The EIP License Agreement is subject to the provisions of ASC 606 and as of June&#160;30, 2022, none of these amounts have been received by the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; No initial transaction price was estimated by management;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; therefore, no revenue was recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30&lt;/span&gt;, 2022, the Company terminated the EIP License Agreement as a result of the Company&#x2019;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.</sesn:LicenseAgreementTextBlock>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i18a706cafcaf41aab0bf2bbae702174f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjUz_b190991e-fb56-4f95-8d58-37c8a23f4a07"
      unitRef="usd">500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i1d04fb2cb1d2410b8938ae078b9fd516_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzY2_6644fcb9-09d6-4a50-844c-b9ea7c07f279"
      unitRef="number">0.04</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="i1d04fb2cb1d2410b8938ae078b9fd516_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTA2Mg_36e2c8f2-666d-4be3-bb47-e7cd471b500e"
      unitRef="number">0.10</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="i1d04fb2cb1d2410b8938ae078b9fd516_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTEzOQ_179d3426-b1fe-4fbe-94b9-a39bd618bb5c"
      unitRef="number">0.02</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="ic6f9d2a8d9b34e2ea5321b0774bc4cd3_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUzMQ_e6073dc2-00cb-48ff-b9ca-c894f8b9d7c8"
      unitRef="usd">300000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i9a026aa3a4334726bbd5d5b4169de5ac_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUzOA_7b36323e-1f05-4d16-99da-3e27466011c8"
      unitRef="usd">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjI5Mw_2eb84144-66b8-464a-a1cf-ab24b4e2e33b"
      unitRef="eur">2400000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjQ0MA_6e98845c-62b4-4287-9537-65a95e7c3182"
      unitRef="usd">2500000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjUyMw_4697a092-f033-4de7-9159-b3c954907257"
      unitRef="number">0.035</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent
      contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjY5Mg_b7e16036-bced-4822-8087-a793ea204004"
      unitRef="number">0.015</sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent>
    <sesn:LicenseMaintenanceFees
      contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzA4NQ_1b9bcaac-c16d-4e1c-bebd-5a7590d96b32"
      unitRef="eur">50000</sesn:LicenseMaintenanceFees>
    <sesn:LicenseMaintenanceFees
      contextRef="i9e0f7d44353c451f9b5eaef787b9e801_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzEwMw_d6091320-8b3b-403a-9dda-60e3b4ab94d5"
      unitRef="usd">52148</sesn:LicenseMaintenanceFees>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i21cd86819fc94d60888b84c9fbec1cd9_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzI1OQ_5f30312c-39f3-422f-b533-2181669f9bd1"
      unitRef="eur">700000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i21cd86819fc94d60888b84c9fbec1cd9_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzI2Mw_ab248c61-dae2-4558-a4bb-76cdaf0b357a"
      unitRef="usd">900000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="iec3b8c8266c54149935b053a4854e949_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzQ4NA_db051222-3923-48bf-9c23-cbc02670c3b2"
      unitRef="eur">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="iec3b8c8266c54149935b053a4854e949_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMzQ4OA_a7bf6267-d5ce-44b2-b742-90ffe16f7362"
      unitRef="usd">600000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNDE5Nw_29eb53a9-1492-4323-a859-149fdbb6b5cd"
      unitRef="usd">250000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNDUyNw_725978b9-e94a-4e06-a63b-fb45e7b6c6ef"
      unitRef="number">0.025</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNDg0NQ_ae9fe615-5763-4538-9b47-98030e0f59a5"
      unitRef="number">0.0175</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="i3fc1be1ed1454f80adf35ecd406cb059_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNDkxOA_b08e492c-f753-4bf7-9806-e0a7a08bfc4a"
      unitRef="number">0.50</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementUpfrontFee
      contextRef="i01807f2cd89e4e9d84b0e1ec13338d5f_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjEzOA_4a4cbd07-4a66-4884-9b6e-e883364374be"
      unitRef="usd">7500000</sesn:LicenseAgreementUpfrontFee>
    <sesn:LicenseAgreementAdditionalUpFrontFee
      contextRef="i01807f2cd89e4e9d84b0e1ec13338d5f_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjMwNA_659acc48-2574-4c56-ab93-eba463625e69"
      unitRef="usd">262500000</sesn:LicenseAgreementAdditionalUpFrontFee>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ic7f3a1555672448da4256c36f647a2ea_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjQ5MA_0c3159f8-2e96-4107-b35f-26703599b59d"
      unitRef="usd">197500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="icedd019379624203beb6559637b67e52_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjYxOQ_a6de7bc1-a875-48aa-9624-024424b931b5"
      unitRef="usd">72500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i71e7893a75ac4fcdbb28b05eddc7e79e_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjY3MA_a194312f-ba9c-498f-affb-165cea38816d"
      unitRef="usd">30000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i56d94eda0f1e46ba9ba00a785398fb15_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjczMg_2551bf09-d424-4dd4-bf15-da7d356bb20b"
      unitRef="usd">50000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i87cb0e785fa74c60b27360b6bae115b5_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjc3MA_fd7acc12-5985-4f7f-811a-f6679adb245e"
      unitRef="usd">75000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i8afbb1e24e95451fb3040230f72e3eea_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjgzNA_ab8e6a4f-e43a-4eaf-b6b8-b331907f1bee"
      unitRef="usd">65000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ie0efda518e014299bbb43462ac3cc850_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzAyMw_625b71b2-ff11-4720-ad1c-222d92077d9d"
      unitRef="usd">22500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="i3d81161a92ef494db5814266170b94b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzE2Ng_8d73a963-5ac4-405f-991a-96254f19c361"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="ida7114209f954433a73b2aa4e6273e7f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzU4MA_bd5d125a-be3c-4369-a807-1bf15d05d808"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:AccountsReceivablePaymentTerms
      contextRef="iaebb9ac802f4499ab5d494233003436d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzYwNQ_f0cdfdc5-a86a-41c9-bedb-956f0ca58468">P30D</sesn:AccountsReceivablePaymentTerms>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8c1ee3d4b0ed4b6d81693a3b78436a98_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzcyMQ_bd8097c3-b024-41d1-bf6d-d8375d41e271"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:LicenseAgreementProceedsFromMilestoneAchieved
      contextRef="i1a23e83ac0484f0bbab51200be62df4c_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzg0NA_868cbc9e-1de8-4c37-ad1f-99c09395e400"
      unitRef="usd">20000000</sesn:LicenseAgreementProceedsFromMilestoneAchieved>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i6542b5648ea045f58f4c69b28422077a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNzk5OQ_336fd2eb-c27f-4b17-b648-399dd6ff170b"
      unitRef="number">0.075</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="ifd055427f2ee4af697e38e23fd5f01bc_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfODAwNQ_0ddce68a-8ebb-49e9-97a2-cf678709f843"
      unitRef="number">0.15</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementOptionPeriods
      contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfODM0NA_24b04ef1-2bc0-42b6-aafe-8693323cc088"
      unitRef="period">2</sesn:LicenseAgreementOptionPeriods>
    <sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod
      contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfODg0Mw_67336d1e-8351-4e90-af67-f49d2b28fe6a"
      unitRef="usd">135000000</sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfODg1Mw_95ac6447-4ed6-45e8-a8c7-24001cd855c4">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfOTM1OQ_0ac12285-3458-4996-b674-170ec1866ff2">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod
      contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfOTQ1Nw_a8c3cf9a-090a-4d56-a336-3d325d1f9e18"
      unitRef="usd">265000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct
      contextRef="i6822798f98d34751ae079338ed021602_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfOTQ5NA_eb84696f-7255-4b92-ae46-85c18d285219"
      unitRef="usd">220000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct>
    <sesn:OtherReceivableAssetPurchaseAgreement
      contextRef="ia2e62709d9af4f339539c651a584c514_I20220715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjA0NzMxMzk3Njk1MQ_9607ca64-1105-4cf8-b14e-e9d29576e320"
      unitRef="usd">70000000</sesn:OtherReceivableAssetPurchaseAgreement>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i0492cdffd25d4cf78dc20d704adfe705_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTE3NDc_5a3acec2-bbd4-4db7-9678-22273989ac68"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount
      contextRef="i0492cdffd25d4cf78dc20d704adfe705_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTE3ODk_da30b3cb-8a21-4e04-8742-91cea5f40c4f"
      unitRef="usd">23000000</sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount>
    <sesn:BusinessCombinationRoyaltyPaymentPercent
      contextRef="i0492cdffd25d4cf78dc20d704adfe705_D20200730-20200730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTIwOTE_93e5e5c0-7ac7-486d-97a0-c03c617ec5a0"
      unitRef="number">0.12</sesn:BusinessCombinationRoyaltyPaymentPercent>
    <sesn:CollaborativeArrangementRoyaltyPeriod
      contextRef="id40d181b700547bea2d9b69343d99848_D20200730-20200730"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMjA4MTU_47181c66-3662-4027-8c47-7a73748caf7b">P12Y</sesn:CollaborativeArrangementRoyaltyPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0208600fe4024d29a9aa9d6917193edb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUwMDU_fb771275-38f3-4d14-98cf-a66329b6ae2a"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i60749fcbb0ad4615afcf10b65d11d107_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUwNjE_5ace05ee-8049-4105-a973-7e0d19ad4684"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0b2ff8e61fcd46c299eab19b8098175a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUyNzY_e4ea983b-b5dd-4a4e-bd17-c118938e50df"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0b2ff8e61fcd46c299eab19b8098175a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUyOTI_cc07047a-9703-408f-b5fa-c25ae333152a"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id4b71a855e3048d9a5e32abd82f7ed34_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTUzNjA_7ea6790e-7bae-43e5-a992-d4dd04c9fc83"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:BusinessCombinationMilestonePayments
      contextRef="ib96799ba5a814f0c8caad764cfa9b749_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTU2MzI_90f72a18-c01a-44a9-a749-ec7bef273328"
      unitRef="usd">3000000</sesn:BusinessCombinationMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="ib96799ba5a814f0c8caad764cfa9b749_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTU3MDM_9bc3e0c5-587d-4038-8d43-01ff1f279017"
      unitRef="usd">23000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib96799ba5a814f0c8caad764cfa9b749_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTU3NjA_ca6b2cbe-b1bf-4000-81f1-693d252b91d7"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8ff51dfb75a942b18163f303609e9cf2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTYxNjk_c905199d-a2d4-4749-954b-b63793ab5ecb"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1922ec39f2664925917602d82aac09b7_D20201130-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTcwNzM_72370c4a-6af9-47da-bee7-c9f4be391903"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i166f7d51c9a04607804af70090d9f047_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTc1MDQ_155b10db-18b3-4106-9233-521180d3fd95"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i166f7d51c9a04607804af70090d9f047_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTc1NDg_61d38458-9198-47dd-b596-2a468346b508"
      unitRef="number">0.50</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i166f7d51c9a04607804af70090d9f047_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTc3MDI_a71c004a-b401-419d-87c9-3899255315ec"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:DeferredRevenue
      contextRef="i33b6c64b39074311ba0d20d253292de1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfNjA0NzMxMzk3ODUxNw_b4c851c9-0e55-4c04-a63e-ce4c43e81545"
      unitRef="usd">1500000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibd9b4c5e3f1a4695a42133604689308c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTgzNTU_0447a5c6-7ca1-4337-aec2-421843742006"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5aa9628d22de45f283290aaf3f3b037b_I20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTkzNzU_0dadc3d7-46d1-457c-a50a-7175c3cb3dd2"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="id693de1f894a4b41bfff465cc3f75051_D20210805-20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTk2MzE_508d3605-c550-4417-a727-55309b05170f"
      unitRef="usd">2000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i8e4b88050bd14031af553100cd13d2ae_I20210805"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83Ni9mcmFnOjMzMTMwNzdiMWEzODRhOTc4MTZlM2Y0NjUxOTIxNDljL3RleHRyZWdpb246MzMxMzA3N2IxYTM4NGE5NzgxNmUzZjQ2NTE5MjE0OWNfMTk2Njg_3ed949c1-3aa6-475d-8ded-771fad60cb6c"
      unitRef="number">0.30</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RleHRyZWdpb246ZmY5NDYzOThjMTYyNDkxOGFmM2VhNWMxYjQ0MGRkZDFfODk4_117c7acd-c8e4-4071-b2c3-a2f790cbd539">RESTRUCTURING AND RELATED ACTIVITIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#x201c;2021 Restructuring Plan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Restructuring Plan included a reduction in the Company&#x2019;s workforce by 18 positions (or approximately 35% of the Company&#x2019;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects that substantially all of the accrued restructuring costs as of June&#160;30, 2022 will be paid in cash by the end&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of September 2022.&lt;/span&gt;&lt;/div&gt;Subsequent to June 30, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="i224d2937076040b695691239c9bdd50d_D20210830-20210830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RleHRyZWdpb246ZmY5NDYzOThjMTYyNDkxOGFmM2VhNWMxYjQ0MGRkZDFfNDE5_58fb319e-2844-42d2-b705-b83a9b0b8cf8"
      unitRef="position">18</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i224d2937076040b695691239c9bdd50d_D20210830-20210830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RleHRyZWdpb246ZmY5NDYzOThjMTYyNDkxOGFmM2VhNWMxYjQ0MGRkZDFfNDUw_e5bf075c-a480-49f1-9d3c-843cf1bba5ed"
      unitRef="number">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RleHRyZWdpb246ZmY5NDYzOThjMTYyNDkxOGFmM2VhNWMxYjQ0MGRkZDFfODk5_ac763922-cf12-4cf3-923d-87d456297432">The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="iee48bd4076a144b6bcecb0df8e12665f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RhYmxlOmQ0OGNjZjZiZmNkOTQ2MWE4ZTM2MGE2ODc1ZTVjMzNjL3RhYmxlcmFuZ2U6ZDQ4Y2NmNmJmY2Q5NDYxYThlMzYwYTY4NzVlNWMzM2NfMC0xLTEtMS03MDA2MA_bfaadc5c-10b3-4628-8ca8-8ae55ae55451"
      unitRef="usd">1497000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RhYmxlOmQ0OGNjZjZiZmNkOTQ2MWE4ZTM2MGE2ODc1ZTVjMzNjL3RhYmxlcmFuZ2U6ZDQ4Y2NmNmJmY2Q5NDYxYThlMzYwYTY4NzVlNWMzM2NfMS0xLTEtMS03MDA2MA_0b6cd199-d50b-4fa3-ba8b-e2e4f8f5a9f4"
      unitRef="usd">1103000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i09ec16c102264bf888a63583634b10b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV83OS9mcmFnOmZmOTQ2Mzk4YzE2MjQ5MThhZjNlYTVjMWI0NDBkZGQxL3RhYmxlOmQ0OGNjZjZiZmNkOTQ2MWE4ZTM2MGE2ODc1ZTVjMzNjL3RhYmxlcmFuZ2U6ZDQ4Y2NmNmJmY2Q5NDYxYThlMzYwYTY4NzVlNWMzM2NfMi0xLTEtMS03MDA2MA_8d1879da-fa95-492b-a717-c2b4e50a065a"
      unitRef="usd">394000</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNzYz_9d4fdac1-f518-42ac-8a19-fc1ba79fa242">SUBSEQUENT EVENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Vicineum&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#x2019;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA. The Company has turned its primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, the Company intends to seek a partner for the further development of Vicineum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our manufacturing operations by terminating the Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A. and the Commercial Manufacturing and Supply Agreement with Baxter on July 17, 2022 and July 20, 2022, respectively. We requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, we have the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. The Company is in the process of assessing the estimated impact of the termination of the Fujifilm MSA and the Baxter CMSA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 21, 2022, the Company terminated its Cooperative Research and Development Agreement with the National Cancer Institute for the development of Vicineum in combination with AstraZeneca&#x2019;s immune checkpoint inhibitor durvalumab for the treatment of BCG-unresponsive NMIBC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OUS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Development Partnerships&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s decision to voluntarily pause further development of Vicineum in the US, the Company has commenced the process to wind down its OUS business development partnerships in MENA and Turkey by providing notice of termination for the MENA License Agreement and EIP License Agreement on July 20, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022 Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to pause further development of Vicineum in the US (the &#x201c;2022 Restructuring Plan&#x201d;). Execution of the 2022 Restructuring Plan is expected to be substantially complete by the end of the fourth quarter of 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#x2019;s workforce as well as additional cost-saving initiatives intended to preserve capital while the Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, the Company estimates that it will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $8&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also expects to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and is in the process of assessing the estimated impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sale of Legacy Technology to Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company executed an asset purchase agreement (the &#x201c;Roche Asset Purchase Agreement&#x201d;) with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30&#160;million payment to the Company upon Roche&#x2019;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2022 and July 6, 2022, the Company and the plaintiffs in the Securities Litigation engaged in in-person mediation sessions in an attempt to resolve the litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which is subject to court approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in an in-person mediation session in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims. Pursuant to that agreement, the individual defendants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will cause the Company to adopt certain enhancements to the Company&#x2019;s corporate governance policies and procedures. In exchange, the plaintiffs will dismiss the complaints and, on behalf of the Company, provide broad customary releases to the individual defendants. The agreement is subject to the execution of a definitive stipulation of settlement and, after notice to the Company&#x2019;s stockholders, court approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transfer to Nasdaq Capital Market &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2022, the Company received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) to transfer the listing of the Company&#x2019;s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the &#x201c;Approval&#x201d;). As a result of the Approval, the Company has been granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, on January 24, 2022, the Company received written notice from Nasdaq indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Company was given until July 25, 2022, to regain compliance with the minimum bid price requirement. In response, the Company submitted an application to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common stock was transferred to the Nasdaq Capital Market effective at the opening of business on July 28, 2022 and will continue to trade under the symbol &#x201c;SESN&#x201d;. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market and requires that listed companies meet certain financial and liquidity requirements and comply with Nasdaq&#x2019;s corporate governance requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company&#x2019;s common stock must be at least $1.00 for at least ten consecutive business days during the second 180-day grace period. If the Company does not regain compliance during this second grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that if its stock price does not recover sufficiently during the second grace period, it would implement a reverse stock split, if necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ia2e62709d9af4f339539c651a584c514_I20220715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNjA0NzMxMzk2NTgwNw_d879b3a3-6b64-4947-9b90-ea6be6d24544"
      unitRef="usd">8000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <sesn:OtherReceivableAssetPurchaseAgreement
      contextRef="ia2e62709d9af4f339539c651a584c514_I20220715"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNjA0NzMxMzk2NTgzMg_995220ac-e98f-4531-b5f6-357a1dcd0b12"
      unitRef="usd">70000000</sesn:OtherReceivableAssetPurchaseAgreement>
    <sesn:ProceedsFromExecutionOfAssetPurchaseAgreement
      contextRef="i924d818132a640e4bbf0b520aa8af43a_D20220715-20220715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNjA0NzMxMzk2NTg0NQ_7f521d62-b3dd-4582-a6d6-74192753793a"
      unitRef="usd">40000000</sesn:ProceedsFromExecutionOfAssetPurchaseAgreement>
    <sesn:OtherReceivableAssetPurchaseAgreement
      contextRef="ibd7f6776eada4e709a71593d6e50e7c4_I20220808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNDg4YmE2NDYwOTQ4YWJhZWEyMDk3YWFiZmI2Mjk5L3NlYzo5MDQ4OGJhNjQ2MDk0OGFiYWVhMjA5N2FhYmZiNjI5OV84Mi9mcmFnOjFlYmEyMDczNDk3YzQxNjU5ZDBiOTFmNjZkZjhjNmM4L3RleHRyZWdpb246MWViYTIwNzM0OTdjNDE2NTlkMGI5MWY2NmRmOGM2YzhfNjA0NzMxMzk2NTgxOQ_81e43055-a2de-4923-b291-7318bf4168ec"
      unitRef="usd">30000000</sesn:OtherReceivableAssetPurchaseAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MYGNO3O5XL87]B9L),R61F('4/3V#$4\5N\+%B9;+?&-U*K66<7ZX$#P0RCP
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M4FG@ZY>(ZQ/)EO5[N'LF)2OJPP4E2KPV4-\_,"9?3_2KO?95[N0_4$L#!!0
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MRV&*'1<(;8#[,\[5TT0[:'HX_P]02P,$%     @ *D (5<%.IYLY#    X\
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MAHZ:02(Z;(TDQ2Q:*D3R87Q_=QCIS'"C73/<(U$XWQF%+AM,Y8$6(A"F'%&
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MP 12H3^&?_PSP;PW06)*LP8]MH622$A(T.MS&9>6-%\E*(2?U^1Q%?:/Z$.
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MQA=;\<*;,KQ,FAOO31$^K@0':>@!?+\P.!_5%[1!\W;Q]']02P,$%     @
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M4I:F3+W,::RC=@YDSQ3=\';C K1_%*,_4$L#!!0    ( "I "%6P$P\ON@4
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M\ )ZGVCMM@,.L+NTCGX 4$L#!!0    ( "I "%5[Q2'17PL  # A   9
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M+%0>PQLJ@5#C:Y2/)_#ZU3ECZ64X$,;9Y5N@YA6<"R6<X*$=$!T.MY6GO%A
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M3^^&K4J]Z/NE]% ,21;*7&CC8Y#O8T[O:(O\(2NXXD2'5QQ-VE+D'&.D*\S
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MHK2R7U^B[S;L@3)RB_JH I#*^Y(U(DJNHI,I'H#*$,M%@86%Y6,B_.&*QM3
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MSA\ <4)%/M&F=/9R\0:BS]H@"V'Z1PC"]O^O]^PEPB;6#5DV1:A6G^C8)!3
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MN10'M#GZ,1@^P]+QZ.AP@,#X3Y#AP>G*?_9+-0I@Z7\N4&R$H0EX/]/(M_A
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M!I;&XVH1'KF99-D W_D8V+UP@/WM</X/4$L#!!0    ( "I "%60,1/LM L
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MYVD)D"0OE8=!<V/[(/IE'=FC-0ZAI/A&*@A 6B<:GH6:V\@G^XB)"B/,+-,
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M -[/#?Q</] "[97[Q7\!4$L#!!0    ( "I "%7XL@DDG 0  /,*   9
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MBT*CMANK*G^MH8:@2Y)?%G0K1>T,Z'VNJ&2:C3M@=\^=_ =02P,$%     @
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MR0H==ZA4W13YDG^_,LV+(D_Y<J'0>1A:@/>S/"^J&V)0_Z#I]#]02P,$%
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M+@VY#.^V?WP[07:\!3^SG(+* 0 8'O>=><QT7<*-O]4@=?@2%L3O^ZRFZ(E
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M(@&TCX@GRG,,:+^T97K.3P"!SI&]I*$O,%_$&F8KW\$/*XU@ K&"4Z.FXDK
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MH^\'22_@Z#4F+Z8W2#[\? ]@$M .VN';0+1WX&H*2.$6:A66M?]5Y76'EG[
MJG:^<1(:QA)"+J"36B_  4#@H',!,#9@NP)+6;^@)X"(GKQ1VDWZ;)7#=VQ]
M6&V;'HY+V[Y@C7E5WX'/DZD4% Q\,3L&ZRK4UI4KK?*10#1^?6!&[C1\VHJX
M0*FUHGXT]]JNXLFFA1V6^T-&;%=@.P=2>?X4U[=]J<V*DYX4?6T9+?^CDGD6
M MTK" *BG_Q# U?^16.=^E:DHJ;E'H1: UN/>C_QE"3?'+57&S7 ]F LD+C!
M_$69A#V&6"Q\K&[A[)##$\305K\(FD4G;P\3<*T=<Y' ;_9WU&NML[&@ IRI
M+T)0&\8&*&1$M"<;VZW*,HA,U\)P6'^OL3XPF96 /!&JTLA"[_;Z_20JUC_4
M)36UN1AYW!JNM!2UG;M7RP-(M6RY*;A8BZ'2 V'?0#)>+]JVPGH25=+;J6:3
MC+JV *#?153T&(T;R$G3YMN==)H=1H*M=QV??;$N[Y0O\-D5',/,<%KXH(KJ
M()E0K+$TK#$&P^93R5TVFKK .8/)0]\#>YKX08DL9$[\(A81C78A/B,RF)^Q
M]0PL-P'2W7@47XG/TKCQ/_$H(%F98O.6>8[6VF)\Q/71N.GJ\[0>T6 'HJ+2
M2J?MF!W&T]1.PA(V->0[U\'V_)9=6HZ#]/!KJ_[<O">[ WR&\"G,XCL:OSMV
MY#JX791-F9IYI#T^KT20P&:!YF_1U@8\F<NQ]FY- MJY.WW+!-B60ZL]OMT9
MC]KV/N71-@ER.79GGM0/AJ]]6"&4W#64_53RFS[(]AD"HX'=,E$)'V$QV485
M/WBGKC:O;VJR&E/_,0Y>4>%2/;V>%_;+ 6,7#19O#;^3NOE09:453L3O5<9@
ME,*>%LN;FEFFHUI%R, OZ?C6LM8Y4$V!WVZA= BS#W!DV,\U(3X.F]MZZM+Q
ML'#B"B!4-HB#HM/)W=Z#2C((5SI<24-G4_O 5QF:'7(,T,( _L8S0$H*$=-$
MJ,!(^:F36KAU.XA+;&OGDEZV*/8 AGU43Y)?M6IE6;@'9K?<:@*? O0JL\!@
M*<&ML$Y%8)NVIB$#ZI903DH.D6I95/0*T4@<\[NQR2J'P-:9Y3W)N6]126'&
MIW \GX,M&NM6N1]A6%%-O5J!T$14OG#:1CE]%7Z[/S.@QE3DM4KWVESP?A,-
MI/.V1"YW->#)WW!E3GVMK^V6=R'!"="4$1J)$XQE_U.AYF[-">)../^&[CR7
MR)[62S/;B 7)LEE2%ILE7X[8XJ90+%I[[UJQMS*CUJ;7@DD&H47A]&9E\U$F
M]ZCW_O8.)TX=#.P^,YYABAK.S@/;5 ^[4T$2*4^0_85XP8*$<. L#E*H#L'4
M9!1,!JX6R*6[[;K/CJ,XM@1UOV8XRM7Z;)DNF%$)ZW,)50J Q"9U-1HP2)%N
MN'EIK)/L&)3D#A]BG!G50NTA[;R!FW&,&[#,F4<W:K[C8,HT#,CV!<Z]DO:C
MG_P&.9I7*5?!6\[L0-:BQ+2"9B\QBA;"#?DJV'A9-'WRL&S*M32R"Y$V: I#
MMD#UWT]9!!$Z6O;<8J>$J*F4\*1 'FVZ*K&2:5T^O2^0V=S@V6@T&#<3$G10
M8S&XU=9Z=<*IT$Q]EEDK]8HS(IXQ=;+UB07-IT\>8K<-ZW"-E)$)%G5$4QQJ
MZLT[F.-E1(1B@[/(L*L,"DL_OX!UWW!J%/=8B(Q=@)^QX/<AFJ$-5W2"Z&D(
M\/5;'-+AVZ'Q5]T,=^R"S0"O%S8.A.KN6_=;.[D&?M:\GDAO-YQ0H=79)K_C
MT'4&9/?!$RX^$:?7#2J;0+LH0P13'8UNIA6N><0D8 LZ8CO$@ITOF85]+Q6-
M$XR"X,#=CUM1@@?R;PG6.96+"3L^.^L8EG%).16#D<Y^D 9MWT8])B8S3,AQ
M-L1WZ[=S^1UO=#P;#[YKWM[ !)53Z^.N^8M#Q,>'M^^GC+9VY<'%</Y"%<&4
M!D\!(^/V6(P;$YD7  Y(N/<+D &6XN[0KU 7_0TX)5&346"-/F6T]]#$>!JB
MZ@47'FS0[X'-% %D8JO&;@D.]9#+H6<['DW,0O!K9^%PB,"B KIGO.B+%[[T
M$)AHMS4%KQ/M,Z;X5:&P.3!B]]T,R?EF )MWHZ1>!;\U':/J]^BGJ*7 O4F)
M^-(--H>5E"T?Z2>>IC(,!<@&W4P_[5'?AK)!@O6Z[GK[>Z @<AU[ILEWO@TD
MDO"=]\-*Z7^C*OJ.8KG%(L0[7R3I=;.R=]Q=LOWR=.T?KM8&)5>DZ8_71KE@
M4Z.D68#6Y^]0FOU5U&:H.BR<GK5;];Y''ZBVKX."Z1-^T#F>N^L%E8C<O01U
MV,67ZK#AF\/AH"T65A&^TBCI 17+;?UINBJ 7?T+?9UL9G7:(8*#T>'#$T#A
M%/,*/T,*7ST;Q0.TL/#6VY3;L+&9D6MK I7ZB._L"]&Y!<?P:8)J1-%1-"&^
M$E_<RT5Q4E?*I:T/M17Q*#S0<8N)?WIW-^: !Z3^/6BD6DK\ 2'/)"N*/'P_
M%'T$Q$&:;N0P-4C>-G'*CDG' YJMUC6_\(MKF7II1_G<&U5N2IAGF3@@6QOD
M&,8 + <H0),LX5 QU_]=.UCF8I-T<Z5#U>W/>N \U%:0SK&_GL7Z!0=K\X%>
M!UKHLCHA<P%<6>*P3*[$5'&-9ON-YHY6X:')Q@Y;"Y,-''O,Z$4!4)KN;,.$
M2#1\)T!\*4UIS0, OY4#!U2#=R$0F*<A@$3OEE)HL5J;:<A^70++_+!*M'=C
MT[5Q5[6&E[0_S]"]XM%?0_QQ>RC>6X4SARX ?8EZP>#0*1)EJH&RM>#P_O>E
M@S<E'@&-\"NM89SMA[/MG%KC+X"D=$J$9R4"$#^,RTK@D%0W!_MVG:X221!R
M+ KD<),CU##!KSCX\]%IF1.N=\!ZGV^H'>[Z:X&DFMH<#=RW8W W(Z(7]W'(
MA,D+E<&MVD'EUDQ_(N+?[Z&$@I9"7S_I^CV28*P/4>KV.R[4&O7E^DV#.5AL
MK?<O<'<NUG#FS@TN%]T:#C8#3#L&CI*NB:.@@+4/;FV_N=(>6*2Z*'C=%(?,
ME+'IQZ/.X<C\@VPK@3V+QI4WH#1X_=S9P<_W?W 0:-!+KF_NNO,,^P[=>3](
M5KN3C" OV)5O7'_SU=GP^>5=<IW^+E+\<'XY%?#O^>B2/R5\1PX7QV?@$N[$
M[Z+,Q5(DDP'>-[P<]/U@-A#MAQFVDQ=5>>2,I^NDCZJ=<X@,P*X]XS=/^94W
M8'6 \&D,0Y9%<K59E77\VP2=/(]?*HU^3:#S_H/>U=B![@/7NMV>P=VH(2*6
M[*T#+Q.6##3'?[S_6Q,NWX$D.6F#*(QO%/N?Y6B289RO#GL/W6_VXR'=)&9X
MR,9KM'Y2*.BO=Z05]%;,8!@55-VO&70R$_Q"](,&4>:P6_9\B&Y#.S QX/K;
M 0[4>DV2'U5/?3TJ3B('0.0?2S0NN9/-.+'03:!JO=C4)C4Y#.G!\9?*R!#G
M=7/N;P;SK(2VP-+_")[[^R.<[O=(NZ'.ULMWVLAH5NK_ )))_KY0INN'>$^#
M'U8&#SFGGX\V7*7AWUCV5Q/W"]43_F'FYG;^>6O \G,LG.5R!H\.!R_.>UR_
M<A\JO:*?:9[JJM)+^G,A!="/-\#W,PUAP'[ #?SO=K_^;U!+ P04    "  J
M0 A5811KP/,#  #1"   &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6RE
M5MMNXD@0_9629W:42$R,@5PF 20@F5E6228B)/NPVH?&+G!K[&YO=QN2O]^J
M-G:(%'C8?<%]J3IUZM)5]#?:_+(IHH.7/%-V$*3.%9=A:.,4<V%/=(&*;I;:
MY,+1UJQ"6Q@4B5?*L[#3;I^%N9 J&/;]V8,9]G7I,JGPP8 M\UR8US%F>C,(
MHJ ^F,E5ZO@@'/8+L<)'=$_%@Z%=V* D,D=EI59@<#D(1M'EN,?R7N!9XL;N
MK($]66C]BS?39!"TF1!F&#M&$/19XP2SC(&(QC];S* QR8J[ZQK]N_>=?%D(
MBQ.=_2D3EPZ"BP 27(HR<S.]^1VW_IPR7JPSZW]A4\GV2#@NK=/Y5ID8Y%)5
M7_&RC<..PD5[CT)GJ]#QO"M#GN6U<&+8-WH#AJ4)C1?>5:]-Y*3BI#PZ0[>2
M]-QP=O,XGSU-YD^SZ?T/&-U?P^SF=C2_N8;19#Y]GLZG-X_]T)$EE@_C+>JX
M0NWL03V#.ZU<:N%&)9B\UP^)84.S4],<=PX"_E&J$^BV6]!I=SH'\+J-VUV/
MU]WG-EIGRMB51JH5")7 ##/A,($1EXET$BW\-5J0%-7-WQ]%H#+0^]@ OZ5+
M6X@8!P$]%HMFC<'PRZ?HK'UU@'ZOH=\[A/Z?L_;_4>&G@E&YHL*LTQ&UP*4(
M$YT70KV"* JCUQ1(06]V-\A%)A0X3:=)&2-06S'"\06^4(>Q%&].PP*=0P,B
MDRL%TEG_J*GWD,9&NM2;4HB)!;WT]XO2DAO6PE)GU&$8T&",LG LX9G-;F%I
M=.XWWZ]'=+\2)F%)/AG?CDC7P+.,":C,_88O'#4Y1_W' XTG/[Z6BCPJ-#6D
M-<+]W70\@2,6_/+IHM-I7W$LX'UA/9#/_C:Z.CZ!.<GN$0*IXJQ,MF&C /F6
M)=5N:!DH.K_:#<GB%:(+*+25+&_AB*C[!+Q(:EB8O4+W]+<F#GMAA*UE$M*J
MUWNH'K=8?D-]E+\B2;QMD4&LK?MJQ9H%I:)3P0W7TMHAMP%.?OT6(!:%=*2T
M266&[PHHILXA54F*":YI:!1U"NH$58%\2[<D%O5083D1QZ8D<^_+C]E9.JM>
M.5$YX&(+CGSH=6FI)NWQ)8P%'3>1NJ8"RQ=4IMVH>@+P&:)6[]LY3(1-H1"O
MS)G2$;6B=O?X3=L!-3)L&AFI=;_UO#NU]_P88E)U*0G;DAJ0H'"(C%))/W5J
M#KE847QO9R-)=X'$3"9<53'3I.)A+,H-*SQBX2JG6./DHR85[HR9',W*#U-+
M9DOEJHG3G#;S>E2-J3?Q:MC?";.25+ 9+DFU?7)^&H"I!FBU<;KP0VNA'8U
MOTSI/P<:%J#[I=:NWK"!YE_,\%]02P,$%     @ *D (5:)F-N$K#0  128
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULK5IM4QLY$OXK*C:UE:T"
M8PQYV4U"%1"RQQ;DV)CL5MW5?9!G9%O+S&@B:0#?K[^G6]+,V-@.N4T5!=@C
MM5K]\O33;;^]-_;6S97RXJ$L*O=N9^Y]_<O^OLOFJI1N8&I5X<G4V%)ZO+2S
M?5=;)7/>5!;[H^'PY7XI=;5S_);?N[;';TWC"UVI:RM<4Y;2+DY58>[?[1SL
MI#<^Z=G<TQO[QV]K.5-CY3_7UQ:O]ELIN2Y5Y;2IA%73=SLG![^<'M%Z7O"'
M5O>N][^@FTR,N:47%_F[G2$II J5>9(@\>=.G:FB($%0XTN4N=,>21O[_R?I
M'_CNN,M$.G5FBC]U[N?O=E[OB%Q-95/X3^;^'RK>YP7)RTSA^+>X#VM'/^^(
MK''>E'$S-"AU%?[*AVB'WH;7PPT;1G'#B/4.![&6[Z67QV^MN1>65D,:_<-7
MY=U03E?DE+&W>*JQSQ^//Y^.SW__?/[Q1IS_@=_CM_L>8NGA?A9%G 81HPTB
M7HHK4_FY$^=5KO+E_?M0I]5IE'0Z'6T5^%M3#<3A<%>,AJ/1%GF'[1T/6=[A
MICLV$Z>^-*KRXOP.OYWX]\G$>8N(^,^ZZP9I1^NE49;\XFJ9J7<[2 .G[)W:
M.?[QAX.7PS=;=#UJ=3W:)OUI_OA&$>(/G6%-4XI_5N*WIEB(@X-@W%WAYTJ<
MF;*6U4+4TGJLK*57N=#(&'&SJ)4X%26B2U<SA*:?\XX/[T^$-R+7#B'J!)+=
M>5GEM$9[53JD:\%2L*AWPH\_O!X=O'KC1&U-;1R>XQ]O*.JQ6T"&UPXJ2'HM
MBX736%K("FGF]*P2R.62_0<PP@HA\UQ3;F/]]1RI*0Y%!FNP &\U?M/"]O;T
M@K3Q0"]/@H29BH]7%Z=G@\XR+]99II2YXC<H:KR:Z0PJ99J1"5>\,T53>6EU
M049LH,BTL5ANL>H.N%>GPUI58%T2]WD\$#?XVPJ[EXY!)A>$6%ACK&EF<]A3
M.J><6Q6T*^[G.IM#7E8T.1D<TO#"LJ%@@+X"'FA*P<+&ACR3:7929MPWV'07
M*PM@>7"V2T& +6XI0,+-D@4A2OC&5A19G@) 4PV *.PE$X;KD<S:>"A+SNN,
M+0NO;"4)P'N'S P6P1B 0UWJ_])F-Y=6S4V1P_9WLFC40)RT%RH6RU[5%4[*
M^7BGU"WL31E086N*E*^X<2 N*EBOJF*)8<U,8_]><,"G"O:Z4Q!=XF$6W8I<
MR6 CD@GCYR(W]Q6?5LJJF0+,&DLF0+V&V=@=DX6 W5 U)*<O";F2#F^)4VVB
M.'HP!HAIO! G,ZLX<L)5/C1_Z:DN2O%>&[< QM,^K[)Y90HST]CP>3 >P-,4
M4-&RI;(9.>]J22E:,&[J&C98.>-4/I!")N7?JY!_O(/?&0U31@)M:\55O%@,
MQ)\*;P#5'>/,7/I.7=H;Y6:*8AB^9W8@FHHB@U3MA F9-'*\$[3 @LV(J364
MJ%ECXQ46_>0(28,X40\@2 A>1!KVDUP0 O(G0TTROZEV63C!:I89FTOXM0ME
M6N?2IO8>5^.3+AB2TG"LGNA"^P5%0BT7W7H*VTQ93]I7IMI;#@S ZPP(EGQ-
MVM#=R!._&I.O>.R:RB,6 HX\F" KE]L&8E!-/6N_E G]9 =L1X!+,8NE78;3
M [@-","%!GNR=09;9XXVTJ)[S_!>!]ZCM64MB8S0<V9BAL"FGU"_I05^DMCW
MO71<"5(2]U%&SY_1Y2U2'U?PC5<M6FP!>V3R)%V+)9X0N/U+ 3ED6Q5U639
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M\=KLH O+S8NE8-/4<D%^1=$1VQ#HJ/$%)U=VRM^I*.60F.%C3OVV_A0V"%^
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MPZ5(,-FU]PEVC3W<8#\/]SK\HQ!'T LZ$ 9AN,=?KZY%S_GK?50+QA4\L:Q
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M.?T'4%D#VL^D-/N)/:#[L\Q_ U!+ P04    "  J0 A5XV ML<L$   R"P
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M,CY6H(LT96HSXHE<WS:\QG9@(A9+0P.MP4W.%GS*S7,^5MAKU2BQ2'FFA<Q
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M+O$CC2N:@._G4IIMAQS4GWV#_P%02P,$%     @ *D (54%6@UUN P  J@@
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M Q5-PPK)&($73(@4TMJ!_';"J -<<T%><J>92'1C  O^=O9I.#WMHT7 SF4
M7P4WM+,PS!#83W#=[3;[[7[##L-6,VP%#9@RP1(&K7XS[-^21;_9Z48-6$K#
M4G@Z(?8N=('5CII1)W18O: 915&C1IUNI4[W$^J<?%L3%+CF!J[G2KYR>W-=
ME*D>?7E6=:O[Z@B;5[# M1-+<4VU*[5Z%_=$Q\](LE.*?#Z,21<A77."BMEN
M]FZ[3J!>[RA#7'I?\OS!HT:#J-(@^H0&,UPC14^<"D^<K7C*#4=]J?JUN)?/
M];DDR3&8K5-:!CO4*S( NM*PNM*(<(S9"A6T6\VB^+-+J)0"/,Y?KEB6W\VH
M>E=?>F$KO'/U[$?]LO(7"7%W 'YTN%1Y_Z1_9*@VKDOJXDP7K:1:K1KQ?=%_
MWLV++O[,U(8+NBMP3:[!S2U]ZJKHC,7$R-QUHY4TU-O<<$L_$ZBL >VOI33'
MB0U0_9Z,_P=02P,$%     @ *D (5>"@15^M @  OP4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL?53K;]HP$/]73MDTM1)J'M 7@TA V<:T5BBD
MW8=I'TQRD&B.G=E.*?_]S@FD=*)\2?RXW^-LWPTV4OW1&:*!EX(+/70R8\J^
MZ^HDPX+I"UFBH)V55 4S-%5K5Y<*65J#"NX&GG?E%BP73CBHU^8J',C*\%S@
M7(&NBH*I[1BYW P=W]DO1/DZ,W;!#0<E6^,"S6,Y5S1S6Y8T+U#H7 I0N!HZ
M([\_[MGX.N IQXT^&(/-9"GE'SN9I4/'LX:08V(L Z/?,TZ0<TM$-O[N.)U6
MT@(/QWOV+W7NE,N2:9Q(_C-/339T;AQ(<<4J;B*Y^8:[?"XM7R*YKK^P:6(O
M/0>22AM9[,#DH,A%\V<ONW,X -R\!PAV@*#VW0C5+N^88>% R0TH&TUL=E"G
M6J/)7"[LI2R,HMV<<":,IHLX>IS$C]'LX2N,'NX@FOX8Q=,[&$WBV=,LGDT7
M<!:S)4=]/G -25J@F^SHQPU]\ []%=Q+83(-4Y%B^A;ODM76;[#W.PY.$GZO
MQ 5TO0X$7A"<X.NV^7=KONY[^:,VJDI,I7*Q!B92B) S@RF,['O)38X:?HV6
M%$4/Z/>Q$V@$>L<%;%'U=<D2'#I4-1K5,SKAIP_^E??YA/U>:[]WBCU<4)&F
M%4>0*WB;2M1HP7(+\;:L R92FV,)G)0XGD"<(:PDIY*V6KD&MB]K*\221%5T
MA.J-HX3D-:TUQVLD&"*A:_3_<S[G3'3@+!<4("M-=Z+/^S!FM)P@,&T5[C#!
M8HD*NGZGX?@(?J=W>PT3IC,HV98:!ZF=^1W?ZYZ_H@W0"\+V!1&L>]N#8S?A
M'A15@6I=MPY-653"-/75KK;=:=04Y6MXT]KNF5KG0@/'%4&]B^M+!U33+IJ)
MD65=HDMIJ.#K848=%I4-H/V5E&8_L0)MSP[_ 5!+ P04    "  J0 A5?%B,
M.%H$  !6$   &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R]6%%3XS80
M_BL:]Z8#,Q!;A@1"D\P0X*;IE(/!A3YT^B#L3:S!EHPD)Y=.?WQ7MF/G[AQ?
MRY"^$,O6KKYO]>VNQ&@EU8N. 0SYG"9"CYW8F.S"=7480\IT3V8@\,M<JI09
M'*J%JS,%+"J,TL3U/6_@IHP+9S(JWMVKR4CF)N$"[A71>9HRM9Y"(E=CASJ;
M%P]\$1O[PIV,,K:  ,QC=J]PY-9>(IZ"T%P*HF ^=B[IQ90.K4$QXXG#2F\]
M$TOE6<H7.YA%8\>SB""!T%@7#'^6< 5)8CTACM?*J5.O:0VWGS?>/Q;DD<PS
MTW ED]]Y9.*Q<^Z0".8L3\R#7/T,%:&^]1?*1!=_R:J:ZSDDS+61:66,"%(N
MRE_VN0K$EH$_W&'@5P9^@;M<J$!YS0R;C)1<$65GHS?[4% MK!$<%W97 J/P
M*T<[,[F^":X>9O>_S>X^D;N/9/H8S#[=! $YN ;#>*(/R3%YPK@)PQF9<DEF
M(NP1'3,%FG!!;GF28'3U$?FP/1RY!L'9)=RP C(M@?@[@%!R*X6)-;D1$41?
MVKM(JF;F;YA-_4Z' 60]<N(=$=^C _(87).##X<5\@[W)W7@3@KW)SO</S'%
MV7,"&! #Z-(@<,/-FOSQ*\XD,P.I_K,M#*7;TW:W-@DO=,9"&#N891K4$IS)
MCS_0@?=3!^C3&O1IE_=)4.Z;G)-0IBDF!>HK?"%<ZQPB8B0Q,1!,&;1;E*&*
M91*!TN0 -[>,W2'YNS6*);MR_7ZQOJT(R\GIR%VV0.[7D/N=D.]!A:@^K! 6
M]E(:"XU7,=>8U:\Y5U\+IL12.J;>%ABO1X?#=D"#&M#@>X"XC$B4*XMD%?,P
M)J\Y4X@H61-@2AQC]4-D"DC&UH5&V!R_DHB9@H3 8JM9TA[ [L5IGZQQB2X!
MG]4\SOX-#]S7DD,524 U6"7D&@J18/@Y2Y 9UGPM14$'YM@.3#&-A3&')6!)
M4B]0[ W+32P5_XN9786@&]?9=QF>UPS/.ST]\9 +GJ<H6"S:"7N6BMD>0"Z5
M8F(!V%S,$7E ^"*'HK9'!',BR"#D<XX#K&8H,BF@C47GVF_,XV'-;+B?XC/<
M VCJ-;W&^P^Y7*>!'7R;039Y[ [I3:HU'PKEMO>8$@"E7^2\Y[>G/-WJDO1_
MDA)Z>!3<X*O 8#UH9]$)YJW;Y#=D_?VHJ_+[SKB;CDP[>^?D3L"QP2,CGI,V
MP:XT1/(,=V/.E2XE9Q67*1GEH6GE4:XSW!(1]7O]'2)JFB_M[K[O*J*;7.'1
MO!5])XJW[D+3KVE_3^KI/ B\%7?3UFEW:WT_]0R^.0.=[9!.TZMI=U-\5^G\
MPC(F6I%W@GCK#C3MFI[O23G[Z,6T:<:TLVV^HW+*=09;RCGY2CGNUE4/SV:+
MXD*K\:26"U/>^NJW]:7YLKPJ-M/+&_<M4PLN-$E@CJ9>[PP5J\I+;#DP,BLN
MCL_2X#6T>(SQX@_*3L#O<RG-9F 7J/^5,/D'4$L#!!0    ( "I "%7+.X&6
M"04  (8>   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;+59[U/J.!3]
M5S+=-SLZLVO;E)\N,(.HL^RHSP5Q/X<2)&-I>$T*SYGWQV]2:M-*#5#B%Z4T
M]^2>F]O#:=+9T.B5+3#FX.<R"%G76G"^NK1MYB_P$K$+NL*AN#.GT1)Q<1F]
MV&P5831+@I:!#1VG82\1":U>)_GN,>IU:,P#$N+'"+!XN431VQ4.Z*9KN=;[
M%R/RLN#R"[O76:$7/,9\LGJ,Q)6=H<S($H>,T!!$>-ZU^N[EP/-D0#+BF> -
MRWT&DLJ4TE=Y,9QU+4=FA /L<PF!Q+\U'N @D$@BCQ\IJ)7-*0/SG]_1;Q/R
M@LP4,3R@P7]DQA==JV6!&9ZC.. CNOD;IX3J$L^G 4O^@DTZUK& 'S-.EVFP
MR&!)PNU_]#,M1"[ K7T2 -, >&B EP8DE;.WF26TKA%'O4Y$-R"2HP6:_)#4
M)HD6;$@HEW',(W&7B#C>N^T/1^"Y?S>Y ?<W_?%D='-_\_ $^@_7X';XT'\8
M#/MW8/@P?AI-Y(TQ^!.,MRL.Z!ST&<.< 13.P!U!4Q(03C #]QBQ.,(S@#BX
M120"SRB(,1"K-L)^'$4D? %7B!$&SJXQ1R1@YP)W,KX&9]_.P3= 0O"TH#$3
MN*QC<T%3)FO[*:6K+27X":5_XO ">,X? #H0EH0/].'7V!?A;A+N%L-M4=RL
MPC"K,$SPO$_P<H6Y+".SC:Z51\NG^)*MD(^[EGA,&8[6V.K]_IO;</XJHV8(
MK$#4RXAZ.O3>@(9<K"P..?"I>,YG.$+R42TCO45J)$A2:=8]M^4X'7N=)[,[
MJ"[428TJ9%G+LJQILU0=^ O\&U,NNO0Q(K[H6M%U_414P#V*7F5?G]WA-0ZV
M!7+/RWAHYSIV\0R!%<I2S\I2UW;I]DDN;="Z28Z&P H<&QG'AG;I[VF(WX1X
MRL4%\UB("SCS$5L _",F:Q2(SF6EJ[R%K><:L>8T&_4/[;H[RFUX+5C>KLTL
MYZ8^YR1;- TP8+)S$QTIR[&Y,_O'QTD[4<72MS(:K9-$L&6RQPR!%8BV,Z)M
M8R+8WKMDNA&%]%Q'_=X[!^O?F+R$9$Y\)++]SA<X M^GLB!)NPW#5?Q! V'I
MTZ&?\-C%,X56+$_.#KE5=3"--,73$%J1IS(EKM8*5-?"%%?7M=HAQ7R5MW#U
MYN)@'4QQ\I.WVD[[HUCKIZM:?F5"W-I)>N@:-1:FT(IDE;5PM;_J1VEB"J5M
M+]V08HK*&;AZ:_"9*DY"JE5$K_P9T4YV].H90BN61AD0MUE9$0U9BI3G5Q@4
M5SD45^L+3E#$UOZ6U0TIYJN,AJMW&H<KXGZ?H9^J8NFA\B30.>T5V:C#,(56
M)*L<!M3^LA^EABE4X9UB]SVY9)3F11GF-B[T'F& HNA-:F)_26.1[B^U?5.:
MK-F=C*_8RH#*;T"OJNI!0]8AY?D51@0J(P+UVR&552_%W?=27#),\U8,E:>
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M.VV-!HK&\I^J?I:[:E:[,G7Z1B[)A'8L78@E%2MJ=7_]!7O.;U7B0L)\2%@
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M#33H#(U063TJU42+PK796Z%-TW;#S+S#*&V V5\*H;<3FZ!YV:,_4$L#!!0
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MR:EQ+KM>TBVTJ-KZG0MMND$[+4S[16D#S/E""+U96(*^H4<_ 5!+ P04
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M3#60SY>4BMV%ZJ#>?9K^"U!+ P04    "  J0 A5J)Z&O)L#  "X$   &0
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M\N?ME\_0@6\N!)AUDATJRBC<%N76:&!%!HFFM)<V$1K>W*!A7.BWA%D8F6Y
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MS36]G5!9 YI?2FF>.G:!^C46?P=02P,$%     @ *D (50OGN)T'!   #A0
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M]KFJ(2\[<AE(5IBF-F=2M4@S3-0CAEPGJ/4%8W(7Z WJ9S'\#5!+ P04
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M;P"D"<#]3 B]FY@#NA]+]!=02P,$%     @ *D (55Z+T7]> @  QP4  !D
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M2\HGXZ^#\; WY- :&52344U!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U
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MEE%:-RO;MIQS8<- >Y9J'9-5,<_7Q=6V9JXW$]%6'%2344U!-175-%334<U
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MM% _'^ Z0>UGC,ESH!MB^)V%?P!02P,$%     @ *D (55V:E_%V @  I@4
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M?&^Y/OZR_#Z)$BXN.*?;BOKT%U!+ P04    "  J0 A5X>Q>$?0!  "B)P
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M4$L! A0#%     @ *D (59\M;XKN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ *D (59E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  J0 A52'4";MH%  "G'P  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ *D (599GFY*2!@  UAT
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M965T-BYX;6Q02P$"% ,4    "  J0 A5")EF-Y\"  #C!0  &
M    @('*+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M*D (53$*Q^X-!P  C1X  !@              ("!GS$  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "I "%64T<6\/PL  &D<   8
M          " @>(X  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  J0 A5]9[/W_L'  #J$P  &0              @(%71   >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "I "%4;TF_IS (  #0&
M   9              " @8E,  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ *D (5; 3#R^Z!0  P X  !D              ("!C$\
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  J0 A5>\4A
MT5\+   P(0  &0              @(%]50  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( "I "%5@%("[>@,  +@'   9
M  " @1-A  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M*D (52\CU,!* P  _ 8  !D              ("!Q&0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  J0 A5Q?-3IG4+  !%(   &0
M            @(%%:   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( "I "%6%XDNN^0(  %\&   9              " @?%S  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ *D (5<2ZL9C#"@
M$QX  !D              ("!(7<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  J0 A5F7.&9FP$   I"@  &0              @($;
M@@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "I "%60
M,1/LM L  'X?   9              " @;Z&  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ *D (5?BR"22<!   \PH  !D
M     ("!J9(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "I "%5A%&O \P,  -$(   9              "
M@0W)  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ *D (
M5:)F-N$K#0  128  !D              ("!-\T  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  J0 A5;F'9GD,*   L'   &0
M        @(&9V@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( "I "%57$6W[Z0,  *$*   9              " @1/E  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ *D (50-!]+D% P  > <
M !D              ("!,^D  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  J0 A5T],R9P0#  !E!@  &0              @(%O[
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "I "%7C8"VQ
MRP0  #(+   9              " @:KO  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ *D (58Z,W ?W @  ;08  !D
M ("!K/0  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  J
M0 A5]OGFH:H%   "#@  &0              @(':]P  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "I "%5!5H-=;@,  *H(   9
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M970S.2YX;6Q02P$"% ,4    "  J0 A5EJPRM@,#  "N!@  &0
M    @('H$@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M "I "%5X'@,?) 0  /L9   9              " @2(6 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ *D (57)2_ON^ @  Y0<  !D
M             ("!?1H! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  J0 A5[4L.S*,"  #M!P  &0              @(%R'0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "I "%5S2OQ@U0,
M $P4   9              " @4P@ 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ *D (5? _\H:, @  W 4  !D              ("!
M6"0! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  J0 A5
MXNU6;R<#   ("0  &0              @($;)P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( "I "%66K'A:50(  - $   9
M      " @7DJ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ *D (54>USS.7!0  ]RH  !D              ("!!2T! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  J0 A5Y0]1%!T%  #E(@
M&0              @('3,@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( "I "%6V@A%DD0(  $ '   9              " @2<X 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ *D (5>RKA" \
M P  N0X  !D              ("![SH! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    "  J0 A5O3^ET1,$  "A%0  &0
M@(%B/@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( "I
M"%4_8QUK_00  (P=   9              " @:Q" 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ *D (5>Y%X?@S!   B1H  !D
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M=#4X+GAM;%!+ 0(4 Q0    ( "I "%4+Y[B=!P0   X4   9
M  " @41E 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
M*D (52Q.@=IM!   $Q4  !D              ("!@FD! 'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6Q02P$"% ,4    "  J0 A5V($TE+\"   B!P  &0
M            @($F;@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4
M Q0    ( "I "%7O(L-)A0(  &0&   9              " @1QQ 0!X;"]W
M;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ *D (55Z+T7]> @
MQP4  !D              ("!V',! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX
M;6Q02P$"% ,4    "  J0 A5@7-TUR $   ]&   &0              @(%M
M=@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( "I "%5Q
M$]2AHB$  !B] @ 9              " @<1Z 0!X;"]W;W)K<VAE971S+W-H
M965T-C4N>&UL4$L! A0#%     @ *D (5493(JM% @  V@0  !D
M     ("!G9P! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
M"  J0 A579J7\78"  "F!0  &0              @($9GP$ >&PO=V]R:W-H
M965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( "I "%7^'X?(G0(  .<&   9
M              " @<:A 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L!
M A0#%     @ *D (58R=QU9H P  JA8   T              ( !FJ0! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  J0 A5EXJ[',     3 @  "P
M        @ $MJ $ 7W)E;',O+G)E;'-02P$"% ,4    "  J0 A5G"N/0&4%
M  #@+   #P              @ $6J0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ *D (51;=:Q0F @  8R@  !H              ( !J*X! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ *D (5>'L7A'T 0
MHB<  !,              ( !!K$! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $P 3 #+%   *[,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>220</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2112106 - Disclosure - RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLES</Role>
      <ShortName>RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - PREPAID EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PREPAIDEXPENSES</Role>
      <ShortName>PREPAID EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2116108 - Disclosure - INTANGIBLE ASSETS AND GOODWIL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2121109 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2124110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2126111 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2128112 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2135113 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2138114 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2145115 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2147116 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2153117 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTS</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2155118 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2159119 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2317302 - Disclosure - INTANGIBLE ASSETS AND GOODWIL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2336305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2339306 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2348307 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INCOMETAXES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2356308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLESDetails</Role>
      <ShortName>RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RECEIVABLES</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - PREPAID EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PREPAIDEXPENSESDetails</Role>
      <ShortName>PREPAID EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/PREPAIDEXPENSES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES - Components of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/LEASES</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2430413 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Equity Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2440419 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2441420 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails</Role>
      <ShortName>INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails</Role>
      <ShortName>INCOME TAXES - Components of Income Tax Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - INCOME TAXES - Components of Deferred Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - LICENSE AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails</Role>
      <ShortName>LICENSE AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/LICENSEAGREEMENTS</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2457430 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2458431 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2460432 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sesn-20220630.htm">sesn-20220630.htm</File>
    <File>sesn-20220630.xsd</File>
    <File>sesn-20220630_cal.xml</File>
    <File>sesn-20220630_def.xml</File>
    <File>sesn-20220630_lab.xml</File>
    <File>sesn-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="588">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sesn-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 220,
   "dts": {
    "calculationLink": {
     "local": [
      "sesn-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sesn-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sesn-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sesn-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sesn-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sesn-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 495,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 13
   },
   "keyCustom": 63,
   "keyStandard": 236,
   "memberCustom": 29,
   "memberStandard": 34,
   "nsprefix": "sesn",
   "nsuri": "http://www.sesenbio.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sesenbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://www.sesenbio.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112106 - Disclosure - RECEIVABLES",
     "role": "http://www.sesenbio.com/role/RECEIVABLES",
     "shortName": "RECEIVABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - PREPAID EXPENSES",
     "role": "http://www.sesenbio.com/role/PREPAIDEXPENSES",
     "shortName": "PREPAID EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116108 - Disclosure - INTANGIBLE ASSETS AND GOODWIL",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121109 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126111 - Disclosure - LEASES",
     "role": "http://www.sesenbio.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128112 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135113 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138114 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145115 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147116 - Disclosure - INCOME TAXES",
     "role": "http://www.sesenbio.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153117 - Disclosure - LICENSE AGREEMENTS",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTS",
     "shortName": "LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155118 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159119 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - BASIS OF PRESENTATION (Policies)",
     "role": "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies",
     "shortName": "BASIS OF PRESENTATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317302 - Disclosure - INTANGIBLE ASSETS AND GOODWIL (Tables)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339306 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348307 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i9a0f7b1dc5054a1f9fc821eab7bd92bd_D20160901-20160930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "icd5b6ec9e9dd43989da9c64d2cdde9bb_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "id227aede38f346d295f8bb264c9c69d9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "id227aede38f346d295f8bb264c9c69d9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - RECEIVABLES (Details)",
     "role": "http://www.sesenbio.com/role/RECEIVABLESDetails",
     "shortName": "RECEIVABLES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i68913e68ad7b4a54a86589572b03f916_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInOtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - PREPAID EXPENSES (Details)",
     "role": "http://www.sesenbio.com/role/PREPAIDEXPENSESDetails",
     "shortName": "PREPAID EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i043a889ad00d41bcbc065be28275a745_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i75f8be7fd9a44548a385a47a21fdcbfa_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - LEASES (Details)",
     "role": "http://www.sesenbio.com/role/LEASESDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430413 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Equity Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i84bae78e3b8749b39293629af79a1b2a_I20191129",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0aa49d50600f4d809f73a21b67293288_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sesn:NumberofVotesEntitledForEachShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "sesn:CommonStockSharesIssuedAndReservedForFuture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440419 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i30153c69f900480b8a7b0d198d30b92d_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441420 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i278e1922f5954901947c7da7b025ffda_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i278e1922f5954901947c7da7b025ffda_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "if0b29b8876ac49d4ada09cbcefec48ec_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50a087530030427d9767a04597f4120d_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "ie820aa9d32f54e368d97eb79949bb246_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "ie820aa9d32f54e368d97eb79949bb246_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
     "shortName": "INCOME TAXES - Components of Pre-tax Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails",
     "shortName": "INCOME TAXES - Components of Income Tax Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - INCOME TAXES - Components of Deferred Tax Liabilities (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails",
     "shortName": "INCOME TAXES - Components of Deferred Tax Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i09ec16c102264bf888a63583634b10b9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0deda99338f64ce4bebf5432e74873d2_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - LICENSE AGREEMENTS (Details)",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
     "shortName": "LICENSE AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i0b2ff8e61fcd46c299eab19b8098175a_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i224d2937076040b695691239c9bdd50d_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457430 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i224d2937076040b695691239c9bdd50d_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458431 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iee48bd4076a144b6bcecb0df8e12665f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "ia2e62709d9af4f339539c651a584c514_I20220715",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460432 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "ia2e62709d9af4f339539c651a584c514_I20220715",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i047316e26c974618a30ac9fb4ccfa022_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i730d01e89cd84c16a9e18e73d5c0ad33_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_TR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TURKEY",
        "terseLabel": "TURKEY"
       }
      }
     },
     "localname": "TR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sesn_A2014EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2014 Employee Stock Purchase Plan [Member]",
        "label": "A2014 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2014EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ATMFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Facility [Member]",
        "label": "ATM Facility [Member]",
        "terseLabel": "ATM Facility"
       }
      }
     },
     "localname": "ATMFacilityMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_AccountsReceivablePaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Payment Terms",
        "label": "Accounts Receivable, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "AccountsReceivablePaymentTerms",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_AccruedLegalFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal Fees",
        "label": "Accrued Legal Fees",
        "terseLabel": "Legal expenses, including preliminary litigation settlement"
       }
      }
     },
     "localname": "AccruedLegalFees",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedRestructuringChargesRelatedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Restructuring Charges Related, Current",
        "label": "Accrued Restructuring Charges Related, Current",
        "terseLabel": "Restructuring charge related"
       }
      }
     },
     "localname": "AccruedRestructuringChargesRelatedCurrent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "terseLabel": "Shares of common stock issued to the selling shareholders (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "label": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "terseLabel": "Total milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Milestone Payments",
        "label": "Business Combination, Milestone Payments",
        "terseLabel": "Business combination, milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationRoyaltyPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Royalty Payment Percent",
        "label": "Business Combination, Royalty Payment Percent",
        "terseLabel": "Royalty payment, percentage"
       }
      }
     },
     "localname": "BusinessCombinationRoyaltyPaymentPercent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ClassOfWarrantOrRightIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued During The Period",
        "label": "Class Of Warrant Or Right, Issued During The Period",
        "terseLabel": "Warrants Issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "label": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "negatedTerseLabel": "Warrants Cancelled (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone",
        "label": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on commercialization milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on development milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on regulatory milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue based on Specified Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalty Period",
        "label": "Collaborative Arrangement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyPeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedforFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CommonStockSharesIssuedAndReservedForFuture": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Issued And Reserved For Future",
        "label": "Common Stock Shares Issued And Reserved For Future",
        "totalLabel": "Total shares of common stock issued and reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssuedAndReservedForFuture",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "label": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "terseLabel": "Discretionary match per participating employee, maximum"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_EBI031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EBI-031 [Member]",
        "label": "EBI-031 [Member]",
        "terseLabel": "EBI-031"
       }
      }
     },
     "localname": "EBI031Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_EczacibasiPharmaceuticalsMarketingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eczacibasi Pharmaceuticals Marketing Agreement",
        "label": "Eczacibasi Pharmaceuticals Marketing Agreement [Member]",
        "terseLabel": "Eczacibasi Pharmaceuticals Marketing Agreement"
       }
      }
     },
     "localname": "EczacibasiPharmaceuticalsMarketingAgreementMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ExpensesPreviouslyClassifiedAsPrepaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses Previously Classified as Prepaid",
        "label": "Expenses Previously Classified as Prepaid",
        "terseLabel": "Expenses previously classified as prepaid"
       }
      }
     },
     "localname": "ExpensesPreviouslyClassifiedAsPrepaid",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/PREPAIDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_FirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Indication [Member]",
        "label": "First Indication [Member]",
        "terseLabel": "First Indication"
       }
      }
     },
     "localname": "FirstIndicationMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_GermanVATRecoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "German VAT recovery",
        "label": "German VAT recovery [Member]",
        "terseLabel": "German VAT recovery"
       }
      }
     },
     "localname": "GermanVATRecoveryMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of Intangible Assets, Cost of Capital, Percentage",
        "label": "Impairment of Intangible Assets, Cost of Capital, Percentage",
        "terseLabel": "Impairment of intangible assets risk adjusted"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsCostOfCapitalPercentage",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_IncreaseDecreaseInDeferredTaxLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Tax Liability",
        "label": "Increase (Decrease) in Deferred Tax Liability",
        "terseLabel": "Increase (decrease) in deferred tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiability",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) of Prepaid Expenses, Noncurrent",
        "label": "Increase (Decrease) of Prepaid Expenses, Noncurrent",
        "negatedTerseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseOfPrepaidExpensesNoncurrent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAdditionalUpFrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Additional Up-Front Fee",
        "label": "License Agreement, Additional Up-Front Fee",
        "terseLabel": "License agreement, additional up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalUpFrontFee",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "label": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "terseLabel": "License agreement, amount payable upon achievement of specified milestone"
       }
      }
     },
     "localname": "LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under First Option Period",
        "label": "License Agreement, Buyout Amount Under First Option Period",
        "terseLabel": "License agreement, buyout amount under first option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderFirstOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period",
        "label": "License Agreement, Buyout Amount Under Second Option Period",
        "terseLabel": "License agreement, buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "label": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "terseLabel": "Buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achieved",
        "label": "License Agreement, Milestone Achieved",
        "terseLabel": "Milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchievementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achievement Expense",
        "label": "License Agreement, Milestone Achievement Expense",
        "terseLabel": "Expenses related to achievement of development milestone"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchievementExpense",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementOptionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Option Periods",
        "label": "License Agreement, Option Periods",
        "terseLabel": "License agreement, option periods"
       }
      }
     },
     "localname": "LicenseAgreementOptionPeriods",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty On Net Product Sales",
        "label": "License Agreement, Percentage of Royalty On Net Product Sales",
        "terseLabel": "Royalty payment obligation, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSales",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "label": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "terseLabel": "Third party minimum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "label": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "terseLabel": "Third party maximum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "label": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "terseLabel": "License agreement, period to pay buyout option once exercised"
       }
      }
     },
     "localname": "LicenseAgreementPeriodToPayBuyoutOptionOnceExercised",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_LicenseAgreementProceedsFromMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Proceeds From Milestone Achieved",
        "label": "License Agreement, Proceeds From Milestone Achieved",
        "terseLabel": "Proceeds from milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementProceedsFromMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "label": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "terseLabel": "License agreement, royalty payment, reduction, conditions not met"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Rate",
        "label": "License Agreement, Royalty Rate",
        "terseLabel": "License agreement, royalty rate"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyRate",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Text Block]",
        "label": "License Agreement [Text Block]",
        "terseLabel": "LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sesn_LicenseAgreementUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Up-front Fee",
        "label": "License Agreement, Up-front Fee",
        "terseLabel": "License agreement, up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontFee",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Maintenance Fees",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LitigationSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement Member",
        "label": "Litigation Settlement [Member]",
        "terseLabel": "Litigation Settlement"
       }
      }
     },
     "localname": "LitigationSettlementMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MENALicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MENA License Agreement",
        "label": "MENA License Agreement [Member]",
        "terseLabel": "MENA License Agreement"
       }
      }
     },
     "localname": "MENALicenseAgreementMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MicrometAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Micromet [Member]",
        "label": "Micromet AG [Member]",
        "terseLabel": "Micromet AG"
       }
      }
     },
     "localname": "MicrometAGMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Lawsuits",
        "label": "Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "NumberOfLawsuits",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberofVotesEntitledForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes Entitled For Each Share",
        "label": "Number of Votes Entitled For Each Share",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberofVotesEntitledForEachShare",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_OperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Rent",
        "label": "Operating Lease, Monthly Rent",
        "verboseLabel": "Monthly rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyRent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeaseOtherMonthlyOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Other Monthly Operating Expenses",
        "label": "Operating Lease, Other Monthly Operating Expenses",
        "terseLabel": "Related operating expenses"
       }
      }
     },
     "localname": "OperatingLeaseOtherMonthlyOperatingExpenses",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeasesAreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Area Of Office Space",
        "label": "Operating Leases Area Of Office Space",
        "terseLabel": "Office space (in square feet)"
       }
      }
     },
     "localname": "OperatingLeasesAreaOfOfficeSpace",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Line Items]",
        "label": "Organization And Basis Of Presentation [Line Items]",
        "terseLabel": "Organization And Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationLineItems",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Table]",
        "label": "Organization And Basis Of Presentation [Table]",
        "terseLabel": "Organization And Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationTable",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OtherReceivableAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Receivable, Asset Purchase Agreement",
        "label": "Other Receivable, Asset Purchase Agreement",
        "terseLabel": "Other receivable, asset purchase agreement"
       }
      }
     },
     "localname": "OtherReceivableAssetPurchaseAgreement",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_ProceedsFromExecutionOfAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Execution Of Asset Purchase Agreement",
        "label": "Proceeds From Execution Of Asset Purchase Agreement",
        "terseLabel": "Payments to company upon execution of the Roche Asset Purchase Agreement"
       }
      }
     },
     "localname": "ProceedsFromExecutionOfAssetPurchaseAgreement",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_QiluPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu Pharmaceutical Co., Ltd.",
        "label": "Qilu Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Qilu Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "QiluPharmaceuticalCoLtdMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RetentionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retention Program [Member]",
        "label": "Retention Program [Member]",
        "terseLabel": "Retention Program"
       }
      }
     },
     "localname": "RetentionProgramMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "label": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "label": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetRelatedToAdoptionOfAccountingStandard",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RoyaltyRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Revenue, Percentage",
        "label": "Royalty Revenue, Percentage",
        "terseLabel": "Royalty revenue, percentage"
       }
      }
     },
     "localname": "RoyaltyRevenuePercentage",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sesn_SaleOfStockCommissionFixedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Fixed Rate",
        "label": "Sale Of Stock, Commission Fixed Rate",
        "terseLabel": "Commission fixed rate"
       }
      }
     },
     "localname": "SaleOfStockCommissionFixedRate",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "label": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "terseLabel": "Aggregate sales price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateSalesPriceInTransaction",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Shares Amount Available For Future Issuance",
        "label": "Sale Of Stock, Remaining Shares Amount Available For Future Issuance",
        "terseLabel": "Shares reserved for future issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingSharesAmountAvailableForFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Weighted-Average Price Per Share",
        "label": "Sale of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_SecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Indication [Member]",
        "label": "Second Indication [Member]",
        "terseLabel": "Second Indication"
       }
      }
     },
     "localname": "SecondIndicationMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent",
        "terseLabel": "Achievement deemed probable, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "terseLabel": "Fair market value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "terseLabel": "Percent of base salary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "terseLabel": "Shares received per award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "label": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "terseLabel": "One-time milestone payment upon first sale of product"
       }
      }
     },
     "localname": "SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "label": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "terseLabel": "Percentage of net sales of quarterly earn-out payments during earn-out periods"
       }
      }
     },
     "localname": "SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "label": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "terseLabel": "Period during which quarterly earn-outs are payable after date of net sales"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "label": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "terseLabel": "Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharesOfCommonStockReservedForIssuanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "label": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "terseLabel": "Shares of common stock reserved for issuance for:"
       }
      }
     },
     "localname": "SharesOfCommonStockReservedForIssuanceAbstract",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_StockIncentivePlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2009",
        "label": "Stock Incentive Plan 2009 [Member]",
        "terseLabel": "Stock Incentive Plan 2009"
       }
      }
     },
     "localname": "StockIncentivePlan2009Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIncentivePlanTwoThousandFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "label": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "verboseLabel": "2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwoThousandFourteenMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Exercise Of Warrants, Value",
        "label": "Stock Issued During Period, Exercise Of Warrants, Value",
        "terseLabel": "Exercises of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfWarrantsValue",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, New Issues, Issuance Costs",
        "label": "Stock Issued During Period, New Issues, Issuance Costs",
        "terseLabel": "Issuance of common stock, issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewIssuesIssuanceCosts",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Exercise Of Warrants",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "negatedTerseLabel": "Warrants Exercised (in shares)",
        "verboseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_UniversityOfZurichMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Zurich",
        "label": "University of Zurich [Member]",
        "terseLabel": "University of Zurich"
       }
      }
     },
     "localname": "UniversityOfZurichMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViciniumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vicinium [Member]",
        "label": "Vicinium [Member]",
        "terseLabel": "Vicinium"
       }
      }
     },
     "localname": "ViciniumMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViventiaBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viventia Bio, Inc.",
        "label": "Viventia Bio, Inc. [Member]",
        "terseLabel": "Viventia Bio Inc."
       }
      }
     },
     "localname": "ViventiaBioInc.Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Or Right Outstanding [Roll Forward]",
        "label": "Warrant Or Right Outstanding [Roll Forward]",
        "terseLabel": "Warrant Or Right Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "WarrantOrRightOutstandingRollForward",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_WarrantsExpiringMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring March 2023 [Member]",
        "label": "Warrants, Expiring March 2023 [Member]",
        "terseLabel": "Warrants, Expiring March 2023"
       }
      }
     },
     "localname": "WarrantsExpiringMarch2023Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2022 [Member]",
        "label": "Warrants, Expiring November 2022 [Member]",
        "terseLabel": "Warrants, Expiring November 2022"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2022Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedMay2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "label": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued May 2015"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedMay2015Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedNovember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "label": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued November 2014"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedNovember2014Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Cost of Capital",
        "label": "Weighted Average Cost of Capital",
        "terseLabel": "Weighted-average cost of capital"
       }
      }
     },
     "localname": "WeightedAverageCostOfCapital",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_XOMAIrelandLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA Ireland Limited [Member]",
        "label": "XOMA Ireland Limited [Member]",
        "terseLabel": "XOMA Ireland Limited"
       }
      }
     },
     "localname": "XOMAIrelandLimitedMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r92",
      "r93",
      "r239",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe",
        "verboseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r238",
      "r249",
      "r351",
      "r354",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r561",
      "r564",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r238",
      "r249",
      "r351",
      "r354",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r561",
      "r564",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r160",
      "r223",
      "r224",
      "r277",
      "r279",
      "r529",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r160",
      "r223",
      "r224",
      "r277",
      "r279",
      "r529",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r205",
      "r222",
      "r223",
      "r224",
      "r225",
      "r238",
      "r249",
      "r304",
      "r351",
      "r354",
      "r388",
      "r389",
      "r390",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r561",
      "r564",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r205",
      "r222",
      "r223",
      "r224",
      "r225",
      "r238",
      "r249",
      "r304",
      "r351",
      "r354",
      "r388",
      "r389",
      "r390",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r561",
      "r564",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r92",
      "r93",
      "r239",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r277",
      "r280",
      "r563",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r277",
      "r280",
      "r563",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r45",
      "r46",
      "r47",
      "r550",
      "r569",
      "r572"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r449",
      "r507",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss Investments"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r400",
      "r401",
      "r402",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r357",
      "r403",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r263",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Total Share Based Compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "netLabel": "Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r75",
      "r201"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r87",
      "r149",
      "r152",
      "r158",
      "r173",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r446",
      "r450",
      "r480",
      "r509",
      "r511",
      "r537",
      "r549"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r87",
      "r173",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r446",
      "r450",
      "r480",
      "r509",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r87",
      "r173",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r446",
      "r450",
      "r480",
      "r509"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r170",
      "r172",
      "r177",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r349",
      "r352",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r349",
      "r352",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r74",
      "r444"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Decrease in the fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r439",
      "r440",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r439",
      "r441"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of equipment included in accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r10",
      "r77"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r77",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r487"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r271",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price per warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r271",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r226",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "netLabel": "Shares of common stock reserved for issuance (in shares)",
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "verboseLabel": "Shares of common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Shares of common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 400,000,000 shares authorized at June\u00a030, 2022 and December\u00a031, 2021; 199,463,645 shares issued and outstanding at June\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r281",
      "r282",
      "r355",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r58",
      "r544",
      "r556"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r273",
      "r274",
      "r278"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current tax benefit (provision)"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r417"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r417",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total current benefit (provision)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r17",
      "r412",
      "r538",
      "r548"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' eligible compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution retirement plan, maximum employee contribution deferred"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r75",
      "r202"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r360",
      "r361",
      "r394",
      "r395",
      "r397",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r348",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r115",
      "r118",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r460",
      "r461",
      "r545",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r118",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r460",
      "r461",
      "r545",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period unvested stock to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares available for sale under 2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r101",
      "r109",
      "r111",
      "r134",
      "r174",
      "r263",
      "r270",
      "r400",
      "r401",
      "r402",
      "r419",
      "r420",
      "r459",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r465",
      "r466",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r347",
      "r466",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r465",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r465",
      "r466",
      "r468",
      "r469",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r240",
      "r305",
      "r306",
      "r311",
      "r347",
      "r466",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r305",
      "r306",
      "r311",
      "r347",
      "r466",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r347",
      "r466",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r347",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r471",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Contingent Consideration Liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "auth_ref": [
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.",
        "label": "Fair Value Option, Disclosures [Table]",
        "terseLabel": "Fair Value Option, Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r193",
      "r194",
      "r197",
      "r198",
      "r530",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r193",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r348",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r11",
      "r178",
      "r180",
      "r187",
      "r191",
      "r511",
      "r536"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWIL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r75",
      "r179",
      "r184",
      "r190",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r356",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r356",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r75",
      "r199"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r75",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D intangible assets:"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r55",
      "r62"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss Before Taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r89",
      "r428"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Pre-tax income (loss) U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r535",
      "r542",
      "r546",
      "r558"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total Loss before Income Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r89",
      "r428"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Pre-tax income (loss) Canada"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r204",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r410",
      "r411",
      "r414",
      "r424",
      "r429",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r110",
      "r111",
      "r148",
      "r409",
      "r425",
      "r430",
      "r559"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit (provision) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r72",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable (net)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Decrease in other receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Total Intangibles",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r192",
      "r195"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r87",
      "r153",
      "r173",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r447",
      "r450",
      "r451",
      "r480",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r87",
      "r173",
      "r480",
      "r511",
      "r539",
      "r552"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r87",
      "r173",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r447",
      "r450",
      "r451",
      "r480",
      "r509",
      "r510",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r14",
      "r15",
      "r87",
      "r173",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r447",
      "r450",
      "r451",
      "r480",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r36",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated litigation liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "RECEIVABLES"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r137",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r48",
      "r50",
      "r55",
      "r57",
      "r76",
      "r87",
      "r100",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r123",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r173",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r461",
      "r480",
      "r543",
      "r555"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "totalLabel": "Net Loss After Taxes",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r115",
      "r116",
      "r124",
      "r127",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r124",
      "r127"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r98",
      "r99",
      "r102",
      "r103",
      "r112",
      "r113",
      "r114",
      "r168",
      "r169",
      "r175",
      "r176",
      "r421",
      "r422",
      "r423",
      "r458",
      "r462",
      "r463",
      "r464",
      "r484",
      "r485",
      "r486",
      "r496",
      "r497",
      "r506",
      "r508",
      "r531",
      "r532",
      "r533",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost, including related operating cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities",
        "verboseLabel": "Unrealized loss of investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PREPAIDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r70",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments",
        "terseLabel": "Payments for restructuring"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r65",
      "r66",
      "r171"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r67",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "verboseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at June\u00a030, 2022 and December\u00a031, 2021; no shares issued and outstanding at June\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r29",
      "r541",
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PREPAIDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock under ATM Offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r399"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercises of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r203",
      "r511",
      "r547",
      "r553"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r406",
      "r528",
      "r587"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r77",
      "r82",
      "r574"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSU",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r208",
      "r211",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING AND RELATED ACTIVITIES"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r207",
      "r210",
      "r213",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions eliminated, period percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r270",
      "r511",
      "r551",
      "r568",
      "r572"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r101",
      "r109",
      "r111",
      "r174",
      "r400",
      "r401",
      "r402",
      "r419",
      "r420",
      "r459",
      "r565",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r146",
      "r147",
      "r150",
      "r155",
      "r156",
      "r160",
      "r161",
      "r163",
      "r276",
      "r277",
      "r529"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "License and related revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of units issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Benefit (Provision)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r331",
      "r332",
      "r335",
      "r336",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Carrying Amounts and Fair Values of Financial Instruments Measured"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r193",
      "r196",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of Pre-tax Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Composition of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of the Status of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r208",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r356",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r364",
      "r380",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r85",
      "r135",
      "r136",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r256",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r244",
      "r245",
      "r246",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Summary of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r271",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrants Outstanding and Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r446",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Common stock purchase price, discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Cancelled RSU (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled RSU (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Unvested grant restricted stock units (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested, ending balance (in shares)",
        "periodStartLabel": "Unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested ending balance (in dollars per share)",
        "periodStartLabel": "Unvested beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Grant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock available for sale (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares under Option (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on the First Anniversary of Date of Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting at End of Each Successive Three-Month Period Thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of original number of shares subject to the option vesting"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Life (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average Remaining Contractual Life (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested stock options outstanding (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r83",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r101",
      "r109",
      "r111",
      "r134",
      "r174",
      "r263",
      "r270",
      "r400",
      "r401",
      "r402",
      "r419",
      "r420",
      "r459",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r134",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Shares available for grant under 2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r263",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock and common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r263",
      "r270",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r263",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock and common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r263",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercises of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r87",
      "r166",
      "r173",
      "r480",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r248",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r270",
      "r272",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r512",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r117",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r588": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r589": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r590": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r591": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r592": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r593": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001485003-22-000108-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001485003-22-000108-xbrl.zip
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MYC^MQMRFS]TS$O1)&'8/H-$DECSVTJ+.MU7N:M[*F]-8Y9A.S6<I@?98"D#
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M^'O$S+MM1K"$H6\\FIX&">2<B2S2!-*MBE@8"1"/1QT4"N67Z6[OK+-:+;]
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M]U(NL<(,<E%GCQNH (V &$L[')@V&K!"5)AC%3#W?+B;?8D;9L@6,\$0BN)
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MYGPOBXJ18Q\M*&W-B 44*&BDB JD@W:1E*AD_9+'QN*QYZ^FGWI;!$=U)$*
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MBM49FC.O*)Y/^;I_.L.C%Z>#_.C?"BYN='LJO[@G)$V?\=.<6LDD Z=8AJ3
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MG!/9/YFD23)ID-3YK)R:@[910MZ1/B1.-2.J:<KYE!K2;^1;+LMMCUL?;"=
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MHO2X,&(RHI2EJYBW$K12I><:TV!89$!C=L8%$LN*?S:7B%)%B,>($#5X\WC
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M99&J.5H('$WD@+2.B2<7(=I4YMIY 5E:)ON,Q'D2%5/>W<\<+4OZU1S-(O]
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M4--F3.69=T[B<>K\<J,YR]+TR[PF=3[' %]BOU<1X*X(,$%I*+-<<4;!$R8
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MB>FVJW?N!E*AKD)=DQ[\#D@7(VH7D"AI*:*3SD?O2$@Z4B:E2-5C;03 B0F
M$X%05$EF!N=Y!CB1P"J%X+(,\Z\8HU&MK5-%VXK./(]C62@WIRXHH^]6C4F7
M?G\,TKU2H[?MGMT\9#IW,5:^L7D54Q53%5,54Q73XQ'370($FF)*F1][922R
MZ,HL#T9H,DE:FRG99#\"?NM(P<3\@TJ3;T^3SZ;B "9[--*P!"F@ ;0!P1!E
MP1I'=$B!N&#*$=M98@!53QNLI]$HXJ/AZ&A$3Y6CV;,5R(727!GCJIX^B)Y.
MNK/>.$XB9V!$9(#29#UU$H%+$P(A#C4)#=+3.=7SKH2C.BH<!6?'A]A//L3N
MP):5?V*31^['X6JWZ"JF*J;96A\Z2WDP@4C-D"CGB.-,2^:LY"B9OX4%OVJX
M-T+IRS ZO7;0^W9*L!P0W.Z>'PT<@=X(\UY<@KR_XO^>=@:=8=R/_8\='\=-
MO?^*OO>V.[K*W_;X--:X][R(PNZ+J4HMI1U)46:#1+@ -,R MIZ"UY(H(W1T
MWJVMT[8V,[?,J:!0L;N*J8II1<6T7">YFMB5-;&3OC@CPC >!6@>"& @#+)9
M)6"3=P916N\::&)_X))?="3*-QN_CR/UG:OYSKH!GO@[ZP9XXN^L&^")O[-N
M@"?^SL<U1NV'?59V;-\?73198;-4$MY8VOFH/-]K.ZQ(;XPW3F9'Q"&EP7#)
MN4],8TA26CTJ@)[R>6N'E:5FC \V+@T0V_BT^V[C#2$\<,QN:E*NM%@)!AP3
M#A1CZ(FPA.KYMEBYDZJLZ@")1WW*XVX/OZ(@=\UQW7LA7.VLL@@0.[L*8BQQ
M:J4F("C',@*"@2;1@%0II!0L%9'/I;5*!:\*7LUYZCN EY?1VT1#=)JA(,((
MKH2U3%*#3'(_"WC5),+\D&UW@IX)QX/1"8&J1"!+CH"+S("QT7$6T8842DL5
MTY9RX?,-*[I5=&LDNFF)/#BJ1/0&;=*:9T41+CLVVK-L_>>%;K63ROV![2ME
M>\5WWVV]4<98;[D"5%;G/R(!2Z4%%SS3QB:>7YM;*Y4*;!78FO/4=SH@%0SU
MBCGNC46=9.8"UAK)$Y%)"OT=9*L=5!X8Y\8$+GG.)=,65. 44+H .E )0@AJ
M?0P^,%U:J*@VD=.%('<^EE$AKD)< Y[Z+B.IM6;<)*9E:5BL;#;]&,JII0QW
MRE%3/=-F -O>A&?*=$8UAPP\%:IXI@RTE@:8M-(I85V*NK1.86UEIL^;-9'
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M8]]W!G$T"'A0"B]:O0]E_9]:3OEN1VMUTMQ0*B(Q"A736@A)E8H^(YE.RO\
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M(N-$"XV$^?Q+ALGQBSI/O*CSE)S4"; /Z\P<7@K7;'W>V=QXHZRDSC("(M(
M2&P 2X4![X46067O5)*U=2;:6<2S3X"M(/#80("@XE1&)KU1**FVG%AODD/O
MDR6,51!H( A\BVALTYT#_T8Z)35/$82G$5 Z!TY3#M$YPD,Y^*;4*H' 4^K&
M^^2&1#^6 $9M=[42[DL54W,S*#%XJ9U6P4F"TCAK@[),,N0<;>+T%N1CV;,U
M*XV9%XVY/$UI[,L0K3F+3@$:)0&53V UM:""E'F/>)E8*9AN,UE[;Z\:*E3P
MKF*J8GH &SL'![_:V-6UL5.A BH#B<D"H\H LB3!.!5+!Q5)%2N%$+1Y-K9V
M$UU^-]%9@:-V$WTXO7][J9OH5EZ#G<ENHIW7__S]?N>W'7%XLD,.OWB2^?>7
MPW>[1[N;Q^]V6+[./X=L]\LOG<._KW03Q9W-G2]O@C'<R<!!<YW9.G<<C$4&
MSI-$G>=>,5>ZB4Y#2.TF>NLF!MQ;=$%B=(*@(TPS:8T4+*+5J"C^0/]J-]%F
MZ.&$C\L4-\)9FWU<FGU<P7GV<94&FJVE8\1'&DVVO[*-FK6IJ&W+'HV23UO8
M&36\=A-=D@I/I-R19_/&C '"L^*B-#8;/L& 6B8DLT;+Y(L*5]5]O*H;I%4N
MNU*<$X$Q,.=8XK$<E.$Q.UA^4:I;7>/YZ?5D^%D30DE@'D(R!-#:TB581* F
MB<BR+R1)6EN7V&8HJFZOF&[7-I553%5,#V I50@I4R2O7<JDEA GE4OH(E=H
M"[)62]E\2WDEB%Q.T/E@,_&)H$ST92 5 8M&04#J+4U48NG35RRE;%)/_2?6
M3?3WTVYL<3*W9J+CQ;RNYF]UNXU>OXAW"]0I0Q,1FFC%0X:QI*D@HLPP+3,G
M1+#GYX!O$9^KW487AV*7A[V/48PY*RSU!H(N8_6$RWP_" ,T.$VHS1Y>D-F/
MU[J-DK2S;S<%9:M7K3@_55Z-?@R+PJP';-AP/63=MV'#/!9H1<'\&JYZ+R2O
MS507 =9G5\%:H?"$9:*IC"* +$9P3" 4*NH\ND ,'8%U!>D*TA6D'S%(&Z88
MP])XCU(,&$VRU)%DHI6J##F=!:1KT&!^"+X[0;>]BS8Y+H%G@0$:+<!J2<#Q
M$(14@0O"U]8199OPZ=Q91?&*X@W!JHKB<T!Q9Y.Q3C##A1WUW&*4!TJ$8>B-
MI6I>*%Y;X=X?P"=:X3(I=="H0"3E"H!G"BX(!2&TRR)D.EI]<RO<"N 5P!L"
M4Q7 ;UJ9NW2.")0KX3U%AP:Y<H8&X9RS0A%FM&<W(WCM]/O >'Z>Q=,<-6,!
M>+0%SQU"ML@$@A?9F6+,"IX).3>RK=5TP<M]._U6.*UP^E3@] YH:K,7'-$)
M'PA#Y5$G7OJV>"T83>A,C6HT T0G2R'02,X%\\!,F0\AF04=,2,I\UXJSG5R
M8FT=39OC]+3"RHGO6<3QT]#F+[TX/G3IM-Z)[;_M="_N3^:5./_-Z(;8523U
M,2M@?W'8,+KB\W*LK>._+Q%6)')P%%O6EQY MGN6EZG5[0WS]]E^_G6WU<GW
M^K9OCUL?;']TNF]X% ?E:%\WQ.ZX>5!WM-IVF/^1.EW;]9W\]L$P_V)TZ.[9
MU4-7EU;M_#:0/5,BW_R'WF!T-N]Y/Q[;8>=C_/E3)PR/+D#MT@?/UYE\^XAU
M^29.AS=_9(GK_]W5QHDC:)?^+'<[ D-#4&MG)4IB4%MG,RTB1EGKDI/,F#=,
MKUU\Z*C_[<3HV^P9]Z-]#S;E!WQNCS_9L\':3U=W:MZ4$^M^TY)=VL+RZ@XN
M!RH[Z>Q\"=?_X_H_K5_W7 ^Z_E.V<;3^^UO[6[NM7[;WVJWMW1<W[\VFW.^+
MO=W-K=W]K<U6_FE_[X_MS8V#_(_]@_S7SM;NP7YK[]?6BXW]_[9^_6/OG_W&
M/\^_7G7M:>ADL/BYM=W-:-([S9<+@W_?>.<32)KO>X3"W[!@A/SY_H_MAT%\
M?O'#SZ$S^'!LSYYWNJ.[&'WHYZM 77;_!.J/UFG\\C?%>$;&RG%>Q'?^S><O
M/QN]-&')QJ])_4QR>>/+Y!F]\;7O79;R9U+>[[+??TWPF[]TIIO5M[KL#PHE
M[U@/N1@*;F9@.5^?R=SFF<9J^C!/=;U?L=_YW-K)[SH:M+:R^0\CW!\_ZD71
MYY5'?C+RO.35WX&'-EO8V>]C\WK@&X\I/-*%HW=1@V;7?]_NF5_8P5'KU^/>
MIT$K]7LGK;T/L9\I?'8F-K++^3%S]#AX?IO=--,HF]MLLWMW=%K(3<YS@ XU
M3=DC=QN@,_,YI:89B]L')J][P@<*+=[NT>Z2J%&<!$*C-CYH]%1:$ZF.B@?A
MB0V<CTY@,4+')[#8XV[QO??B/,YX\HKL_K/#=[_\^KY<<^?+2U+>M[=Y]&YG
M\^_C_'>YGB@]<;[%&;?IZTW_:??+UI?7!R_9WN9?^;.'N'/R\M/KDRT\/-CZ
M?/CN^.3PY._CR3CCSKN_W^]^V> [![O'^;EP][>_CEZ_>WOV>O.7D\.#HZ.=
M@U\[>_^\+GUYTD7MZ\X^X3N;&VQGXTWIML.=3Q 51D 1"&B4$9A0P9="6&W,
MVCIG;275[!V^&W20LH+2XP0E(;PDANED*$>&Q!D= V.2N62]I!<-%.B3F#NP
M(J#T90*4A$[)T@Q%4KD Z%% :0P'C#G&,RQ99=/:NBYGI[ 9H#3/P0)-IWF7
MVNVUAKU6/V;]\YWC..H.6/A?^6WYV1>?X;2D$#K=5N^KPV#GXS TQ2=8..WG
M#S9IXG;[83-^R'N@<__A$@UL5W"[)U\N5[YJC2ZO^D8W;)ST\K)\&?VSFI\[
MF)^+TP27S(^4D4;E/;CD." 3$HQ4'KRE2DB4/DF^MDZGAY37[B*/15WGP"*K
MNBY(72?9(E$\Z5A<6"8I8+(&-&4:,H'40@=%-9K2-*1!ZCI/NMAT>O#8YU U
MGRJ,)/#+9-/\ZL'.#9,Z4Q1"&!<=!@8T8?9@A0I@2* @"$_.,&](RNK(V]+,
MW,VSSLAHK";/G45435ZX)D^R"RMCE#QH< 8U((D.G/,"DC?4*6VEH&QMG;49
MG8Z/K_Q<BY4@&"^.;/=M+#&F9#O]UL?2KV\\S:);XDVQ.QR5L';"* #UU&(4
MS4CH_7(ZR'<V&&38<IWN2 POOHKGQ67I;/3[19RC\.)8LMO=["V==H=[Z8:/
M_-&QKG/<&9[1BH1S0\+I5"%3V901SR SFPB((?M9UOK,:1SW1B62?[VV+DB;
MD>GY'*N<*GS< /&0?*;"PNK!PA1!*DWJ(Z>0(8 "EC&;+E@") GI"?4J6K6V
M+FE;S3[Y:WDAF(O:\GRS\?MPLJQW/J44XWA;W.;/[>XP@T'''>?O[IQ\R 3P
M9$3XLJ/T-M80T[)"3!N#01QN?UW_%Z/EKT42<\/=O>DL511"6FD94,%L=DQE
M.1M*&/ALE1/GF@4OLF.J,N[.'/JN,:;&JO+<.=EM5/ER\Z.JNS_6W4G.E)C!
MH(V%E+0#]%Z!9M2 ]4$Z;1,A@M_<\>AQA)6:SD'&7L9@HG:I*,>@9;NA=7SN
M7MR[CNFV7N=#7N,I)2HWO"_^Y*!4M,7.Q]$1U']UXW J=%%MS\+CA=M=WX]V
M$#?C^._L[)]+YZ^OPJGL<FXEN&/K=-Y_9./3[KN--R[+4['LQWM5AI892\$J
M4KJJ^H B),-"H9>D;?AT_Y%*+QNMXDNNIZ^J_<"J?795M:52-C(>0&HI 6U@
M8'70P -3R$BT29B2TN1DNL3QSMW9FD8[F\Y"]H9'L7^)@DR=IGS<V8@EIRM_
M!$TC:7S#I1K1FB,P;4]Q#F43EV@TH$L^<PY.2RK!@B$D^\A<,L0R.(FTA9RE
M;V3-,#;6HU@"V_B^2C>PK??*:/,$S3"^1*B%@"B2&R<&C8H6!&4B&J:<,_,+
M<M7B['NIYI_]^,%V0BM^+M6$<1S9ZHTHB#_M]TLJ;1SRJC&0!L1 SJ6U&5/,
ML@E;8Z%M=,,(TT:!^\I0YHAI.U,,)3$I)-4*O#&9H2@AP4JIP2D5D[&8A'29
MH:BVHC4JLF)*W["H2%7VI2O[!(%),2 WS@!E3  2D3T1RK-WHI0V2-'(0$<A
M4*9GZ8U2 R7W4M<_>MVWK6'LG[0^3)"8IQ4Q>5"NDE>[.X5=>^D<N\XQ:[#;
MZYZSR0I8\P.LEU/L1&2PTDPJT+$<7*>)@)84P0BIL\"3%BPKJVI3PQKD;]48
M2D-C*+,I=XVDW%^O)Q,VJ)/ :"$)FHD(10\&;0)NI-?&4&_+0/D:27E(.O*J
MF]7C.+\_C'L@91T]L?WW\;R5><PZ,JH5>EJ!E =-Y^Q\7?_]K\O_34R_V4YW
MW,FMHM,=T.G5%.LPGC&690?!R 1H/0=ME =*@V#)&^;*I!JF:3-\I!H+:2C=
MN*O:5K(Q'W6>(!M4650N8%9GF\E&9 *<)A8((@]6$RVC>.RUR4TG&^,BD1DR
M,T_!#UIF9F8DD&^>T$5TMD+1':#H\!*S>$EWOKQ_8XG1WAH-/!J;H<AXT"(2
M2,$)ZK3'A!F*KB$6-9CQ6)1X604AT[I;Z<5\=/KLJDX31C*GL YBEA6@Y X<
MT:9TUHF$684ID16,93SN\^)-YT-?C^Y\L&?%<:A!EB:0H@NI_#D62LW]S ]7
M_5041E+N!"HLYW404$@L[8L#F"1(9)1SE]C:.FU3/=UQL,9A'H-J+V[R157M
MY:KV1$1&<QJDBPZH&Z5_+('L_WB@7 21^93 TF&'MK6:I2J^AF+N2SWZI_':
M"MI+)\1KD.;ASO"<2^B/;]*H<#4_N'H[Q42R( 73E$,TI1^[RR3$2N/!:664
MH(9BI*,:67G-])X:N7DLFKV<@\-5LQ>IV6>3Y_,4XS'3#VU9]C&(2UFS5=[5
M2&F4ALG$L1"1+.0&*?93"H1<5(NW^O%C[)[60$@C B$74OEK+)0*4O,#J?=3
M](,&%64JTYL82D"! K2W JCP*D@924)=0$K,U*6X!D*:J]K+#(14U5ZD:D_P
MCRQ**Z+1X!U+@,HQT)%;8,K92*+3-#5+M><4"&DRX[A]J][%_;E[FV&CLX1@
M7*\?8A^&O0_/RU88](X[H76QM$T&4]5@GI2E]B(+[<]^[V,GQ/#+V:LLO>WN
MWH7L-KZ*KJ+JW%#UW<8488HI)":\ 6)3 '0Q9E05$81E7FFB,4I;4!5QE@K>
MNVK2"H5QGC Z+'3:>D6'AT"'"<[E ['2)@J:IPAH!0-+2 +KDO;H4.1-L[:.
MM"WI+(GE9<'#G()!S6!DU^MO49O6K\>]3X-6ZO=.6MO=CW$P(D/?=*9.7G\,
MN<<_3_O^*+NA9=K9_ Z;K6QRXD$/F_UIST;#B0YZ&_Y_3SO]N/'1=HZ+/'[M
M]??MY<,LF]'5@_!S-%K?VO3L;6:CM;GS1IB0N!0)1$1?.G<D,(9HT(Y()(DS
MAV%M79LV,;61X.HH^$-F'V?2[UH_?G_5/KNJVCK++QJ-(+." RJ;0$ME@1#/
MG4*AO:]=!1O"2P:%F,2L+1^*ZCRM7&2CN$CVHK/?/#S[\]AVAQO=L'4ADPI3
M<X&IZ5;&QEM*O$Z0DC6 G'FPD11"(H5FTD;-5!-/T=9D9/.2D?=7[JK$=U/B
MB=@7\TX%(R)H'T)V(Z@!QS%"5$X8[P01@JVMXW2GSYIL?$+)QL[7^%I--CY\
M5.9NZ82OL=&:3EAL9.9K.B'1D% RB$F4!LJ9;SJB G!4TK#D*+4XO\A,S38^
M*GA8>K;Q6GBH"'"O ,ZW^LSL&3EC($B=$<!*4OH+*0C!H+*")F'CC*2J)A,7
MEDS\M=.U73_'9.*MA/30F<:[W^3C;Q>QRGG3?B_+-9QOZ<Y@<)KW]"B+ZGLG
M)[UR.SW_/ENB+/36QL%.:R^E_$7=M^U6-[/_7OJ/Z_^T_O5SOC>H;;B6&-T\
ME]ZO67C;YS+82R]&DMLO@JM!S;F8[L/I'A/2(ZK @%J*@*',9U,T@?,Z<W=D
M(BK:Q-Q+3:XV/;EZ-Y6N3OF,>CU!R3F1AB8J(1$B #4-8#4*4,[;+.&H>=%K
MRF5;DR8=V7Y2.=4KG"5^CGW?.<^PCME*[T.1QA/K+]X4'C("J;VQ!+;.91,J
M#YD+7DWWNF+!$!>"@2"(!(P^4Q N"?"(2%/D&C76Y.KC5^F%\I ;5+JJ[MU4
M=W*FFJ9<6Q^ 4T8 K2XM)*@ 8R7RI(,RQ*^M\R8-3WRZD9$K+.-*:.23[?=M
MMT8]'H9M_#->_0M4JLV*YX-6TZVL(A5"4D?!FUB*355&*R4CZ"PR2JFF)*8:
M\'C\VKQ0HC&MS55K[Z:UDQG&Z+4B20+S676S+R!!<Z^!Z"PVY@AU)+L'*&<F
M&<L+93R"?-%W&)D0S69%7TN^/IS7![3<62M]S83.6/;UHQQCHZ'U^JSQ0Q*E
M&THYOB:N;ZKTJK3I?@#\Y9J.$IQ;AR$[>9$:0",$.&DS=S+4&:D]9?$[,QXN
ME.C!ZDOOZF3>3G.7%#3Z\<W,$DYZHB U=_YW7Y"JF:\9D6J"*A+G0I">@@HR
M *:,698P =1SY8745-'248RK-J?3/4TK4CVU PB%"?XKG'?_^W>K<]X/L!P#
M* 2Q/::)Y<CCQZR792)-:0??CX-AO^.'F3B6UQ=R.*#1 -R(?@TWE/X6'"[_
MO_5-:']]E5=Y8:,;KO[BTCO_S _>"]-M(?WQ:1'&UF=_9+MOXU]V&+=2BK[V
M?9@CG&]-$<\41<ITDP!5AF7/WRIP2 2(0)$Q);4086W=D+;@BVQ6]! QO 7Q
MOD<(.P_)^RK8K##83*<R_W_VWKRI;:7;%_XJ*MYS[DFJ:!ZUU)JR;Z7* 9*'
M?6.3@-DY\ _5DT!@6WXL.PR?_EVK6[+EB2&!8!*?>Y^=Q+9:/:SU6T.O(4[!
MSB54:TT8]37AV(!+:!EQ%82:B13 )M@,6?1$GL85T]]><3C5]H.U-8<X0I]E
MO1ZZ^O+4Z1LN7(=9+8%,K5DL%'.CD%/&1"BDEL)5::RI%X9!>KJ'2$D]GSXC
M4JZ![^F ;[ZVA0!E/%!H)5.!_<A"202E+E$!5Y&6J<M];#48>IMA,*]FK<.O
M?A=6=STW#ETWU<SUF/(2GG">J#"A$4U\K81A=7?-ZJ^)U6=TG(2YL< .[$*B
M)Q]4&V!UEQ'X'/Y000IZSL;[(-AD[CIDZQ5H,AJ;$R[389XW\WS1OKVD^_^_
MGF_Y*P+P/WWMX29:@G2G+IB\8,S$<<Q#/XC]T&<"<[@-P#_@2G8-\"L"\//U
M.)0O111JEZ2^[Q/&:402'D3$#Z6?I&$H=11LO(^\3>K-]U1Y/?<?KZP>R!J)
MUT@\A<3<5THS$4@%JG8D69SZ 4\"&0<>35F)Q,_M?UPC\9,B\6RC!>ZE"1PJ
M$5RYA,52DEAQ06(F>>2'BJE(@54=T$UW@56]AN(E-D UD6K*@0':EZTAXL.2
M5#["6OTK7.GDH;/\ Z[]#T?]?D=C34W>L:94VLFO')45LI,7HX'^L1(X#PV_
M?\DQGO)2@":K?<RFV%&? Q"!H'-X%Y8%EG1F+MALK<?AN7:ZFN.1(S6@+=TQ
M 2"=20_JGW%XK)B^MGB;'JZO+5KABJADJY/A5>BB]^X )[&?'A6Z410:7M'A
MH("U\X:R>?W[:4-*I$?8Q\,A[RD^6">C/D[EFJ]GDZ0:3DU00E./$^9KC\2"
M>224E%%0M^(XC#?>Q[_A'<8:DWY+3'JR>)4U)OTR3)J-*G&30'L*R#5-(L*4
M"HA(&">A3D42R5"+&%L7_71$R:^[;7EUN6OK"?_Z[,!7;A-.+$$T"6 GB+$2
M%Y6&7YN*OX.I6&^]..YP-&4J<BD'(_BKON[K7K$V"_\0%>S)\UFW>3\#B-E%
M,E+9$""FV.O)T6"@U8?1L)4/C_7P"\_6U<:>0B-K[<QGLXHPTFF@*$ Z;"EC
M-"+<%8SHT%=:Z(BGXNF*@*Q-Q35.O2Y3\?$XM<:CQ^'1K(7(=4(I]8ED'H9L
M:)=P&OO$XU1KGT>"A^'&>V]M(?YQ!M>_3/]O^%-EW]__7_A/]427#\ZRGKUL
M]:;168+>J@=/#5?4K?#*C/@.D2&3=R.8APC6/M>H.>==F,T-&DZ]? COXV!8
M<6RU-=1G ["W^GQ@+E^&Y[K  OP]A3HV[E;/W"2CHZJJT (_+X;P@>F:MS4F
M_SOV*+ICB]Z;VO_/-8H!Q,1E<0Q<S "@6<P%U]QSDXASD8K02Y)3GVXL>/4O
M/-1E82WF" ]W#W=;SH>]_4UGK[6]?,-79;ZM_?;NH=/>=[;W6SN[K</='?S;
MX?[GO9U&&_[Q<:_5:&WO-3X[AVWXH+G;:A_>=_X6_MZ%OY;7[ESFFZ,>'X%@
MUNKM#],=6T1W=R[Y8E0,L_3FA=9,MYQ2)6J-NC"$? );;::0!T=-9S_=[^L!
M-[5B7U:KN6U-M!K6NH7/X+GFSI';O#CH[+?/V$GWG\NF=W1]W)8WQ]Z>W[SH
M7(*&TM'_/K@Y^:;ZPF/A2?L,/K_$.5ZUVE]O6I^. M""NB??OH*V\_&\=?OW
MQ?&%O-G_=I#"][1Y=BJ]*$V9P%:93! F64@2Z;G$E6D<*)92'H=6 \UZ(ZT:
M:*:&/(BY%[/ #3P64S\1B2\H Y54!#1.8*\UJ(I]A(K!""3=SN[A]L'>E_;>
M?LO9_^A\.#K<:^T>'E9Z3GG$,Z@*WY5O-<=C#^?^-T_/5&CA>=QWF>]14)6!
M.&+?$U$L$AG$0HB-U6.(Q>+U$,1ES_F0Y8#-/;GEO-DPGVPX^<#$-J 5Z[E_
M;5OY:_Y%_WJ[Z7!G1W?X%8IAF0_ZN:5UXW&PWJZ/6@Q&?'#C>*X;;SH9B&P'
MKXM _O,S> BF@MJA4TIV>%*:_IDP"%??RT)J0]@X;23WJ,#A^P,0_C;J8@!T
M, (%LS"A&3C5X4#S816$T8?YF+2'JVQX[DCL'S'8<E"9J"V%1G\53C<OAN4K
MX47P!C626-T-;!;4&C:=?S*8BQYUGR6B+MP*'G!.?_7S(L,-?C? .[?LN_X+
M%0KBFZ=G-6U>:!P =*?FL\SY@:0%1-(I<N>REU_!F1;./Q\8 0ZK:"&'&7=N
M"%==H(0"Q"#L_K+S1B+)#76DJ/5Q8$6BP;H\AX4B#>E.!XX05#]\J)MWM!QU
M--#R;G^[T=QX:QX0N0(J&_ S0R)#C32$K\QA,@ G/6E51"!@?,N70H]4WLU[
M,'%]G0_S:YA&8S&MH7>_.RID!\N^?.<%'(\C.F EZ4%)><Z;DH]:S;T/VQ47
M;3G[/>?O4>?&H; K*% VS> EA3I=KK3YH!@">^DSD%9H;YM%PK2_YYU1#W8,
M3@[('9@'=FV JX)??=>=O%_-KR+@*E[IJ(="WSE$';BP3#$>]PK6BP1D&1%^
MGH,)>';N8&6!0A?%[)B;SM5Y)L\GCFY\@:F"4UV$U.8R!/)".C&Y2#!>#KJX
MR47"?EDVQ JY7QE2AV>_&(>Z/P&+X0".>Q-^V>GD5P@0&3R'5RVC F=?<CM.
MX>-.HYH:8M1D9PHY /16CH!974TA@@-O<T!X]Q# 8-S^(.LB@!EDP@W'<26,
MEHXZSO1N](%,@<2,85$=%>\ 3?<,L];F=9;#C^")+K_.NMDMKJ$XAS'/\PZ2
MRW?>&>GQG@YQEIFV P")"VTXH0,L@@4G<;PR?PN)9\MIC+>N<S--2F@G]919
M1:'U)9PL&DP]>&-%T??0SKUFTBH*M]G#K3;/4JFE(C+J.U8DP6KQV LXDXXF
M? "TW1UU &FLEK[IY'W=(QT.9[*$,J>8C2/* 8#D5ECA&<Q()<$EG"K0UC;O
M=/409..GT?_Y_SS?_VL OWVS\6'[T\9;,NH-=-$'XD98,?CAO,'I;_RS!^:'
MT\87;[RUE%S[J+98W1O 4LO[**<!=-T!@J&QG04P>3ZT<Z>^/YZB :<=+757
M %70V "4.TU5Q4ATL^&PY)?)"T&=Z.1G*)L_9Q+M<'AI'\Q]JR/8V7_XW !@
M1NH;[]A"<(5-6+0%)3M.09GS,<^5P9:=P>@,N,%*EE(U>;,!F+!A07>LG%#/
MK(MN5J"![H4LS4H2J18Z/.=#9,=SKM 9H?L5#<$JG#3K:+O]^+R1>6=8OQE^
M\F60Y8-L>.,<Z.\9T'2U0GP,YUGH(>Z_D7KP8P-.)I+&KN (Z![FJK&U)LS_
MR\[11]PT5$LL6DYP.^^-!X9-:XS.@/&J4Z-FS=5G?GW%U0('<-"PN;"Z"<*4
M>ZZ=#M+F1(9M'WRN))CM"E!M708J$YXQ*FZX8=7GN&L*1AS >9A]LYLI\U%'
MX7X[O(]U=/5D1^M4@0W5#1JC7CJT AKW;EQZ%^:>=X%<E#6WG*(/FY(" J-H
MGPB3BE7_A;X?( O#MO ,M]((?G*#C0VRB03" >2Y[B(- 9X"'(U2+D%"F/O[
MGG$N#8&UBLG6-,?"W721A/' #!SRS-0*,:H&[C0L Y9#[+)A%ED/YVQ>6:[,
MZ*#_&0&(#F]>)?3N]9Q].<P1.Y#:+%=6:#)/?RB-X,#[1AW (W!@*YWV31]H
MW^EJ/:RV'+ZH('?ZVTU#K[B+(+_@M.J: .Y\J254QS+@V+VETHB I,WHH![
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M^&GR G"ICTB87L1+X_ 4D>>75:L9Y*TYN;V ZPRMHT5436;RUJQGS8DJ,O8
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M1[(R^C7-,(G<)K#9:^V9>%ASBL8UD6.A^JF?3W*6;0;II.IT4-4J-E&HXRA
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M4YH2/_ BPF(6D%C&*9$N2V.=^EZ2\#5(K4%J%=;V&',ODH!",0\3WV>QB).
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MP#5[:>H&VHT#%1'J*D:8&T@B8I:0@*>Q$BQU$Z[7P+4&KE58VPM<FJXKIJP
M9LW>H4;22^-(,Q*F:4A8RC1)A.:$IQ%S*:C:J:M7T06X!JTU:/V*2]0U:*T
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MA / _=8P37RF/\C%A/"0/T92@NJU:8C(''_6Q2&184#$<E@GL#C,-0?$UGA
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M]DT/SJI:UZ*SFSNQL2O3*(V%M:'P@VJTJ_.\\I\4-9T0%;;Z=*ZR3@>US5P
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MI";^P0U5X]^IH>K/1L6NK(HPYLDMYY,I8V"+Z2!G B*,>M*"XW"<WEL7DA8
MII@2"_W.!):B&"MK!<\703>PR*\L4B"H -YA:6$G@Q]F _,:B^%E-CORZZ@L
MLE F#F0#-5O)9W-2Q=CH%;6\&LD'@QO$WCO[7<SJ1E-:S]%AI0OAC-(1(H>=
M+\IMHR%-HF;+D*JR:M:CRLIBVTN-);TX8P&+N1\'G$7<P[Y>(N5E/@RM\F&2
M^S(6]\9[.A]=NWM=Y@]5,;:O(C7FEP??-MO2:UV=III'GL?1FZ858:[R"4\T
M(]13BDJ?NHI'&^]]>F]N&E+]A-+E.>"$+I;24-EZ!,C6E,KN %16;#"N/0)J
MT,#V$1BWJQCK%\"%H('J04W+SFP/BU)'WL2GA%'G3!,6K.F-7#6O88_?!S,1
MIB *N@50-<IRHR?,O7ZSQ 6CO_;*B8R'F6\(,RG^74GZPU)S GUK6#(T8.$F
MIL5Q6_K8,&M1W,_OD_"@HSHO&ZUU: I4H*J)^7!HS,P<4U7IP$X9-ZK\I,SQ
M=$PIYL5G@#/N9%4GF[JU,SD%7,6HVS=J;[V0QP#VPV0@EA1@*UK+X62QL!H+
M5_A[,0*=;7R4M37!"!U\37F8^/AXA\WCFTB!BV"Q&**9<P9*^(0D4 J8]\&,
M"K#:;?6]6E<4()"RC/6T]  Z[>F!5<T[E7$%U#@:8HWJ<D+US$:[PDV[GFQH
M^FU8BW-2T%Y.*F7CCH[ZH$YB=N*X'ITM7#^P#4_&5>_'Y>SOG"M0.A]GK'7Y
M13XH#ZZN^O;4@F/'YAYPEJ\Q[V1GDJ178 +IK+#UIBV=7,![C ';<S2FS59'
M46<0R\<UVP,VF*OLS&CUI85JJ=96"C%'.^H/^:4NLPP&_+LNC*TGSW77E+GC
M?;" 0#L?_Z,\BC$]E)^_K><=YKVS'/\.EH]3@"V&S@ KJJL%80,6TS\!V05,
M"=")T#HOX%"X04J0B;AKE45;G&."#3 KUBQ $[2&>_5Z]/EH4.U#V?*E))8M
M9[_G_#T"+J5!F2M1W^ N+YECPHR/SU2>0&I=L3$MM$ #Z2G+S5I?(G.5Q%]9
MC/>5%J_*@]HI&22JW#$<TSILDR3<!\3J^<3I*8^0*C52:9LFH&U?>VV%IG:C
M)QW$#+N9"?->W5E@RT+ZLU4A%]K")1E.\E]*QP!Z?$9%8;#*T&AEJU8(,NK;
MM*OR<(TO(A<EL50]HLHOT?O!![#<>TFR.1%RU0N&M<924]ZU;@[*0>F.LU!E
M7F8J0<FLCV*M<L"53&+; MC\]''M*73M%+:>Y@1@2VJPU(P[F(^U[ 4M%BJ!
M-,U2SZ.63T3Y(TM:J4#(Q.-2N*!F"Z6%%R2AAZ&&E&LP^AY0;&VM:#]UEMND
MW!J%L3#_-E9<A3Y+21I$DC :Q2264I$8+'(6N3(5V"J$LGN5[D56&W#!%4AS
MH'(LDW9'TQVDXZIWE[.D=Q>PWD1MG:7A+OZVQ)*:4CD$]:3"OL=WM/E)$IYN
M]G47^4YU_OH"2@Z"\MGJ=(U[@73,<?4U+-1PW6J<IB)VJ9) HW[B$18EG"1!
M1$F2AAY689=,AQOO/;:@,N=_;YK#G[Y!&8Y[-UFY7SG"C6D",)Z";ELAYJ1O
M)1+,M-BH$H--!QC$T(N1.NN6%=@FG9<N]4W= JEKX',W,%;P]JV7%9LQ3=^'
M5 3-K7^W++^!W-5!*0Z2&)BD)C&ZD_9(*ZLL/S+KO(+Y55W.G;K_>/(_F&I>
M.N%_+-/\7L-CL=TQ3GE&=0XUV64XO$CW=HR+<5)$:K%J8M1\^*0SRV_UFT%I
MNC"9UY=>U#I7+>Y(-66 3MBNG*JQ+#:!=7IGPTIQLW*'3S3:8CA2-Z4YFW6-
MGZ#6[LT.U.&CGCR?ULDR[)5KV1-F 5IR-7_T/(P'F/*"*+RLR@>E*T,/S/TA
M&CS_P4I"V= 6)5W@R=VTUW&V@-!<W:7A3=^LA/=Z(_QC8B:HLK'NOASF2"=T
M>@F525&JQB.@T$''G%Q]XPT,&L S=H0YS K-2GRSL%?*8FW+)?3L@[R8\@YE
MV,2MF.]<-WVL&N@<KPD7Z/#UMV,C/5#BAU9_KYE-E<5ESZWF^0/,.!][;O J
M?,IWXKS9V#\Z-#4ZSRI?TF2WRIZ *, [#S3;5]1>7^18G$BJON:74QPT=6,Q
M=2AF2VK&D*V>CRZV?%#,.*+JAI*M[F6]5VG-+N<=H(F>88.I8D?U?M-CZC;]
M'&<O3] :'V3=>45Q^%AS"@GM; SGCS.0GJH\WMKDN5.3;!_?MKZ>:BJISWA$
M?.EJ[(BH2.*ZDO@Q]94.=1P+:JI*W]?"9^GEU-JL69LUC["_O?V=X]MFX]0-
M(Y?!+A.1Q$"8H:^(\'R?R"24@ *@,7)W;=8\TJSY5=64QJ63_MBJ21,SO7G;
MN&V=G891 !NJ B)]/R&,!YIP/XQ)$ <)];THI#2>K8CT6BHPWU.Y":\ONEUN
M^U(8?<$H^TBV8QWAYPLW+>^G-%\!QGR"39U[PW=^:#(B?G&!)6\K3MB/%%B*
MZ987^D]?LRC<"OSH*6H6/7FNHSG.ETA_^%#5 A\NH<"9B*X'QI^O<F[,XCC[
M1^?&K&2.R^*U/;]A,I?C\CC#Y%4GM=@&)/#Y+LA"E(<'G5;WX+S9;0:MB^;U
MR<57_[A]>7O<W0MFDUIL Q*0J>W=V^;M[FWKTY%W\FGWYOCVTFO>?NRV=M2Y
M29"YZ*3-6C(BZ(]!$^0MY:&+W7U][7$T; (2AQ$C:9SX"9.)CE!_I/ZF&R[K
M2_(S5/_+$LGO2&*GR<IDE"\I_36QW#IY,9=//EZ_][CU+P35U4.>-X^)SOP1
M[?PA&#0Y@L]P FM$>C)$.IQ#)":5CAD+B>*Q2UC$%8EE) @<; I&@,(67DL1
MZ>V?4-5B%32]>1/DQ[2\=>;T.G/Z.3L$/5"K_-VJ6_PJ^,[J\"UO6HW30(?<
M]WA,XH!1PN(4&Z"&H%"ZKL^%IU-.PW5UB^=(DQZGO$U5Y5Z4 K<\W>H/SX]+
M7FE^W+UG^L >+,'#>K"L0.;<XKB>Y-E;(32DN7(HOO ;9+M&3\$G@Y%6G[-Q
M[L[J-6=I5=U/NP=9:Z?A[K<OKTYVSF[@/3<G%Z!V>UA)0]XV=\XO][_M73=W
M/I[/.O9//NVY\,X Y,WE_LY>T-KYN]NZN+P]P4H:M\VK_4]?@^.+W:OFMX]I
ML[U'3T-/LR!AG$C-?,)\S,>*74U2C_H1]81,5#C;#"$(&4L9]648IRQ-:1Q3
M-PBU[R:IB!))9UW_C>WM@Z/=2:O&'VC&<N\K?]U]T#PIK513C5]/14UZZD8
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MCAYN.0 EF\XV!SG8RK<<^LZC1'XG;N1Z 7P.!'SYZ$=]-[&DVN2#2V",!0/
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M](J^L@\DHT4__C.*53OS(SM'NX (Q4&2)>*@7H+5HX>96A?/BV<1/H:M_@*
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M*3W]FB]>)KZE^G%EP[]_O=&R,K-IVW3"8M?/[J=;B#$HM1:UAIN0Q[(VX3W
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M#75.X8 U%Z"$@.0B.E@)NHF^6^2JX>_OSM^+RHAP@E&M.'(8.\05<+H.CJ'
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M=F<$&+35 DL5H+G7CYNMLZ,XASD9E &%[/3^T]Z@G5=H,\,QL$Q&S_I)]04
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M?]&KTCHM"SLVS?H N)D[+D7<"N\7#Q"&1+&.V.#(.6;1*14)BS;PI&4@ZIH
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M;3VKG_17'7![.P*A*B03S_POS_@OO^0 (J@KM3&3I>^)#;%0>\[/7#PN7MD
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M]1R68A9'*R)%E*8>#%139(P7* H9:;"8!&?2D%E-"?WCB4S&9QIN>EYHZF<
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MT_Q>!A!9%$P+. QOI,U>RKNE=P/$8">1PYT3Y9\XG6=#(]^.1ECKRPF!DRD
MIB%K31HC -1B?;0H=2)VQH Q'<6]A,)C8ZJ; _^V!ZZIUA$'BP!_&\0M: '+
M03(81ZD@+D@9 6J0G45V\A*AL V@8Y Z&[4_Q\[U3@-P2C]F^' /NGEZV^$A
MA+-!_H#\CWGS] 03&QGG$@6 =(A[#F@A>H' :'3$2E&$<$_!\.0NA,T!/^:
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M\[<W8(4FYRVQ6B/E24B9K!YIPSA*;@7FBA@PHR!B%\.*$="=HK)9.JY2VL8
MM:*=&:B]9G)ZI0R17WD6HWRFLQ@?J'>6C>-<+4G("+)2EM"/2@F2WSPEZ* +
M0B(>V:\),'=Z@ZO^NHQ$%*TC>$X7[@?7'>ZES]Z*YM&'ZX_G^SB)XN._6^WF
MT=LOQ_28?P1[['#O+6M=&_SQOV?87_RG:_\V5VE&;S.M8^_3U];1OR^:1^]
M%(>S8WKPM;7WY_G'\[,.7,=;>Y[]]^88]N-OFD=->/8Q[*%Y$HFP.!*" N '
MQ(/!R#$!]IZ5T9(HM/-X-LW&*!4XE3$HS7F0VH <=R;I4!ULP<QL/M!!Z^5A
M<[]QM/O?_8=D =WYN.\W=K,DIC\CB/HX)BSX"SC6[W93Z@.0=W>=!F^N 96]
M/6'$< R4AJA+CF<"BEYKRU$,VE+N8W14W#:%<VU0^1TS-ZLXT&6O6P=JIC,A
M0/X,&BZ33P(:0#APCZ^P/)> +H (0,+3,_KNG+=YJT;ZOM,MC=J1$C]HNB7;
MT6KYQP\>&"EWJ!3?9+JE?OK%BAU-U%-.MURQP=P/[1>TN /4:%-FW<9+KMC,
M[3U@_V:)_?<3]L\@KL;_]^DB^!.=Y42KJV4MNA9TZ5KS@YYJ<_C(':_2).RG
M>G/D9^6$EZ4N_]=WI(RG)J*I^WRG5J>C,YN .=4M4/K^OXC^#J;JLDZG$S'J
MQ8U-'SW_9>WH^/]^S&2.>[167*_1-@NZXSS$B)QNNSJ #<-/B]T3?X%=D'(1
M7Y;&+[S!P\O8+]WA,]9F'-3VYK/HJ/I@\Q/6,/AX=-EN[87SCZ_W^<?S)C_\
M^RU\_NH"_H:U-J_!#+WX>-3Z]/'HTY?FR^J:__[[S%V$SN'% 6[1UJ?CH[.+
MYLVI^ AK;OY]#'\?X^8-F*VO/W::]%WG\&CWRW]OFL-ZA&\KF:]'QR>4%MAZ
M"01N"H<X!KO516<1&+(L>AJ4XWCKA1#;AIF?:J+-1HK]K%),""^QH;HPA''*
ML3,Z!DHE=050.O%W-''82+%G(,6NIZ68Y-Y0[CEB-CG>9*#(<E8@601L+<.:
MIH8QE&S#<:^'%/L&4WZ>&]0L<QP>T3S_)QP!]$TPV:.%6.7OW\BPIY-A;^>0
MF)0$\V C*D@4B,>@D8W6(,&E#$I:IHC;>D',-C7S$SM^GID^/R?#/UO\LF']
M;\'Z,_"E8$I%Z35R*7C(?7!@A.$"4>=P"-@YE[*$A-GF8KX/YNKPY0FY?ET\
M98K^B*2.S-*YT5'CKXE09\DVC<PW#W.=W3KR ]\V]6/6,;YN)NOB=WAOD_4)
M7]"Z*(S%;^;9NNWVOP[[%@ZAG1+V#X;Q(HT5R=FMO0YL\_2@*@_?:)2GTR@?
M)L"D_](Z]R>&D4('X9!RVB-.J$!&$^ F&S'7Q'%FP]8+)K<EG^^Y<6^#^.FX
M<LV=@AOYO)'/SQS0;^3S#Y'/U]/R&5.%)644 2T8Q 63"&A?(:4Y=:E-E?3%
MU@N-MZ5\#.)?&_F\PLBJ[Y7<^G*4N%@GN@)?5'V8JPZ*F\36J<36#R=.:LXC
MP(FH1(%XQ!A,U4(@R2W%K"B,C?ZVQ-;G,''LGX.4I JV7":!QF^YA]  ^.WW
MU.DHI;OVVZG0ILIV':?'3F3"/N.D5KV#C7E@4JM0YELDM1*]6I[H?9-:'Y8J
M>^=B5WL'*Z9_+?6/;E)%GU&"W"95=),J^NU219_<R_I#HL"I##5U#%NL>U>A
MI#M@[^-)[%N./7[R+-4:$0"8CK>OZ7M]\V=;\+TB*\2L.0.6.FK9GU7\[S$Q
MIG5S=3TV>V[1%M?%6;5^Z2:5?!^5C,Z8VK^$F^F\]?H#_OCWP4U:4XLV\?&-
M_W)\Y#E<SX_/S\Y;]. +V-LWQ]>S;J8F_GCTKG-\WH)G[K/CFW?GK9L_SUHW
M9V##G[4/7S?9\?GNU^9-ZWPZ#'#\-94]JT)Q)V.**?N N*8,.445*@0-*CA*
MF,5;+]BV5O,=3I]]2LE&1CTG&;4>#O4[I=5&(-U/(%U/"R03?1%!*"$B:42\
MX!;9(-,Q<<^)B:E' QA"6O]4:2[YV8JMC719;'[>#@17^;-,B?&51;>"-?>H
MP,4FV/I$;V==%,/BU[(&X'5)F&B#79].51Q/I[#<[)X$;(R!$T023A%Q026R
M:3J&*M(<'SB[@H9EV+7FI/7Q^7XG7G[.^3,;>?Y+R/.U OI+)?M&>-]/>%]/
M"V_%!!561.2M*1"GF"%-C4-.:$N9$=9(^5B<OQZ2<XTR6_925_I^#$#.NX/4
MKFNW&_YJ6]?NM(?M.-ADM4QEM1R?2(PM,UPCHYU!'(-%ZIP0R.&@&!.*"#$W
M]/,99K6$BBQRB*U3T</U[4DMSRQUA98Y'0](79&,?I-L$/G0])3;4U?XMUDL
M^RZI*ROE<*QA7'ZJH?$* >F?]D6,)LPRDE_&KY>ML+=(EK8GRKU^N32%)^JD
M]9PCZ =OWOT_]N+RC[U-E/PY1Z#N89=B$P&L>P+Z0')7:*VM9$(SR;@C8*4N
MF0PXYU^<0.P30+W^;6635M.GTPC=-'O:]OT9 /N]^#EV>I>IO__+WF XF'9&
M%NVO,:";V._])*9L[^O'B_^T6T=G9\V_CV^:>QZWSL%L_?N M%[O\U1(?7SS
MYZ<FK+\U6ZIQ_NH"3&!R^'K_Z\?S)IBGL-8;,&O//^#CHU/6.O_SO/GZ[9?#
MO5/\WYN#N;X,8)HQ1PJ)O#0XS>;%2#,54#!.&>8CCA@GKY^FA/ZQB:)O9-@S
MD6$Q<NT"QTI:PKF3SD</EF^A(Z%2BB++,$+HS,3P[R?#?LZ RG<49#-=)@*V
M6M)8(%50CCC#$EFC& K.Z@A';0PI4D#%R/E.?S].C/W\R:-WFT%K: H^5;+
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M,-SGYL01@XTA$15.2,0+(Y .0B.F?*KS+;C%*D'39=W%:DOQHG[70,K7F:B
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MRS"!O^I8P.:)E?O)!+@$+#X )5T)Z_R+\B8)<N:(>O7/4@IV[& $7!<)W)*
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M8)=?OIH$]H);;T]L-$641""A)-AW@FED4BV2T9CAB MAK$AAN 6SNV<+2@Z
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M_9Z/,0P296[4VXHD>(I;NR=::N^\B8B$J!'W3"5G1[(V/3;,B AH;'42S#F
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M5X<;I, - *VJ9"PU!H5?EE!Z<H+,U?"LUV\/K\L>IJFS:)J3V@:.L?VY; U
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MBS?]MMVYFE=EWS@U^YZ=&)]E!M!A:KG8N:ZU"I[6*DER)RSXY0QPUC4J9?$
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M%CJW'TD)]&GHH)QAM78CV[X_57SX<A*%*[ 2'EFN,>*F(,@$YI'FS!?$.2N
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M6',Z+-"?HI^<]/3W*)F_P2L:,W@-8EAAA<F*9%0C0>3G-=]Z,?@R 'T\PW_
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MJ7-P RZ^<;(+\#5  ',>@Y#(WZ)M#"0L6#R+8P*) F<$/_LK@_? _@!H9*?
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MA\^ 0:M*4SO:DZJX]?A3'%V1C#T1QSP7)E2Q?J5:1]UXL'=;FWK77(9RT?$
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M3M\>=O;,YE3FCL4]>A!/#;_#@>WLZP36^*T^?M%B[W1VT&0U;@\(MSN,KW\
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MOB5+ <U&<Z P^!S(XH73:79V6\%I6E]FR"HND&9"?6]>P(==O0KR&M >@!<
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M?-%MMK2T(4$D86N7NIFFMV0 WJ+('S AWND#HK+^!%V6>+XK8GK;A=Z;UJ>
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M;1B@[.P[.ZSR$^-J,GXF9-QU[+[3KQX=[ZQ@EB:]'Z2".:>+1IL5S%:S'$N
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M$J@Q9)BV1:K6RUV9>TXL_]ZZH&J8>N-9PO%,&?PU0:<-LU7U)EQ&?&O!GLE
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M6/'.$_5"5ESLEK](3&G-=/C/&R5*%,L/]007_.[O2#^P!C9L.-Z(@>^A;7R
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M9DO6LF#,)XX#AZ_ASS %GP>39Q3?D-H/J#E#B6&8"6].ZL,]W)/Z#HG3T,E
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M*\JST,E6LN(=-6X/XE[.S,&>_,!<M#_5C/#//'@0A,W1UU_^'U!+ P04
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M0'#+,#(E56[=%J,A_"'9NV8,O-H9[''4O:9E/'F]?HFAPU]_^']02P,$%
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M+$'EZ;@:4PN2)3*H.1J8JU./M 0!"_5=Z3:;^2;L+1Z['4A?@^3FM?C:LF%
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M<)WJ4HQ<HDYU&2[<ZQ9K&EKZM/]J_^T?>[^^VS]<(_)SQU,:!&8>PW8S;J(
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MB[88SADF3_)=Y\;% )R!TYISX[)9; [%;G%]V9!C>Z8O0]>.0X[6&&FSPQI
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M0JZ\99HT+@/P*0M+]QSI(/_X&M@/9Y52],WT9*LG6"WJO(Y5(F150+)4,MF
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M7<^1OO*)(5?!0M21V\4TRD=?]909W0$QNPAM/N /(<TY<F$X2TB7D$9=&*3
MF00CM9(QZ]C:4;2S/L5UMGHK&N^*3_&R3'&6H4@GV>EP0-_..AE+$8HQ*3%5
M:JP^\-JB0G+&1>&)&.X+-)]1^!"@7?0T+L7UF]+4C/H=:!$W,,TM]$5 =>1U
MO!/0=MR.#1DW[(KJ&Q.)*'R(H@[I2*7VWLJ:@=>2.0=2AN!%@M9),AL4A4><
MD)N6A&6(W:UI,?>SF13(I'7(?#%T_HFLF,?@6(&<K35H2O-HY2T0F]<M&S#G
M?B-B!<INRX-Y>'9R J/S8;D&?V8$D_E3&\^/OF(NP]%%\+VIFW/5EW?B"VU"
MB1L.4^!H27]P.@6A=0X1K X& QJ.)%#I#H?IJC":>%7_ :,1#"8'HVD7OBN-
MFX,1.J;"N-.1:<B&1869Y:*%XSHJF9M[G1Y$U)5[+2%DSI&4RB0,TPXR\\DZ
MEK-#KS0X;5IG_.V:>ZV%#"SJ9UN&W,TK4&:>GNO[[&)[O;G:7GMQ/.N/+HNE
M\YJKFGYFF2X*&7"R%9P))42Z-B OF->WU'N?A1AT3>]N]:17<-J?P/$,_S7(
M-RH?,.:2Z6@GW8%[NNW!,I]%+1W5W*#TD'3KAHM+@]Q@86W7++__A.F 7ZTS
M ^XY#_>N;OA+O+T:7Q56T\D8%-1IV&2"9 $L%>X"!QE+5 L=/$N\]/G)2:=D
M;^CV?_ 4GCFL<J3K$;QDJLXHTYS,46_JQ$67H^>6"X'-X\#WHMFP)[@3Y:0-
MJ7?%([SW)XSR9_KEJ0/#:V.C]XK9Z6C>FI4#,2D6<T!IP5GA6]]*WP'8EL>W
M%5.'K8C;@8XR/<-^!9*LZL<@BL",LJ/:T***TOC7\ZO?^0CG];/I"JZ6,<@?
MCV%P;6+=(FOJR#_<Q7JVXUY>0TQN1AAVA<=/17X+STI*.B2*YJFF#=+: J8J
M;4;9I+U9K%'ILY3;1WSA.RZVR["V W&=WR5SYRYRKY%;S:3G=(O$HHDPM=<[
M@HY:NVASZP$TWP'8O&-@^SP=MF)(!PE[^R>GQ\-SQ*EU<3#MI#@'YJ-.,<;$
MK$!;)S!F%B5$)B(D2>JIS;QUPM:]8'Y(32-&=7"^D TZ&?73!/,4VN_$F?&G
MP]\OYOS:(&KG5.:PSL&)@>S1Y!)3W )':4AI;>V9?A#0#TEJR+ .' @7_3LN
M"547/H>FG4 /.;'HZ!^ZV34+(M=6=U:$9(MUT'KBZ@-P?DA2,V9UD)3XW7$Y
MAR22@U#;(KH"M9TVD@7M0#$NE"\&@['0>H3,'3!^R,W:S+FWP4K'60=SS6W<
M-)O@YD,[R1)X$/G-<BDRD"!9X30IH (%Q)P O;?6U\D!_([H_\W'=QK5#R%%
M7;W;(M<JAT3B!Y$$D5O#.5BEO&AMPG0<U;_KZ?O?<)3ZXUDWD<L?CN<_'8N>
MTA8LZ,*"E5/#03%?O&5$"D%[)<?D6Z>_K01TYT+!R\C/0D[WIJQJG2_P/=1K
M%2*?AL?';X:C>L+W@D_<%6V9U:ZV1'.&#G/IF++>0A2F1+U8L&Z1MST+@>B&
MMEUD!-RU]NN%0CY:+I TLZ"G,2@LS(.KI= %;+))&;.1)*FM%&=UQ,9%3HU5
M>= \J'\7N.O]C#X?X:RE44^1/I"F+8MRKLV+!&GW8(@D%G+@GK"JQ5K9+O[.
MYR(*79*Z>4/2NSM:S7(/+BZ[JWNNAU:@J?%(3(JNMZ#(%#!1,$NF@?5"2ZL7
M['"\W(N?E6QT2?2&]O7]<GS1!W'_VVE_UDES?%.HO4FZF&B8C:EB%J'6)W.F
M,GC' ^@D%FMENR* 9R4PFV!"!YU,'[T+LP/)H6CF0U2U4:]B 4DY2\9DCDJZ
M@@M-[NA,'VF:%>6X+CX[.N?1(-,\%$9,)_8K$*0&^"!4\S*67<^*:FZ@+4_J
M7<F*NG,YTS"WXB8!!,VBM'1NE.A9*,HRSWG,R8JHS$8$9T>SI99B]B(RM#31
M-V7+S?VQBT#KJBW?_;"VU)VO#0,7$8LUJ+]I :&KWD0-9&-"HGM5DZ)1AXE&
M&Q1WEHQ,N1$[?YN=^S8O%TL0O;5A?V$J3'5!TF+>TZ./B$=J'G%Q64:55&UD
M[S5IGJ8PLBPYRXD6+:(VZ!<K#7KD13OB[UN%(W<X^YJ0LR,G[R6V#\.O4U"5
M5W-X%KVM!@53!FMA 'U%:K5FI=@<G :R&.-*W+[]KF?*\#6)VO7VO@9/S_P(
M[^%<<F'F6!,"%V@E\R[9:E<Y.N)T[4;C4M(N2K?@A*$E7_S\I6%M<K=VX#V.
M]>H3H>> 9;8DM=8Q;HQG.J-EM92(N6)L3CE(ZV0C^;C]]A<C)&L2_EY/7M/,
MA_V]3Q_>?OCM\-W!X>''_4^'?]_[M+]&SL-#CVN0[; PVAMY#HJV8'(Y^&"5
M3L9 P0 ^<2M$L46:WD,/7K/8:3#IY_[QV:3_%0\QG8UHV=7+FX[/"-\;$M::
MJ7,VF7KP#LH^C.HLL_'%4)$K5PE&\-J6S+@0)#O>D.RH7%A*4').WI-BV[I.
MJA'VM0O&UL,Q&PG7 P5H9*+-QX.@&UP8NL$S9XG4-JN$=\JT3B9I GSS!^96
M9/96(=O&F=Y!SOU56[<UES-S=2GOG0G5;-5:TOU!2P)>5Y,"U 8NG*OFI4--
M5[ IM_-.2/ 6F;\K3NTU%_[K^=T/F$UBL$G$&!VSQ* :-[>DNF%B*F(L&6+T
MB\U]W]QY_M!RMM]X<O-"VO;$;R8L'7AK[T9V/<=Z 7P=^?0?P[:E N5=$8:%
MA'1-3FY#XESR"+5'L2/3MW:7(1LX\<RT$K17R4K-:3/J\+9+BI^JH"W#P,Z+
MC7W@/BI7F$<9F;;&L!A5;2QI72HEVUA:AYRV7&S<EC\/%@XO0]R-%@Y;S 8%
M)&9$J#/PT-!M;Q3+EF=;$FI17)=E5MLM'.Y4 MH0?>-%P'3&@<[*L#S5_W1.
M# R0T>2TL%EX6;!UX=V.%0%W*A7MB-]!02]=B64X.JF=T&:YK'-8P2(*(S3C
M+BNF'2=$AFR"R+4"+:+0J?7=< ^49R8-+0B^F3##U*'^Z][A_NM7!^\_[G\X
MW/O\]N##W=6J^]_JEVOU<5[];2U*,ANM]48,@V/D24N)AB0E('KGI4+KDQ+6
M9H>]-=[;<9>D^VJ.K]QL&HT$C9QN,JR-R+6OL\P4<ZX80UM$Z=*Z"=SZJ-<V
MT8ZGOX/Y01[UN)6.SO7(K$$DVDC)(*C,5"#+(@<>?6R=_KD8LATL;V\K:;=,
MLO8,ZS3FL'HW@'D?0BY0E1*8*\XPTBR 3 [4+**3%KF@?YMWX6@%?E.1ABV+
MY':8O2OAA;<#NG7Q<D#*N_H'=='5]Y)SR EC8M*&VF4"?%T/,*0="%IC:%\T
M_P"<[;OW-RH?PV[XU($Y>P^TN7:^"+B.W/(/ MN.3[X9&Q<3CS5XL'%!P6!(
M'_>9Y5A-;\$="_7BC\:AL\;$H%I?E5L0D$=<Z=N1CV5(WXT_#&M^^-X@O\:O
M>#P\G<[JFNF"<X.<##>0J5;P%FG)(*\]2L$H9C/G(<FD=/,&BPO VKS^WI"1
MMQUC3;G0@5[^&PYP!,>$<"^?$*GKK(#J%OH>I"I.D2[H6 F1,UUS42%RQ4+Q
MM&=$U$FT5EL6 O:<A*4])^X]5S;@1?M08T45?G./V:TG=^8=>W@--SQA*%/T
M.67#I=$R6<\-=Z9P84P@]LM[/&&WWK%UKY<U.FD/@GD7ZV!7J1B -$PI#4&2
MV"E9&N_U[7F];LXWV<MY*CYP?.<XG')K'(XQ,J5:YULLKQ4XB0P0KR1+)A=-
MEHC*<<&6-*N#>)(NKV7$[+YI-)URJX/+=OEI2Z2#>F&MK$,U'=FWCBX4!9;.
M?,T5!J\R-F^RM[O3L;8L?IMAXS8F1CS8?_4/'$\N^P&)GHHA@-%U&2+6QC^!
M0=:)<2N,<D8'P(U/BE@"_XN3UJTQOXONW!5H?'PM\:&US+IBTHH2_12^T*V
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M 8NG*QXO0\W6TY=GL:Y!S>;M?\4*[/.?P\]'P[,Q#/*;X=EH@G@YFT'3)92
MSLNBZ6J+4K$04V8EH+8E:OKXAN5R7U[WXB_=O%:P#G.&&Z!LZYGKGW!2(0X'
M'T?#+R,XN1C+8G/FF 5ST=<:M! 8X9 L.,^% 6.1YX68???SGRY?&]"K^TTL
M.0]S8(8.*>&U(#A*U,R[S""X&H8SR:"C8\RLNFNOWO)TV=F,=AVH6//.$M/[
MQEFAM?>%I>#IB% JLNB#9B#(LG0B@836H9QKKW_9:O>J?.B@J\<<RL5\E07
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MIV693HI3 MF4U&R9B<O9DEA:CDM#K<XU-/=@T ,G7NTJ]J:&S"KOB&_]MWM
MJ R4I9@)Y:4?3+0&-WB>"#/)&:M\TJE5IM0FY=T?]'>HO)UEUD$VRKQ@PJ2X
MUW JN<FBDEFY+X5,"IH3R=# <B4UUSDC0W8RL52[9<8**$=G^M04?<6 XCI8
MT\IO\X30-@ [2G7;".YIDMNJJ+(%/?;7PX&6D(= #5<A!H7OAG)HH7@620
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MJPFTGJ!H%'4(*#^$Y/&OW1<^/7_L>Z#I$G1_"".'8'H/6 T4)._R.KF%NY_
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MY-P05/EIOI#EY4Q\F--9>2NYS)]H5=%LU>V*JS1@+(2<1H%VUJEIF:<$Q%'
M59)$<8*=NEW9"AX;O[1ZF\2BA<DOJA0'=";:(H.5=]#:<48O+.NAL=RW[ 'P
MOK<T^\#:???3$3A?&Z.V8H?=,W4$8V<[U?7^;K1V/?M<S+DL]:-+J>_^KD6]
M,R%0\T?CNC7Q,RP,E7:/, P2;II_9@PRA 7D69BA+$@%SJP:TCA)'1NA77^^
M_2?Z\/@O[_1*9J%_415$I64I%Z5C\40[T.W8RCN4/5/5]0PT"H-6XXJG-G3N
M(;;)"25/O&0G<U!2<H+A)2.YW=PQ1HI_UZO"J;Q1E[-%+O+ITL08KZN)UX5@
MI'BO33.GSLMZK^-&7='"'!B;3NO5H?,70Y(3%9!,411!'@2FZ+>D$"=A!$D8
MIT&FEW<1=N(MO^J-C>!:Z\S>S*9]&P7Z06LA,"\7V+#1W-1::;:#ZI 7\*VR
MU#7ES.];8$>DKS>V/3/N:PRK>^A1+^C[BBKRJ]RP 4.] +L3"]2/E&Z3R#NI
MM'<LJN"AG"V-(!-&_K$^$KJ<S9:FNM+ZET9X&^[;[%5.TH!$,0T3&*89UAXO
M"B%+XEA/)(E,4A&S6#HUJ/*@T]BFB\8DP#?4!H5<Y'573?"HK[Y8'<3)-GQ]
MZW(AE2P*VP,=GP-L-RD,/&P]SP3MB&UJ7&587(#&(E";M'5%S?NM5:NS'G_<
M[Q%D3X3O0Z-!6=XCA"^IW>>CN_&Y7F\LBB5?+,VID5YTW,HI71B-RL75ST?)
MF[^'DR1E@2!4P-0T)$,9T>Z^S#A,>8J5Y*;P0^!"VK:"Q\;,K7*::TO'?M_6
M6-OQ9Q\(]DR26RI76Q.-TE7-45.+M 'W[3%PG4G0%2E/3&<M=E Z<P7C)6<Y
MW]]3=P?WXMD3$0L495$ N1(((A$12+EB$(N$T("*D#,QF<E[8\\7CWT<W%6U
M^F9)_<WN*-S?]UMW;-C7L*%JTE#Z[M+088PM-R1>:<A^?YE3>ULM#-A)H?M
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M41$J19D81U,O%[/&MAIY:VAL.C7EMN^^>CGG&0?.K]X-JJ^7HF\V'ZQ7U 9
M%Z"%"#08U9VD@$%IHS#A"!(;>QGWU\Z!]&O4[R-=LI>!'*Y152?MNOD#?Y'E
M0ON\S3XW2Z24,3%M402""',&*4]#F-$@1B3!62*=*K%M/7ULLV.C7,<,JFW@
M[":DSG#T/"]8(^%,Q7LM]L2(V\\>E)CVFO62'_9?U"$?ZD/.39?KU4% W;_N
MRUQSRIOE\WRYJ&GC1JO>1F**B<HR(@+]*6.>: \[2##$2:"TPRV5*;$HDM@^
M$:J+!F/[W!L; &V-N #UOH)9PC[29\ J2\"\,@68%P'(UAB'Q)M.HW7B@'&(
M,>B98UKX+]?P?U[!KVT M1&-"PF,&:MP\M[A=TAXZGL8!LITZF<XW%*<SH'R
M:&Y3IP</E]1TCMU;V4QG/>B\Q-PZ6<KD1FG?=";:K*GW;=;4!"NA8I9QR,-0
M:7^2(HA%)O1H*1(FB*1Q9'70X2IXG,<?3=+M7*U"<*O&E'EE1G4"V5,^[LEQ
MLIAY>D*_]^B6=2YGF[=9*PZTYNL4SO>K%,Z>$.Z63>L3Z5?(GCT3\<ZYLK:P
MV>;&GGS>J^3"VEIY*/?5^GZW24+(?%)58WZN:C-37M4QI O:MF5+XC@FL1"0
MA7H^0&$:0Y)2 L- 1@@)F1)JE:UU2M#8UAZUKF!#6;/[24_V<G-#]SB5^\2L
M9^KN"I<U:]ABL6>GHI3\C_?SI]_T(^I-"OV7]=[$R0</0A>VYK7T8'U]QS/'
M=8?2MJC<)@%=S[X4=%8:J7I^%#P-2!(SF'&!(4H%,XV:,^-!<A8G(@XCI\)O
M+L+'1AM5$UU3LJ6N1S%;U7!95@W-&^^Q>VU0EW&Q/'+K">V^#\8:H)O"'^MB
M.=M>C 9Z0W^/!U8=4/-UK.0B>MC#GPZ@[!S1='E&-Y+[7,A'FHNKG^8D2'[2
M-C:S,I(9D32@,(MD8,*I,H@CB:&(HR0)$%(TLMJ(/25H;.3U83Z[!UK0 WBL
M-0:R5MFQY^=!8.T8R0=</;-/HR)H=#3AR:V6_CCF% Z>^.2@F$&YXY2Q+WGB
MY/6^VNO=/&KWRIP*-36'5DU0$*))9-I$)"@0)I\BA315F:EL21(2A"$-SNRS
M=TCTV'CC[7=S?EZ:R7;>JMST!J\VRJ8Y9:;08"[+/YW;C._@<-AQ2S\@]\PV
M!]KSK31?U3KKHWF-.V*]]>P[*/B5F_>= N1T%[^33^CHX<R+*L!EL8H]V=.0
M]*,T;M9$Q$F01"R!'.$4HCA6$$N%8,325.)4"(IB)Z?'7O;8^*Q1'=#%9A?>
MCWJHM,H/UKL_74;!TD/J!]N^G:93L()OM<X>V:L#4K[<*@?)PWI:[I#L.%\=
M'M&-P6[E@IHD_K:T2/.9I"C$A*4)C,.40T04@Q0)"<,8!WJI%F=AXI3+NE_,
MV'CIDO/EPW)*36"N*6[ <T<F.H"F'>F<CU'/_-(J"%;E?_SSR7$0/%'' 2&#
MLL1Q0U\2PHFK.P0NK#RB#\9#^CB?+;Y/GV_-)D)(,!41S6#,,@617H9!QA"'
M@9()(2D/ A;8%5@]+LCES1ZF@FJC'+ _@#H!Y?$/WQ\\/7_XZX50I>0%:(&Z
M]0640T" %\ &.O[O!IS;2?])/(Z>ZQ^^>[A3_),6;)W9G[ZZ8S7J=2Q ,VVS
M(%(9EPJJ.& 0!0&'!"D"(Q6)B"LL(IPX5II^*6-\'+@9L>)8('H'0#N_YRQ0
M>F:^K?@=_][.0=-]E6+>>?ZP998/F;=30OG@A>>6\+EZ>)S.GZ6\D\53SN6!
M!*5I-50F+E3=2CZ_GYE>;G7HZ-MYN2C7-8"92J7(]')(D51")%,*,5,)E#C#
M4B8)I\JQ^GQONHZ/6S8KSQQ,O&Q.'+K6_/$]X'8<-HI![)D+]Z; KE/[+MJ1
MJX-WFXU68]<%N'PP!68&JB_=TPAX+S7D6\]7*D;4$]R'RQ7U);#;5&-;/.G-
M\T8A)2WJ\F=>3M*84\E##B,9(X@$4A KGD(E"1&21(*JT&6;[1QEQK89MU%U
MS*@(OADE'3-2SQH<.^8?"O+>]_:<T':F9Q\P>6+@LU09E&1]@/:21[T\<^!"
M.]N!:I=/-)\:M=[/BRKY?T)%%$4)%A!10B"*&(64T @&).5<9J% )')TRGM2
M=7P^^=O-Y"O:ZENE7)4F!+1[*&U?HVWID8]@! =TR#O6KMD)Z[W<>@,JBT=0
MA<9R3%Z[KLPI-7\?E6(LP?96^\567K=)Y\VRS&>R++523,]R1J>W\YG9/Z[J
M1\_*7%3[R?/9AR:*[GD2X(2D(@I@D(A4N^5! JD*"(RC0+OG22@R0MS+9W;0
MQ(5L?C?U-;N,B%18X3##4)!0S_!<A) 1%$"AY_:8TACS!+L6X!QD/,9=H;/+
M4-A-OSV#V_/,VFH/-M2_ &L#P)8%%V!E@[^Y\@P /4V#7308=(8[ Z*7D]<Y
MC^H0?+%?W%I(E8.C9%'(566TA=0O^*+)TJ$S4?7@U=-DG:2XF<+S61:77-]5
MR'IO;/+_<_=FS8WC6KKH7T%$G^A3%6'TX0!.O9^<3F>U^V3:;MO9._KF@P)C
MFK=ER2W*KO3^]1?@(%'6!$  S;H/E65;(K'6!_+#PL(:$&9I1%D$HR+-(2)Q
M G-.8LCR0*0"\2036DW>AA=];#ZI^X,U*Y9SL'SDH.+3J6+D>M?4%JJUK%HQ
M['-RF-G'/?L?M2"L50<]W7M%05OUNWQ)=332(2"_U61U;Z94JIYZ'0[-1Z-]
M8@S"=D;[Y P4"C32)\@LUNA#)O%@_-*P$@T7$_4A2&_$67V,!*?&>US/9Z]2
M!JX*N"P7)94_U6$EWU5Y@'-5Q4%*4A]#KX_X,X2*(L04\D!M+O."0IR(#*I
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M_%_D$-$H@04J,IBA*"L(PS@1Q:2)O)(;N\52TU4RE/PF+^)[+?R]B]];&<\
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M@Y[*9V"M =A0H7^LISK?K/=(3>4[^5CLN_0,K/1WMU\:>+X<;:F&DGK07=?
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M1[YJ0747JN@WF2L3\)7W/%EW\S<\7;XUS9<F11X%11H$,$X%@TADJ@0>+6#
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M.)1M;!JK"PWAZ2TNY5[Z C^72SQMRQ%3P4E&: !CP57IUTA DN(0BKA B+*
MH<RHP\?!T<9&X&MA@9(6RI>\E=<T^.L0Q'J,[ PXS]RZ'S,?Y?5U0'$6$G5H
MK(%CFS34W@Y2TKG(CD.^EE25X)_]//^YX$T.:_MPARCC. L#R(,80X2I.HW/
M",0<A1QE!*?<J$+1WI'&QATK0<%:4C/6V ^J'F,X@<HS6^Q"R0-/'(7"$4?L
M'V=0?CBJ[GMN.'Z!?7'1+V6ERJ;5]LH7^;=J$N:I2% 804D.:BNICN)HS&"2
MDBC+BC#)D!8G'!QE;'RP*I[92-KN%D MJWF!T6U0#W.",ZA\'[G9H&159'0O
M"B=5&=V^Z^!E1O<JMJO.Z/XO6S23:%B$KSCD6SGEU7(^X^?TL>2OG$UH%$5Q
M)E(HY'L.41Y(0T ("DG (A)S02(]:T!ON+%1P$I @%L)#7H?' ?W, .XAVP0
MTX"O#8,SL ;PW > !HTCG (Y4-.(TP U:QBAC<_!9A''[S)<HPAMC3::1.A?
M9;?Q^CM7'1LY.W_E"_RSK4M[(SZ7TQ?YUQVU*@1C(@PH#"(<0I125<XG9#!.
MXS@K"E'$A5''",/QQ\;(G?@0-_(#VM:SV"YD 0%KE+)WYYM.EMXVS^,4>&;X
M3G+0BM[6I:Y+]383T)/[#+0:N=L56B+G:*]H.OJ@.TA+:-[O*VUOX\#X7+N[
MOC]_6<REJ<OY)&:!M#P)AX)&"92[SP)B+F(8T3P*LSB1^U+]%HXZ(XZ-\#H;
M *]M +QVV+X\0Z$$!X)K%DK0A][".CT5T.$-U)[S^_LSK&4&7]QC>8*A>BJF
M'V>KFF)[FL%Z""<CFW7GC3[.;#VDUT'+]>"%%GQM?1#Z!9>+.G+NO*I>GII3
M4?6W;WCQWWQ9?S(AD<A3'F101#B#JG\XS(G\AP1%%I(T+-(DUN9YGY*.;7U0
MXH&G6CX'X;O^)UIC51G+]'E>C9I8%:(9TT)VQ;34D]]$$_=4;O_>:-U\/);9
M-U@'Q_(4#+1^CN)I,%N!AYBA@RNW5P&&6_&'P''#4AADP!,"8<EQT8B.:"HO
MF3;Y^T_A)"-$]4\C,(Y503U, UBDF$/,,BP_"\,BP\;QL%Y$'9N-T0D'Y&!/
MM7WQQJ5U81,;ZV=J]?QNXYBP0:R*DR)E]ZTCJ\= Z>PX7-;KM+B,FO4CZ/#!
MLUX!WQE#ZW=$RU#:M0C5^8Q=R]WR^B]U2T]5/U .VL9Q,1Q3FL0Q#%&<0J1Z
M[18IBJ$@,8X23&*1AT;!M6;CCVUAV-O5OBX7U?^]J>B_?,0SL'F165D+VWG3
M6R \SH9GUA]B(LQC?>W@=!7]:SCZL/' =M!L10A;WF9([U][;JY^_ZP<D^QV
M,2>J ^ M7ZB^5),D2],XXJIK>2142]0<XC /8!"P%,=)DG.A=<+M5\RQ46]/
M7L!J@<%S*_&9<OLIF8?P^AR=7I\./Y>3-GYO7W_*&W7![6K*;T<TY4-X^5Q.
M_5_'Q7?2(S"0=T]W9ORX]HZ._A?PZ^DBZ,:IISV:A=70Q(_,Q7_.E[RZG"W+
MY92S+_/%)::/;34>&N895^WJ.$(0L91 PJ,4IHPG02(8PZ'^P=_1X<:VBJ_C
MIUZ5R ;L?1Q9C877*5Z>%] U5+6TH!,72'F!$OA(,1T;" T6,J=0#K0@G0JI
MV8*BC=#!A>'X788C>&V--HA:_ZJ36]\UAZX1"DF0!0$L,IQ"E. "$I7@21$+
MY5_RJ ALV]V-,B1BL\7=_PK^)0C"7GFS54S$WP *@K.@^:^+(,8OR\?YHOR'
M? OP$OS[RXS_\S^%:?"W.#@#ZFFL'2J?.:TWU.U'8?U1^#<@13M#:7R6HJ2[
M7UE5+^I>JL%H+SC9]-[6K?ATHBY<3*QW!U>_Y5XMW1FXJK'UTFQOQR'TR1ZI
MK=M_5%.]G2?#1[]GR49XL7B33_P=?YXO5&#QDVJ@O/+KKZO,MY[:.(OC@'&B
M6K8GJGE< 0L:J2Z=,0Z3+(\#'AB1E=GXH^.R5GS0R&U( X;8:[*$/T0]DT@G
M<7NX^8UC)6:]F7:?P6X)DRNN,1Q]6"JR@V:+J2QO8T=DGUZJ<L:KZIS^STM9
MU9&U]8\+SMNJZHD(<1(%#*8ACR&*"(8YDUM9ED@+JT@Q+7)F0EU'1QP;674"
M@Y[$9Z"3V?*H[SCN>K3E%$W/1'4JD,9DI0V.(WHZ/MZ@A*2M_GL*TK]PX+J0
MEU*(Y=O5K%HN:D]"59_[/CSBV<ZR9._2ONH//^,E7Y'I)$TB$1<D@S1.I5V6
ML@#F(DMA'% 1,I1$5!C99:/1;&PDVJ]!>6H5[M& [+N(Y4<^%(,<')X4T->@
M WKP],- #A3&W,KWK;\"%%2]*,$15,[T-?\?76_3N5Y_C2J=OJ;366U/;P):
MF@GTD;.7*;\1_8!)7@<%]5ILM!M>=C.[X_1EL9![)ZE963VHT[YU2\LXE NZ
M8!12%C*(DBR12WV0PXCS" D4J(QLHZ7>I71C6Z[O7YZ>\.)-':*\\]54M3MW
M39.5^LZ7<H9GM,33#3;N5#=<W9W.NN8*_5%SZ7N5;?6JYV@U96==GU,UDSWU
M5A,&Y#J\TA#4*H(?M9+ 2SM4+_"[6N2<RC;L0N4#UJW%QLL@ Z=9W70Q^'Q!
MRTJ)=#5;2AFKDM8:A9,\23*2$[D]I#&'*(\))()@B*,X3U&<9$%FU)C:GZAC
M6TK.?_Y<U UGP4K0CH9Z2@R4='5\H@VV=!\^?>/?H]VLLZQ6"I^]?Q!&D'2E
M/2T?G71U7-"_1M*5-N#.DJ[T1W31IZ^I*76^"KN89+0HHH#(_091W3YSK-:.
M(($\X"*)(QSES.@8Y?!P8UL$MOKR;<>E6)>S.P*\'J&[@],S*6\UX6MD!6MA
M?37>VP>*EX9[6X-]8*.]?8H?;K"W]RJ+@..K&5U( YI_YLW_KV9=S]%>M]$W
MR3%11 E"$/.40(11#G$2,QB%@D0D3'@1ZK43UQ]S;$3320U^8ZW<ORO7+SNA
M[;#)#!PF&T^X>F:<-:2?^Y"NNA+WVQ%[@-0@6MD]M .%++N!V"QPV0RL@]'+
MFK<:+H393+>-.&;#2RV[I#X]XW*A'JP;(:U0^2B4TAYM_"9?REFYY-.RKE.?
M"1:E10II$$BC,4(1Q'$:PB1,1"RIGH;<R.N@.>[H2'TEMG)DEBO! :XE-^RD
MJHF]GMWH 5'?=+X!YEKFUBE\!AJQX=?221EV2Z!<]6+5''78WJQF4&SU:C6\
MW(ZB_A,ORG:3S.7CMZQ3.MZ^EC-^M>1/U41$C##&.8P+U6^>I@$DI!"09W(_
M2Y(@26.CX[0CXXV-DCIQ02=ODV;T!GXHD4$MLV%(X#'$]0C)(8Z>B>@T"(T)
M2!,81\1S;+1!"4=3]?=$HWN9;0I%]:C^4T$'KWBJ3HSOY""+4E5!4A^<S]CF
M'WK?G 2",8)P?89/57D-:1D%"8:!BMA+PY@6*)P\UV$*]TN\6.J1T$DRF;Q:
M[R7S]Y8I(<\ E?\"OI:U/OI=K#1I/H> \)_E;*8.?:5IT,AHFIMQRJ06.*8$
MB0 F:9I"A'(!\US.L<A"$84YBUB:M9-Z.6.CG-).KI%,*%<)>A\QE7J+U6"3
MXWDI:^9$_0MZ IZ!M>R@^8J:I7=_[%_A,D_' ;+.LG9.D67@'!X'L&UG]+BX
MJ:6G84;G3_SKO*J^2&4OYG()G[U(@K^1E% [M:I/7,P7O/G> _[%JR_RU_+G
M;!)&<1R$A$@BIH%JN9U $B>2C47"0I;R2 1&)U;VHHS-^+]=<*@<R64M*?AM
M*G7Z7;[,,\RPH3/"?GHT_1.#@.[? UWC_+7&6;VU8*T)6*LB[1>E"VB_7VMS
M!EI]'+HR3L;4E7?#7I!A'1XG [;E SG]CA;'<#>+GWA6_J.).)BQ.H#M1D@V
MJ+HC@O5N/2B"D,4L@0@7'*)(FK$XS3.8<<3B,.,<A?HMG@P&'AM7]D4'4O8V
MG/1&@+[X%FX3XQG1.)OSA+-G>AP/Q 9G=9Z@'NC SB7D9L=V%K@=/+LSN=]P
M!W@66FZ<XME<;U^7J%QVM6J;E>@GG]&25^M4_74^ D_33* X@B@1\I\BB6 1
MYASR) H)1@%)"JW"<';#CVUQN+CY]NWJX=OE]<,].+_^#"YNKA^NKO^XO+ZX
MNKPW+PYD, ^:_@EOZ/IV2*P%KWT.&Z*#M>S@AY>$#CO<'!8D,AA\\')%YL#L
M*F9D<1<[@NLE<5R\+!8JG)94RP6FRTF6B8!C0B'!A22S**00(RS4D2!"29SE
M(38BL_U#C8ZX&O%6H612XG\UXZL#L.IQDQNP//-03\@ST('VHQ/4(>,<1\,1
MNQP8:% F.:[P>];0N,(V\GU..6?U5KP.?=T,M>=LPC(4BR#)8(1"N1F6>V.8
MQPF"-!,)"N. 1Y$141P=<6Q\T0G<.*]X*V:=.UL'Q(-YHX!IY/LQX/6HQ"F<
MGAEE$\E:VB[+"*SD=1D"KPF-LRCX8^,-' BOJ?YV++SNA7:<<\V7:Q_@^2LN
MIW4BZ;Q7Y_%Q/I7WJ]3>CTYHF!:,)1@FA:H6RR(*"\H*R*C@1299*4KI9#E?
MXJD> QF.;\1'*RG\O452?*!.+0!>+A<E>5G6@3C+.:"]*K.M BHN0.E@QDVF
M$Z3'5!YA]\Q;"O'-<XR5^ KW?B785H.SVJFT'W9C+K,$SQ&SF8X^*,]90O.>
M]6QO<W))[";9J*D</*$99C@*)==%3$ 42IHC#&,8"9YF)$\23FPK8_?'&9N-
MM5D@>[-0M75RX3Z,18AS%&8A#'-,(,I$ 7,DF-S_2A,7$8;RC$]>^8+,!T2Y
M/YX_G-N$0VFZ]A<+;TCK>^I.1&\ E]RZUG<CI-=BW[MP<%_S>V.4CRK]O4O5
M Q7 =W[=-HKUN93FFNK>.6/E\D7==Z8*G'#VZ65Y/5_^%U_>XI)-,D3B/$T(
ME%@R50$\@ 5A.:2Y-$L#QE'!N5D%<+V!Q\;2M_)&CRK53?*'BE]\KC-1RAF=
MOC!)'Y(],*4+Q21<J5;IMH\QGA!-7O$ LV^B:40&?9E!)S20MCZ08H,W:8\J
MP5V&')I!Y2RZ4'/8@0,)S<#8CADTO-Z.OCYS4<YX?810;P/E%OU6/DR73\_3
M^1M??,-+^EC.?FY\WK;#XT$84DP0S%*N8@23 N* 4TAHQ.7_61KFN0FAV8LR
M-HKK1 9/K<S24%H+O>IC63-@\U5>_6_ IV63AT=[=4W,N.^$V=1CPV'FR#,_
MMDJ OI1 J7$&5C/7:;+QI54O0C5SE^N9^V.A/"FWV$%FMCN@';'K"8(,RK>G
M _:>@1W<\920[?LE7M;UC+ZJAT7>O&T+@+,$,48*57F.J]!L#HDH).T6<48%
M$11CK;["6J.-C5E;!]I*6M"):]F%X3#4>ISH#$#/M'<"=I81TD<P<1H$O6^L
M#XAS/J+V[E#F8Q?948EI2<ZFV_IBHT+GUU5T)T89X32-8)'E*40B""#&.(*2
M>'*.(\8":D0]3J4;&U59E]M5W^JKV=7?_6J;5^[V(= CQ0^;6L\D^B&S:DR_
M7M!W1-=N91N4WKW ^GXY\#.(1;++Q117U8WX.U:E-9<WBSM5[+_I\GHC+G\]
MEVVBS><7->[#(V^: DQ(Q((,Q3GD2:A6B8+#/(L3&(:<<XS2K$#99%97!&8/
MFODOEK)H$4?1$,>61/Y(I%6C4AF#E$^G-J<F)TW180[WCOA ;E"E@<K(:'4
M-PM0:P':!M'RHYXBH-$$2%7:1C$#3(1!OLP $S)0[HR_B3'+I#D1T8-9-;;W
M'B[#YD3M-[)M3KV7V>K$>#DYE\\I4\_JERG^.4%1G 9!GL$$L0BBE,@M"N($
MRC_B*$N3(HJPSL9DZ\YCVU2LA -*.CV"VH;K,/V?!()G3M?47YL']NJZP]BM
M./V7G_/7_R.O:>Q<^</:O-V^TR"O\EX%NO=S_Q>LXRY5@8K;Q?RU9)Q]>OM>
M<78UNYJ]\DIEH9S39?E:VZH3AHLBX13#+. <H@)CF(<(PYCC+(D3%*6J<:Q1
MR*7FT$:O[4#1EG5!GI>J.>(N.YD!7@EM'%ZI.P]Z.W8_Z'KF P5L74.G$UNU
MH_CM>X/R[V E/#@_#K--.*4A8NXB*74''CJ(TA"0'?&3IG>PH[&V3L3LYU=5
MX_=B7BTGN""%$ ))(R+-(2)Y +&JNAL+SM,HICP2J5E$W_8@XPOF6\D(IG4!
M:BJE/&O#<=1?%WRJML5@OOJ>^H895^T 6X^33@/0,_>LD:NE.P,7AX Q9I?]
MNCMBD1T##,H6^Q5\SPH'OFGAUSIOPLOJ@ELO=%EO22X>\>(GK^Z:A[W-CIL4
M 2)I1 ,H!,X@XDD(<4(+F(F48<2"D.-4NX2+]K!CVW-L2 QH+7)'"P8N$GW8
M-;Q37L#TO7=IPQHW\6RE!JW8JR19+\@:N)N\(#R0@\D1TF;>)&/ #OJ/].\V
MG,?(6,,-'Y'YU2<>>4M;\C-?E*_R87MM#E-6W1OV-:/\/IN3BB]>FZ+'SR]+
M^;$$1EY3/['O6LORF,4ABV/(PCR6RT-:0)*D&** I (EO, TL#H.]RWYV%:8
M?K/AKI;%4OU8R4U XSHT;3 S_--@>"X^ICD>\,Q<;=C7>C='Z."WE>J_'VI!
M? ;Z"( : K")@=<NQ8//G>L3=^]R?\QI_%#3L?>D?C !K--$GQ?\D4LZ?6T+
M8DJ);\0#_J6<'B3)40#S) \@2@H!"XPRR!,1HB(A/$+8Q$=[8*RQ.64?U!AU
ML/U*X#HEWCAK<2^X>DN"(\A\GZ9OX+21R-ZPNER\I<1GX/Q=08%;[,;(-H#+
M79+CWI&&3G0\IO*.9,>CEYB?NC8-0%H[_8X_SQ?*6%.AJR_5),A8@*,$0T;5
M<0]F <09#6$A,AZ1@HN0:I4+/S;0V*S7MFE-5]QJ)2UHQ-4_I#V([O$S6U>8
M>2826[B,SG1UL+ ZXCUXX\%.?'74ZQ\ :WW?PI7:Y%'?B%YJM=S?2[.&LR_S
MA<JO5@%NJ[IV!<-AGA.L:G]1B"@I8,%8 7$1)IPE!:&QUH;98NRQD<:>&@J+
M5@,@YHNZH(+20?VB65S09E8TW*W^L/9,-BW,-V*CO@[HA%>M 4 GODY9PI/!
M-O# ^@-](#>L:_#-_+%V\!UTRAK><CC/K)VN&^Y9RUO8[4C_F,_9G^5T>CYC
M[QM8KNO7KMZ9F&""12;-2:KVJ)PCB 5.84K"F+ TSA@RZD-C-/K8%HY.^#JA
M9*MYZT9E9T,ZLYL<O3VN-\@]KQ].T3;>ZEJAYFCS:S;VH-MA*UC>;Y#M;F(9
M;+1\Y(OMZKN3@'(24J':5_(8(B;D9EE2'2P*1'.&4!0F1A4T]HPS-@JKQ01T
MNX*V8531'E3U&,D!5IZYIX%I5P%MAT%&AU%P%6FT9Y1APXT.J[H5<W3DZR<P
M0<,RU_-9^PI,TI 5J8@*B((HE/^DRL")$T@Y$XS+37&1&ATD[QQEG"R :RDM
M7OPM$ U>^U.@&>2E;P0\ VL1';_R^Q!P^<)OC3'\Z[Y/S9TO^]XO6Q;%QV]U
M@PZY>]J(>9DPY0U'7'6"BS%$F!"YZA<%Q#$7.8Y#RD-B5 M_ST!C>^$[.6O?
MUJ(OJ6'1^WW BEB$+ AR*$@L:33,!<2AM*[BB&4X"/. !=P@\=@)OL,G%]?I
M$,^MS(Z0U>-6%P^B9WK=> ;OM)Y!\XX!1V!PU2A@WS##]@<XHNQ66X!CW[<C
MV]I[]0E7JES7NGC>N4I'_5E7U?GTMOY**\/YGWC!VJX$YXR5Z@<\76_^JI6/
M@T9!RC/)TQ%1C=O")((YED8:(SQ((LP%BQ.SS!"O\IJ\;P-6C(9$*0/Z"H.>
MQBISJ_^]5FM0JWW6M?@X VO5>^Z7RMK;Y??)T2/.T3P-0YS&P$^:C\$G3X^!
M,:$/,CV.5@6_L@ZZM P"^_OU:9A!/V:1:UOOJ,"LIC;#) H#AADN((U5_[Z@
M$) 4+((1HEF1)X2%1)AL19Q+.+8]3$] @)> SY@ZPG^NJUG8=SYP/['#K#LG
M3==?:*WIZ7G6UJ@9S^JR=Q)&LJ)LR_>76D7VPNMZY=@_D-EJ0><OL^7B;?+O
MMY,@9%D8QJK)65I 1)2GB5%)[P'."$(ARF*MLCCK6XZ-C_\=/V/-&ND]7 ZS
MHYVVGNGLW\]OSZ]/)YUMW0Y$0;9?;DBB_67-#[U;#?)";XO>O8$[/K'L=,RK
MBO/-;/,'OGA243&S9D.7BC3$"#.8%B*'J @I)"S&D(4\2SEE-$G-.AX?'7)L
MKUPM(I C/1GV.SX.KI[5XA8RS^]M(ZRR)=X5BU 2=PF/2F:'G9"U\7'5$?GX
M@,-V1M8&8*M#LOZ5-M'2*L6+7<U8V53X_L9K6YW&0<I9+BDE%0(BG*801Y1"
MGB8(YW&6BKC0CXK>.<;8.*21$JS%- FXW8WB8>YPA(WO/<M[6,"/1D:C@.3=
M^)@$'I^,TU !QN9X&<80'T3B<*SP[DL'C D^*/MF[._AKQI2W6(YN5 6&5\\
MX\7R[5I.X/FOLIK@M,B2E#*8%5$$410G,&<Y@023.$J",,.!5ACOO@'&1G)]
M&8$2$OQ08NJ^R_M@/$)T#L#QS'+&N.B_LT>4/V3OR&M[MH[\;6WG[+WM,"_S
M$:56;_*Q[UE8+)]>JG(F;:*+^1,I9PTWE%->+><SWIWD3K(DR04C%(8HHQ"A
M*(&8!?*]EGLE:=)@3K%6%*OVB&-[T3N952I7)_09>.K$-@S&T =>P^1Q#:=G
M:E@A>=%'<B5QYZ!UCJ2!<>0:T8%,I9.1-3.<3% Z:$9IW6@XH\I$KPT3R^C"
MCSD>O'E95DL\4U4_VU.D),T$PV$& UKO3 L,\X)@*"*:AR0NPKC0VIEZDW!L
M*T$K)YBO!?VX4\'M^2R2+.&$<UB$8:!6Z@ 6&9$&>5"0(,>$!G$Z:0XS[Y?2
MAO@+S.I[:3W.;6].\1(0_K.<S=0O(S@ WIYJ1G$29ZR / U#B%(J8(X3 04J
M0FF4L2)E43O5ES/VEYGH3M;!IGDD)_S;$ZSG*__0*?/M+7-XPM_3<WPG_'LG
M820G_-OR_:5.^/?"Z_J$?_] E@8??>3L9<IO1)VN_^FM;L-3EXZ;Q)CE(2(Y
M%'D60<14J\XBB&$6$\R#* \Q-THR.3#6V(RP3E3%VTW%"4D"3<^IICJD:83P
M 9@U6=@->+[YU!XW<TH\CH@K<CLPTK T=5SE+<+1N,3"JW?YZ2J(P^[T,>(<
M17D.>4SD'B_,U!XO*2!F$<4B8VF>:,4(;=UY;+0@98-2. /7T09.&LXV6^T]
MO]>MXC9GB1L(&#C);)$8R!FFC8B9TVN7U@>=6QL7#.?$VB7GAK-JYQ=LJT6J
MXI.+YWE3QKON<G[1Q&M=S!F?H"C,BH@)E?#.)?W@".8<99"P+!<9RB,:1&9%
M(P^.-SI2:HHA;LA\5E="E,OP K22 R6Z:1W)P[@?IC,/:/HF.0= 6E28U(+G
MA$*3A^\_<+U)+66WRT[J769AQWPMJ=R$\?.?"]YLOU[>YB_+\R=U]^\S>9,F
MKJ'9?;4-=X,HB7E ),L(S"!"*8.$R'T1+A*:<A8'>1QJFSL6 HR-@%H5 .YT
M. .DU@+@6@WPHO0 51-I,Z\U:;UA!G:$S4QI&%R>\?=,61WTYVOH&P5 HP&H
M50!MD%.CA'EG:AOH#2P]SU,PD$'H8RK,;,<3<#QH8MK<=SA+] 2M-PS64^YC
M6=UEH1HB+M]NY7.T/)^QR_]Y*9_5T-=\.4FC-$QYDL" 4!41@Q*YOD0!C)'(
M$:8!1[E16N6AP<:VH'2RUA43>2?H&9AQPZ:1!Q'6\[NYPLWS0M")>09J06OD
M+M?(71] SKPXB08DK@J4'!IJV"(E&DIO%2K1N<;":)76\$*E%7SFS?]OQ.V"
M/^.27?Y21PJ\7](LBQ"5A,&5ZSZ$B& $<9Y@2+(B2W/,<IXE!@6-3,?7>D6&
M+W#T=3[[6><?@>=&<L!;T0W,(I-IT+!$7:,Z#/%T4H/?.KE_5\[_5G30R:Y5
MA^XTB TL3D]0#V1INH3<S,*TP.V@96ERO^$L2@LM-RQ)F^OM+,C+I^?I_(WS
M^FBGL4R[(QE,BSQ!*0Q2%D D5P!(8BZMR2!#+$R3*(XR$_-Q[TACLQV;4\?&
MR6!8NFX_FGJFHA.,?!_0[@ID64<?=.$L#H\UM-%Q9#+N'V=0>_&HNN^-Q>,7
MV''$>S:ZFM652M<<U-0LG20)1GFHHCV*7&XX,YI"',O]9\(3&F=$I(2'%I4O
M-8<?J9UH7V!8%W8]:G&)XL?9A>4,-("NY6[+%+NC&4.D')&.[JB#4I A%.\)
MR?1R.WKZ/)?/T+*D:H_<KK:Y)"(61!0*E0>&XCB"F+,4TI#EE"%>Q(%6.,G^
M(<9FM'02ULX;,Y[9@9\>I9R&BF?VV #$@S&R7WE'A+!C@$'?_?T*OG_-#WQS
MX!RB52]D22PO3UU%JV=.Y6+_G_.IO(WJAGPGU_Y)%&6T#O1@ <<0%5RU"$UB
MF J<922.TR@8INB@OLQCXYQ.2O"Z$G.@? 2#>=:CLI'-WH!;.,N<!:4WJ!4'
M/<W/P.J96"L/E/8CR&,PGZJ/SFPPD/BOD>M@/@7.LA\LAK9<O-3N6W4JY.QS
M752^.>FMQ^[MS+M*BYQ-TB(J,L8#R!(F(!(J2R(- Q@7-$-1C#),S;(D3"48
MW\+2"%9WIJWLW7'F4Z&Y6O@$V#?WUW VPH-&^C:&Y*SA\[,V[:++(EXIX9#"
M;?%S1<C&XP]+K[;P;)&E]8TLCI0OYE/Y<QU@^<I[A'S'7_GLI2'D^>RS_&TZ
MKX^P5Y4'NLA^(BA*"P(YCNHZL0G,$\0ACN."\9@7.:;:09&G2C,V2MS0!^"^
MOWW1J 2:AA72BF-KK=;U7PR.3$^>28VCZB'GQS.C;D[-QE%(JPWXU$U-3Z%>
MV1.+G)C3WS;]L^XAYVJ@ _ !YLSL7-P5Q@</RT\>9+@3=%=X;!RK.[OIP&XM
M%?6E,AA4IZJZ1D_M1G]XQ+-V ?\R7PA>RIW,51<\32C-!&$8XCQ+()*+)RP"
M$<!,1(2G218'#%N<Q0VHPDC/\RY4 _KI5%+#W?WW#RC%8?$L>':!>9K:OXPK
MK-$?] !HSRB7$H)U<8\5"NH0TU74_@=.WD<[QRPD_VLXR>RGQ)FS[ 013NA(
M?3V?S;NBYRI=[XFWX6Z3. F"@& ..>4$(D8"6)"$PB03!4T(P@$R.JPY/-S8
M]GX-FY2UB."W-LSX=XMDAB,HZZT3[K#S3.VK0)&5I."JQ; 5=O^:;=?/^B@J
M+AM;[Q]L^ [71Q7?V>KZ^%5V9++1TO5\QN[X5%F'YU2:_>6RY-6Z*=X#_[7\
M)-7Y[TDDXCA..(54Q *BA'&("4XAD:9SS.) L%RK!, I0HR->.XN[Q_NOE\\
M?+^[NOX#G%]_!G>77\\?+C^#\XN'J_^\>KBZO#=C(*NIT>,EWX![9JL-\>OD
MJU8!L-:@UV,4_%!*@%H+AU$MIX#HB-RL1!B4\DX!Z3T1GG0O.WJ4MN"3*H$@
M[U1;?]7YR_)QOBC_P=DDYM+0B@(*&<ZEH15'%!**&$24Y1G%61)RHZ#_ V.-
MC>P:49OCQK-V4P_P2ES[K?XAO/6HS1&*WOW@-8#W#8"-H& MJ3N2TH##$1<=
M&FE0RM%0^3VSZ%QB1R [JHBKQE22P.164?Y4E8PW=5:^EIC4<16])+L<%SBA
M,8)%(=D%$1JJWG4IC 2E. A8+/+4A&).DF9\)-1)#FA?=#/&.6V"*$T*$2<9
MY)F(Y00E!!81BV!,DR1+@C00(IF\\@69CVZ*^E+]_WN2]!:.P8#WO+3L[AO1
MFX<-7<[ 2ANW&:Q.876T1)TFRZ"+F!/8WB]S;FYJ&^HG;77E'[T1C?]"&O#*
MT[K@CUP._,K;OY+*I+.HX5U'])JN)&]:BO9$[CQO/SJI75;QM</+62R9V>@#
M1Y)90;,=1V9W&[NWJDD*ZR6)=:\/SF(1B#B"))+6"1)$M?C*5(!8'I(P86$8
M&;GH]@TT-J-02@B[9,<FD?1?S4R-O8CJ$9(+G#PS3R-B?[7W0C7'D'#$*7N'
M&90\CBG[GB6.?M_27:6JC=^(O]<QC\N;Q5WY\W%9]Z!DG..")3',HXA#E,8$
MXC",(2%R?QF'$4U"K5:>1T<:&R$TY?#E&MN*JFK+UL(:]?8\#K"F=\H%;+Y]
M4[:(F3NGCJ'ARC6U=YQA'5/'U-UR2QV]P#*"H#M)[$KD3/(D3),P$# JB"JR
MFPAI*= 8Q@47 8_R),_X9#E?XJEFT,#[$8QH836.OX?\08T!UJ?=9@7)]@.I
M&1=P"CR^0P%6F%P>P\3\Y'^?WJX.^[?N/^SY_C[UMH[T]W[1O'/W-_RK?'IY
MZJHY9*D0$<XA"HC\1[W218XH%%PPQGB8YASIMNS>N//8UO56./W6W)LX'7Y/
M3]+>\_O9RN4RJ'Z?MB=TW]Z\WV!MMW>JT>^WO?L+EIMO2E^>7NHSZ#I&9\<V
M_^N\JJ[Y\D8\X%^3+(_RC,4<9@%2-K@@D 11!A,4,L1S+F*6&.W)S<8?VQO<
MQ)S1#=?75,IKN%\WG 3-;;P_:'WO[M>2MZ'5.YV+ORGQ?Z]+%2M37^K@<.=O
M!YXKAX#AZ,/Z">R@V7(?6-[&(E6UOO\=I[Q\55W,:L?%K7Q8'W&O>OL$1[D(
M>2RW#G$H(,I0"O,TS.5V F>9*$*.HE@['U5KR'&RV6(E]5GC?@3/K>#K?AT&
MF8MZX!^Q9;Q ZGL34J-YUT.S%AET,J_[/CA'TR#9TSFJ V5T.D#7+&/3"*B#
M:9EZ=QHN]])(LXT$2[,K3ZBOTL]GZ=6MXWF1,DIS6,0A@:A($FF-RHUC0%F2
MD" .J#"R1@^,-3:N;N/M\"LNIPI[(.8+\+/V=3;-DZ(@1&UI#[F:RGE0EI-Y
MM<!#\.O9H8Y ]<S61\H<>Z@HJ(&+R_HG>T8:OM+)895WUC0Y<LD):2.EJ@=U
M@:M'=<0M_Z<RX5[Q5.7 ]:*ODDRD"<(1#!*YX449$9)G.(-Y@'+&4R2*K#!.
M%M$:>FRTLY8<4"FS13:('N)ZU.('1\],TX-0B5OG?M0_] 3W$\=F#I?+' ^]
M@8?/[# "9&<^A]D=+(_%=][^?'F!%XNW<O:S+O(TR;%@.4U2F&0Q@H@5#.((
M<2CWKP*AO CCPHBHM$8=&T>MWBK%4'4WL%9NPW-R+<3UB,HYCIXYZ@ QX27H
MI&X*R#D\2S=!R=6YNM:8PYZQF\"P==YN=/$I$7L7[5(=I2QB048ABPH.48(Q
M)"**8)%S'F)U9!<1DW/WC;N/\\Q],SK/)CCOPLC.L8;$MZ.^#<.[<&VI[%38
M:;3=Q4?8&SO5VAU7]_Y+=DW_YD_\ ?_BU==RQJ^6_*F:4!0GB+$48I84$*4)
M@1@G$8P$"^* IP$2^JVH=XTP-FN@/2RJA00_E)B@EM.D^MY.)#5<UJ?BX_GU
M]0:-66.]DR :KH.>(53&??+VPG"L(=[VA8-VOMLK]_L6=_N_>&((X%?5;*8.
M++P1WZO&#=W+8?A2SO",EGAZ.Z]*]9A<_EJJ8T8RY5_+:CDA85B@(,20L55K
M"$H8C+'@D0C3-!):!W^.Y1H;D:Z#ZFJ]SIJ 6C@7\+LZ;E'*J5K2O92@E8*@
MTQ#\6.L(+F?RS6URM0Q#F%W-O)[U]0'SZ?MH\D.FTC[4T@WPK@,T3Y3J8\(Z
MW4"Y-QC4T>W-%@3&R\GE;%DNW^Z?\'3:I8A.J,A1&*4"!@D-541X ?,LB"!)
MXZR( T)(H.4-VW/_L1%T(R*H902=D'K$N@_!PP3I !?/1&<&B39!'5%\!]%4
MG/[+S_GK_Y%7-APC?UA3R[[[#4(11Y3I7O5C7[,\W:>/G+U,^8VH#_H>YU-Y
M;=74H[R>+WF;-U*UB2/5NDI8SL,PS2B&<4XCB**00"+5AH+D2<(SCI+ *!O,
M6I*QT<#]R],37KSULI\J</.RK)9XQKI:8UU:5%MWRK2/E_6DZ1E<@TR%9^;I
M=%#3T-?B?W?U@Y4B9^L9ZA+4Y.[RH8[G\%+O[61D744D6,LQ;+S"J7!M13.<
M?$,[FEUUP_KT]DU::"^+IAPPKLJJSOR,2,%Q&F 8AJ* *$ !+/(H@YG<%],X
M*!B+C>K '1EO;)39DQ'40EHEUAX#68_\'$+GF>*,43.F*TTL')'2L=$&I1Y-
MU=\3C.YE)W2TJ'K&Q(0'O*"1B"'.1 I1$:<0HR"'A,1!A 6.PH).GNN2X7(;
MN%AJVF+OQS%YZM^/YN\%^,1_EK.9LJD(GJH^$2?VA]A -F!$\#!#,&69M&^3
M D.""P9CQ(J4XI#P+&Z1O9RQP7#MQO*Y9V.>(-6T/D\!R;=56<MVUK?G'3>5
MV*6XR]8/&_<?OD'#+O5VME'8^<43(MBW3+U=E:]C&B >) &,<L(ARG$.L=S(
MPC"+<T[#G 8D-XYGUQEY; ;9_</-Q?_]MYNOGR_O[N6.Z3^^7SW\ET7<NA;H
MFJS@ TK?;+%OW^F_L+@Q7"Y#W;7&'3[PW02.G6'P1C<X<:/8LQZ_+/C_O/ 9
M??L\?\+E;((8%22*!$0HDC9?D#"8IY1"PB1'A9'(P\!NL[A_S+'Q4W_KLQ(5
M_&B$M=TV'H#<<.OH!L@!MX\&&-IO(H^CXGHC>6#$C]E,'H=@[X92XU([RFFS
MK:J'^3F5S+;@YUU.VY?YXAY/^3VG+XNF.0(GRPEA"4ICN2<2E*N^P2&%!8L9
M9%P$"0F*"./ HM6AH1A:+]+P[0I7Z:]S 9[PXK_YLG8F5RO9S;C)=&[T>,H'
MU,-P5B<Y6,Y!*SM0(H*UQ&=@I0T4\P54^K@C,TOH'!&;Z>B#DIPE-.\)S_8V
MEGO#\N>L%"7%L^4YI?.7NI+U[7Q:4GG_]1XEI&F,0\9AEA>2\W)!(%9I/D6>
M$I&F"8XR;+0QU!IV;%;7_?=OW\[O_@O<? 'W5W]<7WVYNCB_?@#G%Q<WWZ\?
M5,^JVYNO5Q?&7:HT)T%SH^@<6M^[Q+7 8"TQZ$3VM4$T@LG5[E!OT&&WAD9
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MO=+X]<Y+OGZLMQ%[ZC0S*#-B,BV'.<XGV)[IK96Z7T=\)3CH2=YMC#WA:U#
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M9^KH8[@I<1=/YZ$*IA%(CIA%;\Q!N<8(AO?L8W:QA</Q;DX?NV<_P)F@61!
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MID-'WM5EO>V]WKWZN\U UTZ"RDNP=1-H/^%#.]"-JZ#RM;H<K =:;Q=^F<1
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M!AF'$2-1FDFLECK<:F5CWO?4IN;:=%C9#G;&M^*LBG K^T'E@-O*QV)@#%=
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M6A_A"!)&<Y@A1GB4A#EB1IM#SA9,;3*LTMIU918@EZMF'BRU+,)\P]5;62S
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M78"99(B0&":!4/-:@%.(,<HAS2D2&<NS!!G5R#QN>&J3E+8-:.. MLY<3^4
MK.[IHP\$ \\%AMY;:::<<]5)*N6@H=$44LZ9OR^,<O;WCGHH]5[6XVHI15FJ
M5YG,WXG=SFJ*"4HS%D&&B7H%L8HO21!0&&,192S(*0V,;C":=3>U%W/?3""%
M;>'"*]B:+3K](3;P>]SN5Q^ IDT=8-?:#!1?8B?=G8TK=6+D^(G0B=E3;@SR
MJUB(%9G?+O@M?RX6A<[BU8HJ]S_T;6TQ8RD+D@3IU:FN&9:P&&*1J%F<RX@G
M.".AV5TOP_ZFQB&-N54=$W)@L!V97(/9C$T\@C<PG>SC=F@K:(SU1R>&J'CB
MDVN]C4HHAJX?,XKI8XY!297=UPH"S(0DDJ&(0AD+K2221Q"G>0))*+*,9ERM
M$U*K(.2@^:D11FV=9:1Q")AA9.$,P]"11)VM.X0BQ'F??04*AXV/&QB<=>PD
M$#C_*;>W]/WS"RE6>D/@01YGYM[_:,H3_;I<\G\4\_F,A[G(I$0*-I:J,("'
MD B90"XX11+3+(^L3JRL>I_:.[XSN 3%UA' GLCJFV5<8#<*9LPP&+8#$\?.
M;GTE^#3__Y>M\:"U_M_]<8L3:IZHQZ[O49G)"99CXG)KQ+&PZ'Z>J2[,MB[J
M(_VW1<GF2WW OYUIPSP,"&82YC0*]-$;ASFF!+((,2Y1CA)BQ6H6?4^-TW:V
M@C<J.I2%V13>>PC,*&T@8 <F-$=,[>M7VJ/CJ_BD1<_C5HZTA^2D[*-#$X[*
M)6NR%C4[?EDOV1]/R[EZN*Q%I+9O2A2E@@:Q@"(FB2*K+($Y2S ,<<QHHNDJ
MMUI'&?4Z-9K:&EWEO>Z9_7]:;3M7TC(;!#.Z\@[MP$3E!55[50\;E'PI=ACU
M.:X:APT,)TH;5@\[TM.&E@4OR.JGKL71=%3=OHVQY#Q1R\ LCSE$G,209B2
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MEP)%,N4\9Y+-OHL579J&M0:]VKR+^WT/]RJV1E?+0;XSVR[ -0'<+-KU#.+
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M9BG\^6+R[6?\X)\+&\H7"WXL>/%HN25?MJ/[^LR=X^\.#-'4$DO!TV1 >!/
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M'#/(!2FT<U1KIG9[^WBXXGJB;SB\N1,+>Q;_60I74X0N9?Y\.!\A=)4E+/
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M?JUBR3?,XMKRH/'.2F31H2<G\&5@"<\L,<IILKQV.<;ZU/5;AM$<.#L2:Y.
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M9N?^?W_JQR/O[MQOR,$&G.TGK:8?'X;C=(S7XVR@.*/)1XG<"*C&A/7@I73
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MPHT(;%8#;HF/AVJO,V'U'?E\:6>E-=1I7O6&^I2FH<CT(@VLC,ZBN0+<!KQ
MM-?@E-"XOTRE$U:[A_E8SX1'MUB\WQ!99T#;BRP:T'HW9T0'H7@0!A+52'=)
M"W>A#$RC/KA$HQ"L=KWP1KJJNQGR7>NJK5C\]C):KDV/R4U+B$Y26YY?IN,<
MES7WUTNRBZ ^HH7OP7B#]CWWZ$M8HB!S[[)V-(18>S1:+]W8!B(IG76R$(PO
MJ=OHL9O "3C!92992^IJ.YQM6%3=X>%9=;4)K[=65Y=I.IS$L[F;SJO>9[=7
M]X?);#90+/"%\9=B=.@ 2P]H#W(@T7))6%+9=G6[W:?D+34(JH&B'>2PZ\B
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MN'')+57,*:"66M2^6H%AEN'=S!6S40>1:^>#52*]WYK _>%S/[)M3A$^V/:
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M4;$(C)S0Q(4,6K4>1KX5@>.6B[=WK8;33E_0NVIZ?&F!JZ7%?'N;%QBR+$%
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M#IQ8(#.*KN8L$#Q3.GM,.<O6SO(CI/18/-L4/#M(O$?@W,Q*^:@#+S* QQ!
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M6$_I28H_<!&^X.J;O]-F_CI,%W7T)4ZX4,H[B2!B;2&?8H; -:LGEU(:IU7
M;HJE=V-QL]7VHL^X.\53#\MMU6)AN;S _/O%XE>UUV6@=7-0[.E?N$A3DM&$
MI<2<RPZRK0:EB 31DG*2"19#\5(ZWGK%;$WE9J!_L8?9PVJU!]SN*N#3_[R8
MGO]\,UN>+RY6USGN)IYO+_A)CL:%@@RX8;6YB#<0--/@>1!2>X7>M^X&=BC>
M-ELC+^TTO&L$'=FLX1N6I/UHX0<>/N0DX>=XZ6,RA^0Q%W0<8DFU#UHF]R(%
M7R_T"X&%)Z=>V.#@=G59'^=G9Q0=K<I72L[('0FN.%\S$(E!<+K0/TUB6'31
MS;-4PW!RU#,[MD'S@ 5[NP+CF/V@1\L6(_E^2@D!9=5HST8!7FD%7'IK;$A1
MM!]@,THE:W]';@V1.7AUZS8PV7F=?+\,6\[#XKR+U7+;L_O;8KXD'U3E+'F=
M@^[J 3V&VI.2!,$XT]%)9W@>KNM#,S:.]$)HORMF7ZCTL+=LGT5(3'!)(4YM
M\&E!2>\@6NY!A")UL<A<:7X-8IC<4'^'>@-B?5A%;P]E?PGE&7ZI7F07II_D
M7'!:;X5?1_;1*INUEB"=)2'XY" 8'L ESG..-C#>V]G! VP<Z570?DW_OE#9
M=[U\[CBZ2$D+P8H#&Z,GO0B20\X*T*5 ?W04OOGAP2C117_G:?TNF/U@LF=T
M<3KK8X-9[ZVU"G@M!*NE9DE&<*SV32^1/M,B@5.2*QUL$+:W2/P>$^/&%4><
MGMH/#CU$#^V,PIU3]RLO],-BFK#:L+*V8;2C*D_* :G)'U6<BWKCEH-B3I62
MM#>QMU!\>R['C5Z.>$4-#*A_G24WX=RE+'(!C!A U>YMT14D<Q1*\$PS9*W'
M^QV(M1>3.!X$X>,LR*W@=CRIYD?[B&Y2>'9;0*5HY[VL3;E\)@%% SXR"^2U
M>^.M0"\&N2EU&/9>3&JZBS4Y$NR.87=\3C17W&\F'69YT.@HA,UU*I6DZ-6A
M)".68O;>HA3JX'T3FW+X8M+H1[$NAP/?2UB:#Z1<GY0/)J&\(H%H5^>:%B7
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M\*QYY=0CM(R;M!MZQ]I-Y!U YXF3WCJ1*JT_YQ-E4[U378?Q2DV!I0WU.JP
MH9#%6MKE[MZ_&O*P_A9M7=FE'9&P^0'\[FH9^X[6S8:_IW]ANECUKBN/]<21
M2<:<)+A,YE<I7R!Z6>=1%6^*IC4J-QN6L]5KNS)3^V%I8)F/C:;-.BM);9,/
M*=:R*@E*J R!6($JL1 LEX5M.&F]63NKP0X5VJ.GO8R'SPZNOU$_1"+S__D_
M_C=02P$"% ,4    "  J0 A5>!#*B50P @ <+14 $0              @ $
M    <V5S;BTR,#(R,#8S,"YH=&U02P$"% ,4    "  J0 A56KPY M 5  #[
MX@  $0              @ &#, ( <V5S;BTR,#(R,#8S,"YX<V102P$"% ,4
M    "  J0 A5:U7ZF:@6   ?T   %0              @ &"1@( <V5S;BTR
M,#(R,#8S,%]C86PN>&UL4$L! A0#%     @ *D (5;U[OS@;70  4>P# !4
M             ( !75T" '-E<VXM,C R,C V,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( "I "%5BCR4#6>T  %3K"0 5              "  :NZ @!S97-N+3(P
M,C(P-C,P7VQA8BYX;6Q02P$"% ,4    "  J0 A5(E207>^2  "7D08 %0
M            @ $WJ , <V5S;BTR,#(R,#8S,%]P<F4N>&UL4$L%!@     &
-  8 B@$  %D[!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
